
 
FOUNDATION.
CRAFTING THE
FUTURE. 
SOLID
We take great pride and satisfaction in the solid foundation we have established for our 
pharmaceutical formulation business during the year. This robust foundation has been 
the cornerstone of Ajanta's success, allowing us to achieve outstanding results again in 
FY 2024. Our performance highlights our resilience and ability to execute our strategies 
and deliver results in an environment of ever-growing competition. During the year, we 
enhanced efficiencies across functions with our strategic approach and focused execution. 
While achieving growth in our Branded Generics business, we solidified our presence across 
markets by seamlessly executing our strategic intent of growing this business beyond normal 
industry growth. We are ready to craft an even better future in the coming years.
SOLID  
FOUNDATION.
J 4,209 cr.
Revenue
J 1,172 cr.
EBITDA
J 816 cr.
PAT
CRAFTING THE 
FUTURE.
Contents
Corporate Overview	
02
Ajanta at a Glance	
02
Financial Highlights	
04
Letter to Stakeholders	
06
Our Businesses	
08
Our Enablers	
15
Sustainability	
18
Corporate Information	
19
Statutory Reports	
20
Management Discussion and Analysis	
20
Directors‚Äô Report	
30
Report on Corporate Governance	
50
Business Responsibility and  
Sustainability Report	
72
Financial Statements	 114
Consolidated	
114
Standalone	
186
Notice	
254
Ajanta at a Glance 
Our Business is Well-diversified 
and Gives Us an Edge
30+ 
Countries
500+ 
Products
4,800+ 
MRs
7,900+ 
Ajantaites
Branded Generics 
- India
Branded 
Generics - Asia
Branded 
Generics - Africa
Africa Institution
US Generics
4 
Therapy 
Segments
8 
Therapy  
Segments
8
Therapy 
Segments
Antimalarial
Therapy
55
Approved 
ANDAs 
(includes 2 
tentative)
~50%
First-to-market
Leadership
in sub-therapeutic 
segments
Leading
Brands in 
segments
1st
Generic prequalified 
by WHO
22
Under 
Approval 
ANDAs
300+
Products
200+
Products
200+
Products
1 Bn+
Patients treated
44
Products 
on shelf
Ajanta Research Centre, Mumbai
New product launches across markets 
Strong product portfolio under registration and 
development in R&D
Increased market share in existing 
products
Focus on field force productivity enhancement
Growth Levers
Market-wise Sales Contribution
71% Branded Generics
India
Asia
Africa
Africa  
Institution
US  
Generics
FY 2024 Sales 
I 4,162 cr.
23%
6%
15%
25%
31%
Increasing the field presence as needed
Adding field selectively in existing countries
Add new countries
Initiated work to enter selective new countries
Focus on digitalisation & data analytics
Across all functions of the organisation
03
Solid Foundation. Crafting the Future.
Corporate Overview
Statutory Reports
Financial Statements
Notice
02
Ajanta Pharma Limited
Annual Report 2023-24
Financial Highlights
Revenue
(H cr.)
‚ÄÇ CAGR of 13%
‚ÄÇ CAGR of 14%
‚ÄÇ CAGR of 15%
EBITDA/Margin (%)
(H cr.)
26%
35%
28%
21%
28%
PAT and Margin (%)
(H cr.)
18%
23%
21%
16%
19%
ROE2
(%)
RoCE1
(%)
CFO and Cash 
Conversion (H cr.)
67%
58%
61%
99%
67%
Note:
1. RoCE calculated as EBIT/(Net worth + Lease liability + Deferred tax liability)
2. ROE calculated as Net profit/Average net worth
3. Cash Conversion Ratio calculated as CFO (Cash Flow from Operations)/EBITDA
Bonus issue in April 2022 adjusted in all years for 
calculation of EPS and Book Value
EPS
(H)
Payout (Dividend & Buyback) 
% to PAT (H cr.)
25%
38%
61%
81%
79%
Book Value Per Share
(H)
FY23
FY23
FY23
FY23
FY23
FY23
FY23
FY23
FY23
FY22
FY22
FY22
FY22
FY22
FY22
FY22
FY22
FY22
FY21
FY21
FY21
FY21
FY21
FY21
FY21
FY21
FY21
FY20
FY20
FY20
FY20
FY20
FY20
FY20
FY20
FY20
FY24
FY24
FY24
FY24
FY24
FY24
FY24
FY24
FY24
3,743
22%
46
783
18%
479
588
792
264
3,341
28%
55
929
23%
436
713
562
252
2,890
30%
50
999
23%
251
654
576
231
2,588
26%
36
683
19%
116
468
457
199
4,209
31%
65
1,172
23%
642
816
785
283
Ajanta Pharma Limited
04
05
Annual Report 2023-24
Solid Foundation. Crafting the Future.
Corporate Overview
Statutory Reports
Financial Statements
Notice
LETTER TO STAKEHOLDERS
Solid Foundation for 
Better Future 
in API procurements and about 
H 100+ cr. in logistics costs during the 
year. A favourable market condition 
also contributed to this. All this will 
enable us to Craft the Future with 
accelerated growth.
With all these efforts, our Profit After 
Tax grew by 39% to H 816 cr. PAT 
margin expanded to 19% in FY 2024 
from 16% in the previous year. By 
building operational efficiencies 
and following financial discipline of 
profitable growth, we established 
a solid foundation for crafting 
future growth.
During the financial year, your 
Company distributed a total of 
H 642 cr. to shareholders in the form 
of dividend. This translates to a 
remarkable dividend yield of 2.28%, 
based on the closing price as of 
31 March 2024.
Dear Stakeholders,
We are happy to present you the 
outstanding performance your 
Company achieved during this year. 
This performance can be attributed 
to our well diversified business model 
which provides the solid foundation 
and surety for our growth. 
This diversity comes from our 
business being spread across 
3 distinct segments: Branded 
Generics in emerging markets, 
Generics in the USA and Institution 
Business in Africa. 
Segment Review
Our Branded Generics business 
stood at 71% of the total sales in 
FY 2024. This attributed to 31% 
in India, 25% in Asia, and 15% in 
Africa, posting a 10% annual growth 
during the year. During the financial 
year, we further strengthened 
our foundation in these markets, 
launching 42 new products, adding 
300+ people and enhancing our 
promotional efforts. We have a 
strong product portfolio under 
registration and development 
in R&D, which will enable us to 
grow faster.
Generics business in the US 
contributed 23% of the total sales 
in FY 2024 with a growth of 16%. 
This growth was on the back of 
new product launches, some 
opportunities amidst shortages 
and softening of price erosions. 
Our execution in this market has 
been flawless and excellent, and we 
continue to be a preferred partner 
for the distributors. In FY 2025, 
we expect this business to grow at 
a much slower pace in the wake of 
fewer launches, that too towards the 
end of the financial year. We are glad 
to inform you that during the year our 
manufacturing facilities at Paithan 
and Dahej have cleared the US FDA 
inspections with zero observations, 
and we are proud to be among just 
a few to achieve this milestone.
Our Institution business in Africa, 
which consists of antimalarial 
products being distributed through 
multilateral aid agencies, saw growth 
of 31% in the year. This business 
contributed to 6% of total sales. 
As this business is dependent on the 
availability of funds with agencies, 
there is a high level of uncertainty, 
so we remain neutral on this vertical.
Financial Highlights
FY 2024 marked a significant 
milestone for Ajanta Pharma 
with notable achievements 
in sales, PAT, and EBITDA. 
These commendable 
results position us as 
a leading player in the 
pharmaceutical industry.
Revenue from operations grew by 
12% to H 4,209 cr. Our EBITDA grew by 
50% to H 1,172 cr. EBITDA margin grew 
to 28% in FY 2024 from 21% in the 
previous year.
During the year, we took a 
collaborative approach, partnering 
with our vendors and industry experts 
to mitigate the volatility in API prices 
and international logistics cost.
With focused execution of this 
strategic approach, we were able 
to improve efficiency which helped 
in savings of about 300 basis points 
Our balance sheet position remains 
pristine with H 460 cr. as cash and 
liquid investments. We generated 
free cash flow of H 637 cr. in the 
year, which is 78% of PAT. We remain 
prudent in our capital allocation by 
returning excess cash generated in 
the business to shareholders. Given 
this strong financial position, the 
Board of Directors has approved 
the distribution of H 351 cr. to 
shareholders in the form of a 
buyback, including tax, constituting 
0.82% of the total paid-up equity 
share capital.
Our successful efforts in building 
a Solid Foundation gives us the 
confidence for Crafting the Future 
with better performance and 
lesser impact on environment in 
coming years.
At Ajanta, sustainability is our core 
value and we continue to work 
towards it, year after year. 
You would be pleased 
to know that this year, 
we achieved a crucial 
milestone with the 
commissioning of a new 
6.4 MW solar power plant 
at Partur in Maharashtra, 
taking our renewable 
energy portfolio to 
30%+ of our total 
energy consumption.
This plant leads to a remarkable 
reduction of CO2 emissions by 
4,200 tonnes annually which is 
equivalent to planting 300,000 trees 
or saving 15,000 kilolitres of water 
every year. We aim to fulfill over 
50% of our energy requirements 
from green energy in the next two 
years. We are already maintaining 
water neutrality and follow a zero-
discharge policy at our facilities.
We take this opportunity to express 
our deepest appreciation to all our 
employees and their families for their 
consistent contribution in our journey. 
We continue to improve our people 
practices, benchmarking against the 
best in the world, which is confirmed 
by our recognition of 'Great Place to 
Work', second year in a row. We also 
thank you for your continuing trust, 
support, and commitment to Ajanta.
Warm regards,
Yogesh M. Agrawal
Managing Director
Rajesh M. Agrawal
Jt. Managing Director
Rajesh M. Agrawal
Joint Managing Director
Yogesh M. Agrawal
Managing Director
Ajanta Pharma Limited
06
07
Annual Report 2023-24
Solid Foundation. Crafting the Future.
Corporate Overview
Statutory Reports
Financial Statements
Notice
OUR BUSINESSES
Ajanta has a well-diversified 
Branded Generics business 
with sales coming from India 
and 30+ emerging market 
countries across Asia and 
Africa. It is this geographical 
diversification that provides 
business surety, scalability 
and sustainability. It also 
gives us the confidence to 
keep growing faster than 
the market in each of the 
countries we are present in.
We have strengthened this core 
business by penetrating deeper 
into select countries of our existing 
markets and also expanding into 
new promising countries. Our 
focused execution of this strategy 
involved identifying treatment 
gaps to add new products and 
therapies. It also involved expanding 
our field force to widen our reach 
with medical professionals through 
segment-focused marketing. 
This has helped us establish the 
Solid Foundation which is helping 
us in Crafting the Future growth 
at an accelerated pace in this 
vertical. Our expanded field force 
is now helping us reach out to a 
larger number of doctors through 
our continuous medical education 
programmes to keep them abreast 
with the latest developments in 
their therapeutic fields. Our efforts 
to enhance the understanding of 
our customers, enable us to add 
more value to them. It also helps us 
build strong brand recall and faster 
scale-up of our business. Our success 
record in building formidable 
brands in different parts of the 
world reaffirms the effectiveness 
of our strategy. 
In India, we have 300+ strong 
product portfolio across specialty 
segments of Cardiology, 
Antidiabetic, Ophthalmology, 
Dermatology and Pain Management. 
It is built through the introduction 
of first-to-market products, which 
contributes over 50% of the product 
portfolio. Our focused execution 
involves 3,000 strong field force 
promoting these products and 
provide us a very strong position in 
the market.
Branded Generics business in Asia 
and Africa consists of eight major 
therapeutic segments where we 
hold leading positions in our sub-
therapeutic segments. We have a 
basket of more than 200 products 
for these markets. Our strategic 
intent in these markets is to grow 
the chronic portfolio of Cardiology, 
Antidiabetic, Ophthalmology, 
Dermatology and Pain Management. 
We are one of the pioneers to 
introduce field force in some of 
these markets.
We added 27 new products in these 
markets in FY 2024 and further 
enhanced the field force, taking total 
strength to 1,800+. We plan to add 
200 more next year to support the 
deeper penetration in these markets 
through new product launches.
500+
Strong product 
portfolio across 
Specialty segments
Branded Generics
Market Diversification in Branded Generics Enables 
Continued Growth
Ajanta made it to the Asia Book of Records for creating the largest photo collage of CPR workshops conducted 
across India
Leadership 
in molecules and sub-therapeutic segments
3 regions
India, Africa, and Asia
Chronic therapies in focus
Cardiac, Antidiabetic, Ophthal, Derma, and Pain
Ajanta Pharma Limited
08
09
Annual Report 2023-24
Solid Foundation. Crafting the Future.
Corporate Overview
Statutory Reports
Financial Statements
Notice
FY23
957
FY22
813
FY21
712
FY20
673
FY24
1,057
Our India business 
contributed 31% to the 
total revenue, with sales 
of I 1,308 cr. as against 
I 1,174 cr., posting a growth 
of 11%. About 65% of sales 
in India is from chronic 
therapies which is a very 
sticky business. 
In our sales, cardiology contributed 
38%; ophthalmology contributed 
31%; and dermatology contributed 
22% of our India business, with 
remaining 9% coming from pain 
management. In FY 2024, we 
launched 15 new products, including 
4 first-to-market. We also added 
about 200 medical representatives 
in the financial year. 
Ajanta stall @ Association of Physicians of India Conference
CAGR of
14% 
Revenue
(H cr.)
FY23
1,174
FY22
982
FY21
813
FY20
769
FY24
1,308
Branded Generics ‚Äì Asia 
We hold the leadership 
position in many molecules and 
sub-therapeutic segments in many 
of these markets. About 75% of our 
product portfolio in Asia is of chronic 
therapies, which is again a very 
sticky business. 
Ajanta‚Äôs participation @ Annual Gynaecology Conference, Uzbekistan
CAGR of
12% 
Revenue
(H cr.)
Branded Generics ‚Äì India
We continue to outpace the IPM 
by 180 basis points, with Ajanta 
growing at 9.4%, surpassing the IPM 
growth of 7.6%, as per IQVIA MAT 
March 2024. This trend extends to 
most of the therapeutic segments 
we are in, where our growth has 
consistently outpaced the segment 
growth. However, in cardiology our 
growth was lower to IPM due to the 
government-led price revision for 
one of our major products MET XL, in 
Dec 2022. Our overall ranking in IPM 
jumped 1 position to 26th rank. 
In the covered market, we continue 
to be the fourth largest in IPM 
and amongst the top 10 in all our 
therapeutic segments. As per IQVIA 
MAT March 2024, our faster growth is 
contributed mainly by volumes and 
new launches. Volume was about 
2x to IPM, and new launches were 
about 1.4x to IPM. We have 3 brands 
in the top 500 list of brands.
During the year, we launched 18 new 
products in the region solidifying the 
Branded Generics foundation.
New focus
Strengthening 
countries of small 
presence
Optimistic
of consistent  
growth
In Asia, our presence spans 
across the Middle East, 
South East and Central 
Asia, encompassing 
around 10 countries. In 
FY 2024, our sales were 
I 1,057 cr. against I 957 cr., 
growth of 10%. 
Ajanta Pharma Limited
10
11
Annual Report 2023-24
Solid Foundation. Crafting the Future.
Corporate Overview
Statutory Reports
Financial Statements
Notice
Our Africa business is spread across 
20 countries. In FY 2024, sales were 
I 585 cr. against I 559 cr., growth of 5%. 
We launched 9 new products during the 
year in the region. 
Due to rationalisation of the inventory by the distributor 
and the tepid growth in the market, our primary sales 
growth has been low in FY 2024. As the rationalisation 
has completed, we are optimistic of accelerating growth 
in this market.
Ajanta's first-ever Pedia Conclave in Africa
Selective 
product portfolio; strong 
supply chain
Robust 
quality compliance
The US Generics 
Our execution in this market has 
been flawless and excellent, and we 
continue to be a preferred partner 
for the distributors.
During the year, both our 
manufacturing facilities, Paithan and 
Dahej, catering to the US market, 
have cleared the US FDA inspection 
Honoured for the 3rd time 
with the DIANA Award 
as ‚ÄòBest Overall Generic 
Manufacturer‚Äô in less than 
USD 100 million sales.
FY23
FY22
FY21
FY20
FY24
828
696
637
516
964
CAGR of
17% 
Revenue
(H cr.)
Leadership
in many molecules 
and sub-therapeutic 
segments
Top 10
Players in many 
markets
FY23
559
FY22 
587
FY21
413
FY20
356
FY24
585
CAGR of
13% 
Revenue
(H cr.)
Branded Generics ‚Äì Africa
with zero observations, which is a 
testimony to sound quality systems 
built by us. In FY 2024, we filed 7 
ANDAs, received 6 final approvals 
and launched 4 products. We have 
44 products available on shelf and 
22 ANDAs are awaiting approval 
with the US FDA.
The US Generics 
contributed 23% to the total 
revenue on the back of 
softening of price erosion 
and some shortages in 
the market. For FY 2024, 
sales were I 964 cr. against 
I 828 cr., posting a very 
healthy growth of 16%. 
Ajanta Pharma Limited
12
13
Annual Report 2023-24
Solid Foundation. Crafting the Future.
Corporate Overview
Statutory Reports
Financial Statements
Notice
Our Institution business 
in Africa consists of 
antimalarial products, 
which contributed 6% 
of total sales. 
Africa Institution
Higher growth during the year was 
the result of preponement of a few 
supplies of next year and remains 
unpredictable due to reliance on the 
procurement agencies' schedule. 
In FY 2024, sales were H 249 cr.  
against H 190 cr., posting 
a 31% growth. 
Our Enablers - R&D
During the year, we 
strengthened our R&D, 
building efficiencies across 
operations of formulation 
development, analytical 
development and 
regulatory affairs. 
Our highly skilled team of 
800+ scientists, well-equipped 
with state-of-the-art infrastructure 
supported the continued 
development of complex/
difficult-to-make products. 
This enabled us to bring 
differentiated products to the 
market and build the pipeline for 
future growth.
Our R&D spend during FY 2024 
was H 208 cr., 5% of revenue, 
against H 237 cr. in the previous 
year, confirming our efforts of 
efficiency building by filing more 
products for approval across 
our markets.
6%
5%
6%
6%
5%
Strong Capabilities
800+ Scientists
Formulation Development
Analytical Development
API Development
Bio-Analytical Lab
Drug Regulatory Affairs
IPR
FY23
FY22
FY21
FY20
FY24
237
204
139
164
208
R&D Spend (H cr./% of Revenue)
FY23
190
FY22 
206
FY21
271
FY20
244
FY24
249
Revenue
(H cr.)
1st
Generic company 
to obtain WHO 
Pre-Qualification
1 Billion+
Patients treated  
till date
Stagnates
Due to lower  
procurement by 
aid¬†agencies
Ajanta Research Centre, Mumbai
FT-NIR Spectrometers
Ajanta's participation @ Annual World Malaria Scientific Conference, Africa
OUR ENABLERS
Ajanta Pharma Limited
14
15
Annual Report 2023-24
Solid Foundation. Crafting the Future.
Corporate Overview
Statutory Reports
Financial Statements
Notice
Our Enablers - Best-in-Class 
Manufacturing and Supply Chain
Our seven state-of-the-art 
manufacturing facilities are another 
key stone of our solid foundation, 
producing world-class quality 
products. Two of our facilities are US 
FDA-approved and others are WHO 
cGMP compliant. We have been 
able to achieve digitalisation by 
continuously enhancing our quality 
systems to ensure highest quality 
product for our patients. One of 
the key additions to our capability 
during the year was the first-ever 
'Form Fill Seal' machine for drinkable 
ampoules at one of our facilities. 
A drinkable ampoule is an airtight 
container that holds a single dose of 
liquid medication for patient use and 
we are, probably, the first in India to 
use this technology.
Dahej and Paithan received US FDA Approvals with zero observation. 
Among¬†4% in the world.
Digitisation
At Ajanta, we 
have built a strong 
foundation and a 
digital backbone 
by integrating 
most of our 
operations for better 
customer service. 
Be it R&D, manufacturing, quality-
control, marketing, human resource 
or finance, we are able to collate 
and analyse data to provide our 
customers a seamless experience 
in terms of quality product and 
service. This enables us to carry 
out predictive analytics across our 
operational supply chain, helping 
us build efficiencies. 
Higher R&D output through lead 
time management, reduced 
production downtime, responding to 
customers online, are few benefits 
of our digitisation efforts which will 
enable us to craft a future with 
more certainty.
Dahej manufacturing facility
Our supply chain is one 
of the best in the industry 
as we make sure that 
there is no stock-out 
of our products in any 
of our markets even for 
a day. Ajanta has now 
become synonymous with 
high-quality products and 
near perfect scorecard for 
supply assurance.
Ajanta Pharma Limited
16
17
Annual Report 2023-24
Solid Foundation. Crafting the Future.
Corporate Overview
Statutory Reports
Financial Statements
Notice
17
Arvind K. Agrawal
Chief Financial Officer
Gaurang C. Shah
Company Secretary
M/s B S R & Co. LLP
Auditors
M/s Sevekari, Khare & 
Associates
Cost Auditors
CORPORATE INFORMATION
(as on 31 March 2024)
Madhusudan B. Agrawal 
Vice Chairman
CIN No.
L24230MH1979PLC022059
Registered Office
Ajanta House, Charkop, Kandivali (West),
Mumbai ‚Äì 400 067
Tel: +91 22 6606 1000
Website: www.ajantapharma.com
E-mail: corpcom@ajantapharma.com
At Ajanta, operating 
business in an 
environmentally and 
socially responsible way 
is a core value. 
Committed to a  
Sustainable Future
With commissioning of a new 
6.4 MW solar power plant at Partur 
in Maharashtra in FY 2024, our solar 
energy capacity has increased to 
12.69 MW, which fulfills 30%+ of our 
energy requirements. Further, we 
aim to fulfill over 50% of our energy 
requirements from green energy in 
the next two years. 
At Ajanta, we not just meet 
environmental regulations, but go 
beyond compliance to ensure a 
sustainable future. Our air emission 
levels and waste generated quantity 
are much below the permissible limit 
approved by regulatory authorities. 
We conserve water by recycling 
every drop in our manufacturing 
facilities and ensuring zero 
discharge from our units.
We are committed to addressing 
climate change and global 
warming by operating our business 
in a socially, ecologically, and 
economically responsible manner 
to minimise the impact. We have 
well-defined safety, health, and 
environmental policy. The policy 
covers the Company, all our 
subsidiaries, and the contractors 
working within our premises.
Our actual output can be compared with any of the 
below, based on the renewable energy and energy-
saving measures during FY 2024:
SUSTAINABILITY
10,436 
Tonnes of CO2 
emission reduced
740,036 
Trees saved from 
cutting 
Recognitions
SKOCH ESG Award 2024 for Clean 
& Green Energy Utilisation
Apex India Green Leaf Platinum 
Award for Sustainability 2023
Apex India Safe Workplace Gold 
Award 2023 in Pharmaceutical 
sector, Paithan facility
ISO Certifications for Dahej and 
Paithan facilities
Dr. Anjana Grewal 
Independent Director
K. H. Vishwanathan 
Independent Director
Rajesh M. Agrawal 
Joint Managing Director
Mannalal B. Agrawal 
Chairman
Prabhakar R. Dalal 
Independent Director
Chandrakant M. Khetan 
Independent Director
Yogesh M. Agrawal 
Managing Director
Solar power plant @ Partur, Maharashtra
Ajanta Pharma Limited
18
19
Annual Report 2023-24
Solid Foundation. Crafting the Future.
Corporate Overview
Statutory Reports
Financial Statements
Notice
Economic Overview and Outlook
The global economy is set for 
another year of slow but steady 
growth, the International Monetary 
Fund said in April. The strength 
in the U.S. economy is pushing 
world output through headwinds 
from lingering high inflation, weak 
demand in China and Europe, 
and spillovers from two regional 
wars. The IMF forecasts global real 
GDP growth of 3.2% for 2024 and 
2025 - the same rate as in 2023. 
The IMF forecast that global median 
headline inflation will fall to 2.8% by 
the end of 2024 from 4% last year, 
to 2.4% in 2025.
A potential escalation of the 
Middle East conflict would raise 
oil prices and inflation, triggering 
tighter monetary policy from 
central banks. The IMF said that 
in an "adverse scenario" in which 
a Middle East escalation would 
lead to a 15% increase in oil prices 
and higher shipping costs would 
hike global inflation by about 0.7 
percentage points.
Pharmaceutical Sector Overview
Global health systems have 
demonstrated remarkable resilience 
in the face of the pandemic, global 
inflation, and regional conflicts 
and have moved forward to adopt 
novel therapies and increase 
usage. Overall, the global use and 
spending on medicines is exceeding 
pre-pandemic growth rates and is 
expected to continue significantly 
above those trends through 2028. 
The pharmaceutical industry has 
and will continue to have a significant 
impact on the global economy in 
terms of contribution to GDP.
Invoice Spending and Growth
The volume use of medicines 
globally plateaued in 2023 but is 
expected to grow at an average 
2.3% rate through 2028, as per 
the IQVIA report, ‚ÄúGlobal use of 
Medicines 2024‚Äù. It will be driven 
by China, India, and other Asian 
markets all growing faster than 3%. 
Countries in Latin America have 
grown more rapidly than other 
regions in the last five years and 
are expected to grow further at 
1.9% annually through the forecast. 
North America, Western Europe, 
and Japan are expected to grow 
medicine usage more slowly, partly 
due to their already higher per 
capita use. In 2024, Eastern Europe's 
volume growth is expected to return 
to trends prevailing prior to the start 
of the Ukraine conflict.
Management Discussion  
and Analysis
Exhibit 1: Global Invoice Spending and Growth
Invoice Spending and Growth
2023 Spending 
USD Bn
2019-2023 
CAGR
2028 Spending 
USD Bn
2024-2028 
CAGR
Developed
1,276
7.2%
1,775-1,805
5-8%
Pharmerging
304
7.8%
400-430
10-13%
Lower-income countries
28
5.6%
33-37
3-6%
Global
1,607
7.3%
2,225‚Äì2,255
6-9%
Source: Global use of Medicines 2024 by IQVIA
Spending globally is expected to 
grow by more than USD 600 billion, 
reaching USD 2.3 trillion driven by 
existing branded medicines in the 
leading ten developed markets, which 
will grow by USD 385 billion. New 
products will add USD 193 billion but 
will be offset by the impact of patent 
expiries, removing USD 192 billion. 
Other developed markets and fast-
growing Pharmerging markets will 
together add another USD 184 billion. 
In each of these cases, growth drivers 
are an acceleration over the past five 
years, reflecting a rebound from the 
disrupted 2019-2023 period.
The types of medicines driving 
spending and growth vary 
considerably across countries 
broadly correlated with a degree of 
economic development. Generally, 
wealthier countries have higher 
levels of spending on original 
branded products, especially earlier 
in the patented periods of these 
products. Lower-income countries 
have a greater reliance on generic 
drugs and sometimes prefer 
non-original branded versions, called 
branded generics.
The relative amount of medicine 
spending has been shifting over time, 
with some fast-growing countries 
becoming more important to the 
total level of global spending. Volume 
growth, often of older generic 
medicines, has been the primary 
driver of growth in many Pharmerging 
markets, although the more recent 
rising rankings ahead of leading 
developed markets are also driven 
by shifts in the mix of spending.
Annual Report 2023-24
20
21
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Spending and Growth by Regions and Key Countries
Higher global spending growth occurred in key regions after the pandemic, particularly in 2023 in North 
America
Exhibit 2: Spending growth globally and in 5 regions, total market excluding COVID-19 vaccines and 
therapeutics, const USD 2019-2028
Source: Global use of Medicines 2024 by IQVIA
2019
-5%
0%
5%
10%
15%
20%
2020
2021
2022
2023
2024
2025
2026
2027
2028
Global
6-9%
USD 2,225-2,255 Bn
2019
-5%
0%
5%
10%
15%
20%
2020
2021
2022
2023
2024
2025
2026
2027
2028
North America
6-9%
USD 1,050-1,080 Bn
2019
-5%
0%
5%
10%
15%
20%
2020
2021
2022
2023
2024
2025
2026
2027
2028
Western Europe
4-7%
USD 390-410 Bn
2019
-5%
0%
5%
10%
15%
20%
2020
2021
2022
2023
2024
2025
2026
2027
2028
Asia-Pacific
5-8%
USD 120-140 Bn
2019
-5%
0%
5%
10%
15%
20%
2020
2021
2022
2023
2024
2025
2026
2027
2028
India
7-10%
USD 38-42 Bn
-5%
0%
5%
10%
15%
20%
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Africa & Middle East
4.5-7.5%
USD 63-67 Bn
 2024-28 CAGR Const USD	
	
 2028 Spending
Management Discussion and Analysis
Company Overview 
Ajanta Pharma is a specialty 
pharmaceuticals formulation 
company with a well-diversified 
Branded Generics business spread 
across India, Asia, and Africa as 
also US Generics and Institutional 
business in Africa. In Branded 
Generics business, the Company 
has a strong chronic-focused 
product portfolio led by a first-
to-market strategy and front-end 
presence which helps it outgrow the 
market. The Company is committed 
to investing in R&D for product 
innovations to fill identified gaps.
Performance Highlights 
The following analysis and discussion 
are based on the consolidated 
financials of the Company for 
the financial year 2024. It covers 
different business verticals as well as 
the consolidated financial position 
as a whole.
Branded Generics
During the year, Branded Generics 
business in India, Asia, and Africa 
contributed 71% to the total sale 
of H¬†4,162 cr.
In India, Ajanta‚Äôs sales grew by 9.4% 
surpassing IPM growth rate of 7.6% 
as per IQVIA MAT March 2024. The 
180 basis points outperformance 
of the IPM came on the back of 
15 new product launches, including 
4 first-to-market, and consistent 
growth in the existing products. This 
also helped the Company jump to 
26th rank in IPM from 27th in the last 
financial year.
India
FY23
FY24
1,174
1,308
11% 
Asia
FY23
FY24
957
1,057
10% 
Africa
FY23
FY24
559
585
5% 
Total	
(H cr.)
FY23
FY24
2,690
2,949
10% 
Annual Report 2023-24
22
23
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Management Discussion and Analysis
March 20
March 24
March 24
March 24
March 24
March 21
March 22
March 23
March 24 
9%
12%
6%
17%
8%
12%
Cardiac
Opthal
Derma
Pain
Mar 2024 MAT
Exhibit 3: IPM vs Ajanta Pharma Growth
The Branded Generics business in 
Asia and Africa consists of eight 
major therapeutic segments and 
we hold the leading position in all 
our sub-therapeutic segments.
Basket of More than 200 
Products
Our Asia business is spread across 
the Middle East, South East Asia, and 
Central Asia regions with a presence 
in 10 countries. This business saw 
a growth of 10% in the year and 
contributed 26% to total sales. 
We launched 18 new products in 
these markets in the financial year. 
The growth was well-diversified in 
terms of new product launches, 
besides volume growth of 
existing products. 
Our Africa business grew by 5% in the 
year. Here also our product basket 
is spread across various therapeutic 
segments and enjoys leadership 
position in some of them. 
We launched 9 new products 
in these markets in the financial 
year. Due to rationalisation of the 
inventory by our distributor, our 
primary sales growth for the year  
has been lower. As the rationalisation 
is completed now, we are confident 
of accelerating growth in Africa.
The US Generics
The US Generics recorded 16% 
growth for the year and contributed 
23% to total sales. This growth was 
on the back of softening of price 
erosions, shortages and ease in 
API price. We have 44 products on 
the shelf and 22 ANDAs are awaiting 
approvals. During the year, we filed 
7 ANDAs, received 6 final approvals 
and launched 4 products.
Africa Institutional
This business consists of antimalarial 
products being distributed through 
multilateral aid agencies, which 
saw growth of 31% and contributed 
6% to total sales. As this business 
is dependent on the availability of 
funds with agencies, there is a high 
level of uncertainty and we remain 
neutral on this vertical.
Exhibit 4: US and Africa Institutional Sales Bar Graph
31% 
FY23
FY24
190
249
Africa Institutional	
(H cr.)
16% 
US Generics	
(H cr.)
FY23
FY24
828
964
Operational and Financial Performance
During FY 2024, we significantly enhanced capital allocation to the Branded Generics business with accelerated 
product filing and enhanced ground presence. 
We have scaled up our margins on the back of the enhanced contribution of Branded Generics business and 
normalisation of freight costs. This has added surety, scalability, and sustainability to the business.
Exhibit 5
(H cr.)
Particulars
FY 2024
% to RO
FY 2023
% to RO
% Growth
Revenue from Operations
4,209
-
3,743
-
12%
EBITDA
1,172
28%
783
21%
50%
Profit Before Tax
1,114
26%
745
20%
49%
Net Profit
816
19%
588
16%
39%
Total Comprehensive Income
817
19%
603
16%
36%
IPM (7.6%)
2.9%
4.0%
4.0%
4.1%
0.7%
1.3%
Ajanta (9.4%)
Growth Structure
‚ÄÇ Volume‚ÄÉ
‚ÄÇ Price‚ÄÉ
‚ÄÇ New Product
~1.4X
to IPM 
~2X
to IPM 
11%
13%
4%
8%
18%
18%
8%
10%
4%
8%
9%
16%
‚ÄÇ IPM‚ÄÉ
‚ÄÇ Ajanta Pharma
‚ÄÇ IPM‚ÄÉ
‚ÄÇ Ajanta Pharma
IPM = Indian Pharmaceutical Market, Source: IQVIA, MAT
Annual Report 2023-24
24
25
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Revenue from Operations
Revenue from operations stood at 
H¬†4,209 cr. in FY 2024 against H 3,743 
cr. in FY 2023, registering a growth 
of 12%. 
Material Costs
Material cost moved to 25% in 
FY 2024 from 28% in FY 2023, an 
improvement of 300 basis points on 
the back of ease in API prices.
Employee Expenses
Personnel expenses accounted for 
21% of the revenue from operations 
in FY 2024 and previous year. Total 
cost stood at H 900 cr. in FY 2024 
against H 785 cr. in FY 2023.
Other Expenses
Other expenses stood at H 1,070 cr. 
in FY 2024 (25% of revenue from 
operations) against H 1,124 cr. 
in FY 2023 (31% of revenue from 
operations), a 600 basis point 
decrease over the previous year. 
We have been able to build 
excellent operational efficiencies 
across functions during the year, 
with clear focus on getting more 
from the existing base. Our efforts 
in this direction bore good fruits 
with international logistics cost 
going down by about H 103 cr., in 
spite of improving on deliveries. 
Similarly, R&D cost came down to 
H 208 cr. in FY 2024 against H 237 cr. 
in FY 2023, though the output from 
R&D saw a good increase in terms 
of product filings.
With our continued focus on 
Branded Generics business, we 
have allocated higher resources 
on product registrations, 
promotions, and the launch of 
new products, resulting in higher 
marketing expenses.
Operating Profit Margin
EBITDA in FY 2024 stood at H 1,172 
cr. against H 783 cr. in FY 2023, a 
growth of 50% over the previous 
year. This positive performance was 
attributed to the combined benefits 
of reduction in API prices, reduced 
logistics cost and stabilisation in 
US price erosion. EBITDA as % to 
revenue stood at 28%, which is 
among the best in the industry. 
We expect this to now remain at 
this level or see small improvement 
in coming years.
Other Income
Other Income stood at H 85 cr. in 
FY 2024 against H 99 cr. in FY 2023. 
Major component in both the years 
was the forex gain.
Net Profit Margin
Profit After Tax was at H 816 cr. in 
FY 2024 against H 588 cr. in FY 2023. 
PAT margins stood at 19% in FY 2024 
against 16% in FY 2023.
Return on Net Worth
Return on Net Worth improved to 
23% in FY 2024 against 18% in the 
previous year.
Return on Capital Employed
Return on Capital Employed stood 
at 31% in FY 2024 compared to 22% 
in FY 2023.
Balance Sheet
Non-current Assets
The non-current assets have gone 
up to H 1,907 cr. in FY 2024 from 
H¬†1,845 cr. in FY 2023. Our CAPEX 
was H 160 cr. for the year which was 
mostly the maintenance CAPEX. 
The CAPEX including maintenance 
CAPEX for FY 2025 is estimated to be 
about H 250 cr.
Current Assets
Current Assets stood at H 2,731 
cr. in FY 2024 against H 2,834 
cr. in FY 2023. Receivables days 
slightly increased to 109 days from 
104 in FY 2023 due to increase in 
businesses across verticals. The 
absolute amount stood at H 1,247 cr. 
against H 1,057 cr. in FY 2023.
Inventory in terms of the number 
of days to sales has improved to 
73 days in FY 2024 from 80 days in 
FY 2023 due to the easing of the 
supply chain. In absolute amounts, it 
has marginally increased to H 828 cr. 
in FY 2024 from H 816 cr. in FY 2023. 
Current Ratio for FY 2024 stood at 
3.05 against 2.49 in FY 2023.
Management Discussion and Analysis
Shareholders‚Äô Funds
Shareholders‚Äô funds increased to 
H¬†3,567 cr. in FY 2024 from H 3,388 
cr. in FY 2023. Earnings per share 
stood at H 65 in FY 2024 against 
H 46 in FY 2023. During the year, the 
Company paid H 642 cr. as dividend 
against H 479 cr. in FY 2023 through 
a combination of dividend and share 
buyback (including tax).
Non-current Liabilities
Non-current liabilities in FY 2024 
stood at H 175 cr. against H 152 cr. 
in FY 2023, mainly consisting of 
deferred tax and lease liabilities.
Current Liabilities
Current liability stood at H 896 
cr. in FY 2024 against H 1,139 cr. 
in FY 2023. Trade payable days 
increased from 79 in FY 2023 to 
85 in FY 2024. Our strong balance 
sheet combined with a focus on 
cash conservation provides us the 
confidence that we will continue with 
our consistent performance.
Consolidated Cash Flow 
The Company had a healthy cash flow during FY 2024; the snapshot of this is 
in Exhibit 6.
Exhibit 6
(H cr.)
Particulars
FY 2024
FY 2023
Opening Cash and Cash Equivalents
330
206
Cash flows from:
a)	 Operating Activities
785
792
b)	 Investing Activities
65
(560)
a)	 Financing Activities
(1,051)
(108)
Closing Cash and Cash Equivalents
129
330
Empowered Team
We are proud to mention that 
your Company‚Äôs Human Resource 
Development efforts to make Ajanta 
a preferred place to work got the 
prestigious ‚ÄòGreat Place to Work‚Äô 
recognition for the second year in 
a row. Our people practices which 
are now benchmarked globally, 
including skill development, 
personality enhancement, and 
employee engagement through 
internal communications foster 
happiness at work.
Ajantaites are truly empowered. 
The Company‚Äôs culture is centred on 
the four core values of Excellence, 
Transparency, Integrity, and 
Discipline. These values drive over 
7,900 Ajantaites on the mission 
to provide life-saving drugs to 
needy patients.
Your Company is committed to 
providing a safe, secure, and 
healthy work environment to 
employees. We continuously strive 
to exceed our own internal and 
industry benchmarks in workforce 
productivity and performance. 
Annual Report 2023-24
26
27
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
The Occupational Health and Safety 
(OHS) system at our manufacturing 
facilities has enabled workers and 
employees to operate in a safe and 
healthy working environment.
The professional objectives for 
employees and teams across 
levels are directly linked with the 
organisation‚Äôs objectives and 
philosophy. This conveys and 
provides a sense of purpose and 
direction to all employees. The 
key areas for driving HR initiatives 
include a strong emphasis on 
building a culture of inclusion and 
respect, ensuring a safe work 
environment, focusing on building 
capabilities and careers and 
protecting human rights.
The Company continues to support 
the capabilities of differently-
abled employees. We ensure 
strict adherence to our internal 
codes and have a clearly defined 
zero-tolerance policy towards 
discrimination of any kind. 
Risk Management
We operate in over 30 highly 
regulated countries with their 
own specific complex operating 
environments. In addition, this 
business landscape is dynamic and 
constantly evolving. This brings to 
the fore a multitude of risks which 
are closely monitored, mapped, 
and mitigated through our robust 
Enterprise Risk Management (ERM) 
framework. By effectively identifying, 
assessing, and mitigating risks we 
strive to enhance our resilience, drive 
sustainable growth, and maximise 
value creation.
The ERM involves engaging with 
all functional heads to identify 
internal and external events that 
may have an adverse impact on 
the achievement of the Company‚Äôs 
objectives. It¬†also entails periodic 
monitoring of changes in both the 
internal and external environment 
leading to the emergence of a new 
threat/risk. The major risks identified 
are regulatory, competition, supply 
chain disruption, cyber & data 
security, economic & political, 
and Environmental, Social, and 
Governance (ESG). A review of 
the risk management policy is 
carried out annually by the Risk 
Management Committee. Our ERM 
framework plays a significant role 
in safeguarding the interests of our 
Company, our shareholders, and 
our stakeholders.
Internal Controls and Adequacy
Your Company has a robust 
and reliable system of internal 
controls as we believe that it is the 
prerequisite of good governance. 
The control framework is designed to 
continuously assess the adequacy, 
effectiveness, and efficiency of 
internal controls. The management is 
committed and ensures an effective 
internal controls environment, 
commensurate with the size and 
complexity of the business. This 
assures compliance with internal 
policies, applicable laws, regulations, 
the accuracy of records, operational 
efficiency, protection of resources & 
assets, and overall risk minimisation. 
These controls have been designed 
to provide reasonable assurance 
over time.
The current system of Internal 
Financial Controls (IFC) is aligned 
with the requirement of the 
Companies Act, 2013 and is in line 
with the globally accepted risk-
based framework. The Internal Audit 
(IA) function of the Company reports 
to the Chairperson of the Audit 
Committee, thereby maintaining its 
objectivity. Our dedicated internal 
audit team supported by external 
audit firms help to enhance and 
protect organisational value by 
providing risk-based objective 
assurance, advice and insight. The 
annual internal audit plan is carved 
out from a comprehensively defined 
Audit Universe that encompasses 
all businesses, functions, risks, 
compliance requirements, and 
maturity of controls. The internal 
audit plan is approved by the 
Audit Committee at the beginning 
of every year. Each quarter, the 
Audit Committee is presented with 
key control issues and the actions 
Management Discussion and Analysis
taken on issues highlighted in the 
previous reports. 
The Audit Committee deliberates 
with the management, considers 
the systems as laid down, and meets 
the internal auditors and statutory 
auditors to ascertain their views on 
the internal control framework.
The Company recognises the fact 
that any internal control framework 
would have some inherent limitations 
and hence has inculcated a 
process of periodic audits and 
reviews to ensure that such systems 
and controls are updated at 
regular intervals.
Cautionary Statement
Statements in the Management Discussion and Analysis describing the Company‚Äôs objectives, projections, 
estimates, and expectations may be forward-looking statements. Actual results may differ materially from 
those expressed or implied due to various risks and uncertainties. Important factors that could make a 
difference to the Company‚Äôs operations include global and Indian demand-supply conditions, finished goods‚Äô 
prices, changes in government regulations and policies, tax regimes, economic conditions within India and 
the countries within which the Company conducts business and other such factors. The Company does not 
undertake to update these statements.
Annual Report 2023-24
28
29
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Directors‚Äô Report
Dear Shareholders,
Your directors have pleasure in presenting Forty-Fifth Annual Report and Audited Financial Statements of the Company 
for the Year ended 31 March 2024.
Summarised Position of the Financials Statements is Given Below:
(H cr.)
Particulars
Consolidated
 Standalone
Year ended 31 March
2024
2023
2024
2023
Revenue from operations
4,209
3,743
3,971
3411
Other Income
85
99
116
133
Profit before Depreciation, Finance Costs and Tax expense
1,257
882
1236
832
Profit after Tax
816
588
807
559
Total Comprehensive Income
817
603
805
556
Earnings Per Share (EPS) (H) (Basic)
64.82
45.89
64.11
43.61
The Company discloses consolidated and standalone financial results on a quarterly basis, which are subjected to 
limited review and publishes consolidated & standalone audited financial results annually.
	
Performance Review
	
	
Company continues to be engaged in the development, manufacturing and sale of specialty pharmaceutical 
formulations with specific emphasis on branded generics in various therapeutic segments in India and more 
than 30 countries across Asia & Africa.
	
	
During the year under review, Consolidated Revenue from operations augmented at H¬†4,208.71 cr., an increase 
of 12% over the previous year.
	
	
Consolidated Profit After Tax stood at H¬†816.17 cr. higher by 39% compared to previous year. Exports contributed 
68% of the revenue.
	
Dividend
Two Interim Dividends of K 25 and K 26
	
	
During the year under review, the Board declared following interim dividend(s):
Particulars
Interim Dividend ‚Äì FY 2024
1st
2nd
Date of Declaration
27 July 2023
31 January 2024
Record Date
04 August 2023
08 February 2024
Date of Payment
17 August 2023
20 February 2024
Rate of Dividend per share (Face Value of H¬†2 per share)
25
26
%
1250
1300
Total Pay-out (H¬†in crore)
315 cr.
327 cr.
	
	
Dividend pay-out is in accordance with the Company‚Äôs Dividend Distribution Policy which is available on the 
website of the Company and can be accessed at https://ajantapharma.com//images/DividendPolicy.pdf
	
Subsidiaries, Associates and Joint Ventures
	
	
The Company continues to have four overseas subsidiaries and it does not have any Associate company or 
Joint Venture. There is no change in Subsidiaries.
	
	
Salient features of the Financial Statements of subsidiaries are provided in the AOC-1 statement annexed 
herewith as ‚ÄúAnnexure A‚Äù.
	
	
Audited Financial Statements of subsidiaries 
are available on Company‚Äôs website at 
www.ajantapharma.com and the same are 
also available for inspection at the Registered 
Office of the Company during business 
hours as stipulated under Section 136 of The 
Companies Act, 2013 (the ‚ÄúAct‚Äù). The same will 
be made available to interested members upon 
getting request.
	
	
Ajanta Pharma USA Inc. is a material subsidiary 
in accordance with the provisions of The SEBI 
(Listing Obligations and Disclosure Requirements) 
Regulations, 2015 (The ‚ÄúListing Regulations‚Äù) 
read with the Company‚Äôs ‚ÄúPolicy on Material 
Subsidiaries‚Äù. The policy can be accessed 
at 
https://ajantapharma.com//images/
PolicyonMaterialSubsidiaries.pdf
	
Share Capital
	
	
There was no change in authorised share capital 
of the Company during the year under review.
	
	
Buyback of 22,10,500 equity shares representing 
2.59% of the subscribed and paid-up share 
capital of the Company, through ‚ÄúTender Offer‚Äù 
route, at a price of H¬† 1,425/- (Rupees One 
Thousand Four Hundred and Twenty-Five only) 
per equity share for an aggregate amount of 
H¬† 315.00 cr., was started in March 2023, and 
successfully completed in April 2023.
[
Employee Stock Option Scheme
	
	
	
The Company has formulated and 
implemented Employee Stock Option 
Scheme, 2011 (‚ÄúESOS 2011‚Äù) and Ajanta 
Pharma Share-Based Incentive Plan 2019 
(‚ÄúSBIP 2019‚Äù). The Schemes are administered 
by the Nomination and Remuneration 
Committee (‚ÄúNRC‚Äù).
	
	
	
During the year under review, the Committee 
conducted a comprehensive evaluation 
of the Company's compensation and 
benefits structure to optimise operational 
efficiency and sustained long-term growth. 
After careful consideration, the Board on 
the recommendation of NRC decided 
to suspend/withdraw ESOS 2011 as the 
scheme had become dormant.
	
	
	
During FY 2024, 1,000 shares were issued 
against the options exercised and 87,600 new 
options were granted under the SBIP 2019.
	
	
	
Disclosures with regard to Employees‚Äô 
Stock Options Scheme are put up on the 
Company‚Äôs website and can be accessed 
at http://www.ajantapharma. com/
AnnualReports.aspx
	
Credit Rating
	
	
Company‚Äôs bank facilities are rated by Credit 
Analysis and Research Limited (‚ÄúCARE‚Äù). They 
have assigned rating CARE AA/CARE A1+ for 
long-term/short-term bank facilities, which 
connotes stability. This reaffirms the reputation 
and trust the Company has earned for its sound 
financial management and its ability to meet its 
financial obligations.
	
Listing at Stock Exchanges
	
	
The Equity shares of the Company continue to 
be listed on BSE Limited and The National Stock 
Exchange of India Limited.
	
Directors and Key Managerial Personnel
	
	
Board of the Company comprise of eminent 
professionals having diverse skillset, domain 
expertise and business acumen. The Executive 
Directors possess the required expertise & 
acumen to manage and grow the business 
and the Non-Executive & Independent 
Directors bring in the expertise in the fields of 
finance, accounting, corporate governance, 
forex management, risk management, people 
management etc. Independent Directors also 
contribute in bringing independent judgement 
on Board‚Äôs decisions. This Board mix facilitates 
sustained growth of the Company.
	
	
During the year under review, none of the 
Non-Executive Directors had any pecuniary 
relationship or transactions with the Company, 
other than sitting fees, commission and 
reimbursement of expenses, if any.
[
Retirement by Rotation
	
	
	
Mr. Mannalal B. Agrawal retires by rotation 
at the ensuing AGM and being eligible, has 
offered himself for re‚Äëappointment. The 
Board recommends his re-appointment.
[
Independent Directors
	
	
	
Mr. Chandrakant Khetan, Mr. K.H. 
Viswanathan, Mr. Prabhakar Dalal and 
Dr. Anjana Grewal, have been Independent 
Directors for 2 terms of 5 years each and 
hold office up to 17 July 2024. The Board 
places on record its deepest appreciation 
for the invaluable services, inspirational 
guidance, thoughtful contribution & 
expertise rendered by them.
Annual Report 2023-24
30
31
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Appointment of new 
Independent Directors
	
	
	
At the Board meeting held on 02 May 2024, 
the Board, based on recommendations 
of the Nomination and Remuneration 
Committee, has appointed Mr. Rajesh Dalal, 
Mr. David Rasquinha, Ms. Medha Joshi and 
Ms. Simi Thapar as additional Independent 
Directors. They have been appointed in 
accordance with the guidelines set out under 
the ‚ÄúPolicy for Determining Qualifications of 
Directors‚Äù. Their appointment is subject to 
approval of members at the ensuing Annual 
General Meeting and proposal to that 
effect are included in the Notice convening 
the Annual General Meeting.
	
	
	
All the Independent Directors meet the 
independence criteria prescribed under 
Section 149(6) of the Act as also under 
the Listing Regulations and are also 
in compliance with the other statutory 
requirements. They have also affirmed 
compliance to the Code of Conduct for 
Independent Directors.
	
	
	
Based on disclosures provided by them, 
none of them are disqualified/debarred from 
being appointed as Director under Section 
164 of the Act/Listing Regulations order or 
any other authority and are independent 
from the management.
	
	
	
The Board is of the opinion that the 
Independent Directors possess the required 
skillset, competences and expertise in 
the fields of strategic thinking, general 
management & administration, corporate 
governance, finance, forex management, 
people management, global business & 
economics, CSR, Stakeholder management, 
sales & marketing, risk management etc. 
and they hold highest standards of integrity 
& probity, Skill set, expertise & competencies 
matrix of all the Directors is provided in the 
Report on Corporate Governance forming 
part of this Annual Report.
[
Policies on Appointment and 
Remuneration of Directors
	
	
	
Company‚Äôs ‚ÄúPolicy for Determining 
Qualifications of Directors‚Äù sets out 
guiding principles for selection of persons 
who are qualified to become Directors/
Independent Directors.
	
	
	
The ‚ÄúPolicy for Remuneration of Directors 
and Employees‚Äù sets out guidelines to 
ensure that level and composition of 
remuneration is reasonable and sufficient to 
attract, retain and motivate the Directors, 
Key Managerial Personnel (‚ÄúKMP‚Äù) and 
Senior Management employees.
The policies are available at:
	
	
	
https://ajantapharma.com//images/
	
	
	
Policyfordeterminingqualificationsof
	
	
	
Director.pdf
	
	
	
https://ajantapharma.com//images/
	
	
	
PolicyforRemunerationofDirectorsand 
Employees.pdf
	
	
	
The same are briefly mentioned in the 
Report on Corporate Governance.
[
Key Managerial Personnel
	
	
	
Mr. Yogesh M. Agrawal, Managing Director; 
Mr. Rajesh M. Agrawal, Joint Managing 
Director; Mr. Arvind K. Agrawal, Chief 
Financial Officer and Mr. Gaurang C. Shah, 
Company Secretary, are the KMPs of the 
Company as on the date of this report.
[
Board and Directors‚Äô Evaluation
	
	
	
Performance evaluation of the Board, Board 
committees and individual Directors was 
carried out by the Board, in accordance with 
the criteria laid down in the ‚ÄúPolicy on Board 
Evaluation‚Äù, which are in alignment with the 
best corporate governance practices.
	
	
	
Further, at a separate meeting, the 
Independent 
Directors 
evaluated 
performance of Non-Independent Directors, 
Board as a whole and of the Chairman of 
the Board.
	
	
	
A consolidated report on performance 
evaluation was shared with the Chairman 
of the Board for his review and discussion 
with Board and each Director.
	
	
	
The manner of evaluation of Board of 
Directors performance and matters 
incidental thereto, are detailed in the Report 
on Corporate Governance.
Directors‚Äô Report
	
Board Meetings
	
	
Board of Directors of the Company met 5 times 
during the year under review. Details of meetings 
are given in the Report on Corporate Governance.
	
Board Committees
	
	
The Board has constituted Audit Committee, 
Nomination and Remuneration Committee, 
Corporate Social Responsibility Committee, 
Stakeholders' Relationship Committee, Risk 
Management Committee, Executive Committee 
and ESG Committee. All the recommendations 
made by these Committees to the Board were 
accepted by the Board.
	
	
At the Board meeting held on 02 May 2024 the 
CSR Committee has been renamed as the ‚ÄúCSR 
& Sustainability Committee‚Äù.
	
	
Details of committees, its composition, committee 
meetings held etc. are provided in the Report on 
Corporate Governance.
	
Related Party Transactions (RPTS) and 
Policy
	
	
All RPTs for the year under review were on 
arm‚Äôs length basis and in the ordinary course 
of business. Further, all RPTs entered into by 
the Company during the financial year were in 
accordance with the Company‚Äôs Policy on RPTs 
and in pursuance of approval granted by the 
Audit Committee. Pursuant to Regulation 23(3) 
of the Listing Regulations and Rule 6A of the 
Companies (Meetings of Board and its Powers) 
Rules, 2014, the Audit Committee granted 
omnibus approval to the transactions likely to 
be entered into by the Company with related 
parties during the year which are of repetitive 
nature. Members may refer to Note No. 54 to 
the Financial Statement which sets out RPT 
disclosures pursuant to IND AS-24.
	
	
All the RPTs effected in accordance with the 
approval are placed before the Audit Committee 
on a quarterly basis for review and noting.
	
	
Apart from remuneration and sitting fees, there 
is no pecuniary transaction with any director, 
which had potential conflict of interest with 
the Company.
	
	
During the year, the Company had not entered 
into any transactions with related parties 
(save and except transactions with company‚Äôs 
subsidiaries), which could be considered as 
material in accordance with the Company‚Äôs 
‚ÄúPolicy on materiality of RPT‚Äù or which are 
required to be reported in Form AOC-2 in terms 
of Section 134(3)(h) read with Section 188 of the 
Act and Rule 8(2) of the Companies (Accounts) 
Rules, 2014.
	
Corporate Social Responsibility (‚ÄúCSR‚Äù)
	
	
The Company‚Äôs CSR initiatives go beyond charity. 
Company believes before that as a responsible 
corporate citizen, it should consider its impact on 
society as much as creating business impact.
	
	
The Board had at its meeting held on 05 May 
2023, approved the Annual Action Plan of CSR 
activities to be undertaken during the year 
in accordance with the CSR policy. The CSR 
activities were carried out through the eligible 
charitable trusts and NGOs. CSR Committee 
reviewed and monitored the CSR projects and 
expenditure undertaken by the Company as per 
the plan and apprised the Board of the same.
	
	
Company has spent more than 2% of the 
average net profits during three preceding 
financial years. Thrust areas for CSR continued 
to be healthcare, education, rural development, 
community welfare, upliftment of socio-economic 
backward society, women empowerment & 
promoting sports.
CSR spend more 
than obligation
	
	
Chief Financial Officer has certified that the 
funds disbursed for CSR during the financial year 
2024, have been used for the purpose and in the 
manner approved by the Board.
	
	
CSR policy and CSR activities undertaken during 
the year are annexed as ‚ÄúAnnexure B‚Äù to this 
report, in accordance with Sections 134 & 135 
of the Act read with Rule 8 of the Companies 
(Corporate Social Responsibility Policy) 
Amendment Rules, 2021 and Rule 9 of the 
Companies (Accounts) Rules, 2014.
	
Management Discussion and Analysis
	
	
Pursuant to Regulation 34 read with Part B of 
Schedule V of the Listing Regulations, a detailed 
review of the business operations, performance, 
future outlook, major events occurred during the 
Annual Report 2023-24
32
33
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
year as well as state of company‚Äôs affairs is given 
in the Management Discussion and Analysis, 
which forms part of this report.
	
Report on Corporate Governance
	
	
The Board of Directors reaffirm their continued 
commitment to good Corporate Governance & 
ethical practices. The Company is committed 
to maintain highest standard of Corporate 
Governance and elevating the same to the best 
global practices.
	
	
Report on Corporate Governance for the 
year under review, forms part of this report. 
A certificate from M/s. Alwyn D‚ÄôSouza & Co., 
Practicing Company Secretaries confirming 
compliance with Corporate Governance norms 
as stipulated under the Listing Regulations, is 
also annexed and forms part of this report.
	
Business Responsibility and 
Sustainability Report
	
	
Company has been conducting business 
in a sustainable manner so as to create 
maximum value for all its stakeholders. It is 
also committed to ensure that its actions 
positively impact the economic, societal and 
environmental dimensions.
Sustainable business  
practices to maximise 
stakeholders value
	
	
Business Responsibility and Sustainability 
Report (‚ÄúBRSR‚Äù) for FY 2024 in accordance with 
Regulation 34(2) (f) of the Listing Regulations, 
forms part of this report. It enumerated various 
initiatives taken by the Company in environment, 
social and governance fields.
	
Annual Return
	
	
Pursuant to Section 92(3) read with Section 134(3)
(a) of the Act, the Annual Return as on 31 March 
2024 in Form MGT-7 is placed on the Company‚Äôs 
website at https://ajantapharma.com//images/
DraftAnnualReturn-FY2023-24.pdf.
	
Unclaimed Dividend/Shares
	
	
In pursuance of Regulation 39 read with 
Schedule VI of the Listing Regulations, the details 
of shares lying in unclaimed suspense account 
and unclaimed shares/dividend transferred to 
Investor Education and Protection Fund, are 
provided in the Report on Corporate Governance.
	
Auditors and Audit Reports
[
Statutory Auditors
	
	
	
M/s. B S R and Co. LLP, Chartered 
Accountants (ICAI Registration No.: 
101248W/W-100022) (‚ÄúBSR‚Äù) are the 
Statutory Auditors of the Company. At the 
43rd AGM held on 04 August 2022, Members 
re-appointed BSR for a further period of five 
years, i.e. from the conclusion of the 43rd 
AGM till the conclusion of the 48th AGM of 
the Company to be held in the year 2027.
	
	
	
Auditors‚Äô Report on the financial statements 
of the Company for the financial year 
ended 31 March 2024 is enclosed with the 
financial statements, which forms part of 
this Annual Report. The report is unmodified 
i.e. it does not contain any qualification, 
reservation, adverse remark or disclaimer. 
Notes on financial statement referred to in 
the Auditor‚Äôs Report are self-explanatory 
and do not call for any further comments.
[
Internal Auditors
	
	
	
M/s. Aneja Assurance Private Limited 
conducted internal audit of important 
centralised functions. For other locations, 
viz. factories, C&F agents and warehouses, 
other Chartered Accountant Firms having 
requisite expertise and resources are 
appointed as Internal Auditors. Important 
audit observations and corrective actions, 
improvements are presented to the Audit 
Committee in each meeting. No instances 
of fraud, suspected fraud, irregularity or 
failure of internal control systems of material 
nature were reported by the internal 
auditors during the year.
[
Secretarial Auditors, Audit Report, 
Secretarial Compliance Certificate
	
	
	
Pursuant to Section 204 of the Act and the 
Companies (Appointment and Remuneration 
of Managerial Personnel) Rules, 2014 & 
Regulation 24A of the Listing Regulations, 
Board has appointed M/s. Alwyn D‚ÄôSouza 
& Co., Practicing Company Secretaries 
to undertake the Secretarial Audit of the 
Company for year ended 31 March 2024.
Directors‚Äô Report
	
	
	
Secretarial Audit Report is annexed to 
this report as ‚ÄúAnnexure C‚Äù. There are no 
qualifications or reservations or adverse 
remarks in the Secretarial Audit Report. The 
report is self-explanatory and does not call 
for any further comments.
	
	
	
M/s. Alwyn D‚ÄôSouza & Co., Practicing Company 
Secretaries, have also issued Secretarial 
Compliance Report for the year ended 31 
March 2024 confirming that the Company has 
maintained proper records as stipulated under 
various Rules and Regulations applicable to 
the Company and that no action has been 
taken against the Company or its material 
subsidiaries or promoters/directors by SEBI/
Stock Exchanges. The Company disseminates 
the Report on the websites of BSE and NSE 
within the prescribed time.
	
	
	
On the recommendations of the Audit 
Committee, Board of Directors have 
re-appointed M/s. Alwyn D‚ÄôSouza & 
Co., Practicing Company Secretaries, 
to conduct the secretarial audit of the 
Company for FY 2025. They have consented 
and confirmed their eligibility for the said 
re‚Äëappointment.
[
Cost Auditors
	
	
	
The Company maintains cost accounts and 
records as per the provisions of Section 
148(1) of the Act and the same are audited 
by the Cost Auditors. In accordance with 
Section 148(6) of the Act read with Rule 6(6) 
of the Companies (Cost Records and Audit) 
Rules, 2014, cost audit report, in Form No. 
CRA-4 (in XBRL mode), for the year ended 
31 March 2023, was filed with the Ministry of 
Corporate Affairs, within the prescribed time.
	
	
	
M/s. Sevekari Khare & Associates, practicing 
Cost Accountants have expressed their 
inability to continue as cost auditors 
due to personal reasons. Based on the 
recommendation of the Audit Committee, 
Board has appointed M/s. RA & Co., 
practicing Cost Accountants, to audit 
the cost records of the Company for 
FY 2025 They have confirmed that their 
appointment is in accordance with the 
applicable provisions of the Act and rules 
framed thereunder and that they are not 
disqualified to be appointed as the Cost 
Auditors of the Company for the year ending 
31 March 2025.
	
	
	
In accordance with the provisions of Section 
148 of the Act read with the Companies 
(Audit and Auditors) Rules, 2014, the 
remuneration to be paid to the Cost 
Auditor for FY 2024 is required to be ratified 
by the members. Accordingly, the Board 
of Directors recommends the same for 
approval by members at the ensuing AGM. 
The proposal forms a part of the notice of 
the AGM.
	
	
	
During the year under review, the Statutory, 
Internal, Secretarial and Cost Auditors have 
not reported to the Audit Committee, any 
instances of fraud committed against the 
Company by its officers or employees, the 
details of which need to be mentioned in 
the Directors' report.
	
Secretarial Standards
	
	
During FY 2024, the Company has complied with 
all the applicable Secretarial Standards issued 
by the Institute of Company Secretaries of India 
as amended.
	
Internal Control System, Risk 
Management and Compliance Framework
	
	
The Company has a well-established internal 
controls framework comprising a set of policies, 
procedures and systems, instrumental in 
enhancing the efficiency and effectiveness of 
business operations, reducing risks and costs, and 
improving decision-making and accountability.
	
	
The Internal control framework ensures 
the following:
	
	
[
Establishment of policies and procedures, 
assignment of responsibility, delegation of 
authority, segregation of duties to provide 
a basis for accountability and controls;
	
	
[
Physical existence and ownership of assets 
at a specified date;
	
	
[
Proactive anti-fraud controls and a risk 
management framework to mitigate fraud 
risks to the Company;
	
	
[
Recording of all transactions occurred 
during a specific period; 
Annual Report 2023-24
34
35
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
	
	
	
Accounting of assets, liability, and 
revenue and expense components at 
appropriate amounts;
	
	
[
Preparation of financial information 
as per the timelines defined by the 
relevant authorities.
	
	
The internal financial controls are adequate 
and operating effectively. Effectiveness of 
internal financial controls is ensured through 
management reviews, controlled self‚Äëassessment 
and independent testing by the internal audit 
team Risk Management.
	
	
The Company also has Risk Management 
Policy and framework in place which defines 
roles and responsibilities at various levels of the 
risk management process. Risk Management 
Committee (‚ÄúRMC‚Äù) oversees the implementation 
of Risk Management Policy as well as risk 
management and mitigation framework. The 
Company has also laid down procedures to 
inform Board members about the risk assessment 
and its minimisation, which is periodically 
reviewed to ensure that risk control is exercised 
by the management effectively.
	
	
Risks are categorised into Regulatory, 
Competition, Supply Chain Disruption, Cyber 
Security including Data Security, Economic & 
Political Environment, Environmental, Social 
& Governance Risks and other critical risks. 
The in-house Internal audit team acts as Risk 
co-ordinator and engages with all functional 
heads to identify internal and external events 
that may have an adverse impact on the 
achievement of Company‚Äôs objectives and 
periodically monitors changes in both internal 
and external environment leading to emergence 
of a new threat/risk.
	
	
Risk Management system followed by the 
Company is detailed in the Management 
Discussion and Analysis report and in the Notes 
to Accounts.
[
Statutory Compliances
	
	
	
The Company has a comprehensive 
framework for monitoring statutory 
compliances and internal policies. 
Business and corporate functions ensure 
implementation of laws at the primary 
level through checks and controls in their 
operational processes. Compliances 
are further mapped into the compliance 
monitoring tool and affirmed at regular 
frequency by the compliance owners and 
compliance reports are submitted to the 
Board on a quarterly basis.
	
Supply Chain
	
	
A sustainable and seamless supply chain is 
critical for the timely availability of our medicines 
to our patients across the globe. Your Company 
also works with our suppliers to promote 
Responsible sourcing practices, uphold ethical 
standards and drive sustainability in supply 
chain. Company continuously supports supply 
chain and distribution partners to maintain 
an uninterrupted supply and distribution 
of medicines.
	
	
Company has requisite processes in place 
for sustainable sourcing and sustainability 
parameters are integrated into overall 
supply chain.
Thrust on responsible 
sourcing, ethical practices 
and sustainability in 
supply chain
	
Vigil Mechanism/Whistle-Blower Policy
	
	
The Board of Directors adopted the Whistle-
Blower Policy in accordance with Section 177(9) 
of the Act, and Regulation 22 of the Listing 
Regulations. The Whistle-Blower Policy aims to 
conduct the affairs of the Company in a fair and 
transparent manner by adopting the highest 
standards of professionalism, honesty, integrity, 
and ethical behaviour. All permanent employees 
and Whole-time Directors of the Company are 
covered under the Whistle-Blower Policy.
	
	
A mechanism has been established for employees 
and other stakeholders to report their concerns 
about unethical behaviour, actual or suspected 
fraud or violation of the Code of Conduct and 
Ethics, and leak of price-sensitive information. It 
also provides for adequate safeguards against 
the victimisation of whistle blowers and allows 
direct access to the Chairperson of the Audit 
Directors‚Äô Report
Committee and also Managing Director of the 
Company in exceptional cases.
	
	
It is posted on the intranet and website of the 
Company and the same is available at https://
ajantapharma.com//images/Whistle-Blower-
Policy-Feb-2023.pdf.
	
	
The same is reviewed by the Audit Committee 
from time to time. It is affirmed that no person 
has been denied access to the Audit Committee.
	
Policy on Sexual Harassment of Women 
at Work Place
	
	
Company is dedicated in providing a safe, 
conducive and healthy working environment that 
enables its employees to work without fear of 
prejudice and gender bias. It is the continuous 
endeavour of the management to create 
and provide an environment that is free from 
discrimination and sexual harassment.
	
	
The Company has laid down policy on prevention 
and prohibition of sexual harassment at the 
workplace. The policy provides for protection 
against sexual harassment of women at the 
workplace and for the prevention and redressal 
of such complaints. Company conducts 
awareness sessions to sensitise employees 
about the policy.
	
	
It has a vigorous mechanism in place to redress 
complaints reported under it and has constituted 
an Internal Complaints Committee (‚ÄúICC‚Äù) at 
all the locations where there are more than 10 
women employees, to address the complaints 
for sexual harassment.
	
	
During the year under review, no complaint of 
sexual harassment has been received.
	
Code of Conduct
	
	
The Board of Directors has laid down a ‚ÄòCode of 
Conduct‚Äô (the ‚ÄúCode‚Äù) for all the Board members 
and the senior management of the Company 
and this Code is posted on the website of the 
Company. An annual declaration is obtained 
from every person covered by the Code.
	
	
Pursuant to SEBI (Prohibition of Insider Trading) 
Regulations, 2015 in order to regulate, monitor 
and report trading by insiders as also for 
ensuring fair disclosure of un-published price 
sensitive information, the Company has put in 
place a comprehensive ‚ÄúCode of Conduct for 
prevention of insider trading‚Äù and ‚ÄúAjanta‚Äôs Code 
of Practices & Procedures for Fair Disclosure of 
Unpublished Price Sensitive Information‚Äù.
	
	
The data management and monitoring of insider 
trading is done through ESSCOM portal. The 
Company has also put in place a Structured 
Digital Database for monitoring the sharing of 
unpublished price sensitive information.
	
	
Details of these Codes are given in the Corporate 
Governance Report.
	
Human Resource, Health & Safety
	
	
Human Resources are invaluable assets and the 
topmost priority for the Human Resource function 
is to provide a work environment which is safe, 
diverse, inclusive and full of growth opportunities. 
It invests in their training and professional 
development to equip them with the necessary 
skills, domain expertise and latest technology in 
line with the business strategy.
	
	
Your Directors would like to take this opportunity 
to express their gratitude and appreciation 
for the passion, dedication and commitment 
of the Ajantaites and look forward to their 
continued contribution.
Company once again 
recognised as a ‚ÄúGreat 
Place to Work‚Äù
	
Managerial Remuneration and 
Particulars of Employees
	
	
There were 7,844 permanent employees of the 
Company as of 31 March 2024. The information 
pursuant to Rule (1) of the Companies 
(Appointment and Remuneration of Managerial 
Personnel) Rules, 2014 is annexed to this report 
as ‚ÄúAnnexure D‚Äù.
	
	
Information pursuant to Rule 5(2) & 5(3) of the 
Companies (Appointment and Remuneration of 
Managerial Personnel) Rules, 2014 also forms part 
of this report pursuant to Section 136(1) of the Act. 
Any shareholder interested in obtaining a copy of 
the same may write to the Company Secretary at 
the registered office address of the Company.
Annual Report 2023-24
36
37
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
	
Conservation of Energy, Technology 
Absorption, Foreign Exchange Earnings & 
Outgo
	
	
Pursuant to Section 134 of the Act read with 
Companies (Accounts) Rules, 2014, particulars 
relating to conservation of energy, technology 
absorption, foreign exchange earnings and 
outgo, are disclosed in ‚ÄúAnnexure E‚Äù.
	
Loans, Guarantees & Investments
	
	
Pursuant to Section 134(3)(g) of the Act, details of 
loans, guarantees and investments are disclosed 
in Notes to Financial Statements.
	
Other Disclosures
	
	
During the year under review:
	
[
There was no amount proposed to be 
transferred to the Reserves;
	
[
There were no changes in the nature of 
business of the Company;
	
[
There were no agreements entered 
into during the year which comes within 
the purview of Regulation 30A of the 
Listing Regulations;
	
[
Company issued and allotted equity 
shares as per its Stock Option Scheme and 
there was no instance wherein it failed to 
implement any corporate action within the 
statutory time limit;
	
[
The Company did not accept any deposit 
within the meaning of Sections 73 and 
74 of the Act read with the Companies 
(Acceptance of Deposits) Rules, 2014 and 
accordingly no amount on account of 
principal or interest on public deposits was 
outstanding as on 31 March 2024;
	
[
No provision of money has been made for 
the purchase of its own shares by employees 
or by trustee for the benefit of employees;
	
[
There were no Suspension of Company‚Äôs 
securities;
	
[
There were no remuneration or commission 
received by Managing Director/Whole-Time 
Director from subsidiaries;
	
[
The Company has not issued shares 
with differential voting rights and sweat 
equity shares;
	
[
The Company does not have any defaults in 
loan payments and as such question of one 
time settlement does not arise;
	
[
There were no significant or material 
orders passed by the regulators or courts 
or tribunals which could impact the going 
concern status of the Company and its 
future operations;
	
[
There were no material changes and 
commitments which occurred after the 
close of the year till the date of this report, 
which may affect the financial position of 
the Company; 
	
[
There was no application or proceedings 
made under the Indian Bankruptcy 
Code, 2016.
	
Directors‚Äô Responsibility Statement
	
	
The financial statements are prepared in 
accordance with the Indian Accounting 
Standards (Ind AS) under the historical cost 
convention on accrual basis except for certain 
financial instruments, which are measured at 
fair values, the provisions of the Companies 
Act, 2013 (to the extent notified) and guidelines 
issued by SEBI.
	
	
To the best of their knowledge and belief and 
according to the information and explanations 
obtained by them and pursuant to Section 134 
of the Act (including any statutory modification(s) 
and/or re-enactment(s) thereof for the time 
being in force), your Directors confirm:
	
	
a)	
that in the preparation of the annual 
accounts for the year ended 31 March 
2024, the applicable Accounting Standards 
have been followed along with proper 
explanation relating to material departures, 
if any;
	
	
b)	
that they had selected accounting policies 
and applied them consistently and made 
judgements and estimates that were 
reasonable and prudent so as to give a true 
and fair view of the state of affairs of the 
Company at the end of the financial year 
ended 31 March 2024 and of the profit of 
the Company for the period;
	
	
c)	
that proper and sufficient care has been 
taken for the maintenance of adequate 
accounting records in accordance with the 
provisions of the Act for safeguarding the 
Directors‚Äô Report
assets of the Company and for preventing 
and detecting fraud and other irregularities;
	
	
d)	
that the annual accounts/financial 
statements have been prepared on a going 
concern basis;
	
	
e)	
that proper internal financial controls were 
in place and that the financial controls were 
adequate and were operating effectively;
	
	
f)	
that they had devised proper systems to 
ensure compliance with the provisions of all 
applicable laws and that such systems were 
adequate and operating effectively.
	
Green Initiative
	
	
The MCA had undertaken the Green Initiative in 
Corporate Governance by allowing paperless 
compliances by companies through electronic 
mode. We request all the shareholders to support 
the ‚ÄòGreen Initiative‚Äô of the Ministry of Corporate 
Affairs and the Company‚Äôs continuance towards 
greener environment by enabling the service of the 
Annual Report, AGM Notice and other documents 
electronically to your e-mail address registered 
with your Depository Participant/ Registrar and 
Share Transfer Agent. The Company appeals to 
you, its Shareholders, who are yet to register the 
e-mail addresses that they take necessary steps 
for registering the same so that you can also 
become a part of the initiative and contribute 
towards a greener environment.
	
Gratitude & Acknowledgements
	
	
Your Directors place on record earnest 
appreciation for the contribution made by 
each and every Ajantaite during the year 
under review. Company‚Äôs consistent growth was 
made possible by their hard work, solidarity, 
cooperation and dedication. The Directors also 
wish to express their gratitude to the Investors 
for the confidence and faith that they continued 
to repose in the Company. Board takes this 
opportunity to thank all shareholders, analysts, 
business partners, government and regulatory 
authorities, financial institutions, banks, 
distributors, suppliers, business associates, 
medical professionals and customers for their 
continued guidance, encouragement and 
splendid support.
For and on Behalf of the Board of Directors
Mannalal B. Agrawal
Chairman
Mumbai, 02 May 2024 	
DIN: 00073828
Annual Report 2023-24
38
39
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
[Statement containing salient features of the financial statement of subsidiaries/ associate companies/ 
joint ventures (Pursuant to first proviso to sub-section (3) of Section 129 read with rule 5 of companies 
(Accounts) Rules, 2014)]
Part "A": Subsidiaries
1
Sr. No. 
1
2
3
4
2
Name of the Subsidiary
Ajanta Pharma 
(Mauritius) Limited 
(Consolidated)
Ajanta Pharma 
Philippines Inc. 
Ajanta Pharma 
USA Inc.
Ajanta Pharma 
Nigeria Ltd.
3
Reporting period for the subsidiary concerned, if 
different from the holding company's reporting period
31 March 2024
31 March 2024
31 March 2024
31 March 2024
4
Reporting currency for the subsidiary
MUR
PHP
USD
NN
5
Reporting exchange rate as on the last date of 
the relevant financial year in the case of foreign 
subsidiaries Rupee equivalent of 1 unit of foreign 
currency as at 31 March 2024 (H)
1.80
1.48
83.40
0.06
6
Share Capital
9.44
1.38
6.07
1.37
7
Reserves & Surplus
78.87
80.28
122.95
(1.49)
8
Total Assets
89.30
156.30
1,091.20
0.12
9
Total Liabilities (excluding Share Capital and  
Reserves & Surplus)
0.99
74.63
962.18
0.24
10
Investments
-
-
-
-
11
Turnover
60.77
264.13
944.27
-
12
Profit before taxation
(17.73)
25.23
32.62
(0.00)
13
Provision for taxation
0.03
6.25
7.73
-
14
Profit after taxation
(17.76)
18.99
24.89
(0.00)
15
Proposed Dividend
-
-
-
-
16
% of shareholding
100%
100%
100%
100%
Part "B": Associates and Joint Ventures: None
	
For and on behalf of Board of Directors of Ajanta Pharma Limited
	
Yogesh M. Agrawal 	
Rajesh M. Agrawal
	
Managing Director 	
Joint Managing Director
	
DIN: 00073673 	
DIN: 00302467
	
Arvind K. Agrawal 	
Gaurang C. Shah
	
Chief Financial Officer	
Company Secretary
Mumbai, 02 May 2024	
	
FCS No. 6696
Annexure ‚ÄúA‚Äù ‚Äì AOC ‚Äì 1
Annexure ‚ÄúB‚Äù ‚Äì Report on CSR
[Pursuant to Section 134(3)(o) of the Companies Act, 2013 and Rule 9 of the Companies (Corporate Social 
Responsibility) Rules, 2014]
1.	
Brief Outline on CSR Policy of the Company:
	
Corporate Social Responsibility (CSR) at Ajanta Pharma Limited stems from the ideology of providing sustainable 
value to the society in which the Company operates. It lays emphasis on contributing in the fields of healthcare, 
education, reducing inequalities, promotion of sports and other areas prescribed under schedule VII of the 
Companies Act, 2013, for development & upliftment of the underprivileged and economically backward groups.
2.	
Composition of the CSR Committee:
#
Name of Director
Designation/Nature of 
Directorship
Number of meetings of CSR 
Committee held during the year
Number of meetings of CSR Committee 
attended during the year
a)
Mr. Mannalal B. Agrawal
Chairman
4
4
b)
Mr. Chandrakant M. Khetan
Member
4
4
c)
Mr. Yogesh M. Agrawal
Member
4
4
d)
Mr. Madhusudan B. Agrawal
Member
4
3
3.	
Provide the web-link where composition of CSR Committee, CSR policy and CSR projects approved 
by the Board are disclosed on the website of the Company.
#
Particulars
Weblink
a)
CSR Committee
https://ajantapharma.com/ajanta/Investors/board_committees
b)
CSR Policy
https://ajantapharma.com//images/CSRPolicy2021.pdf
c)
CSR Projects
https://ajantapharma.com//images/Annual-Action-Plan-2025.pdf
4.	
Provide the details of Impact Assessment of CSR Projects carried out in pursuance of Sub-Rule (3) 
of Rule 8 of the Companies (Corporate Social Responsibility Policy) Rules, 2014, if applicable:
	
Impact assessment of the qualifying projects will be done in FY 2025.
5.	
Details of the amount available for set off in pursuance of Sub-Rule (3) of Rule 7 of the Companies 
(Corporate Social Responsibility Policy) Rules, 2014 and amount required for set off for the Financial 
Year, if any:
	
Company has been consistently spending more than the CSR budget. However, it is not claiming any set off of 
excess amount spent.
6.	
Average Net Profit of the Company as per Section 135(5): H¬†818.76 cr.
7.	
(a)	 Two percent of average net profit of the Company as per Section 135(5): H¬†16.38 cr.
	
(b)	 Surplus arising out of the CSR projects or programmes or activities of the previous financial 
years: Nil
	
(c)	 Amount required to be set off for the financial year, if any: None
	
(d)	 Total CSR obligation for the financial year (7a+7b-7c): H¬†16.38 cr.
8.	
(a)	 CSR amount spent or unspent for the financial year:
	
	
Total amount spent on CSR during the year was H¬†17.34 cr. and was more than CSR obligation of the Company. 
Hence there was no unspent amount for the year.
	
(b)	 Details of CSR amount spent against ongoing projects for the financial year: N.A.
Annual Report 2023-24
40
41
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
	
(c)	 Details of CSR amount spent against other than ongoing projects for the financial year:
1
2
3
4
5
6
Sr. 
No.
Name of the Project/Activity
Item from 
Schedule 
VII to the 
Act
Local Area (Yes/No) 
State/District
Amount spent 
for the project  
(J¬†in cr.)
Mode of Implementation ‚Äì Through Implementing 
Agency name
a)
Eradicating hunger, poverty, 
malnutrition, promoting 
healthcare
(i)
1.	 Maharashtra  
(*35 districts)
2.	 Tamil Nadu 
(Chennai)
3.	 Gujarat  
(Valsad)
4.	 West Bengal 
(Birbhum) 
5.	 New Delhi
7.27
Ajanta Foundation (CSR00002155), 
Samta Foundation (CSR00002029), 
Mamta Foundation (CSR00002657), 
Manisha Y Agrawal Foundation (CSR00021696),
Anvi Medical and Education (CSR00004174)
b)
Promoting education, 
including special education 
& employment enhancing 
vocation skills especially 
among children, women, 
elderly & the differently 
abled and livelihood 
enhancement projects
(ii)
8.50
Ajanta Foundation (CSR00002155), 
Samta Foundation (CSR00002029),
Prakashchand Jain Bahuuddeshiya Sanstha 
(CSR00009230), 
Mamta Foundation (CSR00002657), 
Manisha Y Agrawal Foundation (CSR00021696), 
Sai Disha Samajik Vikas Sanstha 
(CSR00032944),
Shirpur Education Society (CSR00013815), 
Shiva Trust Aurangabad (CSR00012532), 
R.C. Patel Educational Trust, Shirpur 
(CSR00013817), 
Shree Gajanan Maharaj Bahuuddheshiya 
Sanstha (CSR00047405), 
Krea University (CSR00012893), 
Resourceful Education Foundation 
(CSR00004174)
c)
Promoting gender equality, 
empowering women, 
setting up homes & hostels 
for women and orphans; 
setting up old age homes; 
reducing inequalities faced 
by backward groups 
(iii)
1.25
Mamta Foundation (CSR00002657),
Kalawati Devi Memorial Charitable 
(CSR00035323), 
Manisha Y Agrawal Foundation (CSR00021696),
Birbhum Welfare Society (CSR000233346)
Lokhit Media Sangh (CSR00051836)
Republican Pratisthan (CSR00062240)
Shrimad Rajchandra Educational Trust 
(CSR00003298)
d)
Ensuring environment 
sustainability, ecological 
balance, protection of flora 
and fauna, animal welfare, 
agroforestry, conservation 
of natural resources and 
maintaining quality of soil, 
air and water 
(iv)
0.12
Bharuch Citizen Council Trust
e)
Training to promote sports 
& Olympic sports
(v)
0.20
Foundation for Promotion of Sports & Games 
(CSR00001100)
	
* Aurangabad, Ahmednagar, Akola, Amravati, Beed, Bhandara, Buldhana, Chandrapur, Dhule, Gadchiroli, Gondia, Hingoli, Jalgaon, 
Jalna, Kolhapur, Latur, Mumbai, Nagpur, Nanded, Nandurbar, Nashik, Osmanabad, Palghar, Parbhani, Pune, Raigad, Ratnagiri, Sangli, 
Satara, Sindhudurg, Solapur, Thane, Wardha, Washim & Yavatmal
	
(d)	 Amount spent in Administrative Overheads: Nil
	
(e)	 Amount spent on Impact Assessment, if applicable: Nil
	
(f)	 Total amount spent for the Financial Year (8b+8c+8d+8e): H¬†17.34 cr.
Annexure ‚ÄúB‚Äù ‚Äì Report on CSR
	
(g)	 Excess amount for set off, if any:
Sr.
No.
Particular
Amount 
(K¬†in Crore)
A.
Two percent of average net profit of the Company as per Section 135(5)
16.38
B.
Total amount spent for the Financial Year
17.34
C.
Excess amount spent for the financial year [(ii)-(i)]
0.96
D.
Surplus arising out of the CSR projects or programmes or activities of the previous financial years,  
if any
0.00
E.
Amount available for set off in succeeding financial years [(iii)-(iv)]
0.96
9.	
(a)	 Details of Unspent CSR amount for the preceding three financial years: None
	
(b)	 Details of CSR amount spent in the financial year for ongoing projects of the preceding 
financial Year(s):
	
	
No project qualifies as ongoing project in the preceding Financial Year.
10.	 In case of creation or acquisition of capital asset, furnish the details relating to the asset so 
created or acquired through CSR spent in the financial year: Not Applicable
11.	 Specify the reason(s), if the Company has failed to spend two per cent of the average net profit as 
per Section 135(5): Not Applicable
Ajanta Pharma Limited	
For and on behalf of the Corporate Social Responsibility Committee of 
	
Ajanta Pharma Limited
Yogesh M. Agrawal	
Mannalal B. Agrawal
Managing Director 	
Chairman of the Corporate Social Responsibility Committee
DIN 00073673	
DIN 00073828
Mumbai, 02 May 2024
Annual Report 2023-24
42
43
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Form No. MR-3 
For The Financial Year Ended 31 March 2024
[Pursuant to Section 204(1) of the Companies Act, 2013 
and Rule No. 9 of the Companies (Appointment and 
Remuneration of Managerial Personnel) Rules, 2014]
To,
The Members,
Ajanta Pharma Limited
We have conducted the secretarial audit of the compliance 
of applicable statutory provisions and the adherence 
to good corporate practices by Ajanta Pharma Limited 
(CIN: L24230MH1979PLC022059) (hereinafter called ‚Äúthe 
Company‚Äù).
The Secretarial Audit was conducted in a manner 
that provided us a reasonable basis for evaluating 
the corporate conducts/statutory compliances and 
expressing our opinion thereon.
Based on our verification of the Company's statutory 
registers, books, papers, minute books, forms and returns 
filed and other records maintained by the Company and 
the information provided by the Company, its officers, 
agents and authorised representatives during the conduct 
of secretarial audit, we hereby report that in our opinion, 
the Company has, during the audit period covering the 
financial year ended on 31 March 2024 complied with the 
statutory provisions listed hereunder and also that the 
Company has followed proper Board-processes and has 
required compliance mechanism in place to the extent, in 
the manner and subject to the reporting made hereinafter:
We have examined the books, papers, minute books, 
forms and returns filed and other records maintained by 
the Company for the financial year ended on 31 March 
2024 according to the provisions of:
(i)	
The Companies Act, 2013 (the Act) and the Rules 
made thereunder;
(ii)	
The Securities Contracts (Regulation) Act, 1956 
(‚ÄòSCRA‚Äô) and the Rules made thereunder;
(iii)	
The Depositories Act, 1996 and the Regulations and 
Bye-laws framed thereunder;
(iv)	 Foreign Exchange Management Act, 1999 and 
the Rules and Regulations made thereunder for 
compliance to the extent of Foreign Direct Investment, 
Overseas Direct Investment and External Commercial 
Borrowings, as applicable;
Annexure ‚ÄúC‚Äù ‚Äì Secretarial Audit Report
(v)	
The following Regulations and Guidelines prescribed 
under the Securities and Exchange Board of India Act, 
1992 (‚ÄòSEBI Act‚Äô) as amended from time to time: -
	
(a)	
The Securities and Exchange Board of India 
(Substantial Acquisition of Shares and Takeovers) 
Regulations, 2011;
	
(b)	
The Securities and Exchange Board of India 
(Prohibition of Insider Trading) Regulations, 2015;
	
(c)	
The Securities and Exchange Board of India 
(Issue of Capital and Disclosure Requirements) 
Regulations, 2018;
	
(d)	
The Securities and Exchange Board of India 
(Share-Based Employee Benefits and Sweat 
Equity) Regulations, 2021;
	
(e)	
The Securities and Exchange Board of India 
(Registrars to an Issue and Share Transfer Agents) 
Regulations, 1993 regarding the Companies 
Act and dealing with client ‚Äì Not Applicable to 
the Company;
	
(f)	
The Securities and Exchange Board of India 
(Buyback of Securities) Regulations, 2018;
	
(g)	 The Securities and Exchange Board of India 
(Delisting of Equity Shares) Regulations, 2021 - 
Not applicable to the Company;
	
(h)	
The Securities and Exchange Board of India 
(Issue and Listing of Non-Convertible Securities) 
Regulations, 2021 ‚Äì Not applicable to 
the Company;
	
(i)	
The Securities and Exchange Board of India 
(Depositories and Participants) Regulations, 2018.
(vi)	 Other specific business/industry related laws 
applicable to the Company:
	
The Company has complied with specific applicable 
laws, rules, regulations and guidelines viz. Drugs and 
Cosmetics Act, 1940 and related Rules; The Prevention 
of Food Adulteration Act, 1954; The Pharmacy Act, 
1948; Food and Safety Standards Act, 2006; The Drugs 
(Control) Act, 1950; Food and Drug Administration 
licensing terms and conditions; Legal Metrology Act, 
2009 and the applicable Rules and other applicable 
general laws, rules, regulations and guidelines.
We have also examined compliance with the applicable 
clauses of the following:
(i)	
Secretarial Standards with regard to Meeting of Board 
of Directors (SS-1) and General Meetings (SS-2) issued 
by The Institute of Company Secretaries of India; and
(ii)	
SEBI 
(Listing 
Obligations 
and 
Disclosures 
Requirements) Regulations, 2015.
During the period under review the Company has 
complied with the provisions of the Act, Rules, Regulations, 
Guidelines, Standards, etc. mentioned above.
We further report that
The Board of Directors of the Company is duly constituted 
with proper balance of Executive Directors, Non-Executive 
Directors and Independent Directors. No changes in the 
composition of the Board of Directors took place during 
the period under review.
Adequate notice is given to all directors to schedule the 
Board Meetings, agenda and detailed notes on agenda 
were sent at least seven days in advance and a system 
exists for seeking and obtaining further information and 
clarifications on the agenda items before the meeting and 
for a meaningful participation at the meeting.
The minutes of the Board Meetings and Committee 
Meetings have not identified any dissent by members of 
the Board/Committee of the Board, hence we have no 
reason to believe that the decisions by the Board were 
not approved by all the directors present. The Minutes of 
the Board Meetings and Committee Meetings were duly 
approved at the meeting by the Chairman of the Meeting.
We further report that there are adequate systems and 
processes in the Company commensurate with its size 
and operations, to monitor and ensure compliance with 
applicable laws, rules, regulations and guidelines. As 
informed, the Company has responded appropriately 
to communication received from various statutory / 
regulatory authorities including initiating actions for 
corrective measures, wherever found necessary.
We further report that during the audit period the following 
events/actions have taken place, having a major bearing 
on the Company‚Äôs affairs in pursuance of the above 
referred laws, rules, regulations, guidelines and standards:
1.	
Approval of the Shareholders of the Company was 
obtained at the Annual General Meeting held on 
18 July 2023 for the amendment of the Object Clause 
of the Memorandum of Association of the Company.
2.	
The Company has extinguished 22,10,500 fully 
paid-up Equity Shares of H¬†2 each on 19 April 2023 
in compliance with the provisions of the Companies 
Act, 2013 and the Rules made thereunder and 
Regulations 11 of The Securities and Exchange Board 
of India (Buyback of Securities) Regulations, 2018.
3.	
Allotment of 1,000 Equity Shares of H¬†2/- each under 
Ajanta Pharma Share-Based Incentive Plan, 2019.
4.	
During the financial year, the Board of Directors of the 
Company has withdrawn/suspended the Employees 
Stock Option Scheme, 2011 as all the options granted 
under the said scheme had been exercised and no 
options were outstanding.
Alwyn D‚ÄôSouza & Co.
Company Secretaries

Alwyn D‚ÄôSouza
FCS 5559

Proprietor
Place: Mumbai
Certificate of Practice No. 5137
Date: 02 May 2024
UDIN: F005559F000318366
Note: This report is to be read with our letter of even date 
which is annexed as Annexure A and forms an integral part 
of this report.
Annual Report 2023-24
44
45
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Annexure ‚ÄúC‚Äù ‚Äì Secretarial Audit Report
Annexure A
To,
The Members,
Ajanta Pharma Limited
Our Secretarial Audit Report of even date is to be read along with this letter.
1.	
The compliance of provisions of all laws, rules, regulations, standards applicable to Ajanta Pharma Limited 
(hereinafter called ‚Äòthe Company‚Äô) is the responsibility of the management of the Company. Our examination was 
limited to the verification of records and procedures on test check basis for the purpose of issue of the Secretarial 
Audit Report.
2.	
Maintenance of secretarial and other records of applicable laws is the responsibility of the management of 
the Company. Our responsibility is to issue Secretarial Audit Report, based on the audit of the relevant records 
maintained and furnished to us by the Company, along with explanations where so required.
3.	
We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about 
the correctness of the contents of the secretarial and other legal records, legal compliance mechanism and 
corporate conduct. Further part of the verification was done on the basis of electronic data provided to us by 
the Company and on test check basis to ensure that correct facts as reflected in secretarial and other records 
produced to us. We believe that the processes and practices we followed, provides a reasonable basis for our 
opinion for the purpose of issue of the Secretarial Audit Report.
4.	
We have not verified the correctness and appropriateness of financial records and Books of Account of 
the Company.
5.	
Wherever required, we have obtained the management representation about list of applicable laws, compliance 
of laws, rules and regulations and major events during the audit period.
6.	
The Secretarial Audit Report is neither an assurance as to the future viability of the Company nor of the efficacy 
or effectiveness with which the management has conducted the affairs of the Company.
Alwyn D‚ÄôSouza & Co.
Company Secretaries

Alwyn D‚ÄôSouza
FCS.5559

Proprietor
Place: Mumbai
Certificate of Practice No. 5137
Date: 02 May 2024
UDIN: F005559F000318366
Details pursuant to Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014
1
Name & Designation of Director & KMP
Ratio of the remuneration of each Director 
to the median remuneration of the 
employees of the Company for the FY 2024
% increase/(decrease) 
in remuneration in the FY 2024
(i)
Mr. Mannalal B. Agrawal
2:1
10.29%
(ii)
Mr. Madhusudan B. Agrawal
86:1
16.10%
(iii)
Mr. Yogesh M. Agrawal
444:1
38.16%@
(iv)
Mr. Rajesh M. Agrawal
444:1
38.16%@
(v)
Mr. Chandrakant M. Khetan
3:1
15.12%
(vi)
Mr. K H. Viswanathan
2:1
16.62%
(vii)
Mr. Prabhakar Dalal
2:1
17.46%
(viii)
Dr. Anjana Grewal
2:1
18.08%
(ix)
Mr. Arvind K. Agrawal, Chief Financial Officer
38:1
12.85%
(x)
Mr. Gaurang C. Shah, Company Secretary
20:1
10.27%
2
The Percentage increase in the median remuneration of 
employees in the financial year
14.09%
3
The number of permanent employees on the rolls of 
company
7,844
4
Average percentile increase already made in the salaries 
of employees other than the managerial personnel 
in the last financial year and its comparison with the 
percentile increase in the managerial remuneration 
and justification thereof and point out if there are 
any exceptional circumstances for increase in the 
managerial remuneration.
Average increase in remuneration of employee for the FY 2024 was 
14.09%. As against that, managerial remuneration has increased 
17.09%. Increase in median remuneration is little higher than overall 
increase in the remuneration, as it includes commission of MD & JMD 
which is linked to profitability. 
6
Affirmation that the remuneration is as per the 
remuneration policy of the Company.
Yes
Notes:
* Includes sitting fees and commission paid to Non-Executive Directors.
@ Includes Commission
Annexure ‚ÄúD‚Äù ‚Äì Median Remuneration
Annual Report 2023-24
46
47
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
A)	 Conservation of the Energy
1.	
Steps taken for conservation of energy & reducing CO2:
	
[
Increased Renewable Energy consumption by 
installing 8.8 MW solar plant
	
[
Implemented project to collect & recycle solvent 
waste generated from QC
	
[
All hazardous waste generated from Guwahati & 
Dahej plants now goes for pre-processing/Co-
processing in cement industry,
	
[
Energy recycling project completed for WFI water 
stream at Guwahati plant
	
[
Retrofitting with EC fan in place of conventional 
Fan Motor in HVAC at Dahej
	
[
Implementation 
of 
new 
technologies, 
harmonisation of best energy conservation 
practices at all sites
	
[
All new procurement and modification of 
any project, energy saving considered as a 
prime objective
	
[
Installation of energy monitoring system at 
all locations
	
[
AFD panel installation for Chillers
	
[
Installation of chiller for Auto tube cleaning systems
	
[
Installation of boiler for Steam recovery systems
	
[
Installation of high-capacity Dehumidifiers for 
Steam coil and thyristor panel
	
[
Installation of heavy capacity for AHU Steam coil
	
[
Purifier system waste water recovery and use for 
change room
Annexure ‚ÄúE‚Äù ‚Äì Conservation of Energy, 
Technology Absorption etc.
2.	
Steps taken by the Company for utilising 
alternate sources of energy:
	
Reduced conventional energy and enhanced use 
of green, clean and renewable energy for reduced 
environmental impact and increased sustainability. 
Solar plants added at manufacturing sites and other 
locations for captive use of green power.
3.	
Capital Investment on energy conservation 
equipment:
	
Company has invested significantly on energy 
conservation projects across all units.
B)	 Technology Absorption
1.	
Research and Development (R&D) initiates
	
[
Development of Preservative free Ophthalmic 
products in novel preservative free bottles.
	
[
Development and launch of non-comedogenic 
dermatological formulations.
	
[
Utilisation of Novel Tangential drug layering 
technology for development of new products.
	
[
Development of Oral Solid Dosage (OSD) form 
products by utilisation combination of two 
processing steps, which offer advantage of less 
processing time with improved uniform quality.
	
[
Continued previous year‚Äôs efforts of development 
of tablets for conversion from non‚Äëaqueous to 
aqueous coating procedure.
	
[
Development of complex generic products for 
ANDA filings (US market).
	
[
Development of robust and cost-effective 
formulations for various therapeutic category.
	
[
Development & launch of product for¬†treatment of 
pain caused due to nerve damage (neuropathic 
pain).
	
[
In-house Synthesis of Process impurities, 
Pharmacopeia impurities, chiral impurities 
and Degradation impurities to fulfil internal 
requirement of FD & ADL Department. 
	
[
Development of cost effective & efficient 
FTNIR analytical methodology for existing 
commercialised product of ANDA, ROW & 
Domestic market.
2.	
Benefits derived as a result of R&D
	
[
7 New ANDAs filed with USFDA
	
[
Received approvals for 6 ANDAs from USFDA
	
[
Developed and stabilised 26 new products for 
Branded Generics for Domestic & ROW market
	
[
Total 15 APIs successfully developed for 
Domestic, ROW & ANDA market
	
[
6 APIs charged for stability study, 5 scaled up for 
commercial production.
	
[
10 Dossier filed to DCG(I) for Domestic Market
	
[
DCG(I) Approval for 6 products received including 
3 products approvals for 1st time in country as 
detailed below:
 ‚àí
2 approvals for 1st time in country for products 
having novel triple drug combination of 
antihypertensive therapeutic category.
 ‚àí
1 approval for 1st time in country for new 
dosage form (Jelly) for drug of 1 therapeutic 
category.
	
[
Total 516 product Dossier filed for export 
registration in ROW market
	
[
Total 469 product registration for ROW 
market received
	
[
1 patent applications made for novel 
compositions for treatment of hypertension
	
[
58 no. of FTNIR method developed & 30 
no. of method implemented at mfg. site for 
commercial utilisation
	
[
Under Life Cycle Management (LCM) activity, 
18 FTNIR method developed & 17 method 
implemented at mfg. site
3.	
In case of imported technology: No import of 
technology during the year.
4.	
Expenditure on R&D
Particulars
(H¬†in Crore) 
Capital Expenditure
4.83
Recurring Expenditure
207.73
Total
212.56
Total R&D expenditure as a percentage 
of total consolidated turnover
5.05%
C)	 Foreign Exchange Earnings and Outgo
	
1.	
Activities relating to initiatives taken for increasing 
exports are discussed in Management Discussion 
& Analysis in this annual report.
	
2.	
Total foreign exchange earned in terms of actual 
inflow as well as outgo in terms of actual outflow 
during the year:
	
[
Earnings in foreign currency H¬†2,386.47 cr. 
(previous year H¬†2,242.02 cr.)
	
[
Outgo in foreign currency H¬† 398.83¬† cr. 
(previous year H¬†429.31 cr.).
Reduction in energy 
consumption 
and cost
Reduction in per 
unit production cost
Reduction of 
CO2 emission by 
7,066 Mt per annum
Reduction in water 
use per unit of 
production
Reduction of 
Scope 1 & Scope 2 
emission
Recycle of 40 KLD 
condensate
Reduction in boiler 
fuel consumption
Ensuring zero 
discharge of 
hazardous waste 
from two units
Impact of the above measures:
Annual Report 2023-24
48
49
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Annual Report 2023-24
50
51
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Report on Corporate Governance
	
Company‚Äôs Philosophy on Corporate 
Governance
	
	
Corporate Governance is key for creating and 
maximising the stakeholder value and the 
Company is committed to sound corporate 
practices founded on integrity, fairness, 
transparency, accountability and responsibility. 
The Company believes in sustainable growth 
that emanates from the top leadership and 
percolates down through the organisation to 
the various stakeholders, which is reflected in its 
sound corporate governance structure, business 
practices and operational efficiency.
	
	
Over the years, we have strengthened our 
governance practices, and it is our endeavour 
to have the best-in-class governance standards 
and go beyond the regulatory requirements.
	
Board of Directors
	
	
A.	 Composition and Category of 
Directors
	
	
a)	
As on 31 March 2024, the Board comprised of 
8 Directors, out of which 4 are from Promoter 
group and 4 are Independent Directors 
(‚ÄúIDs‚Äù) including one Woman Director. No 
director is having permanent Board seat.
	
	
b)	
No charter document gives additional 
rights such as board nomination rights or 
transaction related rights or control-based 
rights to the non-controlling shareholders or 
give disproportionate voting power (in any 
form) to the controlling shareholders.
	
	
c)	
Composition of Directors, their other directorships & committee memberships and their attendance in 
Board/Annual General Meeting (‚ÄúAGM‚Äù) during the financial year, are given below:
Name of the Director
Category
Attendance
Other 
Directorships
Committee  
Membership
Other entities in which 
person acting as Director
Category of 
other entities 
Directorship
Board
AGM
Member
Chairman
Mr. Mannalal B. Agrawal
P, NE
5
Yes
-
1
1
-
-
Mr. Madhusudan B. 
Agrawal
P, E
4
Yes
3
0
0
	
[ Inspira Infra 
(Aurangabad) Limited
Managing 
Director
	
[ Inspira 
Projects Limited
Director
	
[ Samta Mines and 
Minerals Limited
Director
Mr. Yogesh M. Agrawal
P, E
5
Yes
-
0
0
-
-
Mr. Rajesh M. Agrawal
P, E
5
Yes
1
1
0
	
[ SBFC Finance Limited Director
Mr. Chandrakant M. 
Khetan
ID
5
Yes
2
0
1
	
[ Entremonde 
Polycoaters Limited 
Managing 
Director
	
[ DGP 
Securities Limited
Director
Mr. K. H. Viswanathan
ID
5
Yes
-
1
0
-
-
Mr. Prabhakar R. Dalal
ID
5
Yes
1
2
1
	
[ Poonawalla 
Fincorp Limited
Director
Dr. Anjana Grewal
ID
5
Yes
0
1
0
-
-
	
Notes:
	
i.	
P ‚Äì Promoter, E - Executive, NE ‚Äì Non-Executive, ID ‚Äì Independent;
	
ii.	
Mr. Mannalal B. Agrawal and Mr. Madhusudan B. Agrawal are brothers. Mr. Yogesh M. Agrawal and Mr. Rajesh M. Agrawal are sons 
of Mr. Mannalal B. Agrawal;
	
iii.	
For calculation of Committee memberships/Chairmanships, only Audit Committee and Stakeholders' Relationship Committee are 
reckoned;
	
iv.	
None of the Directors (a) hold membership in more than 10 public limited companies; (b) is member of more than 10 committees 
or chairperson of more than 5 committees across all the public companies in which he/she is a director;
	
v.	
For calculation of other Directorship/ Committee memberships/ Chairmanships - private companies, Section 8 companies and 
foreign companies are excluded.
	
	
d)	
The Board fulfils the criteria laid down 
under the Board‚Äôs ‚ÄúPolicy for determining 
qualifications of Directors‚Äù and ‚ÄúPolicy on 
diversity‚Äù. The Board has the repertoire of 
skills, attributes, experience, independence 
and knowledge to ensure its continued 
effectiveness. All the Directors have 
distinguished personality and have proven 
expertise in various fields. Executive 
Directors have the deep understanding, 
expertise and exemplary competencies 
of strategic thinking, business acumen, 
global business & economics, Stakeholder 
relationship, Technology & business 
transformation. The Non-Executive 
Director and Independent Directors are 
professionals with rich experience in 
management, corporate governance, 
finance, sales & marketing, accounts 
& finance, forex & risk management, 
sustainability, general administration and 
other required attributes.
	
	
e)	
Executive Directors provide strategic 
management of the Company‚Äôs businesses 
within the overall framework laid down by the 
Board and ensures business development 
and operational excellence in accordance 
with the set business objectives.
	
	
f)	
Non-Executive Directors & Independent 
Directors (IDs) play critical role in setting 
up Board processes, issues of strategy, 
reviewing performance, standards of 
conduct etc. IDs also bring independent 
judgement on Board decisions.
	
	
g)	
There are no Board cross linkages or any 
association with any business competitors, 
key suppliers or vendors.
	
	
h)	
All the Committees have a balanced and 
non‚Äëconflict mix of Directors.
The Key elements of Corporate Governance:
Ensure adherence to 
regulatory framework
Implementing best-in-class 
policies and processes
Detailed disclosures to Board 
for informed decisions
Contribute to the society 
through CSR & ESG initiatives
Board & KMP possessing 
repertoire of skills & expertise
Appropriate risk assessment 
and mitigation practices
Annual Report 2023-24
52
53
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
	
	
B.	
Board Meetings and Attendance
	
	
a)	
Board & Committee meetings are 
pre-scheduled and annual calendar of 
meetings is decided well in advance, 
to facilitate full attendance and active 
participation of Board members.
	
	
b)	
During the year, meetings were held 
physically and video conferencing 
arrangements for joining the meetings were 
made in accordance with the prescribed 
guidelines, for Directors who opted for it.
	
	
c)	
Company Secretary prepares agenda 
for the meetings in consultation with the 
Chairman and the Managing Director 
("MD"). Detailed agenda papers of Board 
and Committee Meetings are sent to all 
the Directors/Members at least one week 
in advance. At the Board Meeting, the MD & 
Joint MD apprises the Board on the overall 
performance of the Company, segment and 
geography wise performance and other 
important developments in the pharma 
industry and the Company. Agenda items 
which are unpublished and price sensitive, 
are circulated at a shorter notice.
	
	
d)	
Minutes of Board meetings of subsidiaries, 
Board Committees and other critical 
information & papers are made available 
to the Board for effective decision-making.
	
	
e)	
The Board also, inter-alia, reviews the 
strategy, business performance, regulatory 
changes, annual business plan & capital 
expenditure budgets, compliance reports, 
foreign exchange exposure, internal 
financial controls & financial reporting 
systems, HR & employment initiatives, 
quarterly/ half-yearly/ annual results, 
audit reports, important developments in 
subsidiaries etc.
	
	
f)	
There was no dissent from any Directors 
on any of the decisions of the Board 
or Committees.
	
	
g)	
Draft minutes of the Board & Committees are 
circulated to Directors within 15 days from 
the date of the meeting and suggestions, if 
any, are incorporated in the final document.
	
	
h)	
During the year, 5 Board Meetings were held 
on 05 May 2023, 27 July 2023, 31 October 
2023, 31 January 2024 and 5 March 2024.
	
	
C.	 Directors Retiring by Rotation
	
	
	
Pursuant to Regulation 36(3) of Listing 
Regulations and Secretarial Standards 
issued by the Institute of Company 
Secretaries of India, details of the 
Director retiring by rotation and seeking 
re-appointment is mentioned in the Annual 
General Meeting Notice, which forms part of 
the Annual Report.
	
	
D.	 Independent Directors & their 
Familiarisation
	
	
i.	
All the IDs have confirmed that they are 
independent of the management. Maximum 
tenure of IDs is in accordance with the Act.
	
	
ii.	
During the year under review, one 
separate meeting of IDs was held 
without management being present, on 
31 January 2024 which was attended by 
all the IDs. Mr. Chandrakant M. Khetan, lead 
Independent Director chaired the meeting.
	
	
iii.	
The IDs inter-alia reviewed performance 
of Non‚ÄëIndependent Directors, Chairman 
and Board as whole as also assessed the 
quality, quantity and timeliness of flow 
of information between the Company 
management and the Board.
	
	
iv.	
IDs also met the Statutory Auditors and 
Internal Auditor and discussed on key audit 
findings, controls, access to the information, 
management support, etc.
	
	
v.	
In order to enable the IDs take informed 
decision on various proposals placed in the 
meeting and for their effective involvement 
in board processes, in-house orientation/ 
familiarisation programmes are done 
for the IDs at each Board meeting. They 
are apprised of company‚Äôs businesses & 
segments, operating plans & budgets, 
important policies, risk management plan, 
regulatory updates etc.
	
	
vi.	
Details of such orientation programmes 
conducted for IDs are put on the website of 
the Company. The link can be accessed at: 
https://ajantapharma.com//images/DFP-
14-04-2023. Pdf.
Report on Corporate Governance
	
	
E.	
Performance evaluation of Board, 
Committees and Directors
	
	
i.	
The Company believes that the process of 
performance evaluation at the Board level 
is pivotal to its Board engagement and 
effectiveness. Nomination and Remuneration 
Committee of the Company empowers the 
Board to formulate a process for effective 
evaluation of the performance of individual 
directors, Committees of the Board and the 
Board as a whole pursuant to the provisions 
of the Act and Regulation 17 and Part D 
of Schedule II to the Listing Regulations. 
Board has set out criteria for performance 
evaluation of all the Directors, Board as a 
whole and Board committees, in accordance 
with the ‚ÄúPolicy for Evaluation of Directors‚Äù.
	
	
ii.	
Performance of Chairman was evaluated 
on parameters such as effective leadership, 
seeking participation from board members, 
maintaining critical balance of different 
views, monitoring effectiveness of Corporate 
Governance practices, guidance & counsel 
in critical matters, moderatorship, conduct 
of impartial discussions etc.
‚ÄúOutstanding‚Äù rating 
to Board, Individual 
Directors & Committees
	
	
iii.	
Performance of individual Directors was 
evaluated on the parameters such as devoting 
time, participation & contribution, upholding 
ethical standard of integrity & probity, 
safeguarding interest of all Stakeholders & 
managing conflict of interest, keeping abreast 
of Company affairs & external environment, 
domain knowledge, bringing individual 
judgement of Board decisions.
	
	
iv.	
Performance 
evaluation 
of 
Board 
and Board Committees was done on 
the basis of parameters such as its 
composition, discharge of functions, 
effectiveness & contribution, review of 
executive management performance, 
business acumen in strategic matters, 
setting tone of Corporate culture & 
values, providing leadership & direction, 
suggestion & recommendations to the 
Board, effectiveness in ensuring statutory 
compliances, risk management.
	
	
v.	
Board also assessed the fulfilment of the 
independence criteria as specified in 
Listing Regulations, by the IDs and their 
independence from the management.
	
	
vi.	
Performance evaluation done by the Board 
and IDs revealed ‚ÄúOutstanding‚Äù rating for 
the Board as a whole, Individual Directors 
and Board Committees.
	
	
F.	
Matrix setting out the core skills/ expertise/ competencies available with the Board of 
Directors
	
	
	
The Board comprises of Directors possessing repertoire of skills, expertise and competencies in various 
fields. Specific skills and attributes possessed by Board members are as under:
Skills
Mannalal 
Agrawal
Madhusudan 
Agrawal
Yogesh 
Agrawal
Rajesh 
Agrawal
Chandrakant 
Khetan
Prabhakar 
Dalal
K. H. 
Viswanathan
Dr. Anjana 
Grewal
Strategic thinking &  
business planning
ÔÉº
ÔÉº
ÔÉº
ÔÉº
ÔÉº
ÔÉº
ÔÉº
ÔÉº
Industry knowledge & expertise
ÔÉº
ÔÉº
ÔÉº
ÔÉº
General Management & 
administration
ÔÉº
ÔÉº
ÔÉº
ÔÉº
ÔÉº
ÔÉº
ÔÉº
ÔÉº
Sales & Marketing
ÔÉº
ÔÉº
ÔÉº
ÔÉº
Accounting & finance
ÔÉº
ÔÉº
ÔÉº
ÔÉº
ÔÉº
ÔÉº
ÔÉº
ÔÉº
Forex & Risk management
ÔÉº
ÔÉº
ÔÉº
ÔÉº
ÔÉº
ÔÉº
ÔÉº
ÔÉº
Sustainability
ÔÉº
ÔÉº
ÔÉº
ÔÉº
ÔÉº
ÔÉº
ÔÉº
ÔÉº
Corporate governance & 
regulation
ÔÉº
ÔÉº
ÔÉº
ÔÉº
ÔÉº
ÔÉº
ÔÉº
ÔÉº
Global business & economics
ÔÉº
ÔÉº
ÔÉº
ÔÉº
ÔÉº
ÔÉº
ÔÉº
ÔÉº
Stakeholder relationship & CSR
ÔÉº
ÔÉº
ÔÉº
ÔÉº
ÔÉº
ÔÉº
ÔÉº
ÔÉº
Technology & business 
transformation
ÔÉº
ÔÉº
Annual Report 2023-24
54
55
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
	
	
G.	 Code of Conduct
	
	
a)	
Company recognises that integrity at 
workplace and in business practices is 
critical and expects honest and ethical 
personal conduct, from the Directors and 
Senior management. It has laid down 
Code of Conduct for all Board Members 
& Senior Management Personnel (‚Äúthe 
Code‚Äù) which is posted on the website of 
the Company (https://ajantapharma.com 
//images/CodeofConductforDirectorsand 
SeniorManagement.pdf). The Code sets out 
guidelines for ethical conduct & avoiding 
conflict of interest.
	
	
b)	
All Board Members & Senior Management 
personnel affirm compliance with the Code 
on an annual basis and the declaration 
to that effect by the MD is attached to 
this report.
	
	
H. Prevention of Insider Trading
	
	
a)	
‚ÄòAjanta‚Äôs Code of Conduct for Insiders‚Äô 
(‚ÄúACCI‚Äù) and the ‚ÄòCode of Practices 
and Procedures for Fair Disclosure of 
Unpublished Price Sensitive Information‚Äô 
(‚ÄúCFD‚Äù) have been formulated and 
implemented in accordance with the SEBI 
(Prevention of Insider Trading) Regulations, 
2015 (‚ÄúPIT‚Äù). Company Secretary has 
been appointed as Compliance Officer 
for ensuring implementation of ACCI 
and CFD.
	
	
b)	
ACCI 
lays 
down 
obligations 
and 
responsibilities of designated persons, 
mechanism for preventing insider trading, 
handling of UPSI, disclosure of UPSI 
for legitimate purpose, prohibited and 
permitted transactions, consequences 
for violation etc. Company periodically 
educates designated persons about ACCI.
	
	
c)	
During the year, there has been due 
compliance with ACCI & CFD by all insiders 
and requisite disclosures were made to the 
Stock Exchanges. Company also maintains 
Structured Digital Database to ensure 
compliance with statutory requirements.
Fully Compliant with Insider 
Trading norms & disclosures
	
	
d)	
Company maintains adequate and effective 
system of internal controls and tool/
software to monitor trading in securities 
by the Insiders. The Audit Committee 
reviewed the systems for internal controls 
on ACCI and found to be adequate and 
operating effectively.
	
	
e)	
Pledge/de-pledge of shares by Promoters 
is disclosed to the Stock Exchange(s) timely.
Composition of Board Committees
(as on 31 March 2024)
Audit Committee
Nomination and Remuneration Committee
Stakeholders‚Äô Relationship Committee
‚ÄÇ Mr. Chandrakant M. Khetan (C)
‚ÄÇ Mr. Prabhakar R. Dalal (C)
‚ÄÇ Mr. Mannalal B. Agrawal (C)
‚ÄÇ Mr. Mannalal B. Agrawal (M)
‚ÄÇ Mr. Chandrakant M. Khetan (M) 
‚ÄÇ Mr. Rajesh M. Agrawal (M)
‚ÄÇ Mr. K. H. Viswanathan (M)
‚ÄÇ Mr. K. H. Viswanathan (M)
‚ÄÇ Dr. Anjana Grewal (M)
‚ÄÇ Mr. Prabhakar R. Dalal (M)
‚ÄÇ Dr. Anjana Grewal (M)
-
Corporate Social Responsibility Committee
Risk Management Committee
Executive Committee
‚ÄÇ Mr. Mannalal B. Agrawal (C)
‚ÄÇ Mr. Yogesh M. Agrawal (C)
‚ÄÇ Mr. Yogesh M. Agrawal (C)
‚ÄÇ Mr. Madhusudan B. Agrawal (M)
‚ÄÇ Mr. Rajesh M. Agrawal (M)
‚ÄÇ Mr. Madhusudan B. Agrawal (M)
‚ÄÇ Mr. Chandrakant M. Khetan (M)
‚ÄÇ Mr. K. H. Viswanathan (M)
‚ÄÇ Mr. Rajesh M. Agrawal (M)
‚ÄÇ Mr. Yogesh M. Agrawal (M)
‚ÄÇ Mr. Arvind Agrawal (M)
-
	
Audit Committee
	
	
a)	
The Company has a qualified and 
independent Audit Committee which has 
been formed in pursuance of Regulation 18 
of the Listing Regulations and Section 177 
of the Act.
	
	
b)	
The primary objective of the Committee 
is to monitor and provide effective 
supervision of the management‚Äôs financial 
reporting process to ensure accurate and 
timely disclosures, with the highest level 
of transparency, integrity and quality of 
financial reporting. It oversees the work 
carried out in the financial reporting 
process by the management, the internal 
auditors and the independent auditors. All 
possible measures have been taken by the 
Committee to ensure the objectivity and 
independence of the independent auditor.
	
	
c)	
Committee comprises of 4 Directors, out 
of which 3 are IDs. All the members of the 
Committee are financially literate and have 
the ability to read and understand the 
financial statements.
	
	
d)	
During the year under review, the Committee 
met 4 times on 05 May 2023, 27 July 2023, 
31 October 2023 and 31 January 2024. All 
the Committee members were present at all 
the meetings conducted during the year.
	
	
e)	
The Company Secretary acts as Secretary 
of the Committee. Chief Financial Officer 
("CFO"), Statutory Auditors and Internal 
Auditors are permanent invitees to the 
Committee meetings.
	
f)	
Chandrakant M. Khetan, Chairman of the 
Committee had attended the Annual General 
Meeting of the Company held on 18 July 2023.
	
g)	
Items placed before the Audit Committee and its 
frequency of review during the year:
Items placed before the Audit Committee
Frequency 
of review
Review quarterly/annual financial statements 
and auditor‚Äôs report thereon before submission to 
the Board
Q
Review internal audit reports relating to internal 
control weaknesses & discussion with internal 
auditors of any significant findings and follow up 
thereon
Q
Items placed before the Audit Committee
Frequency 
of review
Review action taken report on audit observations 
in earlier internal Audit reports
Q
Review adequacy of internal audit function and 
frequency of internal audit
Y
Review report on Foreign Exchange Management
Q
Approve payment to statutory auditors for other 
services rendered, if any during the year
Y
Review Company‚Äôs investments in subsidiaries  
vis-√†-vis subsidiary assets
Q
Recommend revision in Policy on Related Party 
Transactions and Policy on Material Subsidiary
Y
Review Annual Operating Plan, Financial Budget 
& Capex plan
Y
Recommend appointment of Cost & Tax Auditors
Y
Review adequacy of internal controls for 
prevention of insider trading
Y
Review Cost & other statements annexed to the 
Report as well as Cost Audit report
Y
Approve nature & scope of statutory audit and 
areas of concern, if any
Y
Approve remuneration of Statutory Auditors &  
non-audit services and progressive billing of 
Statutory Auditors
Y
Recommend Risk Management policy and 
amendment in Risk Management plan
Y
Scrutiny of inter-corporate loans and investments
Q
Recommendation for appointment of Statutory 
Auditors, Internal Auditors & CFO
E
Approval or any subsequent modification of 
transactions with related parties
HY
Review the functioning of the whistle-blower 
mechanism
Y
Review Management Discussion & Analysis and 
results of operations
Y
Review and monitor the auditor‚Äôs independence, 
performance and effectiveness of audit process
Y
Evaluation of internal financial controls and risk 
management systems
Y
	
HY ‚Äì Half Yearly; Y ‚Äì Yearly; Q ‚Äì Quarterly; E ‚Äì Event based
	
Nomination and Remuneration 
Committee
	
	
a)	
The Nomination and Remuneration 
Committee functions in accordance with 
Section 178 of the Act, and Regulation 19 
of the Listing Regulations. It discharges 
the Board‚Äôs responsibilities of Nomination 
and Remuneration of the Company‚Äôs 
Executive/Non-Executive 
Directors, 
Report on Corporate Governance
Annual Report 2023-24
56
57
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Senior Management and Key Managerial 
Personnel. It also has the overall 
responsibility of approving and evaluating 
the performance of individual directors, 
Board as a whole and Board Committees. 
It also administers Stock Option Schemes of 
the Company.
	
	
b)	
Committee comprises of 4 Directors, all IDs. 
During the year under review the Committee 
met 3 times, on 05 May 2023, 27 July 2023 
and 31 January 2024. All the Committee 
members were present at all the meetings 
conducted during the year.
	
	
c)	
The Company Secretary acts as Secretary 
of the Committee.
	
	
d)	
Items placed before the NRC and its 
frequency of review during the year:
Items placed before the Nomination & 
Remuneration Committee
Frequency 
of review
Consider recommending to the Board, 
re-appointment of Managing Director and 
Joint Managing Director
E
Recommend to the Board, remuneration 
to Whole-time Directors and Senior 
Management &KMP
Y
Formulate criteria for determining 
qualifications, positive attributes and 
independence of a Director
E
Recommend to the Board, Policy for 
remuneration of directors and employees
E
Formulate criteria for evaluation of 
performance of directors, Board & Board 
Committees
E
Determine eligible employees for granting 
options under Ajanta Pharma Share-Based 
Incentive Plan 2019
E
Allot shares exercised under ESOP
E
Decide mechanism for effective 
performance evaluation of Directors, Board 
and Committees
Y
Review following policies and recommend 
to Board:
	
[ Policy for Determining Qualifications, 
Positive Attributes and Independence 
of a Director;
E
Items placed before the Nomination & 
Remuneration Committee
Frequency 
of review
	
[ Policy for Remuneration of Directors 
and Employees;
	
[ Policy for Board & Independent 
Directors Evaluation Criteria;
	
[ Policy on Board Diversity.
E
	
	
Y ‚Äì Yearly; E ‚Äì Event based
	
Board Evaluation Criteria for 
Independent Directors:
	
	
NRC has adopted the performance evaluation 
criteria for Independent Directors which is in-
line with the Guidance Note of SEBI on Board 
Evaluation. The details of the performance 
evaluation carried out for FY 2024 is provided 
in¬† the performance evaluation section of 
this report.
	
Remuneration of Directors
	
	
a)	
Based on the recommendations of the 
NRC, the Board has formulated Policy for 
Remuneration of Directors and Employees. 
The policy can be accessed on the following 
link https://ajantapharma.com//images/
PolicyforRemunerationofDirectorsand 
Employees.pdf.
	
	
b)	
There were no pecuniary relationships or 
transactions between the Non-Executive 
Directors and the Company during the 
FY 2024, save and except remuneration 
drawn as mentioned below.
	
	
c)	
Executive Directors are paid remuneration in 
the form of salary, perquisites and commission 
in accordance with the Remuneration Policy 
and limits prescribed under the Act. No 
royalty has been paid to the Promoter or 
Promoter Group during the year.
	
	
d)	
IDs are paid sitting fees and commission 
on net profits in accordance with the 
remuneration policy and based on their 
performance evaluation.
	
	
e)	
Except Mr. Chandrakant M. Khetan no other 
non-executive directors hold shares of 
the Company and no stock options were 
granted to any Directors during the year.
Report on Corporate Governance
	
	
f)	
Remuneration paid to Executive and Non-Executive Directors during the year ended 31 March 2024:
(H Lakh)
Remuneration to Directors
Salary
Perquisite
PF
Sitting Fees
Commission
Total
Mr. Mannalal B. Agrawal
-
-
-
7.77
-
7.77
Mr. Madhusudan B. Agrawal
382.2
38.22
#
-
-
420.64
Mr. Yogesh M. Agrawal
1236.00
123.6
#
-
800.00
2159.82
Mr. Rajesh M. Agrawal
1236.00
123.6
#
-
800.00
2159.82
Mr. Chandrakant M. Khetan
-
-
-
8.71
4.96
13.67
Mr. Prabhakar R. Dalal
-
-
-
6.79
3.00
9.79
Mr. K. H. Viswanathan
-
-
-
7.77
3.00
10.77
Dr. Anjana Grewal
-
-
-
5.85
3.00
7.49
	
	
#H¬†21,600
	
Stakeholders‚Äô Relationship Committee
	
	
a)	
The Stakeholders Relationship Committee 
looks into various aspects of interests of 
shareholders. It ensures protecting investor 
interests and oversees the mechanism for 
redressal of investors‚Äô grievances.
	
	
b)	
Committee comprises of 3 Directors out of 
which 1 is ID. During the year under review, 
the Committee met 2 times, on 27 July 2023 
and 31 January 2024. All the Committee 
members were present at all the meetings 
conducted during the year.
	
	
c)	
Company Secretary acts as Secretary of the 
Committee. He has also been appointed as 
the Nodal Officer in accordance with the 
statutory requirements.
	
	
d)	
The Committee reviewed adherence to the 
service standards for investors adopted by 
the Company‚Äôs Registrar & Share Transfer 
Agent and various measures & initiatives 
taken for ensuring timely receipt of dividend 
warrants/ annual reports/ statutory notices 
by the shareholders of the Company and 
resolution of grievance as also for facilitating 
e-voting by shareholders.
	
	
e)	
Items placed before the Stakeholders' 
Relationship Committee and its frequency 
of review during the year:
Items placed before Stakeholders‚Äô 
Relationship Committee
Frequency 
of review
Review transfer of unclaimed dividend & 
shares to Investor Education & Protection 
Fund (IEPF) account
Y
Review effectiveness of resolving 
grievances of security holders
HY
Review of measures taken for effective 
exercise of voting rights by shareholders
Y
Review measures taken for reducing 
quantum of unclaimed dividend
Y
Items placed before Stakeholders‚Äô 
Relationship Committee
Frequency 
of review
Review status of dematerialisation of 
shares
HY
Review shareholding pattern & pledge of 
promoters holding
HY
Review internal audit report of Internal 
Auditors of Registrar & Transfer Agents
Y
Review of service standards in respect of 
various services rendered by the Registrar 
& Share Transfer Agent
Y
	
	
HY ‚Äì Half Yearly; Y ‚Äì Yearly; 
	
	
f)	
During the year 3 complaints were received 
which were resolved satisfactorily and 1 
complaint was pending as on 31 March 2024.
	
Corporate Social Responsibility 
Committee
	
	
a)	
Composition, terms of reference and powers 
of the Corporate Social Responsibility 
(‚ÄúCSR‚Äù) Committee are in accordance with 
Section 135 of the Act and Companies 
(Corporate Social Responsibility Policy) 
Rules, 2014.
	
	
b)	
CSR policy is placed on the website and it 
can be accessed at https://ajantapharma. 
com//images/CSRPolicy2021.pdf.
	
	
c)	
Committee draws annual action plan for 
the CSR and periodically reviews all the CSR 
activities undertaken as per the plan and 
the CSR policy.
	
	
d)	
Committee comprises of 4 Directors out of 
which 1 is ID. During the year under review 
the Committee met 4 times, on 05 May 
2023, 27 July 2023, 31 October 2023 and 31 
January 2024. All the Committee members 
were present at the meetings conducted 
during the year except in meeting held on 
31 January 2024 in which Mr. Madhusudan 
Agrawal was granted leave of absence.
Annual Report 2023-24
58
59
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Report on Corporate Governance
	
	
e)	
The Company Secretary acts as Secretary 
of the Committee.
	
	
f)	
Items placed before the CSR Committee 
and its frequency of review during the year.
Items placed before the CSR Committee
Frequency 
of review
Review/recommend CSR budget & annual 
action plan for the Financial Year
Y
Review CSR contributions & CSR activities 
undertaken
Q
Approve CSR report to be annexed to the  
Directors' Report
Y
Review impact assessment reports of CSR 
contributions made
E
Note amendments made in CSR  
regulatory framework
E
	
	
Y ‚Äì Yearly; Q ‚Äì Quarterly; E ‚Äì Event based
	
	
g)	
The Committee has been renamed as CSR and 
Sustainability Committee at the Board meeting held 
on 02 May 2024.
	
Risk Management Committee
	
	
a)	
The Risk Management Committee functions 
in accordance with Listing Regulations 
and Risk Management Policy adopted by 
the Company. Business Risk Evaluation 
and Management is an ongoing process 
within the Organisation. The Company has 
a robust risk management framework to 
identify, monitor, mitigate and minimise risks 
and also identify business opportunities.
	
	
b)	
During the year under review the Committee 
met 2 times, on 01 September 2023 and 
12 February 2024. All the Committee 
members were present at the meetings 
conducted during the year.
	
	
c)	
The Company Secretary acts as Secretary 
of the Committee.
	
	
d)	
Items placed before the Risk Management 
Committee and its frequency of review 
during the year:
Items placed before Risk Management 
Committee
Frequency 
of review
To formulate Risk Management policy
E
To review Forex management policy and 
its implementation
Y
To consider/approve the revised Risk 
Management Plan including ESG risks
E
To review Internal control system
Y
To monitor and oversee implementation of 
the Risk Management policy and evaluate 
adequacy of Risk Management systems
Y
Appointment, removal and terms of 
remuneration of the Chief Risk Officer
E
	
	
Y ‚Äì Yearly; E ‚Äì Event based
	
Executive Committee
	
	
a)	
Executive Committee deals with urgent 
operational matters viz., granting powers & 
authorities to employees, opening of bank 
accounts and change in authorities from time 
to time, availing various banking facilities 
and other routine administrative matters.
	
	
b)	
9 meetings of Executive Committee were 
held during the year.
	
	
c)	
All the Committee members were present at 
all the meetings conducted during the year.
	
Environmental, Social, and Governance 
(ESG) Committee
Board has constituted ESG Committee comprising of 
senior officials of the Company as under:
Mr. Satish Agrawal (C)
President Tech & Operations
Mr. Arvind Agrawal (M)
CFO
Mr. Jagdish Joshi (M)
EVP
Mr. Thampy Jacob (M)
Sr. VP - HR
Mr. Gaurang Shah (M)
Company Secretary & VP - Corp. 
Affairs
Mr. Pankaj Barbind (M)
DGM - Sustainability
	
	
a)	
The ESG Committee oversees and reviews 
the Company‚Äôs ESG programme, strategy, 
initiatives, policies, reporting & disclosures; 
reviews the implementation of targets, 
standards and metrics established to 
assess and track the Company‚Äôs ESG 
performance as also to ensure that the 
Company‚Äôs performance is consistent 
with the Company‚Äôs long-term strategic 
objectives, good corporate citizenship and 
the ESG strategy;
	
	
b)	
The Committee meets once every month 
to review the progress of various ESG 
initiatives of the Company and decide on 
new initiatives.
	
General Body Meetings
	
	
a)	
AGMs are generally held within 4 months from the end of financial year except for the previous year. AGMs 
during last 3 years were held on:
AGM
Date
Time
Venue
No. of special 
resolutions passed
42nd 
14 July 2021
11.00 a.m.
Ajanta House, Charkop, Kandivali (West), Mumbai ‚Äì 400 067
(through video-conference)
1
43rd 
04 August 2022
11.00 a.m.
Ajanta House, Charkop, Kandivali (West), Mumbai ‚Äì 400 067
(through video-conference)
-
44th 
18 July 2023
11.00 a.m.
Ajanta House, Charkop, Kandivali (West), Mumbai ‚Äì 400 067
(through video-conference)
1
	
	
b)	
No extra-ordinary general meeting was held 
during the three preceding financial years.
	
	
c)	
Notice of AGM is sent to Shareholders at 
least 25 days prior to the meeting date 
and the same is also made available on the 
Company and Stock Exchange(s) websites.
	
	
d)	
There were no instances where minority 
shareholders had proposed any agenda 
item at the AGM.
	
	
e)	
Company usually proposes single/ 
separate resolutions for the items requiring 
members‚Äô approval.
	
	
f)	
E-voting facility is provided at general 
meetings to enable the Shareholders 
vote electronically. Proper instructions 
w.r.t. the e-voting are circulated to all the 
Shareholders and they are assisted to vote 
electronically in case of any difficulty.
	
	
g)	
All the Board Members, Statutory Auditors, 
Secretarial Auditor attend the AGMs.
	
	
h)	
All resolutions proposed by the Board were 
passed by shareholders and voting results 
of resolutions passed through Postal Ballots 
are available on the Stock Exchange(s) & 
Company‚Äôs website.
	
Postal Ballot
	
	
During the year under review, no postal ballot 
was conducted.
	
Means of Communication
	
	
Company communicates with its stakeholders 
through multiple channels such as disclosures, 
press releases, analyst meetings, investor calls, 
as also through social media.
	
	
a)	 Financial Results
	
	
	
The annual, half-yearly and quarterly 
results are posted on website https://
ajantapharma.com/ajanta/Investors/
quarterly_results/?year=2023-24 submitted 
to the Stock Exchanges and published in 
Economic Times and Maharashtra Times 
newspapers within 48 hours.
	
	
b)	
Press releases, Presentations, etc.
	
	
	
Press and media releases, presentations etc. 
are also posted by website and submitted 
to the Stock Exchanges. Presentations on 
performance of the Company are also 
placed on the website for the benefit of 
the institutional investors, analysts and 
other shareholders.
	
	
c)	
Investor Calls
	
	
	
Company also conducts calls/meetings 
with investors after declaration of quarterly 
financial results, to brief them on the 
performance of the Company. These calls 
are attended by the MD, Joint MD & CFO. 
Transcript & audio recordings of such calls 
is uploaded on website as well as filed with 
the Stock Exchanges.
	
	
d)	 Website
	
	
	
Company‚Äôs website contains a dedicated 
section ‚ÄòInvestors‚Äô wherein information 
appropriate/useful for shareholders is 
available. Investor information on website 
is accessible, accurate and comprehensive.
	
	
	
Contact of Investor Relation person is also 
placed on website.
Annual Report 2023-24
60
61
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
	
	
e)	
Annual Report
	
	
	
As a part of green initiative, the Company 
has been sending Annual Report, Notices 
and other communications only via e-mail 
to those shareholders whose e-mail IDs are 
registered with the Depositories/Registrar 
& Share Transfer Agent (‚ÄúRTA‚Äù). Notice 
and Annual Report are also available on 
the website.
	
	
f)	
Unclaimed shares/dividend
	
	
	
Reminders for unpaid dividend are sent to 
shareholders regularly and all the efforts 
are taken to ensure that the claims, if any 
are attended swiftly. All the requests for 
claiming of unclaimed shares and dividend 
by the shareholders are attended quickly 
and necessary support/guidance is 
extended for processing the claims.
	
	
g)	 Filing with the Stock Exchanges
	
	
	
Quarterly Results, Shareholding Pattern, 
material developments related to the 
Company that are potentially price-
sensitive in nature or that could impact 
continuity of publicly available information 
regarding the Company, are disclosed to 
the stock exchanges in accordance with 
the Policy for determination of Material 
Events/Information. They are also available 
on website.
	
	
h)	
Investor Servicing
	
	
	
For enabling the investors to escalate 
their unresolved grievances, the Company 
has put up designated e-mail address, 
investorgrievance@ajantapharma.com. 
This e-mail id is checked on daily basis and 
immediate actions are taken for resolving 
Investor Complaints, if any. Company also 
keeps watch on the grievances lodged on 
SCORES (centralised web-based system 
provided by SEBI) and NEAPs (NSE platform) 
for resolving investor complaints and they are 
resolved promptly. Company has received 
very few complaints during the year and they 
are resolved promptly.
	
	
	
Company is also registered on SEBI‚Äôs 
common Online Dispute Resolution Portal 
(‚ÄúODR‚Äù) which combines online conciliation 
and online arbitration for resolution of 
disputes arising in the Indian Securities 
Market. The same can be accessed 
through https://smartodr.in/login
	
	
i)	
Launch of ‚ÄòSwayam‚Äô
	
	
	
Our Registrar and Share Transfer Agents 
Link Intime India Pvt Ltd. has developed 
‚ÄùSWAYAM‚Äô is a secure, user-friendly 
web-based application, that empowers 
shareholders to effortlessly access various 
services. The shareholders need to get 
themselves registered and have first-hand 
experience of the portal. This application 
can be accessed at https://swayam.
linkintime.co.in. It would be very effective 
resolution of Service Request -Generate 
and Track Service Requests/Complaints 
through SWAYAM.
‚ÄùSWAYAM‚Äù web-based 
application for investor 
services
	
General Shareholders Information
 
 
A. 45th Annual General Meeting to be 
held on: 18 July 2024 at 11.00 a.m. 
through video-conferencing or Other 
Audio-Visual Means.
	
	
B.	
Financial Calendar: 1 April 2024 to  
31 March 2025
	
	
C.	 Reporting Calendar: Within 45/ 60 days 
from the end of the quarter/ financial 
year respectively, as stipulated under the 
Listing Regulations.
	
	
D.	 Dividend Payment Date: First and 
Second Interim Dividend(s) paid on 27 July 
2023 and on 31 January 2024 respectively, 
are proposed as final dividend.
	
	
E.	
Listing on Stock Exchanges:  
BSE Limited (Code: 532331),  
National Stock Exchange of India Limited  
(Code: AJANTPHARM). 
Annual Listing Fees have been paid 
for both the stock exchanges within 
stipulated time.
	
	
F.	
ISIN number for CDSL and NSDL: 
INE031B01049
	
	
G.	 Stock Market Data:
Bombay Stock Exchange (BSE)
National Stock Exchange (NSE)
High (J)
Low (J)
High (J)
Low (J)
Apr-23
1,325.50
1,207.80
1,325.60
1,207.90
May-23
1,345.30
1,240.55
1,339.00
1,246.75
Jun-23
1,550.00
1,292.90
1,550.00
1,292.85
Jul-23
1,735.10
1,378.50
1,735.00
1,386.60
Aug-23
1,804.70
1,666.30
1,805.00
1,666.55
Sep-23
1,903.85
1,650.55
1,904.45
1,665.50
Oct-23
1,814.35
1,665.00
1,815.00
1,650.05
Nov-23
1,994.75
1,746.00
1,995.95
1,750.00
Dec-23
2,100.00
1,852.55
2,100.00
1,850.25
Jan-24
2,355.05
2,058.45
2,353.95
2,053.65
Feb-24
2,315.70
2,015.30
2,319.75
2,015.05
Mar-24
2,307.05
2,003.55
2,317.65
1,998.35
 
 
H. Performance of APL Share price in Comparison to Nifty 500:
 Nifty 500‚ÄÉ
 APL
4,500.00
5,000.00
2,000
2,200
1,800
1,600
1,400
1,200
1,000
800
600
400
200
0
4,000.00
3,500.00
3,000.00
2,500.00
2,000.00
1,500.00
1,000.00
500.00
0.00
Apr-23
May-23
Jun-23
Jul-23
Aug-23
Sep-23
Oct-23
Nov-23
Dec-23
Jan-24
Feb-24
Mar-24
	
	
I.	
Registrar and Transfer Agents (‚ÄúRTA‚Äù)
	
	
	
Link Intime India Private Limited Unit: Ajanta 
Pharma Limited 101, 247 Park, L B S Marg, 
Vikhroli West, Mumbai ‚Äì 400 083 Tel No.: 
+91 022 49186000 Fax: +91 022 49186060 
E-mail: rnt.helpdesk@linkintime.co.in
	
	
J.	
Share Transfer System
	
	
a)	
Transmission, dematerialisation of shares, 
dividend payment and all other investor 
related matters are attended to and 
processed by the Company‚Äôs RTA as per 
the prescribed timeline upon receipt of 
complete documents.
	
	
b)	
Stakeholders' Relationship Committee 
periodically reviews and takes note 
of transfer, transmission, remat, split & 
consolidation of share certificates etc.
	
	
c)	
Audit of share transfer related activities is 
done by the Company Secretary in practice 
and compliance certificate is submitted to 
the Stock Exchanges on quarterly basis.
	
	
d)	
Vide circular dated 24 January 2022, SEBI 
has notified that all requests for duplicate, 
split and consolidation shall be processed 
in only demat mode. In view thereof, 
shareholders holding equity shares in 
physical form are urged to have their shares 
dematerialised at the earliest.
Report on Corporate Governance
Annual Report 2023-24
62
63
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
 
 
K. 
Distribution of Equity Shareholding as on 31 March 2024
No. of shares held
Shareholders
Shares
No.
%
No.
%
Up to 500
53,690
94.04
22,72,101
1.80
501-1000
1,158
2.03
8,12,418
0.65
1001-2000
1,201
2.10
15,67,013
1.24
2001-3000
313
0.55
7,55,888
0.60
3001-4000
146
0.26
5,07,147
0.40
4001-5000
97
0.17
4,39,467
0.35
5001-10000
173
0.30
12,12,988
0.96
10001 & above
317
0.56
11,83,48,633
93.99
TOTAL
57,095
100.00
12,59,15,655
100.00
	
	
L.	
Pattern of Shareholding
% of total 
no. of 
shares
Promoters Holding
66.21%
Banks/ FIs/ Mutual Funds
16.92%
FIIs/ OCBs/ NRIs
8.86%
Indian Public
7.11%
Sovereign Wealth Funds
0.00%
Alternate Investment Funds
0.56%
Private Corporate Bodies
0.24%
IEPF
0.09%
In Clearance
0.00%
	
	
M.	 Dematerialisation of Shares and Liquidity
	
	
	
Relevant data for the average daily turnover for FY 2024 is given below:
Bombay Stock Exchange (BSE)
National Stock Exchange (NSE)
BSE + NSE
In No. of Shares
10,828
1,62,208
1,73,035
In value terms H
2,01,28,837
27,55,08,408
29,56,37,245
	
	
N.	 Outstanding GDR/ ADR/ Warrants 
or any convertible instruments, 
conversion date and likely impact on 
equity 
	
	
	
Company has not issued these types 
of securities.
	
	
O.	 Commodity price risk or foreign 
exchange risk and hedging activities
	
	
a)	
The Company does not have any significant 
exposure in commodities directly and 
does not carry out any commodity 
hedging activities.
	
	
b)	
Currency risks mainly arise out of exports 
and overseas operations. Since about 
68% of the Company‚Äôs income is by way 
of exports with major currency exposure 
being in USD/EUR, the Company generally 
does currency hedging for 6 to 18 months 
and up to the extent of 50% to 75% of its net 
foreign exchange earnings. It uses forward 
exchange contracts and/or options to hedge 
against its net foreign currency exposures as 
advised by the Risk Management Committee 
and forex consultants. All material foreign 
exchange transactions are fully covered.
	
	
P.	
Plant Locations
	
	
	
Company has 7 Manufacturing Plants as 
detailed below:
	
	
	
i.	
B-4, B-5, B-6, MIDC 
Industrial Area, Paithan, Dist. 
Aurangabad, Maharashtra
	
	
	
ii.	
31-O, MIDC Industrial Area, 
Chikalthana, Aurangabad, Maharashtra
	
	
	
iii.	
Gut No. 11/12/14/15, 
Chitegaon, Paithan Road, Dist. 
Aurangabad, Maharashtra
	
	
	
iv.	
Gut No. 378, Plot No. 8, Waluj, 
Aurangabad, Maharashtra
	
	
	
v.	
Plot No. Z-103 /A, Dahej SEZ - Part II, 
Dist. Bharuch, Gujarat
	
	
	
vi.	
Mirza Palashbari Road, Mouza 
Chayani Kamrup (R), Dist. 
Guwahati, Assam
	
	
	
vii.	 Plot No. M-55, 56, 57 ISEZ 
Phase-II, Pithampur, Dist. Dhar, 
Madhya Pradesh
	
	
Q.	 Contact Details for Correspondence:
Particulars
Name & contact details
Address
For Corporate Governance, IEPF 
and other secretarial matters
Compliance & Nodal Officer
Mr. Gaurang C. Shah
VP ‚Äì Legal & Company Secretary
E-mail: investorgrievance@ajantapharma.com
Ajanta House, 98 Govt. Ind. Area,
Charkop, Kandivali (West),
Mumbai ‚Äì 400 067
Tel.: +91 022 - 66061000;
Fax: +91 022 - 66061200/1300
Website: http://www.ajantapharma.com/
For Financial Statements 
related matters and institutional 
investors
Mr. Rajeev Agarwal
AVP ‚Äì Finance
E-mail: rajeev.agarwal@ajantapharma.com
For Corporate Communication 
related matters
Mr. Abhineet Kumar
DGM ‚Äì Corporate Communication
E-mail: abhineet.kumar@ajantapharma.com
For shares held in physical form Link Intime India Private Limited
E-mail: rnt.helpdesk@linkintime.co.in
Link Intime India Private Limited
Unit: Ajanta Pharma Limited
C¬†101, 247 Park, L B S Marg, Vikhroli 
(West),
Mumbai ‚Äì 400 083
Tel.: +91 022 49186000; 
Fax: +91 022 49186060
For shares held in demat form
Concerned Depository participants of investors
	
	
R.	
Credit Ratings
	
	
	
Company‚Äôs bank facilities are rated by Credit 
Analysis and Research Limited (CARE). They 
have assigned rating Care AA/Care A1+ for 
long/short-term borrowings, which indicates 
very strong/high degree of safety regarding 
timely payment of financial obligations.
	
	
S.	
Updating KYC & Nomination
	
	
a)	
Updation of Permanent Account Number 
(PAN) and bank account details of all 
shareholder(s) is being done in accordance 
with the regulatory requirements.
	
	
b)	
Members holding shares in electronic form 
are requested to register/change their 
nomination and bank details with their 
Depository Participants.
	
	
c)	
Members holding shares in physical form 
are advised to register their nomination by 
submitting Form SH‚Äì13.
	
	
d)	
If a member desires to opt out or cancel 
the earlier nomination and record a fresh 
nomination, he/she may submit the same 
in Form ISR-3 or SH-14, as the case may 
be to the RTA. The said forms can also be 
downloaded from the Company‚Äôs website 
https://ajantapharma.com/ajanta/
Investors/investor_information_KYC_forms.
	
	
e)	
SEBI has mandated holders of physical 
securities to furnish PAN, nomination/
declaration to opt-out of Nomination, 
Contact details, Bank Account details and 
Specimen Signature details to RTA.
	
	
f)	
Further SEBI has extended the last date 
for submission of ‚Äòchoice of nomination‚Äô for 
Report on Corporate Governance
Annual Report 2023-24
64
65
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
demat accounts and mutual fund folios to 
30 June 2024.
	
	
g)	
Vide Circular dated 25 January 2022, SEBI 
has clarified that listed entities/RTAs shall 
now issue a Letter of Confirmation in lieu 
of the share certificate, while processing 
any investor service requests in physical 
form for transfer, transmission, remat, split & 
consolidation of share certificates etc.
	
	
T.	
Reconciliation of Share Capital Audit
	
	
	
Practicing Company Secretary carries out 
the Share Capital Audit to reconcile the total 
admitted capital with NSDL & CDSL with 
the total issued, listed and paid-up capital. 
This audit is carried out every quarter and 
report thereon are submitted to the Stock 
Exchanges and is also placed before the 
Board of Directors. No discrepancies were 
noticed during these audits.
	
	
U.	
Employees Stock Option Scheme
	
	
	
During the year 87600 new options were 
granted under Ajanta Pharma Share-Based 
Incentive Plan 2019. 1000 options granted 
earlier were exercised during the year and 
the same were allotted and listed on the 
Stock Exchanges.
	
	
V.	
The Company does not have any fixed 
deposit programme nor has any proposal 
involving mobilisation of funds in India 
or abroad.
	
	
W.	 Subsidiary Companies
	
	
a)	
Financial statements including investments 
made by the subsidiaries were reviewed by 
the Audit Committee. The Board periodically 
reviewed, material developments, financial 
& operating performance and strategies 
as well as all the significant transactions 
and arrangements entered into by 
the subsidiaries.
	
	
b)	
Minutes of the Board Meetings of the 
subsidiary Companies were placed at the 
Board Meetings held during the year.
	
Other Disclosures
	
	
a)	
Transactions with related parties are 
disclosed in Note no. 54 of the Financial 
Statements. There were no transactions with 
related party which are not at arm‚Äôs length 
or amounts to more than 10% of revenues. 
No royalty has been paid to the Promoter 
or Promoter Group in the previous year. 
Comprehensive Related Party Transaction 
policy has been formulated which is available 
at: https://ajantapharma.com//images/
PolicyonRelatedPartyTransactions. pdf.
	
	
b)	
Company has put in place compliance 
management tool to monitor and ensure 
compliance with all applicable laws and 
regulatory requirements. The tool provides 
system driven alerts to the respective task 
owners for timely complying with the statutory 
requirements. There were no instances 
of material non-compliance nor has any 
penalties/strictures been imposed by Stock 
Exchanges or SEBI or any other statutory 
authorities on any matters related to capital 
market, during last 3 financial years.
	
	
c)	
Company has put in place vigil mechanism/ 
Whistle‚ÄëBlower Policy and details of 
the same are provided in the Directors' 
report. Policy is available on the website 
(https://ajantapharma.com//images/ 
Whistle-Blower-Policy-Feb-2023.pdf). No 
personnel have been denied access to the 
Audit Committee.
	
	
d)	
Company has complied with and disclosed 
all the mandatory corporate governance 
requirements under Regulation 17 to 27 and 
46(2) of the Listing Regulations.
	
	
e)	
There was no non-compliance of any 
requirement of corporate governance 
report. Further, all the disclosures are 
made to the Stock Exchanges and other 
regulatory bodies timely. Company has 
also adopted following non-mandatory 
requirements specified in Part E of Schedule 
II of the Listing Regulation
	
[
Non-Executive Chairman is provided 
with an office at the Company‚Äôs expense 
and also allowed reimbursement of 
expenses incurred in performance of 
his duties.
	
[
Financial performance highlights 
were sent to shareholders on a half-
yearly basis.
	
[
The auditors have issued an unmodified 
opinion to the financial statements of 
the Company.
	
[
M/s. Aneja Assurance Private Limited, 
Internal Auditors submits their 
internal audit reports directly to the 
Audit Committee.
	
	
f)	
Disclosures on Commodity price risk or 
foreign exchange risk and hedging activities 
have been made in earlier paragraphs in 
this report.
	
	
g)	
Company had not raised any funds 
through preferential allotment or qualified 
institutional placement.
	
	
h)	
Practicing Company Secretary has certified 
that none of the Directors on the Board 
of the Company have been debarred 
or disqualified from being appointed or 
continuing as directors of companies by 
the Board/Ministry of Corporate Affairs or 
any such statutory authority. The same is 
annexed to this report.
	
	
i)	
There were no instances where the Board 
had not accepted any recommendation of 
any committees during the financial year.
	
	
j)	
Total fees for all services paid by the 
Company and its subsidiaries, on a 
consolidated basis, to the statutory auditor 
and all entities in the network firm/network 
entity of which the statutory auditor is a 
part, is mentioned in Notes to Accounts.
	
	
k)	
Disclosures in relation to the Sexual 
Harassment of Women at Workplace 
(Prevention, Prohibition and Redressal) 
Act, 2013:
Sr.
No.
Particulars
No. of 
complaints
1
Number of complaints filed during 
the financial year
Nil
2
Number of complaints disposed of 
during the financial year
N.A.
3
Number of complaints pending as on 
end of the financial year
N.A.
	
	
l)	
Details of material subsidiary of the 
Company:
Name of 
Material 
Subsidiary
Date of 
Incorporation
Place of 
Incorporation
Name of 
Statutory 
Auditor
Date of 
appointment 
of Statutory 
Auditor
Ajanta 
Pharma 
USA INC
07 
December 
2012
New 
Jersey, 
USA
KNAV PA 14 
November 
2019
	
	
Mr. Chandrakant Khetan, lead Independent 
Director of the Company is nominated on the 
Board of Ajanta Pharma USA Inc. Web-link of 
policy for determining material subsidiaries 
is 
https://ajantapharma.com//images/
PolicyonMaterialSubsidiaries.pdf
	
	
m)	
Certificate from MD and CFO pursuant to 
Regulation 17(8) of the Listing Regulations 
[Part B of Schedule II], is attached to 
this Report. MD and the CFO also gives 
quarterly certification on financial results to 
the Board in terms of Regulation 33(2) of the 
Listing Regulations.
	
	
n)	
Disclosures have also been received from 
the senior management that there were no 
transactions with the Company either by 
them or their relatives during the FY 2024, 
having potential conflict with the interests 
of the Company.
	
	
o)	
No loans and advances were provided by 
the Company or its subsidiaries, to firms/
companies in which directors are interested.
	
Unclaimed Shares & Dividend
	
	
a)	
As per Regulation 39(4) and Schedule VI 
of the Listing Regulations, shares which 
remained unclaimed in the custody of the 
Company for seven years are required to 
be transferred to the Unclaimed Suspense 
Account opened by the Company.
	
	
	
Accordingly, unclaimed shares lying in the 
Company‚Äôs Unclaimed Suspense Account 
are as follows:
#
Particulars
Shareholders
No. of 
shares
1
Outstanding shares at the 
beginning of the year
6
6,750
2
Shareholders approached the 
Company for transfer
0
-
3
Shareholders whose shares  
were transferred from  
suspense account
0
-
4
Shares transferred to IEPF 
account
3
3,375
5
Outstanding shares at the  
end of the year
3
3,375
	
	
b)	
These shares including all benefits accrued 
thereon shall be transferred by the Company 
to the IEPF Authority in accordance with 
provisions of Section 124(5) and (6) of the 
Report on Corporate Governance
Annual Report 2023-24
66
67
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Act and Rules framed thereunder. The 
voting rights in respect of such shares shall 
remain frozen till the rightful owner claims 
such Equity Shares.
	
	
c)	
As per Section 124(6) of the Act read with 
the Investor Education and Protection 
Fund Authority (Accounting, Audit, Transfer 
and Refund) Rules, 2016 (‚ÄúIEPF Rules‚Äù), all 
the dividends which have not been paid 
or claimed for 7 (seven) consecutive years 
or more and underlying shares, shall be 
transferred to the Investor Education and 
Protection Fund Authority (‚ÄúIEPF Authority‚Äù), 
after complying with the procedure. 
Accordingly, undermentioned dividend and 
underlying shares have been transferred to 
the IEPF Authority during the year.
Financial year
Amount of unclaimed 
dividend transferred (K¬†Lakh)
Number of shares 
transferred
2015-16
11.96
3,719
2016-17  
(1st Interim)
9.98
3,046
	
	
d)	
Members 
whose 
shares/unclaimed 
dividends, etc. have been transferred to 
IEPF may claim the shares by making an 
application to IEPF Authority in Form IEPF-5 
(available on www.iepf.gov.in) along with 
requisite fee as decided by the Authority 
from time to time. The Member can file only 
one consolidated claim in a financial year as 
per the IEPF Rules and amendments thereto.
 
 
i. 
Guidelines for Investors to file claim in 
respect of the unclaimed dividend or 
shares transferred to the IEPF:
	
[ Login to website of MCA at https://www.
mca.gov.in/content/mca/global/en/
home.html and click on ‚ÄòInvestor Relations‚Äô 
tab under ‚ÄòMCA Services‚Äô section for filing 
the web-based form IEPF-5 for the refund 
of dividend/shares. Read the instructions 
provided on the website/instruction kit 
carefully before filling the form.
	
[ Submit the duly filled form by 
following the instructions given on the 
website. On successful uploading, an 
acknowledgement will be generated 
indicating the SRN. Please note down the 
SRN details for future tracking of the form.
	
[ Take a print out of the duly filled Form No. 
IEPF-5 and the acknowledgement issued 
after uploading the form.
	
[ Submit an indemnity bond in original, 
copy of the acknowledgement and self-
attested copy of the Form, along with 
other documents as mentioned in the 
Form No. IEPF-5 to the Nodal Officer (IEPF) 
of the Company at its Registered Office 
in an envelope marked ‚ÄòClaim for refund 
from IEPF Authority/Claim for shares from 
IEPF‚Äô as the case may be. Kindly note that 
submission of documents to the Company 
is necessary to initiate the refund process.
	
[ Form IEPF-5 completed in all respects 
will be verified by the Company and on 
the basis of Company‚Äôs e-Verification 
Report, refund will be released by the 
IEPF Authority in favour of claimant's 
aadhaar‚Äëlinked bank account through 
electronic transfer and/ or the shares 
shall be credited to the demat account 
of the claimant, as the case may be.
	
	
ii.	
Dividends remaining unpaid/
unclaimed and the dates by which 
dividend and underlying shares will 
be transferred to IEPF:
Financial Year
Date of 
declaration
Tentative date for 
transfer to IEPF
2016-2017 (2nd Interim) 18.03.2017
23.04.2024
2018-2019 (Interim)
31.10.2018
06.12.2025
2019-2020 (Interim)
05.11.2019
11.12.2026
2020-2021 (Interim)
03.11.2020
09.12.2027
2021-2022 (Interim)
29.10.2021
04.12.2028
2022-2023 (Interim)
03.11.2022
09.12.2029
2023-2024 (1st Interim)
27.07.2023
01.09.2030
2023-2024 (2nd Interim) 31.01.2024
01.03.2031
	
	
Details of unclaimed dividends and shareholders 
whose shares are liable to be transferred to the 
IEPF Authority are also put on the Company‚Äôs 
website. Shareholders who have not yet 
encashed their unclaimed/unpaid amounts are 
requested to correspond with the Company‚Äôs 
RTA at the earliest to claim the same and avoid 
transfer of dividend and underlying shares 
to IEPF.
	
Shareholders‚Äô Right
	
	
a)	
To receive copies of the Annual Report, 
balance sheet and profit & loss account 
and auditor‚Äôs report.
	
	
b)	
To participate and vote in general meetings.
	
	
c)	
To receive corporate benefits such as 
dividend, rights and bonus, once approved.
	
Policies
	
	
Company has framed following policies and codes for setting up best corporate governance practices and 
for achieving the ultimate objective of maximising stakeholder value.
Name of the Policy/Code
Intranet/Internet (with weblink)
Code of Conduct for Directors &  
Senior Management
https://ajantapharma.com//images/
CodeofConductforDirectorsandSeniorManagement.pdf
Business Responsibility and  
Sustainability policies
https://ajantapharma.com//images/BusinessResponsibilityPolicies.pdf
Ajanta Third-Party Code
https://ajantapharma.com//images/Third-Party-Code-of-Conduct.pdf
Code of Practices & Procedure for Fair 
Disclosure of UPSI
https://ajantapharma.com//images/
CodeofPracticesnProceduresforFairDisclosure2019.pdf
Dividend distribution policy
https://ajantapharma.com//images/DividendPolicy.pdf
CSR Policy
https://ajantapharma.com//images/CSRPolicy2021.pdf
Policy for determination of materiality
https://ajantapharma.com//images/Policyfordeterminationofmateriality.pdf
Policy for determining qualifications  
of Director
https://ajantapharma.com//images/
PolicyfordeterminingqualificationsofDirector.pdf
Policy for remuneration of Directors & 
Employees
https://ajantapharma.com//images/
PolicyforRemunerationofDirectorsandEmployees.pdf
Policy on Archival of Documents
https://ajantapharma.com//images/ed3a5c00-25bd-4cd8-a933-
06d0be554702ArchivalPolicy.pdf
Policy on Material Subsidiaries
https://ajantapharma.com//images/PolicyonMaterialSubsidiaries.pdf
Policy on Related Party Transactions
https://ajantapharma.com//images/PolicyonRelatedPartyTransactions.pdf
Risk Management Policy
https://ajantapharma.com//images/RiskManagementPolicy.pdf
Whistle-Blower Policy
https://ajantapharma.com//images/Whistle-Blower-Policy-Feb-2023.pdf
Ajanta‚Äôs Code of Conduct for Insiders
On Intranet
Policy on Board Diversity
On Intranet
Policy on Board evaluation
On Intranet
Policy on preservation of documents
On Intranet
Policy on Procedure for inquiry in case of leak 
of UPSI
On Intranet
Risk Management Plan
https://ajantapharma.com//images/Risk-Management-Policy-And-Plan.pdf
Policy on Succession Plan
-
IP policy
-
Investment Policy
-
Policy on Internal Financial Controls
-
For and behalf of the Board of Directors
Mannalal B. Agrawal
Chairman
Mumbai, 02 May 2024
DIN: 00073828
Report on Corporate Governance
Annual Report 2023-24
68
69
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS
[Pursuant to Regulation 34(3) read with sub-clause (10)(i) of Clause C of Schedule V of the SEBI 
(Listing Obligations and Disclosure Requirements) Regulations, 2015]
To,
The Members of
Ajanta Pharma Limited
Ajanta House, 98 Govt. Industrial Area
Charkop, Kandivali (West), Mumbai - 400 067
We have examined the relevant registers, records, forms, returns and disclosures received from the Directors of Ajanta 
Pharma Limited having CIN: L24230MH1979PLC022059 and having registered office at Ajanta House, 98 Govt. Industrial 
Area, Charkop, Kandivali (West), Mumbai ‚Äì 400 067 (hereinafter referred to as ‚Äòthe Company‚Äô), produced before us by 
the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Sub-clause 10(i) 
of Clause C of Schedule V of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) 
Regulations, 2015.
In our opinion and to the best of our information and according to the verifications (including Directors Identification 
Number (DIN) status at the portal www.mca.gov.in) as considered necessary and explanations furnished to us by 
the Company, We hereby certify that none of the Directors on the Board of the Company as stated below for the 
Financial Year ended on 31 March 2024 have been debarred or disqualified from being appointed or continuing as 
Directors of companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs or any such other 
Statutory Authority.
Sr.
No.
Name of Director
DIN
Designation
Date of appointment
1
Mannalal Bhagwandas Agrawal
00073828
Director
31.12.1979
2
Madhusudan Bhagwandas Agrawal
00073872
Whole-time Director
31.12.1979
3
Yogesh Mannalal Agrawal
00073673
Managing Director
29.04.2000
4
Rajesh Mannalal Agrawal
00302467
Whole-time Director
30.04.2013
5
Chandrakant Mohanlal Khetan
00234118
Director
20.10.2008
6
Prabhakar Ramchandra Dalal
00544948
Director
13.06.2014
7
Viswanathan Hariharan Kalpati
06563472
Director
30.04.2013
8
Dr. Anjana Grewal
06896404
Director
13.06.2014
Ensuring the eligibility for the appointment/continuity of every Director on the Board is the responsibility of the 
management of the Company. Our responsibility is to express an opinion on these based on our verification. This 
certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with 
which the management has conducted the affairs of the Company.
For Alwyn D‚ÄôSouza & Co.
Company Secretaries
Alwyn D‚ÄôSouza
FCS No. 5559
Place: Mumbai
C. P. No. 5137
Date: 02 May 2024
UDIN: F005559F000318399
Report on Corporate Governance
DECLARATION PURSUANT TO SCHEDULE V OF THE LISTING REGULATIONS
In accordance with Regulation 26 (3) and Schedule V of the Listing Regulations with the Stock Exchanges, I hereby 
declare that the Directors and Senior Management of the Company have affirmed compliance with the Code of 
Conduct as applicable to them for the year ended 31 March 2024.
For Ajanta Pharma Limited
Yogesh M. Agrawal
Managing Director
Mumbai, 02 May 2024
DIN: 00073673
Annual Report 2023-24
70
71
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Report on Corporate Governance
CERTIFICATE PURSUANT TO REGULATION 17(8) OF THE LISTING REGULATIONS
We, Mr. Yogesh M. Agrawal, Managing Director and Mr. Arvind K. Agrawal, Chief Financial Officer hereby certify for the 
financial year ended 31 March 2024 that:
(a)	
We have reviewed Ind AS financial statements and the cash flow statement for the year and that to the best of 
our knowledge and belief:
	
(i)	
these statements do not contain any materially untrue statement or omit any material fact or contain 
statements that might be misleading;
	
(ii)	
these statements together present a true and fair view of the Company‚Äôs affairs and are in compliance with 
Ind AS, applicable laws and regulations.
(b)	
There are, to the best of our knowledge and belief, no transactions entered into by the Company during the year 
which are fraudulent, illegal or violative of the Company‚Äôs code of conduct.
(c)	
We accept responsibility for establishing and maintaining internal controls for financial reporting and that we have 
evaluated the effectiveness of internal control systems of the Company pertaining to financial reporting and we 
have disclosed to the auditors and the Audit Committee, deficiencies in the design or operation of such internal 
controls, if any, of which we are aware and the steps we have taken or propose to take to rectify these deficiencies.
(d)	
We have indicated to the auditors and the Audit committee:
	
(i)	
that there are no significant changes in internal control over financial reporting during the year;
	
(ii)	
that there are no significant changes in accounting policies during the year; and
	
(iii)	
that there are no instances of significant fraud of which we have become aware.
For Ajanta Pharma Limited
For Ajanta Pharma Limited
Yogesh M. Agrawal
Arvind K. Agrawal
Managing Director
Chief Financial Officer
DIN: 00073673
Mumbai, 02 May 2024
CERTIFICATE OF COMPLIANCE OF CONDITIONS OF CORPORATE GOVERNANCE
To,
The Members of AJANTA PHARMA LIMITED,
1.	
We have examined the compliances of the conditions of Corporate Governance by AJANTA PHARMA LIMITED (‚Äúthe 
Company‚Äù) for the financial year ended 31 March 2024, as prescribed in Regulations 17 to 27, clauses (b) to (i) of 
sub-regulation (2) of regulation 46 and paras C, D and E of Schedule V of SEBI (Listing Obligations and Disclosures 
Requirements) Regulations 2015 (‚ÄòListing Regulations‚Äô).
2.	
The compliance of the conditions of Corporate Governance is the responsibility of the management. Our 
examination was limited to procedures and implementation thereof, adopted by the Company for ensuring the 
compliance of the conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the 
financial statements of the Company.
3.	
In our opinion and to the best of our information and according to the explanations given to us and representations 
made by the Management, we certify that the Company has complied with the conditions of Corporate Governance 
as stipulated in the above-mentioned Listing Regulations.
4.	
We further state that such compliance is neither an assurance as to the future viability of the Company nor the 
efficiency or effectiveness with which the Management has conducted the affairs of the Company.
For Alwyn D‚ÄôSouza & Co.
Company Secretaries
Alwyn D‚ÄôSouza
FCS No. 5559
Place: Mumbai
C. P. No. 5137
Date: 02 May 2024
UDIN: F005559F000318401
Business Responsibility and 
Sustainability Report
During the year, we have made 
significant strides in this direction 
toward achieving our targets and 
upholding our responsibilities. You will 
be happy to know that we have taken 
a major step in renewable energy 
generation by installing additional 
8.8 MW solar unit this year. This addition 
contributed significantly to reduce CO2 
emission by approximately 7,066 Mt per 
annum, furthering our commitment to 
sustainable energy practices.
Statement by Managing Director
Dear Valued Partners,
I am delighted to share with you our 
progress and achievements in the 
long-term Sustainability, including 
Environmental, Social, and Governance 
(ESG) initiatives and business 
responsibility¬†practices. 
In the evolving ESG landscape, we are committed to 
continuous improvement and innovation across all aspects 
of our operations. Through our initiatives such as waste 
reduction, energy efficiency improvements, renewable 
energy projects and water conservation, we aim to minimise 
our environmental footprint and mitigate climate change. 
The ESG Committee, comprising key functional heads, meets 
regularly to review progress and make informed decisions on 
sustainability initiatives.
At Dahej and Guwahati locations, we upgraded Effluent 
Treatment Plants (ETPs) with advanced UF and RO systems 
to recycle RO permeate for cooling tower usage. Proactive 
measures led to a commendable 30% reduction in 
wastewater generation at Dahej plant. 
Projects like condensate recovery systems have enabled 
to recycle around 40 KLD of condensate, thereby reducing 
boiler fuel consumption and consequent CO2 emission.
The health and safety of our employees are of paramount 
concern. We have comprehensive OH&S management 
systems in place, including regular risk assessments, safety 
training, and emergency preparedness measures, to ensure 
a safe work environment for all. We have got ISO 14001 
and ISO 45001 certifications for two of our major sites and 
two more sites have been recommended for the same, 
awaiting certification.
Our robust Code of Conduct for Directors and Senior 
Management underscores our commitment to fostering 
ethical business conduct. We recognise the importance of 
our suppliers in our journey towards sustainability. Through 
our Value Chain Assessment and engagement initiatives, 
we ensure that our suppliers adhere to ESG principles and 
promote sustainable practices. 
We actively engage with our Stakeholders to identify and 
address their needs and concerns, prioritising sustainability 
issues based on their impact on both our strategic objectives 
and stakeholder interests. Through our community welfare 
programmes, we contribute to the well-being of local 
communities and promote inclusive growth.
We have implemented projects to 
collect and recycle solvent waste 
generated from Quality Control 
(QC) at our Paithan and Chitegaon 
sites. Moreover, hazardous waste 
generated from our Guwahati 
& Dahej plants now undergoes 
processing in the cement industry, 
thereby significantly reducing 
exposure of these sites from landfills.
Our CSR initiatives include providing 
healthcare services, supporting 
education and rural & tribal area 
development. Our support for 
sports persons, including Olympic 
and Paralympic athletes, highlights 
our dedication to promoting talent 
and excellence.
Ajanta remains steadfast in its commitment to ESG principles 
and responsible business practices. We are deeply grateful 
for your continued support and partnership as we strive to 
build a sustainable future for all stakeholders.
Thank you for being a part of this journey.
Warm regards,
Yogesh Agrawal
Managing Director
Annual Report 2023-24
72
73
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Business Responsibility and Sustainability Report
Section A ‚Äì General Disclosure 
I.	
Details of the Listed Entity
1. 
Corporate Identity Number 
(CIN) of the Listed Entity -
	
L24230MH1979PLC022059
2. 
Name of the Listed Entity - 
Ajanta Pharma Limited
3. 
Year of incorporation -
	
31/12/1979
4. 
Registered office address -
	
Ajanta House 98, Govt Industrial 
Area, Charkop, Kandivali 
(West), Mumbai- 400067, 
Maharashtra, India. 
5. 
Corporate address -
	
Ajanta House 98, Govt Industrial 
Area, Charkop, Kandivali 
(West), Mumbai- 400067, 
Maharashtra, India. 
II.	
Products/services
16 Details of business activities (accounting for 90% of the turnover):
Sl. No.
Description of Main Activity
Description of Business Activity
% of turnover of the entity
1
Manufacture and sale of 
pharmaceutical products
Pharmaceutical
100
17 Products/Services sold by the entity (accounting for 90% of the entity‚Äôs Turnover):
Sl. No.
Products/Services
NIC Code
% of total Turnover contributed
1
Pharmaceutical products
24232
100
III.	 Operations
18 Number of locations where plants and/or operations/offices of the entity are situated:
Locations
Number of plants
Number of offices
Total
National
7
9
16
International
0
7*
7
	
* Apart from these we have presence in 22 countries through our promotional agents, distributors and supervisors but we don‚Äôt have 
physical offices there.
6. 
E-mail ‚Äì
	
legal.info@ajantapharma.com
7. 
Telephone -
	
022 66061000
8. 
Website -
	
www.ajantapharma.com 
9. 
Financial year for which 
reporting is being done -
	
1 April 2023 ‚Äì 31 March 2024
10. Name of the Stock Exchange(s) 
where shares are listed -
	
Bombay Stock 
Exchange Limited 
	
National Stock Exchange of 
India Limited
11. Paid-up Capital ‚Äì
	
H 251,831,310/-
12. Name and contact details 
(telephone, email address) of the 
person who may be contacted 
in case of any queries on the 
BRSR report
	
Mr. Arvind K. Agrawal - CFO
	
022 66061000
	
arvind.agrawal@ajantapharma.com
13. Reporting boundary - Are the 
disclosures under this report made 
on a standalone basis (i.e. only for 
the entity) or on a consolidated 
basis (i.e. for the entity and all 
the entities which form a part 
of its consolidated financial 
statements, taken together).
 
Consolidated*
14. Name of assurance provider
	
None
15. Type of assurance obtained
	
None
* Note - 
a.	
All the quantitative disclosures are on consolidated basis unless otherwise specified. 
b.	
The qualitative information is primarily presented for Indian operations. 
c.	
The previous year‚Äôs figures are restated from standalone to consolidated basis where specified.
19 Markets served by the entity:
a.	
Number of locations
Locations
Number
National (No. of States)
28 states and 8 Union Territories
International (No. of Countries)
30
b.	
What is the contribution of exports as a percentage of the total turnover of the entity?
	
68%
c.	
A brief on types of customers
	
Patients who use our medicines are our ultimate customers. We reach them through wholesalers and distributors 
who are our primary customers.
IV.	 Employees
20 Details as at the end of Financial Year:
a. 
Employees and workers (including differently abled)*:
S. No.
Particulars
Total
Male
Female
(A)
No. (B)
% (B / A)
No. (C)
% (C / A)
EMPLOYEES
1.
Permanent (D)
7962
7258
91.16%
704
8.84%
2.
Other than Permanent (E) 
123
120
97.56%
3
2.44%
3.
Total employees (D+E)
8085
7378
91.26%
707
8.74%
WORKERS
4.
Permanent (F)
111
111
100%
-
-
5.
Other than Permanent (G)
2172
2063
94.98%
109
5.02%
6.
Total workers (F+G)
2283
2174
95.23%
109
4.77%
b. 
Differently abled Employees and workers*:
S. No.
Particulars
Total
Male
Female
(A)
No. (B)
% (B / A)
No. (C)
% (C / A)
DIFFERENTLY-ABLED EMPLOYEES
1.
Permanent (D)
3
3
100%
-
-
2.
Other than Permanent (E) 
-
-
-
-
-
3.
Total differently abled 
employees (D+E)
3
3
100%
-
-
DIFFERENTLY-ABLED WORKERS
4.
Permanent (F)
1
1
100%
-
-
5.
Other than Permanent (G) 
-
-
0
-
-
6.
Total differently abled 
workers (F+G)
1
1
100%
-
-
	
* Disclosure is on standalone basis.
21
Participation/Inclusion/Representation of women
Total
No. and percentage of Females
(A)
No. (B)
% (B / A)
Board of Directors
8
1
12.5%
Key Management Personnel
4
-
-
Business Responsibility and Sustainability Report
Annual Report 2023-24
74
75
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Business Responsibility and Sustainability Report
22 Turnover rate for permanent employees and workers
FY 2024 
FY 2023
FY 2022
Male
Female
Total
Male
Female
Total
Male
Female
Total
Permanent Employees
23%
18%
23%
27%
21%
27%
22%
20%
22%
Permanent Workers
1%
-
1%
2%
-
2%
5%
-
5%
	
* Previous year‚Äôs Turnover rates are on standalone basis
V. 
Holding, Subsidiary and Associate Companies (including Joint Ventures)
23 (a)	 Names of holding / subsidiary / associate companies / joint ventures
S. No.
Name of the holding / subsidiary / 
associate companies / joint ventures 
(A)
Indicate whether holding/
subsidiary/ Associate/ 
Joint Venture
% of shares held by 
listed entity
Does the entity indicated at column A, 
participate in the Business responsibility 
initiatives of the listed entity? (Yes/No)
1.
 Ajanta Pharma USA Inc
Subsidiary
100%
Yes
2.
 Ajanta Pharma Philippines Inc
Subsidiary
100%
Yes
3.
 Ajanta Pharma Mauritius Limited
Subsidiary
100%
Yes
4.
 Ajanta Pharma Nigeria Limited
Subsidiary
100%
Yes
VI.	 CSR Details
24.	 (i)	
Whether CSR is applicable as per section 135 of Companies Act, 2013: (Yes/No)	
Yes
	
(ii)	
Turnover (H in crore)	
4,208.71
	
(iii)	
Net worth (H in crore)	
3,567.36
VII.	 Transparency and Disclosures Compliances
25 Complaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible 
Business Conduct:
Complainant 
group of 
Stakeholder
Grievance 
Redressal 
Mechanism 
in Place
Grievance Redressal Mechanism in Place 
FY 2024
FY 2023
No. of complaints
No. of complaints
(Yes/No)*
(If Yes, then provide web-link for grievance redressal 
policy)
Filed 
during the 
year
Pending 
resolution 
at close of 
the year
Filed 
during the 
year
Pending 
resolution 
at close of 
the year
Communities
Yes
Yes. Communities can raise their grievance through 
the concerned Plant head or CSR head.
-
-
-
-
Investors 
(other than 
shareholders)
Yes
There is dedicated email address of Company viz. 
investorgrivance@ajantapharma.com
Nil
Nil
Nil
Nil
Shareholders
Yes
Company‚Äôs Registrar & Transfer Agent, M/s. Link 
Intime India Pvt. Ltd., look after all the grievances/ 
enquiries/queries of Shareholders. Shareholders 
can also raise / escalate their grievances to the 
dedicated email address viz. investorgrivance@
ajantapharma.com 
3
1
4
-
Employees & 
workers
Yes
Employees can put their grievances in the complaint/
suggestion boxes placed at each office/plant.  
They can also raise their grievance to  
whistleblower@ajantapharma.com for any  
wrong doing observed in the Company.
-
-
-
-
Customers
Yes
Yes. Customers address their grievances through 
email on product.complaint@ajantapharma.com  
or enquiry form placed on Company‚Äôs website  
www.ajantapharma.com/ajanta/Contact 
188
12
168
4
Value Chain 
Partners
Yes
Yes. Value chain partners can raise their grievance 
to the concerned functional heads or location head. 
The same is attended promptly by the concerned 
functional head or location head.
-
-
-
-
26 Overview of the entity‚Äôs material responsible business conduct issues
Please indicate material responsible business conduct and sustainability issues pertaining to environmental and 
social matters that present a risk or an opportunity to your business, rationale for identifying the same, approach 
to adapt or mitigate the risk along-with its financial implications, as per the following format
Material issue identified
Whether 
risk or 
opportunity
Rationale for identifying the risk 
/ opportunity
In case of risk, approach to adapt or mitigate
Financial 
implications of the 
risk or opportunity
Product 
Quality and 
Safety
Risk 
Any deficiency in product 
quality & safety has very 
high adverse impact, both 
on the well-being of patients 
and business operations like 
decreased sales, reputational 
damage and regulatory 
actions.
Reduced revenue and actions 
from regulators in the form of 
penalties etc. 
[	 Company has in place, stringent 
Pharmacovigilance processes and 
adheres to Global Quality Standards to 
ensure best quality products.
[	 Active monitoring of product safety 
throughout their lifespan, employing 
rigorous quality control and quality 
assurance to ensure highest quality 
standards, cGMP compliance, and 
adherence to all regulatory requirements.
[	 Technological advancements, cGMP 
training, automation, and digitalisation to 
enhance efficiency and product quality.
[	 Periodic quality review of third-party 
locations is done to ensure quality and 
safety of products emanating from these 
locations.
Negative 
Occupational 
Health and 
Safety
Risk
Employees are the most 
important assets of the 
company and ensuring their 
health and safety is our prime 
objective. Poor OHS practices 
can lead to a cascade of 
negative consequences 
like absenteeism, reduced 
productivity, increased 
healthcare costs, etc. 
Poor OHS will result in 
frequent safety incidents, 
lower employee morale and 
productivity.
[	 Targeted EHS Training and Competency 
Building by both internal and external 
experts. 
[	 Periodic emergency drills 
[	 Robust Occupational Health -and Safety 
management system (ISO 45001:2018) at 
two major sites, with additional locations 
in India under process. 
[	 Each site conducts annual Occupational 
Safety and Health (OSH) Hazard 
Identification and Risk Assessments for all 
routine and non-routine activities, utilising 
multiple risk assessment techniques, such 
as Hazard Identification (HAZID), Hazard 
and Operability studies (HAZOP), and 
HIRA, to proactively identify and mitigate 
potential hazards associated with our 
processes.
Negative
Product 
development, 
innovation & 
pricing
Opportunity Innovative and first-to-market 
products developed after 
extensive R&D help us stay 
relevant in our market and 
grow consistently. It is essential 
for a wider consumer base 
and long-term sustainability.
The development of 
complex and novel drug 
delivery systems enables the 
Company to stay ahead 
of the competition and 
contribute towards product 
accessibility.
[	 Operational excellence and cost-
effectiveness, supporting the 
development of life-saving medications 
at affordable price.
Positive
Annual Report 2023-24
76
77
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Business Responsibility and Sustainability Report
Material issue identified
Whether 
risk or 
opportunity
Rationale for identifying the risk 
/ opportunity
In case of risk, approach to adapt or mitigate
Financial 
implications of the 
risk or opportunity
.
Corporate 
Governance
Risk
Compliance with laws and 
regulations is essential to have 
a good corporate image, 
smooth operations and 
create long term stakeholder 
value. 
Ethical breach or non-
compliances can erode 
stakeholder trust, impact 
employee morale, regulatory 
actions and adverse impact 
on financial performance. 
Upholding strong corporate 
governance facilitates 
responsible decision-making 
and financial transparency, 
vital for investor attraction.
[	 Strong corporate governance ensuring 
ethical conduct, regulatory compliance, 
and transparency.
[	 Maintain zero-tolerance for any ethical 
lapses or breaches of business integrity. 
[	 Code of Conduct for Directors and Senior 
Management outlines clear expectations 
regarding ethical behaviour, prohibiting 
illegal or harmful practices, bribery, 
and corruption, and ensuring proper 
management of conflicts of interest. 
[	 Senior Management and the Board 
actively monitor legal and regulatory 
compliance. This ensures minimising the 
risk of non-compliance and potential 
financial or reputational penalties. 
[	 Regular internal communication and 
training programmes on ethics standards 
and compliance systems. 
Negative
Talent 
Acquisition 
and 
Management
Opportunity Building a sustainable 
workforce involves attracting, 
developing, and retaining 
top talent, which cultivates a 
highly skilled and motivated 
workforce, essential for driving 
innovation and productivity. 
[	 By prioritising employee welfare and 
conducting various engagement and 
development programmes, Ajanta 
enhances employee motivation, 
satisfaction and retention. The company 
invests in training and professional 
development to equip them with the 
necessary skills, domain expertise, and 
latest technology in alignment with the 
business strategy. 
[	 This skilled workforce drives long-term 
business growth and creates value for all 
stakeholders.
Positive
Data Integrity 
and Cyber 
Security
Risk
Integrity of data is 
paramount for conducting 
safe and effective clinical 
trials, developing reliable 
medications, and maintaining 
patient safety. 
Breaches in data integrity 
could erode trust in products 
and compromise patient 
well-being. 
Cybersecurity breaches can 
disrupt critical processes, 
leading to delays, lost 
productivity, and increased 
costs. 
[	 Data integrity and security are central 
to our Information Security Management 
System (ISMS). 
[	 Implemented comprehensive policies and 
guidelines that govern data-handling 
practices across the organisation. Strong 
IT management & monitoring system, 
anti-virous, fire walls to prevent any data 
integrity and cyber security breaches.
[	 Training and awareness sessions are 
conducted for the employees to make 
them conversant with the latest trends in 
data integrity and cyber security.
[	 Meet all data privacy compliance 
requirements and our Disaster Recovery 
Plan safeguards data security, availability, 
and integrity in the event of disruptions or 
natural disasters.
Negative
Material issue identified
Whether 
risk or 
opportunity
Rationale for identifying the risk 
/ opportunity
In case of risk, approach to adapt or mitigate
Financial 
implications of the 
risk or opportunity
Energy 
Management
Opportunity Ajanta aims at prioritising 
operational efficiency through 
continuous energy transition 
and efficiency improvement 
and expecting long-term cost 
savings. 
[	 Our commitment to decarbonisation 
involves leveraging energy efficiency to 
reduce dependency on fossil fuels
[	 Investment in an 8.8 MW captive 
solar power plant demonstrates our 
dedication to renewable energy, 
fostering sustainability and minimising 
environmental impact. 
[	 This transition is expected to annually cut 
CO2 emissions by approximately 7,066 
Mt per annum, showcasing tangible 
environmental benefits.
[	 Further initiatives for solar power 
generation are underway, the impact of 
which will be seen in the coming years.
Positive
Water and 
Wastewater
Risk
Climate change and 
increasing water scarcity 
pose a significant risk to 
our operations. Similarly, the 
discharge of untreated or 
poorly treated wastewater 
can contaminate nearby 
water sources, harming 
aquatic ecosystems, affecting 
biodiversity, and endangering 
human health in communities 
relying on these water 
sources. These can lead to 
regulatory non-compliances 
and consequential actions.
[	 Ajanta is committed to become water 
positive by 2025 by minimising wastewater 
generation, deployment of Advanced 
treatment systems to recover and reuse 
wastewater and deployment of Rainwater 
Harvesting system 
[	 Zero Liquid Discharge systems are 
implemented at Guwahati and Dahej 
facilities. For other locations, treated 
water discharge is in compliance with the 
regulatory norms.
Negative
Waste
Risk
Improper management of 
hazardous waste carries 
significant environmental 
and health hazards. Non-
compliance with waste 
management regulations 
can lead to substantial fines, 
operational disruptions, 
and damage to reputation. 
Additionally, ineffective 
waste management drives 
up costs due to inefficiencies 
and increased disposal 
expenses.
[	 Aiming for a 10% annual decrease in waste 
generation. 
[	 Solvent Waste Recycling Initiative such 
as project to collect and recycle solvent 
waste generated from quality control (QC) 
activities at our sites. 
[	 Zero Landfill for Hazardous Waste at two 
of our major facilities, 
[	 Our Extended Producer Responsibility 
programme collects and sends pre-
consumer and post-consumer plastic 
waste for recycling. 
Negative
Annual Report 2023-24
78
79
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Business Responsibility and Sustainability Report
Material issue identified
Whether 
risk or 
opportunity
Rationale for identifying the risk 
/ opportunity
In case of risk, approach to adapt or mitigate
Financial 
implications of the 
risk or opportunity
Human  
Rights
Risk
Violations of human rights 
in our operations or supply 
chain can lead to non-
compliance of laws and 
consequential regulatory 
actions, unrest & instability in 
the communities where we 
operate and reputational 
damage. This can disrupt 
our supply chains, hinder our 
ability to recruit and retain 
talent, and adversely impact 
our business operations.
[	 Comprehensive Human Rights Policy 
outlining our commitment to upholding 
human rights across all our stakeholder 
interactions.
[	 Conduct thorough due diligence 
assessments to ensure there are no human 
rights violations within our operations. 
[	 Promote a workplace culture that 
celebrates diversity and prohibits all forms 
of discrimination and harassment and 
there is dedicated grievance channel. 
[	 Committed to working with Third Party 
(TP)/ Value Chain Partners who operate 
consistent with Ajanta values and ethical 
principles, including respect for human 
rights. 
[	 Conduct human rights training for 
employees and value chain partners.
Negative
Section B ‚Äì Management and Process Disclosures
This section is aimed at helping businesses demonstrate the structures, policies and processes put in place towards 
adopting the NGRBC Principles and Core Elements.
S. 
No.
Disclosure Questions
P1
P2
P3
P4
P5
P6
P7
P8
P9
Policy and management processes
Yes
1. a Whether your entity‚Äôs policy/policies cover each principle 
and its core elements of the NGRBCs. (Yes/No/NA)
b Has the policy been approved by the Board? 
(Yes/No/NA)
c Web Link of the Policies, if available
https://ajantapharma.com//images/BusinessResponsibilityPolicies.pdf
2
Whether the entity has translated the policy into 
procedures. (Yes / No/ NA)
Yes
3
Do the enlisted policies extend to your value chain 
partners? (Yes/No/NA)
Yes
4
Name of the national and international codes/
certifications/labels/ standards (e.g. Forest Stewardship 
Council, Fairtrade, Rainforest Alliance, Trustee) standards 
(e.g. SA 8000, OHSAS, ISO, BIS) adopted by your entity 
and mapped to each principle.
cGMP standards, CDSCO: 
India, USFDA, ISO 9001:2015, 
WHO
ISO 45001:2018*
ISO 14001:2015*
CDSCO : India,
ISO 9001:2015
5
Specific commitments, goals and targets set by the entity 
with defined timelines, if any
As provided below
6
Performance of the entity against the specific 
commitments, goals and targets along-with reasons in 
case the same are not met
* We‚Äôve successfully implemented Occupational Health and Safety (ISO 45001:2018) and Environmental Management (ISO 14001:2015) 
systems at two of our major sites & awaiting certification at other two sites.
Business Ethics
[	 Conduct two awareness programmes every year on BRSR Principles for various stakeholders including 
value chain partners.
[	 Initiated a drive to create awareness among stakeholders through different initiatives, including circulating 
ESG questionaries; conducting online training sessions and facilitating one-to-one interactions.
Product Sustainability & Safety
[	 Invest H 10 Cr in R&D by FY 2026 to develop specific technologies that improve the environmental and 
social impact of our products and processes.
[	 Undertake Life Cycle Assessment of 4 key products by FY 2026.
[	 Invested around 10% of our targeted expenses in R&D to minimise environmental impact and actively 
pursuing sustainable product development. Achieving this by optimising batch cycles, reducing solvent 
use through improved energy efficiency, and minimising the packaging of some products. 
[	 Completed life cycle assessments of our two major products.
P1
P2
Annual Report 2023-24
80
81
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Business Responsibility and Sustainability Report
Employee well-being
Create a workplace culture that supports employee health, happiness and personal growth through 
a variety of initiatives, including:
[	 Offering health and life insurance coverage for employees and family.
[	 Providing opportunities for professional development and career advancement.
[	 Encouraging work-life balance by offering flexible work arrangements.
[	 Extending subsidised canteen facility.
[	 Conducting town hall meetings to get employee feedback/suggestions.
[	 Promoting diversity, equity and inclusion by creating an environment where all employees feel valued 
and respected.
[	 Providing a supportive work environment that encourages open communication, collaboration 
and teamwork.
[	 Settled all hospitalisation and other claims expeditiously 
[	 Revised HR policy to increase local and outstation travel allowances. 
[	 Increased the number of Privileged Leave and Privileged Leave accumulation limit to promote the work 
life balance.
[	 Reduced company loan interest rate to help employees in contingencies.
[	 Conducted various training and employee engagement programmes.
Stakeholder engagement
[	 Provide necessary mechanism to the Stakeholders for raising their grievances and address the 
same swiftly. 
[	 Conduct stakeholder survey every three years to understand their concerns and expectations.
[	 Requisite mechanism in place to enable shareholders, employees, vendors, communities and other 
stakeholders to raise their grievances and give suggestions.
[	 Conducted training & orientation programmes for vendors and contract manufacturers on ESG 
and sustainability. 
Human Rights
[	 To conduct annual training and awareness programmes on human rights including POSH.
[	 To ensure 100% compliance with labor laws and the protection of human rights.
[	 No human rights violations /complaints related to child, forced and involuntary labor, discriminatory employment, or 
sexual harassment. 
[	 Conducted webinars and awareness programmes for employees on POSH.
[	 Internal Complaint Committee is in place at all locations to address the complaints of sexual harassment.
[	 Business Integrity Committee in place to address grievances or violations of human rights.
[	 Conducted Open House Meetings at all locations to promote transparency and open communication, providing a 
platform for Ajantaites to give feedback and suggestions.
P3
P4
P5
Specific commitments, goals and targets set by the entity with defined timelines
Performance of the entity against the specific commitments, goals and targets
Environment Management
[	 We aim to achieve 50% use of renewable power by FY 2026 and 100% by FY 2032.
[	 Become water positive by FY 2025
[	 Reduce waste per unit of production by 10% every year and overall by 30% by 2030
[	 Focus on digitalisation to reduce paper waste by 80% by 2026
[	 Reduce energy consumption by 10% by 2026 and 15% by 2028
[	 Reduce Scope 1 and Scope 2 emissions by 10% by 2026 and 30% by 2030
[	 Achieved 30% use of green energy till Mar‚Äô 24.
[	 Reduced fresh water withdrawal/unit of production by 14% during FY 23-24. 
[	 Achieved 8% waste reduction/unit of production in comparison to last FY.
[	 With continuous digitalisation, we have significantly reduced paper waste.
[	 Achieved 4% energy reduction by implementing EC fan installation for AHU, CRS for boiler and EMS system at Dahej & 
Guwahati sites for effective monitoring and control. Many more projects in pipeline. 
[	 Till date contributed to reduce 23% Scope 2 emission by installing and operating 12.69 MWp capacity captive solar 
plant all across our facilities. More projects are under pipeline. Reduced total Scope 1 and Scope 2 emission per unit 
by 27% in FY 2024 compared to last year.
Public Advocacy
[	 Ajanta will continue to ensure that all public advocacy issues in the broader public interest occurs through industry 
forums and associations.
[	 Company addresses and takes up all such issues through industry forums and associations.
Inclusive growth and Equitable development
[	 Continue to undertake CSR activities in the areas of education, healthcare, rural development & promotion 
of sports for the benefit and upliftment of marginalised and economically weaker sections, as well as 
local communities.
[	 Conduct Social Impact Assessments (SIA) of CSR projects through implementation agencies, as applicable.
[	 Details of CSR initiatives and beneficiaries are provided in the Principle 8 section of this report.
Consumer service
[	 Ensure 100% compliance with labeling norms and regulations.
[	 Ensure 100% resolution of customer complaints.
[	 Undertake consumer satisfaction survey once a year.
[	 Conduct consumer awareness programme.
[	 Stringent quality control and assurance checks are in place to ensure no product recalls. 
[	 CAPA implementation for any complaints. 
[	 All the consumer complaints are attended on top priority and corrective actions are taken promptly.
* Baseline Year 2021
P6
P7
P8
P9
Specific commitments, goals and targets set by the entity with defined timelines
Performance of the entity against the specific commitments, goals and targets
Annual Report 2023-24
82
83
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Business Responsibility and Sustainability Report
Governance, leadership and oversight
7
Statement by director responsible for the business responsibility report, highlighting ESG related challenges, targets and 
achievements (listed entity has flexibility regarding the placement of this disclosure)
Director‚Äôs message is given at the beginning of this report.
8
Details of the highest authority responsible for implementation and oversight of the Business Responsibility policy (ies).
ESG Committee
9
Does the entity have a specified Committee of the Board/ Director responsible for decision making on sustainability 
related issues? (Yes / No/ NA).
Yes
The Company has constituted an ESG Committee comprising all the important functional heads for decision-making on day-
to-day sustainability-related issues. The Committee meets once a month to review the progress in implementing ESG initiatives. 
The CSR Committee is recently re-constituted as the ‚ÄúCSR and Sustainability Committee‚Äù for overseeing and reviewing the ESG 
& sustainability initiatives and progress on quarterly basis. The Board reviews the ESG and sustainability performance annually.
10 Details of Review of NGRBCs by the Company
Subject for Review
Indicate whether review was undertaken by
Director/Committee of the Board/Any other Committee
P1
P2
P3
P4
P5
P6
P7
P8
P9
a.
Performance against above policies and follow up action ESG Committee
b.
Description of other committee for performance against 
above policies and follow up action
Performance against above policies is monitored and reviewed by the 
ESG committee and necessary actions are taken.
c.
Compliance with statutory requirements of relevance to 
the principles and rectification of any non-compliances
ESG Committee
d.
Description of other committee for compliance with 
statutory requirements of relevance to the principles and 
rectification
Respective functional heads, in consultation with the ESG committee
Subject for Review
Frequency
(Annually / Half yearly /Quarterly/ Any other-please specify)
P1
P2
P3
P4
P5
P6
P7
P8
P9
a.
Performance against above policies and follow up action
Annually
b.
Compliance with statutory requirements of relevance to 
the principles and rectification of any non-compliances
Annually
11
Has the entity carried out independent assessment/ 
evaluation of the working of its policies by an external 
agency? (Yes/No). 
No*
Yes1
Yes2
No*
No*
Yes3
No*
No*
Yes1
If yes, provide name of the agency.
1.	 TUV India company conducted the ISO 9001:2015 certification audit
2.	 TUV company conducted the ISO 45001:2018 certification audit
3.	 TUV company conducted the ISO 14001:2015 certification audit
* The Company internally reviews the working of the above-mentioned policies.
12
If answer to question (1) above is ‚ÄúNo‚Äù i.e. not all Principles 
are covered by a policy, reasons to be stated:
P1
P2
P3
P4
P5
P6
P7
P8
P9
The entity does not consider the Principles material to its 
business (Yes/No)
NA
The entity is not at a stage where it is in a position 
to formulate and implement the policies on specified 
principles (Yes/No)
NA
The entity does not have the financial or/human and 
technical resources available for the task (Yes/No)
NA
It is planned to be done in the next financial year (Yes/No)
NA
Any other reason (please specify)
NA
Section C ‚Äì Principle Wise Performance Disclosure
PRINCIPLE 1 Businesses should conduct and govern themselves with integrity, and in a 
manner that is Ethical, Transparent and Accountable.
Essential Indicators
1
Percentage coverage by training and awareness programmes on any of the principles during the financial year:
Segment
Total number of 
training and awareness 
programmes held
Topics/principles covered under the training and its impact
%age of persons in 
respective category 
covered by the 
awareness programmes
Board of Directors
6
P1 to P9
100%
Key Managerial 
Personnel
6
P1 to P9
100%
Employees other than 
BOD and KMPs
3311
The trainings covered upskilling and reskilling of employees 
on the following:
[	 ESG aspects
[	 Occupational Health and Safety
[	 Prevention of Sexual Harassment
[	 Human Rights
[	 Consumer Safety
[	 Cyber Security
[	 Regulatory compliance
[	 Code of Conduct on ethics
[	 Collaborative Leadership
[	 Emotional Intelligence
[	 Stress Management
[	 Specific to department / business function
[	 Trainings covered P1 to P9
100%
Workers
407
Training programmes covered:
[	 Health & Safety Trainings
[	 Code of Conduct
[	 Prevention of Sexual Harassment
[	 Human Rights
[	 Regulatory compliance
[	 Trainings covered Principles 1, 2, 3, 5 and 6
100%
* Disclosure is provided on standalone basis
2
Details of fines / penalties /punishment/ award/ compounding fees/ settlement amount paid in proceedings  
(by the entity or by directors / KMPs) with regulators/ law enforcement agencies/ judicial institutions, in the 
financial year
Particular
NGRBC Principle
Name of the regulatory/ 
enforcement agencies/ 
judicial institutions
Amount (In K)
(For Monetary Cases only) Brief of the Case
Has an appeal been 
preferred? (Yes/No)
Monetary
Penalty/ Fine
NIL
NA
NA
NA
NA
Settlement
NIL
NA
NA
NA
NA
Compounding fee
NIL
NA
NA
NA
NA
Particular
NGRBC Principle
Name of the regulatory/ 
enforcement agencies/ 
judicial institutions
Brief of the Case
Has an appeal been preferred? (Yes/No)
Non-Monetary
Imprisonment, Punishment
NIL
NA
Annual Report 2023-24
84
85
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Business Responsibility and Sustainability Report
3
Of the instances disclosed in Question 2 above, details of the Appeal/ Revision preferred in cases where  
monetary or non-monetary action has been appealed.
Case Details
Name of the regulatory/ enforcement agencies/ judicial institutions
NA
NA
4
Does the entity have anti-corruption or anti-bribery policy? (Yes/ No)
Yes
	
The Company‚Äôs Code of Conduct for Directors and Senior Management provides for adherence to ethical 
conduct & practices and discourages bribery and corruption while interacting business with any third Parties. 
 https://www.ajantapharma.com/images/CodeofConductforDirectorsandSeniorManagement.pdf 
	
The Ethics policy framed under the NGRBC principles mandates that the business does not engage in illegal and 
abusive practices, bribery and corruption and addresses conflicts of interest involving employees, supply chain 
and business partners. https://www.ajantapharma.com/images/BusinessResponsibilityPolicies.pdf 
 
The Third-Party Code of Conduct of the Company expects its TP/ value chain partners to adhere to the principles 
of the Code of Conduct and Ethics Policy. The Company encourages its TP comply with applicable laws and 
regulations and industry standards related to anti-corruption and dissuades from committing acts of bribery in 
its value chain. https://www.ajantapharma.com/images/Third-Party-Code-of-Conduct.pdf
	
The Human Resource Policy ‚Äì Code of Conduct of Ajanta treats demanding/ accepting bribes connected with the 
business of the organisation as an act of serious misconduct. The Policy is available on Company‚Äôs Intranet portal. 
The Company also discourages accepting any gifts or favours by employees from any suppliers or third parties.
5
Number of Directors/ KMPs/ employees/ workers against whom disciplinary action was taken by any law 
enforcement agency for the charges of bribery/ corruption:
Particular
FY 2023-24
FY 2022-23
Directors, KMPs, Employees, Workers
NIL
NIL
6
Details of complaints with regard to conflict of interest:
Case Details
FY 2023-24
FY 2022-23
Number
Remark
Number
Remark
Number of complaints received in relation to issues of 
Conflict of Interest of the Directors & KMP
NIL
NA
NIL
NA
7
Provide details of any corrective action taken or underway on issues related to fines / penalties / action taken by 
regulators/ law enforcement agencies/ judicial institutions, on cases of corruption and conflicts of interest.
None
8
Number of days of accounts payables in the following format:
Particular
FY 2023-24
FY 2022-23
Number of days of accounts payables
151 days
129 days
9
Open-ness of business
Provide details of concentration of purchases and sales with trading houses, dealers, and related parties along-with loans and 
advances & investments, with related parties, in the following format:
Parameter
Metrics
FY 2023-24
FY 2022-23
Concentration of 
Purchases
a.	 Purchases from trading houses as % of total purchases
-
-
b.	 Number of trading houses where purchases are made from
-
-
c.	 Purchases from top 10 trading houses as % of total purchases 
from trading houses
-
-
Concentration of Sales
a.	 Sales to dealers / distributors as % of total sales
68.58%
68.33%
b.	 Number of dealers / distributors to whom sales are made
35
35
c.	 Sales to top 10 dealers / distributors as % of total sales to 
dealers / distributors
57.84%
60.07%
Share of RPTs in
a.	 Purchases (Purchases with related parties / Total Purchases)
0.76%
0.84%
b.	 Sales (Sales to related parties / Total Sales)
-
-
c.	 Loans & advances (Loans & advances given to related 
parties / Total loans & advances)
-
-
d.	 Investments
-
-
Leadership Indicators
1
Awareness programmes conducted for value chain partners on any of the Principles during the financial year:
Total number of awareness 
programmes held
Topics / principles covered under 
the training
Percentage of value chain partners covered (by value of business done 
with such partners) under the awareness programmes
2
 BRSR Core Disclosures
100%*
	
* Ajanta is accelerating its efforts towards building a sustainable future, and we consider our suppliers as key partners in this journey. 
Recognising their crucial role in our commitment to Business Responsibility and Sustainability, we have actively engaged them to embrace 
sustainable practices. 
	
We‚Äôve established clear supplier criteria that go beyond traditional metrics. In addition to evaluating general 
competence, financial health, and capacity, we now place a strong emphasis on their commitment to ESG factors.
	
This year, we focused heavily on enhancing internal proficiency and implemented operational changes and 
procedures to minimise waste and enhance energy efficiency. The Company also launched Value Chain Assessment 
of 100% of the Value Chain partners, as per BRSR Core Framework issued by SEBI on 12 July 2023 prescribing the 
ESG disclosures for value chain. Out of our total valued partners, approximately 10% of upstream and 11% of 
downstream value chain partners (by value of business) submitted the assessment on the Nine Attributes and their 
corresponding ESG parameters. Ajanta is committed to build safe and sustainable environment and is continuously 
taking various measures & initiatives on ESG front as also for inclusive growth.
2
Does the entity have processes in place to avoid/ manage conflict of interests involving members of the 
Board? (Yes/No) 
Yes
If Yes, provide details of the same.
	
Ajanta prioritises ethical governance and has robust processes in place to manage potential 
conflicts of interest involving board members.
 
Code of Conduct: Our Code of Conduct for Directors and Senior Management sets clear legal and ethical 
standards. This code emphasises honest, fair, and ethical behaviour, including the responsible handling of any 
potential conflicts between personal and professional interests.
 
Policy On Materiality of Related Party Transactions and Dealing with Related Party Transactions: We have laid down 
comprehensive ‚ÄúPolicy on Materiality of Related Party Transactions and Dealing with Related Party Transactions‚Äú 
that governs transactions with board members and their relatives. We restrict related party transactions to the 
bare minimum. Further, any transactions involving board members or entities in which they have a stake, require 
prior approval by the Audit Committee and the Board of Directors. In such cases, the concerned board member(s) 
abstain from relevant discussions and voting.
Annual Report 2023-24
86
87
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Business Responsibility and Sustainability Report
 
Annual Declarations: Board members and senior management are required to submit annual declarations 
confirming their adherence to the Code of Conduct and disclosing any potential conflicts of interest in their 
business dealings.
	
These measures demonstrate Ajanta‚Äôs commitment to transparency, accountability, and responsible 
corporate governance.
	
Code of Conduct for Directors and Senior Management -  
https://www.ajantapharma.com/images/CodeofConductforDirectorsandSeniorManagement.pdf
	
Policy on Materiality of Related Party Transactions and Dealing with Related Party Transactions ‚Äì 
	
https://www.ajantapharma.com/images/PolicyonRelatedPartyTransactions.pdf
PRINCIPLE 2 Businesses should provide goods and services in a manner that is sustainable  
and safe.
Essential Indicators
1
Percentage of R&D and capital expenditure (capex) investments in specific technologies to improve the 
environmental and social impacts of product and processes to total R&D and capex investments made by  
the entity, respectively.
S. No. Particulars
FY 2023-24
FY 2022-23
Details of improvements in environmental and social impacts
1
R&D
 19%
 28%
Refer to page 51 of Annual Report
2
Capex
 23%
 72%
2
a.‚ÄÇ Does the entity have procedures in place for sustainable sourcing? (Yes/No) 
Yes
b.	 If yes, what percentage of inputs were sourced sustainably?
	
100% of the company‚Äôs suppliers are covered by the Third Party Code of Conduct.
	
As part of engagement with Ajanta, all suppliers are expected to abide by the Third Party Code of Conduct, 
which includes parameters on human rights, fair employment practices, environmental sustainability, animal 
welfare, anti-bribery and fair competition, data privacy, good manufacturing practices, management systems, 
etc., among others
3
Describe the processes in place to safely reclaim your products for reusing, recycling and disposing at the end  
of life, for 
Ajanta is committed to responsible product stewardship throughout the life cycle of our medicines. We are 
continuously evaluating opportunities to improve our practices. This includes exploring the feasibility of take-
back programmes for unused medicines and further developing our plastic packaging recycling initiatives. The 
Company is adhering to the requirements of Plastic Waste Management Rules laid down by the Central Pollution 
Control Board. We have complied with the Extended Producers Responsibility (EPR) obligation under the Plastic 
Waste Management (PWM) Rules 2016. The Company is recycling 100% of the packaging foils with the help of its 
implementation partners.
(a)
Plastics (including 
packaging)
For handling post-consumer plastic waste, we‚Äôve partnered with authorised vendors who reclaim and 
collect plastics. All post-consumer plastic waste undergoes 100% co-processing in the cement industry.
(b)
E-waste
Not Applicable
(c)
Hazardous waste
For expired or damaged medicine stock, we have a well-defined process for reclamation from stockists 
in accordance with our standard operating procedures. This reclaimed medicine is then disposed 
of safely using a certified incineration route that adheres to regulatory guidelines. We are actively 
investigating potential future options for take-back programmes for unused medicines reaching the 
end of their life cycle.
(d)
Other waste
Not Applicable
4
a.‚ÄÇ Whether Extended Producer Responsibility (EPR) is applicable to the entity‚Äôs activities (Yes/No)
Yes
 b.
If yes, whether the waste collection plan is in line with the Extended Producer Responsibility (EPR) plan submitted to 
Pollution Control Boards?
Yes, we comply with Plastic Waste Management Rules, 2016 (including subsequent amendments) and the Extended 
Producer Responsibility (EPR) guidelines. Our waste collection plan aligns with our EPR plan submitted to the 
Pollution Control Board (PCB).
Leadership Indicators
1
Has the entity conducted Life Cycle Perspective / Assessments (LCA) for any of its products (for manufacturing 
industry) or for its services (for service industry)? (Yes/No)
Yes, we have conducted life cycle assessment for our products Feburic 40 and Met XL 50.
NIC Code
Name of Product 
/Service
% of total 
Turnover 
contributed
Boundary for which the 
Life Cycle Perspective / 
Assessment was conducted
Whether conducted by 
independent external 
agency (Yes/No)
Results 
communicated 
in public domain 
(Yes/No)
If yes, provide 
the web-link.
24232
Feburic 40
0.96%
Cradle to gate
Yes, by SIPL Private 
Limited
No
NA
24232
Met XL 50
1.24%
Cradle to gate
Yes, by SIPL Private 
Limited
No
NA
2
Percentage of recycled or reused input material to total material (by value) used in production  
(for manufacturing industry) or providing services (for service industry).
S. No. Indicate input material
Recycled or re-used input material to total material  
(In % to Total Material considering the Value)
FY 2023-24
FY 2022-23
Since we are in the pharmaceutical business, we do not recycle or reuse input material.
PRINCIPLE 3 Businesses should respect and promote the well-being of all employees,  
including those in their value chains.
Essential Indicators
1
a.‚ÄÇ Details of measures for the well-being of employees:
% of employees covered by
Category
Total (A)
Health insurance
Accident insurance
Maternity benefits
Paternity Benefits
Day Care facilities
Number 
(B)
% (B / A)
Number 
(C)
% (C / A)
Number 
(D)
% (D / A)
Number 
(E)
% (E / A)
Number 
(F)
% (F / A)
PERMANENT EMPLOYEES
Male
7258
6724
93%
7191
99%
0
0
8
0.11%
0
0%
Female
704
641
91%
562
80%
704
100%
0
0
87
12%
Total
7962
7365
93%
7753
97%
704
100%
8
0.11%
87
1%
OTHER THAN PERMANENT EMPLOYEES
Male
120
120
100%
120
100%
0
0%
0
0%
0
0%
Female
3
3
100%
3
100%
3
100%
0
0%
0
0%
Total
123
123
100%
123
100%
3
100%
0
0%
0
0%
Annual Report 2023-24
88
89
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Business Responsibility and Sustainability Report
b.‚ÄÇ Details of measures for the well-being of workers:
% of workers covered by
Category
Total (A)
Health insurance
Accident insurance
Maternity benefits
Paternity Benefits
Day Care facilities
Number 
(B)
% (B / A)
Number 
(C)
% (C / A)
Number 
(D)
% (D / A)
Number 
(E)
% (E / A)
Number 
(F)
% (F / A)
PERMANENT EMPLOYEES
Male
111
111
100%
111
100%
0
0%
0
0%
0
0%
Female
0
0
0%
0
0%
0
0%
0
0%
0
0%
Total
111
111
100%
111
100%
0
0%
0
0%
0
0%
OTHER THAN PERMANENT EMPLOYEES
Male
2063
2063
100%
2063
100%
0
0%
0
0%
0
0%
Female
109 
109
100%
109 
100%
109 
100%
0
0%
109
100%
Total
2172
 2172
100%
2172
100%
109
100%
0
0%
109
5%
c.‚ÄÇ Spending on measures towards well-being of employees and workers (including permanent and other than 
permanent) in the following format
FY 2023-24
FY 2022-23
Cost incurred on well-being measures as a % of total revenue of the company*
0.14%
0.16
	
* Spending on well-being measures comprises spending on Health Insurance, Accident Insurance and Maternity benefits.
2
Details of retirement benefits, for Current Financial Year and Previous Financial Year.
Benefits*
FY 2023-24
FY 2022-23
No. of employees 
covered as a % of 
total employees
No. of workers 
covered as a % of 
total workers
Deducted and 
deposited with 
the authority 
(Y/N/N.A.)
No. of employees 
covered as a % of 
total employees
No. of workers 
covered as a % of 
total workers
Deducted and 
deposited with 
the authority 
(Y/N/N.A.)
PF
100%
100%
Yes
100%
100%
Yes
Gratuity
100%
100%
Yes
100%
100%
Yes
ESI
100%
100%
Yes
100%
100%
Yes
	
* Retirement benefits are paid as per the applicability and eligibility requirements of the local laws.
3
Accessibility of workplaces
Are the premises / offices of the entity accessible to differently abled employees and workers, as per the 
requirements of the Rights of Persons with Disabilities Act, 2016? 
Yes
Ajanta prioritises accessibility in our workplaces to promote inclusion for all employees and workers. We have implemented 
accessibility features in our offices, including elevators and ramps at the corporate locations, as well as other sites wherever 
required. These features create a barrier-free environment that facilitates easy movement and navigation for individuals with 
disabilities.
If not, whether any steps are being taken by the entity in this regard. ‚Äì Not Applicable
4
Does the entity have an equal opportunity policy as per the Rights of Persons with Disabilities Act, 2016?
Yes
If so, provide a web-link to the policy.
The Policy is available on the intranet of the Company.
5
Return to work and Retention rates of permanent employees and workers that took parental leave. 
Gender
Permanent Employees
Permanent Workers
Return to work rate
Retention Rate
Return to work rate
Retention Rate
Male
NA
NA
NA
NA
Female
100%
96%
-
-
Total 
100%
96%
-
-
6
Is there a mechanism available to receive and redress grievances for the following categories of employees and 
worker? If yes, give details of the mechanism in brief.
Category
Yes/No
If Yes, then give details of the mechanism in brief
Permanent Workers
Yes
The Company established a three-way approach to receive and redress 
grievances of employees: 
Open door policy: The employees may specify their grievance to their line 
manager or directly to the HR manager.
Committees for issues related to Human Rights: The Company has an Internal 
Complaints Committee (ICC) and a Business Integrity Committee. The ICC has 
been formed to address Sexual Harassment grievances, whereas the Business 
Integrity Committee caters to grievances or violations of Human Rights. 
Suggestion Box: We have kept suggestion box at each plant/site. Employees 
are encouraged to provide suggestions, raise concerns with respect to health 
and safety practices or any other concerns. We ensure that every complaint is 
attended seriously and dealt with in an impartial, confidential and transparent 
manner.
Additionally, the Company through its Whistle-blower Policy (Vigil Mechanism) 
encourages all its employees and workers to raise legitimate concerns/make 
disclosures/raise alarms, which the individual genuinely believes is a violation 
of the Codes or any malpractice, corruption, fraud or unethical conduct or 
misuse of position that could have a grave impact on the operations, business 
or image of the Company. 
The Company has also adopted a policy on prevention of sexual harassment 
at the workplace in line with the provisions of the Sexual Harassment of 
Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and 
the Rules made thereunder. Employees/workers are provided with a complaint 
mechanism, through which incidents of sexual harassment may be reported, 
investigated and resolved.
Other than Permanent 
Workers
Yes
Permanent Employees
Yes
Other than Permanent 
Employees
Yes
7
Membership of employees and worker in association(s) or Unions recognised by the listed entity:
Category
FY 2023-24
FY 2022-23*
Total employees / 
workers in respective 
category
(A)
No. of employees / 
workers in respective 
category, who are part of 
association(s) 
or Union
(B)
% (B/A)
Total employees / 
workers in respective 
category
(C)
No. of employees / 
workers in respective 
category, who are part 
of association(s) 
or Union
(D)
% (D/C)
Total Permanent employees
Total
7962
-
0%
7803
-
0%
Male
7258
-
0%
7129
-
0%
Female
704
-
0%
674
-
0%
Total Permanent Workers
Total
111
102
92%
112
103
92%
Male
111
102
92%
112
103
92%
Female
0
-
-
-
-
-
	
* Previous year figures are restated due to consolidation.
Annual Report 2023-24
90
91
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Business Responsibility and Sustainability Report
8
Details of training given to employees and workers:*
Category
FY 2023-24
FY 2022-23**
Total (A)
On Health and Safety 
Measures
On Skill Upgradation
Total (D)
On Health and Safety 
Measures
On Skill Upgradation
Number (B)
% (B/A)
Number 
(C)
% (C/A)
Number (E)
% (E/D)
Number (F)
% (F/D)
Employees
Total
7258
7191
99%
6501
90%
7129
7059
99%
5736
80%
Male
704
562
80%
308
44%
674
565
84%
420
62%
Female
7962
7753
97%
6809
86%
7803
7624
98%
6156
79%
Workers
Total
111 
111 
100%
111 
100%
112 
112 
100%
112 
100%
Male
0
-
0%
- 
0%
0
-
0%
-
0%
Female
111 
111 
100%
111 
100%
112 
112 
100%
112 
100%
	
* Disclosure is provided only for permanent employees and workers.
	
** Previous year figures are restated due to consolidation.
9
Details of performance and career development reviews of employees and worker:*
Category
FY 2023-24
FY 2022-23
Total (A)
No. (B)
% (B/A)
Total (D)
No. (E)
% (E/D)
Employees
Male
7258
7190
99%
7129
7057
99%
Female
704
561
80%
674
564
84%
Total
7962
7751
97%
7803
7621
98%
Workers
Male
111 
111 
100%
112 
112 
100%
Female
0
-
0%
0
-
- 
Total
111 
111 
100%
112 
112 
100% 
	
* Disclosure is provided only for permanent employees and workers.
	
** Previous year figures are restated due to consolidation
10
Health and safety management system
	
a.	
Whether an occupational health and safety management system has been implemented by the entity? 
(Yes/ No)
	
	
Yes, the company places utmost emphasis on Occupational Health and Safety (OH&S) management. Following 
are the objectives and commitments:
	
	
[	
Provide safe and healthy working conditions for the prevention of work-related injury and ill health.
	
	
[	
Eliminate hazards and reduce OH&S risks.
	
	
[	
Continual improvement of the EHS management system.
	
	
[	
Fulfil legal and other obligations.
	
	
All work-related risks & their causes in the work environment are identified. To mitigate the same, personal 
protective equipment are provided & awareness training related to SOPs and best practices is provided to 
the employees and workers.
	
	
Each site is supervised by the EHS team and the site management who conduct workplace inspections 
& hazard identifications which are then notified to the EHS head. Safety & Environmental audits are also 
conducted through external agencies to identify the gaps and to establish compliances. Central Safety 
Committee and emergency response team are also formed who periodically conduct workplace & work zone 
monitoring at the sites. As a safety measure, signages including general safety instructions, (also in vernacular 
languages), Life Safety Rules etc. are placed in all the factories. Process Safety Risk Assessment & Material 
Safety Data Sheet (MSDS) are also kept at all sites.
	
	
Health insurance & compensation, Occupational health center, first aid at points, firefighting systems (smoke 
detectors, fire alarm systems, fire extinguishers), SOPs to operate plant activities in emergencies, ambulance, 
Government approved on site Emergency plan are provided at all the sites. Further, Safety Risk Assessment & 
Safety Audit is done by regulatory bodies. In order to ensure that the suppliers comply with EHS regulations, 
the Company assesses their data on various Health and Safety parameters and certifications of their sites.
	
b.	
What are the processes used to identify work-related hazards and assess risks on a routine and non-
routine basis by the entity?
	
	
We firmly believe that risk assessments are integral to ensuring the health, safety, and well-being of everyone 
in the workplace. At our company, risk assessment is conducted through the Hazard Identification and Risk 
Assessment (HIRA) method, which comprises of 3 steps:
	
	
1.	
Spot the Hazard (Hazard Identification).
	
	
2.	
Assess the Risk (Risk Assessment).
	
	
3.	
Make the Changes (Risk Control).
	
	
By following HIRA methodology, we ensure systematic identification of hazards, evaluate associated risks and 
implement necessary controls. In addition, periodic internal audits and leadership rounds are conducted to 
identify unsafe acts/conditions, further aiding in the improvement and optimisation of risk levels. Corrective 
Actions and Preventive Actions (CAPA) are implemented based on the incident and its cause. Furthermore, 
follow-up on the implementation of CAPA is performed to reassess the process if necessary. 
	
c.	
Whether you have processes for workers to report the work related hazards and to remove themselves 
from such risks? (Yes/ No)
	
	
We are committed to fostering a safe work environment by proactively identifying and mitigating potential 
hazards. Here are some key highlights of our approach:
	
	
Hazard Identification and Risk Management:
 
 
Standardised Procedures: We have established robust Standard Operating Procedures (SOPs) that guide the 
timely identification and mitigation of work-related hazards and risks. These SOPs ensure a consistent and 
comprehensive approach to workplace safety across all our facilities.
	
 
Comprehensive Training: We provide all employees with occupational health and safety training. These 
training modules equip employees with the knowledge and skills to identify potential hazards, evaluate 
associated risks, and implement appropriate control measures.
 
 
Emergency Preparedness: Employees receive hands-on training during safety and emergency evacuation 
drills. This training covers the proper use of emergency equipment, such as fire hydrants, fire-fighting systems, 
leak and spill control methods, and safety alarms. Additionally, we regularly assess staff competency in 
handling emergency situations.
	
	
Employee Engagement and Hazard Reporting:
	
 
Multiple Reporting Channels: We have implemented various systems to encourage employees to report work-
related hazards. These include readily accessible safety suggestion boxes at each site, allowing employees 
to anonymously report concerns and details of identified hazards.
	
	
By prioritising these initiatives, we cultivate a culture of safety where employees are empowered to identify and 
report hazards, and management is committed to taking effective corrective actions. This ongoing process 
safeguards our workforce and fosters a safe and healthy work environment.
	
d.	
Do the employees/ worker of the entity have access to non-occupational medical and healthcare 
services? (Yes/ No)
	
	
Yes. There is a Group Mediclaim policy for employees and workers.
Annual Report 2023-24
92
93
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Business Responsibility and Sustainability Report
11
Details of safety related incidents, in the following format:
Safety Incident/Number**
Category*
FY 2023-24
FY 2022-23
Lost Time Injury Frequency Rate (LTIFR) 
(per one million-person hours worked)
Employees
 -
-
Workers
 0.14
0.09
Total recordable work-related injuries
Employees
 1
4
Workers
1
6
No. of fatalities
Employees
-
-
Workers
-
-
High-consequence work-related injury or ill health (excluding fatalities)
Employees
-
-
Workers
-
-
	
* Including in the contract workforce
	
** Disclosure is provided on standalone basis
12
Describe the measures taken by the entity to ensure a safe and healthy workplace.
	
At Ajanta, we ensure a safe and healthy work environment for all employees through a multi-pronged approach 
that encompasses risk identification, training, emergency preparedness, and continuous improvement. 
	
Risk Management and Employee Protection:
 
Proactive Hazard Identification: We are committed to identifying all potential work-related risks and their root causes 
within our facilities. This proactive approach helps us prevent accidents and safeguard employee well-being.
 
Personal Protective Equipment (PPE): Appropriate PPE are provided to all employees and workers based on their 
specific job functions. This PPE helps mitigate risks associated with their daily tasks.
 
Safety Awareness Training: We prioritise employee education through comprehensive training programmes. These 
programmes raise awareness of potential hazards, equip staff with safe work practices, and ensure they properly 
utilise PPE.
 
Regular Inspections and Audits: Our EHS team and site management conduct regular workplace inspections to 
identify and address any potential hazards. Additionally, we undergo independent safety and environmental audits 
by qualified professionals to ensure compliance with regulatory requirements.
 
Central Safety Committee: A dedicated Central Safety Committee oversees safety protocols and procedures 
across all our facilities.
 
Emergency Response Teams: We have established well-trained and equipped Emergency Response Teams, 
including first aiders and firefighters, to promptly address any emergencies that may arise.
 
ISO Certifications: We are committed to international best practices in safety and environmental management. 
Two of our major sites have successfully implemented ISO 14001 (environmental management) and ISO 45001 
(occupational health and safety management) standards. We are actively working towards achieving these 
certifications at two additional sites, demonstrating our ongoing commitment to continuous improvement.
 
Zero Lost Time Accidents (LTA): We are proud to maintain a zero Lost Time Accident record during the reporting 
year. This achievement reflects the effectiveness of our safety programmes and the dedication of our employees 
to working safely.
 
VOC Sensor Technology: We have implemented VOC (Volatile Organic Compound) sensor technology in our solvent 
storage areas to detect potential leaks. This ensures for immediate response and minimises the risk of exposure 
to harmful chemicals.
	
 Awards and Accolades:
Paithan facility has been 
awarded the prestigious 
‚ÄúApex India Safe Workplace 
Gold Award 2023‚Äù.
‚ÄúMost Preferred Workplace in 
Manufacturing 2023-24‚Äù by Marksmen 
Daily, highlighting our excellence in 
employee safety, skills development, 
diversity, and engagement.
Ajanta has maintained 
‚ÄúGreat Place To Work¬Æ 
Certification‚Äù for the second 
consecutive year. 
	
These achievements speak volumes of our unwavering dedication to fostering a high-trust, high-performance culture.
13
Number of Complaints on the following made by employees and workers:
Particulars
FY 2023-24
FY 2022-23
Filed during 
the year
Pending 
resolution at the 
end of year
Remarks
Filed during 
the year
Pending 
resolution at the 
end of year
Remarks
Working 
Conditions
Nil
Nil
-
Nil
Nil
-
Health & Safety
Nil
Nil
-
Nil
Nil
-
14
Assessment for the year:
Particulars
% of your plants and offices that were assessed (by entity or statutory 
authorities or third parties)
Health, Safety practices 
100%*
Working Conditions
100%**
 
* Health and safety practices - All the manufacturing and R&D locations are audited by internal experts to ensure the compliance of 
safety regulations and identification of major improvement areas. 
	
All our six formulation units and R&D locations have been assessed on health and safety practices by third party auditors (TUV India 
Limited and Chola MS respectively), as per requirements of the ISO 45001:2018 standards.
 
** Working conditions - All the sites are assessed on their working conditions by the external and internal audits. 
15
Provide details of any corrective action taken or underway to address safety-related incidents (if any) and on 
significant risks/ concerns arising from assessments of health & safety practices and working conditions.
	
Ajanta prioritises the health and safety of employees and the environment. We are committed to continuous 
improvement in Environment, Health, and Safety (EHS) practices throughout our operations. Key initiatives 
undertaken during the past year that demonstrate this commitment are enumerated below.
	
Enhancing Operational Safety:
 

Static Dissipation Measures: We implemented static charge dissipation systems in the expanded production and 
solvent storage areas at Dahej plant. This reduces the risk of electrostatic ignition, a potential fire hazard.
 

Battery Safety Upgrades: The battery storage area at Dahej plant has been isolated and equipped with a hydrogen 
detection and fire control system. This ensures compliance with safety standards and minimises the risk of fire 
or explosion.
 

Electrical Panel Protection: Key electrical panels at our manufacturing sites are now protected by CO2 flooding 
systems. This advanced fire suppression technology effectively extinguishes electrical fires, safeguarding personnel 
and equipment.
	
Independent Safety Audits: 
	
Regular inspections, audits, and testing at each of our sites are conducted by qualified third-party specialists. 
This independent evaluation ensures adherence to safety protocols and identifies areas for further improvement.
Annual Report 2023-24
94
95
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Business Responsibility and Sustainability Report
	
Automatic Solvent Transfer System:
	
The implementation of a SCADA-based automatic solvent transfer system at Waluj plant has significantly enhanced 
safety and operational efficiency.
	
Reduced Physical Hazards: The system eliminates the need for manual handling of solvent drums, minimising the 
risk of slips, falls, and other physical injuries.
	
Improved Respiratory Protection: Automatic transfer minimises operator exposure to hazardous solvents during 
the transfer process, protecting respiratory health.
	
Reduced Chemical Hazards: Automatic transfer minimises the risk of spills and splashes, protecting personnel from 
skin irritation and burns.
	
Enhanced Fire Safety: Solvent transfer occurs under a nitrogen blanketing system, significantly reducing fire risk.
	
Automatic Water Jet System for Tank Cleaning:
	
We have implemented automatic water jet cleaning systems with sodium hypochlorite dosing in all our formulation 
units. This eliminates the need for personnel to enter confined spaces for tank cleaning, a hazardous activity that 
requires continuous oxygen monitoring or artificial oxygen supply.
Leadership Indicators
1
Does the entity extend any life insurance or any compensatory package in the event of death of 
(A) Employees (Y/N)
Yes
(B) Workers (Y/N)
Yes
	
The Company provides death coverage under the EDLI and Gratuity Policies. Benefits like provident fund, pension 
as applicable, are settled on a priority basis.
2
Provide the measures undertaken by the entity to ensure that statutory dues have been deducted and deposited 
by the value chain partners.
 
Clear Procedures: We have well-defined mechanisms in place to guarantee that all necessary statutory dues 
are deducted and deposited in accordance with applicable regulations for all transactions with our value chain 
partners. We obtain monthly statutory payment challans for verification from vendors / contractors before 
processing their invoices. This activity is also reviewed as part of the internal and statutory audit.
 
Employee Well-being: Our systems ensure that wages and statutory dues, like PF and ESIC, are paid correctly and 
timely for contract workers.
 
Ethical Partnerships: Through our Third-Party Code of Conduct, we emphasise the importance of ethical and 
honest business practices for our value chain partners. This code expects them to act professionally, unbiased, 
and with integrity in all dealings, including adherence to applicable laws and regulations.
3
Provide the number of employees/workers having suffered high consequence work- related injury / ill-health / 
fatalities (as reported in Q11 of Essential Indicators above), who have been rehabilitated and placed in suitable 
employment or whose family members have been placed in suitable employment:
Particulars
Total no. of affected employees/ workers
No. of employees/workers that are rehabilitated 
and placed in suitable employment or whose family 
members have been placed in suitable employment
FY 2023-24
FY 2022-23
FY 2023-24
FY 2022-23
Employees
Nil
Nil
Nil
Nil
Workers
Nil
Nil
Nil
Nil
4
Does the entity provide transition assistance programmes to facilitate continued employability and the 
management of career endings resulting from retirement or termination of employment? (Yes/ No/ NA)
 
Yes. Skill-upgradation training programmes is offered to employees throughout their employment. These 
programmes equip them with in-demand skills that can be beneficial in securing new employment opportunities 
after retirement or termination of employment. 
5
Details on assessment of value chain partners:
Particulars
% of value chain partners (by value of business done with such 
partners) that were assessed
Health and safety practices
Approximately 10% of upstream value chain partners and 11%  
of downstream value chain partners.*
Working Conditions
 
* During FY 2023-24 Value Chain Assessment was conducted based on the BRSR Core framework and capacity-building workshops were 
organised for our Value chain partners. Additionally, these partners undergo continuous assessment and monitoring through audits/
inspections focused on working conditions and health & safety practices such as ISO/WHO certifications, quality checks, sanitary 
practices, fire safety, human rights etc.
6
Provide details of any corrective actions taken or underway to address significant risks / concerns arising from 
assessments of health and safety practices and working conditions of value chain partners.
 
Corrective actions are taken wherever necessitated on the above-mentioned parameters. Training and awareness 
sessions are conducted for value chain partners to ensure that they adhere to the required health & safety practices.
PRINCIPLE 4: Businesses should respect the interests of and be responsive to all its 
stakeholders.
Essential Indicators
1
Describe the processes for identifying key stakeholder groups of the entity.
 
Ajanta employs a comprehensive stakeholder engagement process to identify and understand the needs of those 
most impacted by, and who have a significant impact on, our business. Any individual or group of individuals or 
institution that adds value to the business chain of the Company is identified as a core stakeholder. The stakeholder 
groups are identified as part of the stakeholder engagement mechanism and accordingly customers, employees, 
suppliers & vendors, regulators, business partners, local communities and investors/shareholders are identified as 
critical stakeholders. Ajanta actively engages with stakeholders, carefully identifying critical material issues, and 
is committed to effectively addressing stakeholder expectations. As a responsible company, we are steadfast in 
our commitment to cultivating strong and meaningful relationships with stakeholders.
Annual Report 2023-24
96
97
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Business Responsibility and Sustainability Report
2
List stakeholder groups identified as key for your entity and the frequency of engagement with each  
stakeholder group.
Stakeholder Group
Whether identified 
as Vulnerable 
& Marginalised 
Group
Channels of communication 
(Email, SMS, Newspaper, 
Pamphlets, Advertisement, 
Community Meetings, 
Notice Board, Website, 
Other- Please Specify)
Frequency of 
engagement 
(Annually, Half-
yearly, Quarterly, 
others- Please 
specify)
Purpose and scope of engagement including 
key topics and concerns raised during such 
engagement
Employees
No
Direct and other 
communication 
mechanisms
On-going
[	 To empower employees to voice their ideas 
and concerns. 
[	 To foster a culture of transparency and 
open communication
[	 To keep them motivated and create a more 
engaged workforce
Customers 
(Healthcare 
professionals, 
Dealers & 
Distributors)
No
E-mails, Meetings and 
Website
On-going
[	 Deepen customer understanding and 
satisfaction.
[	 Strengthen partnerships and collaboration.
[	 Optimise product development and 
delivery.
Regulators
No
Meetings and other 
communication 
mechanisms
Need based
[	 Demonstrate adherence to regulations and 
best practices.
[	 Collaborate on developing effective 
industry standards.
[	 Proactively address regulatory issues and 
prevent violations.
Suppliers & 
Vendors
No
E-mails and Meetings
On-going 
[	 Build strong, collaborative relationships.
[	 Optimise supply chain efficiency and 
innovation.
[	 Ensure continuity and mitigate potential 
disruptions/delays
Business Partners 
(third party 
manufacturers)
No
E-mails and Meetings
Need based
[	 Foster a strategic partnership for mutual 
success.
[	 Optimise production efficiency and quality 
control.
[	 Ensure supply chain resilience and minimise 
disruptions.
Local 
Communities and 
NGOs
Yes
Directly or through CSR 
implementation partners
Ongoing
[	 Build trust and positive relationships
[	 Collaborate on social and environmental 
initiatives
[	 Contribute to community well-being
Investors / 
Shareholders
No
E-mail, Newspaper 
Advertisement, Website, 
Annual General 
Meetings, Disclosures to 
Stock Exchanges and 
Investor Meetings/Calls/ 
Conferences
Need based and 
Quarterly
[	 Enhance investor confidence through clear 
communication and transparency.
[	 Align business strategy with long-term 
shareholder value.
[	 Demonstrate responsible corporate 
governance.
Leadership Indicators
1
Provide the processes for consultation between stakeholders and the Board on economic, environmental, and 
social topics or if consultation is delegated, how is feedback from such consultations provided to the Board.
 
Ajanta prioritises open communication with stakeholders on economic, environmental, and social issues. Functional 
department heads directly engage with relevant stakeholder groups on these topics. 
	
We conducted a stakeholder engagement and materiality assessment in FY 2021-22. This process identified key 
sustainability issues, assessed potential risks, and developed mitigation strategies. 
	
In FY 2023-24, the material topics were reviewed based on their impact on Ajanta‚Äôs strategic objectives and 
stakeholder interests. Following consultations with relevant stakeholders, a revised list of material issues was 
presented to the Board for their consideration and further action.
2
Whether stakeholder consultation is used to support the identification and management of environmental, and 
social topics (Yes/No).
 
 If so, provide details of instances as to how the inputs received from stakeholders on these topics were 
incorporated into policies and activities of the entity. 
	
Stakeholder consultation plays a vital role in managing environmental and social initiatives at Ajanta. We actively 
engage with stakeholders to identify our most pressing sustainability issues (material topics). During the review 
process in FY 2023-24, we prioritised these topics based on their impact on both Ajanta‚Äôs strategic objectives and 
the interests of our stakeholders, which was validated by key departments, senior management, and the Board 
before implementation.
3
Provide details of instances of engagement with, and actions taken to, address the concerns of vulnerable/ 
marginalised stakeholder groups.
 
Ajanta prioritises engagement with vulnerable and marginalised stakeholder groups. We collaborate with various 
implementation agencies to deliver impactful programmes focused on healthcare, education, & community 
development. To bring quality and reliable healthcare to rural and tribal regions of India, we tackle critical needs 
in rural and tribal areas through Samta Foundation and other implementation agencies. The Foundation conducts 
cataract surgeries, eye and skin camps and supports patients from rural areas visiting city hospitals by providing 
meals and shelter. Other implementation agencies also provide support and aid to the vulnerable and marginalised 
stakeholders for their education & healthcare needs.
	
Implementation agencies have contributed in areas such as:
	
[	
Mega Medical Health check-up camp.
	
[	
Nutrition projects for pediatric patients.
	
[	
Sanjeevani Multi-Specialty Hospital provides medical care at affordable cost.
	
[	
Runs Benz Hospital for Cancer Treatment.
	
[	
Runs Parkinson‚Äôs Disease & Movement Disorder Society.
	
[	
Manages Society for Rehabilitation of Crippled Children for medical treatment of needy children.
	
[	
Educational help by paying school fees for deserving children from marginalised groups. 
	
[	
Providing financial aid to schools and educational institutes for putting up infrastructure and other requirements. 
	
While we haven‚Äôt received any specific reported concerns from vulnerable and marginalised stakeholder groups, our 
ongoing CSR efforts demonstrate a proactive commitment to addressing their needs within our local communities
Annual Report 2023-24
98
99
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Business Responsibility and Sustainability Report
PRINCIPLE 5 Businesses should respect and promote human rights.
Essential Indicators
1
Employees and workers who have been provided training on human rights issues and policy(ies) of the entity, in 
the following format
Benefits
FY 2023-24
FY 2022-23*
Total (A)
No. of employees/ 
workers covered (B)
% (B)
Total (C)
No. of employees/ 
workers covered (D)
% (D/C)
Employees
Permanent
7962
7751
97%
7803
7621
98%
Other than 
permanent
123
123
100%
39
39
100%
Total 
Employees
8085
7874
97%
7842
7660
98%
Workers
Permanent
111
111
100%
112
112
100%
Other than 
permanent
2172
2172
100%
2518
2518
100%
Total Workers
2283
2283
100%
2630
2630
100%
* Previous year figures are restated due to consolidation
2
Details of minimum wages paid to employees and workers
Category
FY 2023-24
FY 2022-23*
Total (A)
Equal to Minimum  
Wage
More than Minimum 
Wage
Total (D)
Equal to Minimum  
Wage
More than Minimum 
Wage
No. (B)
% (B/A)
Number 
(C)
% (C/A)
No. (E)
% (E/D)
No. (F)
% (F/D)
Permanent Employees
Male
7258
-
-
7258
100%
7129
-
-
7129
100%
Female
704
-
-
704
100%
674
-
-
674
100%
Total
7962
-
-
7962
100%
7803
-
-
7803
100%
Other than Permanent
Male
120
-
-
120
100%
29
-
-
29
100%
Female
3
-
-
3
100%
10
-
-
10
100%
Total
123
-
-
123
100%
39
-
-
39
100%
Permanent Workers
Male
111
-
-
111
100%
112
-
-
112
100%
Female
0
-
-
0
100%
0
-
-
0
100%
Total
111
-
-
111
100%
112
-
-
112
100%
Other than Permanent
Male
2063
2063
100%
-
-
2410
2410
100%
-
-
Female
109
109
100%
-
-
108
108
100%
-
-
Total
2172
2172
100%
-
-
2518
2518
100%
-
-
* Previous year figures are restated due to consolidation
3
Details of remuneration/salary/wages
a.
Median remuneration / wages:
Particular*
Male
Female
Number
Median remuneration/ 
salary/ wages of 
respective category
Number
Median remuneration/ 
salary/ wages of 
respective category
Board of Directors (BoD)
3**
21,59,81,600 
0
0
Key Managerial Personnel
4***
11,71,99,759
-
0
Employees other than BoD and KMP
7182
4,70,670
551
6,13,735
Workers
111
9,25,342
-
-
* Disclosure is on a standalone basis.
** Only Executive directors are considered.
*** Two executive directors are included in both BOD & KMP disclosure
b.
Gross wages paid to females as % of total wages paid by the entity, in the following format:
Particular*
FY 2023-24
FY 2022-23
Gross wages paid to females as % of total wages
8%
8%
* Disclosure is on standalone basis.
4
Do you have a focal point (Individual/ Committee) responsible for addressing human rights impacts or issues 
caused or contributed to by the business?
 
Yes. We have established Internal Complaints Committee (ICC) and Business Integrity Committee across the 
Company. The ICC has been formed to address Sexual Harassment related grievances, whereas the Business 
Integrity Committee caters to grievances or violations pertaining to Human Rights.
No complaints of sexual harassment or violation of human rights were received during the year.
5
Describe the internal mechanisms in place to redress grievances related to human rights issues.
 
The Company considers human rights as one of its fundamental and core values and strives to support, protect 
and promote human rights to ensure that fair and ethical business and employment practices are followed.
	Ajanta prioritises a safe and inclusive work environment for all employees. We are committed to human rights and 
strive to uphold them through our policies and practices. Ajanta also has zero-tolerance toward and prohibits all 
forms of slavery, coerced labour, child labour, human trafficking, violence or physical, sexual, psychological or verbal 
abuse. As a matter of policy, Ajanta does not hire any employee or engage with any agent or vendor against their 
free will. An internal Business Integrity Committee addresses grievances related to human rights violations. Also, 
we have established ICC to address complaints / grievances specific to sexual harassment. 
	To empower employees to report any wrongdoing, we have a confidential whistle-blower mechanism that enables 
them to raise the concerns without any fear of retaliation or reprieve.
6
Number of Complaints on the following made by employees and workers:
Particulars
FY 2023-24
FY 2022-23
Filed during 
the year
Pending 
resolution at the 
end of year
Remarks
Filed during 
the year
Pending 
resolution at the 
end of year
Remarks
Sexual Harassment
Nil
Nil
-
Nil
Nil
-
Discrimination at workplace
Nil
Nil
-
Nil
Nil
-
Child Labour
Nil
Nil
-
Nil
Nil
-
Forced Labour/Involuntary 
Labour
Nil
Nil
-
Nil
Nil
-
Wages
Nil
Nil
-
Nil
Nil
-
Other human rights related 
issues
Nil
Nil
-
Nil
Nil
-
Annual Report 2023-24
100
101
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Business Responsibility and Sustainability Report
7
Complaints filed under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) 
Act, 2013, in the following format:
Particulars
FY 2023-24
FY 2022-23
Total Complaints reported under Sexual Harassment on of Women at Workplace 
(Prevention, Prohibition and Redressal) Act, 2013 (POSH)
Nil
Nil
Complaints on POSH as a % of female employees / workers
Nil
Nil
Complaints on POSH upheld
Nil
Nil
8
Mechanisms to prevent adverse consequences to the complainant in discrimination and harassment cases.
 
The company has established Internal Complaints Committees (ICCs) and Business Integrity committee at 
all locations to address complaints regarding sexual harassment. Our sexual harassment policy ensures that 
employees who use the complaint procedure will not face reprisals, retaliation, or coercion.
9
Do human rights requirements form part of your business agreements and contracts? (Yes/No/NA)
 
Yes, in certain business agreements and contracts where relevant. 
10
Assessments for the year:
Name of the Assessment
% of your plants and offices that were assessed (by entity or statutory 
authorities or third parties)
Child labour 
100%
Forced/involuntary labour 
100%
Sexual harassment
100%
Discrimination at workplace
100%
Wages
100%
11
Provide details of any corrective actions taken or underway to address significant risks / concerns arising from 
the assessments at Question 10 above.
 
In FY 2023-24, we have not received any corrective action directives, as we are compliant to the laws as applicable.
Leadership Indicators
1
Details of a business process being modified / introduced as a result of addressing human rights grievances/
complaints.
 
No human rights grievances / complaints were received during the reporting period. Ajanta is committed to 
upholding basic human rights principles in all its operations. To this end, the employees are trained through various 
awareness programmes.
2
Details of the scope and coverage of any Human rights due-diligence conducted
 
The Company has not undertaken formal human rights due diligence. However, its policies embody human rights 
principles, and all employees and value chain members are expected to adhere to them. Further, grievance 
redressal system is in place to address any grievance or concerns raised w.r.t. violation of human rights. 
3
Is the premise/office of the entity accessible to differently abled visitors, as per the requirements of the Rights of 
Persons with Disabilities Act, 2016? (Yes/No)
 
The premises/ offices of the Company are accessible to differently abled visitors as per the requirements of the 
Rights of Persons with Disabilities Act, 2016. The office has ramps, elevators and other infrastructure facilities for 
differently abled visitors.
4
Provide details of any corrective actions taken or underway to address significant risks / concerns arising from 
the assessments at Question 4 above.
 
Not Applicable
PRINCIPLE 6: Businesses should respect and make efforts to protect and restore the environment.
Essential Indicators
1
Details of total energy consumption (in Joules or multiples) and energy intensity:
Parameter
FY 2023-24
FY 2022-23*
From renewable sources (in Giga Joules)
 
 
Total electricity consumption (A)
37,571.89
 16,238.45
Total fuel consumption (B)
-
 -
Energy consumption through other sources (C.)
-
-
Total energy consumed from renewable sources (A+B+C)
 37,571.89
 16,238.45
From non-renewable sources (in Giga Joules)
 
 
Total electricity consumption (D)
 2,01,156.21
 2,20,044.07
Total fuel consumption (E)
 77,124.63
 64,564.54
Energy consumption through other sources (F)
-
-
Total energy consumed from non-renewable sources (D+E+F)
2,78,280.85
 2,84,608.61
Total energy consumed (A+B+C+D+E+F)
3,15,852.74
 3,00,847.06
Energy intensity per rupee of turnover
(Total energy consumed / Revenue from operations)
 0.00000750
0.00000804
Energy intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP) 
(Total energy consumed / Revenue from operations adjusted for PPP)**
0.00017171
0.00018392
Energy intensity in terms of physical output
(Production Output in Base unit of measurement)
0.00005650
0.00006068
Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external 
agency?
No
If yes, name of the external agency.
 
	
* Previous year figures are restated due to consolidation.
	
** The revenue from operations has been adjusted for PPP using the latest PPP conversion factor published by the World Bank for India 
for the year 2022, which is 22.88
2
Does the entity have any sites / facilities identified as designated consumers (DCs) under the 
Performance, Achieve and Trade (PAT) Scheme of the Government of India? (Yes/No)
No
If yes, disclose whether targets set under the PAT scheme have been achieved. In case targets have not been achieved,  
provide the remedial action taken, if any.
None of our sites comes under PAT scheme as Designated Consumers
3
Provide details of the following disclosures related to water:
Parameter - Water withdrawal by source (in kilolitres)*
FY 2023-24
FY 2022-23*
(i)	 Surface water
Nil
Nil
(ii)	 Groundwater
1,40,291
1,48,798
(iii)	 Third party water
2,70,660
2,73,962
(iv)	 Seawater / desalinated water
Nil
Nil
(v)	 Others
Nil
Nil
Total volume of water withdrawal (in kilolitres) (i+ii+iii+iv+v)
4,10,951
4,22,760
Total volume of water consumption (in kilolitres)
4,10,951
4,22,760
Water intensity per rupee of turnover
(Total water consumption / Revenue from operations)
0.00000976 
0.00001130 
Water intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP)
(Total water consumption / Revenue from operations adjusted for PPP)
0.00022341
0.00025845
Water intensity in terms of physical output 
(Production Output in Base unit of measurement)
0.00007352
0.00008526
Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external 
agency? (Yes/No)
No
If yes, name of the external agency.
 
	
* Disclosure is provided on standalone basis
Annual Report 2023-24
102
103
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Business Responsibility and Sustainability Report
	
Note : In the Financial Year 2024, recycled water met around 25% of our total water demand.
4
Provide the following details related to water discharged:
Parameter - Water discharge by destination and level of treatment (in kl)*
FY 2023-24
FY 2022-23*
(i)	 To Surface water
 
 
	
No treatment
Nil
Nil
	
With treatment ‚Äì please specify level of treatment
Nil
Nil
(ii)	 To Groundwater
	
No treatment
Nil
Nil
	
With treatment ‚Äì please specify level of treatment
Nil
Nil
(iii)	 To Seawater
	
No treatment
Nil
Nil
	
With treatment ‚Äì please specify level of treatment
Nil
Nil
(iv)	Sent to third-parties
	
No treatment
Nil
Nil
	
With treatment ‚Äì please specify level of treatment
Nil
Nil
(v)	 Others
	
No treatment
Nil
Nil
	
With treatment ‚Äì please specify level of treatment
-
15700
Total water discharged (in kilolitres)
-
15700
Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external 
agency? (Y/N)
No
If yes, name of the external agency.
 
	
* Disclosure is provided on standalone basis
5
Has the entity implemented a mechanism for Zero Liquid Discharge?
Yes
	
If yes, provide details of its coverage and implementation.
	
[	
Our bulk drug unit at Waluj and Guwahati unit operates with Zero Liquid Discharge (ZLD). We are implementing 
Zero Liquid Discharge (ZLD) at other facilities which are near completion.
	
[	
To reduce water usage, we implemented a project at our Dahej facility to recycle wastewater. This project 
segregates streams like condensate and purified water system rejects for recycling.
	
[	
We also upgraded our wastewater treatment plant (ETP) at all the facility plants with advanced treatment 
technologies such as UF and RO.
	
[	
We comply with Pollution Control Board consent conditions for treated water discharge.
6
Please provide details of air emissions (other than GHG emissions) by the entity:
Parameter*
Please specify unit
FY 2023-24
FY 2022-23
NOx
mg/nm3
21.8
 22.1
SOx
mg/nm3
23.2
 24.6
Particulate matter (PM)
mg/nm3
27.8
 27.2
Persistent organic pollutants (POP)
 
0
0
Volatile organic compounds (VOC)
 
0
0
Hazardous air pollutants (HAP)
 
0
0
Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external 
agency? (Y/N)
Yes
If yes, name of the external agency.
MoEF approved laboratories are auditing 
and monitoring this emission data. 
	
* Disclosure is provided on standalone basis.
7
Provide details of greenhouse gas emissions (Scope 1 and Scope 2 emissions) & its intensity:
Parameter
Unit
FY 2023-24
FY 2022-23*
Total Scope 1 emissions (Break-up of the GHG into CO2, CH4, N2O, HFCs, 
PFCs, SF6, NF3, if available)
Metric tonnes of 
CO2 equivalent
6,390.22
4,368.55
Total Scope 2 emissions (Break-up of the GHG into CO2, CH4, N2O, HFCs, 
PFCs, SF6, NF3, if available)
40,007.74
51,847.35
Total Scope 1 and Scope 2 emissions per rupee of turnover
(Total Scope 1 and Scope 2 GHG emissions / Revenue from operations)
0.00000110 
0.00000150 
Total Scope 1 and Scope 2 emission intensity per rupee of turnover 
adjusted for Purchasing Power Parity (PPP)
(Total Scope 1 and Scope 2 GHG emissions / Revenue from operations 
adjusted for PPP)
0.00002522
0.00003437
Total Scope 1 and Scope 2 emission intensity in terms of physical output
(Production Output in Base unit of measurement)
 0.00000830
0.00001134
Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external 
agency? (Y/N)
 No
If yes, name of the external agency.
 
	
* Previous year figures are restated due to consolidation.
8
Does the entity have any project related to reducing Green House Gas emission? (Yes/ No)
Yes
	
If Yes, then provide details.
	
We initiated and implemented many projects that help in the reduction of greenhouse gas (GHG) emissions and 
minimise their environmental impact.
	
Some of the green initiatives undertaken during the last year are:
 
Energy Efficiency Improvements: We have invested in energy-efficient technologies and practices to reduce our 
energy consumption and lower our GHG emissions. This includes upgrading to more energy-efficient machinery, 
optimising heating, ventilation, and air conditioning (HVAC) systems, and implementing energy management systems.
 
Renewable Energy Integration: We have invested in and implemented captive solar plant installations totaling 
around 8.8 MW during the last year to meet green energy needs. By shifting to renewable energy sources, we are 
continuously and significantly reducing reliance on fossil fuels and decreasing our carbon footprint.
 
Waste Reduction and Recycling: We have implemented waste reduction and recycling programmes to minimise 
the amount of waste sent to landfills and reduce emissions associated with waste disposal.
	
By implementing these and other initiatives, Ajanta is making significant contributions to reducing GHG emissions 
and mitigating climate change.
	
 Awards and Accolades:
Apex India Green Leaf Platinum Award for 
Sustainability 2023 - This award highlights 
Ajanta‚Äôs commitment to renewable energy, 
resource efficiency, and waste management.
SKOCH ESG Award 2024 for Clean & Green Energy 
Utilisation - This award recognises Ajanta‚Äôs pursuit 
of innovation and best practices in sustainable 
energy use.
Annual Report 2023-24
104
105
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Business Responsibility and Sustainability Report
9
Provide details related to waste management by the entity:
Parameter*
FY 2023-24
FY 2022-23
Total Waste generated (in metric tonnes)
Plastic waste (A)
56
60
E-waste (B)
0.70
0.83
Bio-medical waste (C)
18.9
21.02
Construction and demolition waste (D)
 0
0
Battery waste (E)
4.67
4.32
Radioactive waste (F)
0
0
Other Hazardous waste. Please specify, if any. (G)
546
495.47
Other Non-hazardous waste generated (H).
Please specify, if any. (Break-up by composition i.e. by materials relevant to the sector)
1872.3
1832.18
Total (A+B+C+D+E+F+G+H)
2498.57
2413.82
Waste intensity per rupee of turnover
(Total waste generated / Revenue from operations)
0.00000006 
0.00000007 
Waste intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP) 
(Total waste generated / Revenue from operations adjusted for PPP)
0.00000002 
0.00000002 
Waste intensity in terms of physical output
(Production Output in Base unit of measurement)
0.00000045
0.00000049
	
For each category of waste generated, total waste recovered through recycling, re-using or other recovery 
operations (in metric tonnes)
Category of waste
FY 2023-24
FY 2022-23
(i)	 Recycled
0
0
(ii)	 Re-used
0
0
(iii)	 Other recovery operations
2109.39
1892.18
Total
2109.39
1892.18
	
For each category of waste generated, total waste disposed by nature of disposal method (in metric tonnes)
Category of waste
FY 2023-24
FY 2022-23
(i)	 Incineration
385.51
303.60
(ii)	 Landfilling
3.67
0
(iii)	 Other disposal operations
0
191.87
Total
389.18
495.47
Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external 
agency? (Y/N)
No
If yes, name of the external agency.
	
* Disclosure is provided on standalone basis.
10
Briefly describe the waste management practices adopted in your establishments. Describe the strategy  
adopted by your company to reduce usage of hazardous and toxic chemicals in your products and processes  
and the practices adopted to manage such wastes.
 
We have waste management systems in place at all our facilities. Plastic waste generated from factory gets 
recycled through authorised recyclers & for handling post-consumer plastic waste we have engaged with PWP & 
all post-consumer 100% plastic waste get co-processed through cement industry. The spent solvent generated 
from our API is recycled through government authorised recyclers. E-waste & non-hazardous waste such as glass 
bottles, MS/SS scarp and paper waste are sent to authorised recyclers. 
	
We reduce waste through technological interventions and ongoing initiatives including sustainable packaging, 
waste source segregation, process optimisation etc. For example, we have reduced plastic packaging box size 
for one of our major products thereby substantially reducing use of plastic. 
11
If the entity has operations/offices in/around ecologically sensitive areas (such as national parks, wildlife 
sanctuaries, biosphere reserves, wetlands, biodiversity hotspots, forests, coastal regulation zones etc.) where 
environmental approvals / clearances are required, please specify details in the following format:
Sr. No.
Location of 
operations/offices
Type of operations
Whether the conditions of environmental 
approval/clearance are being complied with? 
(Y/N)
If no, the reasons thereof and corrective 
action taken, if any.
None of our sites are located in ecologically sensitive sites.
12
Details of environmental impact assessments of projects undertaken by the entity based on applicable laws, in 
the current financial year:
Name and brief 
details of project
EIA Notification No.
Date
Whether conducted by 
independent external 
agency (Yes / No)
Results communicated  
in public domain  
(Yes / No)
Relevant Web link
Not Applicable
13
Is the entity compliant with the applicable environmental law/ regulations/ guidelines in India, such 
as the Water (Prevention and Control of Pollution) Act, Air (Prevention and Control of Pollution) Act, 
Environment protection act and rules thereunder (Y/N/NA).
Yes
	
If not, provide details of all such non-compliances, in the following format:
Specify the law/regulation/ 
guidelines which was not 
complied with
Provide details of the  
non-compliance
Any fines / penalties / action taken by regulatory 
agencies such as pollution control boards or by courts
Corrective action taken,  
if any
NA
NA
Nil
Nil
14
If the entity has undertaken any specific initiatives or used innovative technology or solutions to improve resource 
efficiency, or reduce impact due to emissions / effluent discharge / waste generated, please provide details of 
the same as well as outcome of such initiatives, as per the following format:
Initiative undertaken
Outcome of the initiative
We are committed to responsible manufacturing practices 
and continuously seek innovative solutions to reduce 
emissions, effluents, and waste generation.
Advanced Effluent Treatment: Upgraded Effluent Treatment 
Plants (ETPs) at Dahej and Guwahati with advanced, fully 
automatic Ultrafiltration (UF) and Reverse Osmosis (RO) 
systems.
This allows us to recycle RO permeate for cooling towers, 
significantly reducing our freshwater consumption.
Wastewater Reduction at Source: Implemented project 
to identify and address the root causes of wastewater 
generation at our Dahej facility.
This proactive approach has resulted in a commendable 30% 
reduction in wastewater production.
Waste Reduction and Resource Recovery:
We are committed to paper reduction initiatives across all 
sites and are promoting digitisation 
Through process optimisation and digitalisation efforts, we have 
successfully eliminated approximately 7 million paper pages 
annually.
Condensate Recovery: Condensate recovery systems at two 
of our sites have yielded impressive results.
These systems recycle around 40,000 liters per day of 
condensate, reducing boiler fuel consumption and promoting 
resource efficiency.
Energy Recycling for Water Purification: Completed energy 
recycling project for the WFI (Water for Injection) water stream 
at Guwahati facility.
Further optimising resource utilisation.
Emission Reduction and Air Quality Management:
Implemented VOC sensor technology in solvent storage areas 
to proactively detect potential leaks.
This allows immediate response and minimises the risk of harmful 
chemical emissions.
Solar Power Integration: A SCADA (Supervisory Control and 
Data Acquisition) system has been installed to monitor the 
power generation of on-site solar plants.
This investment in renewable energy contributes to reducing our 
dependence on fossil fuels and lowers greenhouse gas emissions.
Sustainable Infrastructure and Resource Management:
Chitegaon site has implemented rainwater harvesting project
Further diversifying our water resources and promoting rainwater 
conservation.
Energy Efficiency Upgrades: 
Retrofitted selected HVAC (Heating, Ventilation, and Air 
Conditioning) units at Dahej facility with energy-efficient 
EC fans
Reduced energy consumption.
Annual Report 2023-24
106
107
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Business Responsibility and Sustainability Report
Initiative undertaken
Outcome of the initiative
Expanding Environmental Management Systems: 
Two additional sites are undergoing the process of achieving 
ISO¬†14001 certification for environmental management. 
Demonstrates our commitment to continuous improvement and 
adherence to international best practices.
Renewable Energy Integration:
Actively transitioning to renewable energy sources. The 
installation of an 8.8 MW solar power plant this year 
significantly increases our renewable energy consumption.
This shift will contribute to annual CO2 emission reductions of 
approximately 7,066 Mt per annum.
These achievements motivate us to continue pioneering sustainable practices throughout our operations. We remain committed 
to responsible resource management, environmental stewardship, and building a greener future.
15
Does the entity have a business continuity and disaster management plan? (Yes/ No)
	
Give details in 100 words/ web link.
	
Yes, Ajanta has a robust Business Continuity and Disaster Management Plan, ensuring the company‚Äôs ability 
to adapt during emergencies arising from natural calamities or unforeseen events that could disrupt business 
operations. The workforce is continuously trained through mock drills and disaster management exercises to 
effectively execute this plan.
	
The company also has a risk management plan and policy which covers all critical risks that may disrupt or 
materially impact its operations, outlining mitigation measures to address them.
	
In our pursuit of operational excellence, several change management initiatives are underway across our 
organisation, including information technology and automation in the areas of manufacturing, research & 
development, supply chain and shared services. There are continuous efforts also to strengthen our data resiliency.
16
Disclose any significant adverse impact to the environment, arising from the value chain of the entity. What 
mitigation or adaptation measures have been taken by the entity in this regard.
	
We are committed to minimising our environmental impact and continuously monitor our value chain for potential 
environmental concerns. To date, we haven‚Äôt identified any significant adverse impacts
17
Percentage of value chain partners (by value of business done with such partners) that were assessed for 
environmental impacts.
	
During the reporting period, approximately 10% of upstream and 11% of downstream value chain partners (by 
value of business) were assessed for environmental impacts.
PRINCIPLE 7- Businesses, when engaging in influencing public and regulatory policy,  
should do so in a manner that is responsible and transparent.
Essential Indicators
1
a. Number of affiliations with trade and industry chambers/ associations.
Eight (8)
	
b.	
List the top 10 trade and industry chambers/ associations (determined based on the total members of 
such body) the entity is a member of/ affiliated to.
Sr. 
No.
Name of the trade and industry chambers/ associations
Reach of trade and industry chambers/ associations (State/
National/ International)
1
Indian Pharmaceutical Alliance (IPA)
National
2
Pharmaceuticals Export Promotion Council of India 
(PHARMEXCIL)
National
3
Federation of Indian Exporters Organisation (FIEQ)
National
4
Indian Drug Manufacturers‚Äô Association (IDMA)
National
5
Bombay Chamber of Commerce & Industry
 State
6
All India Association of Industries (AIAI)
National
7
Indo American Chamber of Commerce
National
8
Federation of Indian Chambers of Commerce and Industry
National
2
Provide details of corrective action taken or underway on any issues related to anti- competitive conduct by the 
entity, based on adverse orders from regulatory authorities.
Name of authority
Brief of the case
Corrective action taken
The company did not receive any adverse orders from regulatory authorities necessitating the aforementioned actions
PRINCIPLE 8 Businesses should promote inclusive growth and equitable development.
Essential Indicators
1
Details of Social Impact Assessments (SIA) of projects undertaken by the entity based on applicable laws,  
in the current financial year.
Name and brief 
details of project
SIA Notification No.
Date of 
notification
Whether conducted by 
independent external 
agency
(Yes / No)
Results communicated in 
public domain
(Yes / No)
Relevant Web link
The company implements its CSR initiatives directly or through qualified implementation agencies, adhering to all applicable 
laws. For CSR projects requiring impact assessment, the implementing agencies conduct the assessment as mandated by law.
2
Provide information on project(s) for which ongoing Rehabilitation and Resettlement (R&R) is being undertaken by 
your entity, in the following format:
Sr. 
No.
Name of Project for 
which R&R is ongoing State
District
No. of Project 
Affected Families 
(PAFs)
% of PAFs covered 
by R&R
Amounts paid to PAFs 
in the FY (In INR)
Not Applicable
3
Describe the mechanisms to receive and redress grievances of the community.
	
The company implements community welfare programmes in partnership with implementation agencies. These 
partnerships create communication channels for communities to raise concerns and have them addressed. In 
addition, the company has established mechanisms for communities to directly submit grievances to company 
officials, ensuring a prompt response.
Annual Report 2023-24
108
109
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Business Responsibility and Sustainability Report
4
Percentage of input material (inputs to total inputs by value) sourced from suppliers:
Particular*
FY 2023-24
FY 2022-23
Directly sourced from MSMEs/ small producers
16%
24%
Directly from within India
92%
87%
	
* Disclosure is provided on standalone basis
5
Job creation in smaller towns ‚Äì Disclose wages paid to persons employed (including employees or workers employed 
on a permanent or non-permanent / on contract basis) in the following locations, as % of total wage cost
Particular*
FY 2023-24
FY 2022-23
Rural
5%
4%
Semi-urban
20%
19%
Urban
7%
7%
Metropolitan
68%
70%
	
* Note ‚Äì
	
The disclosure is specific to Indian operations of Ajanta. 
	
Locations are classified based on the RBI classification system and Census 2011.
Leadership Indicators
1
a.‚ÄÉ Do you have a preferential procurement policy where you give preference to purchase from suppliers 
comprising marginalised /vulnerable groups? (Yes/No/NA) 
	
	
Ajanta treats MSME vendors at par with non-MSME vendors, while also following preferential payment norms 
for MSMEs.
	
b)	
From which marginalised /vulnerable groups do you procure? 
	
	
MSME registered vendors
	
c)	
What percentage of total procurement (by value) does it constitute? 
	
	
16%
2
Details of beneficiaries of CSR Projects:
Sr. No. CSR Project
No. of persons benefitted from CSR Projects % of beneficiaries from vulnerable and 
marginalised groups
1
Health:
y	
Cataract & Other camps
y	
Family Planning
y	
Malnutrition
y	
Skin, Plastic Surgery & Others
42,729+ people
3,428+ people
71,208+ people
25,805+ people
We prioritise serving marginalised and 
vulnerable groups through our impactful 
CSR initiatives
2
Education:
y	
Different Educational Institutions
99,000+ people
3
Sports Promotion:
y	
Training of athletes for Olympic
15,000 individuals
PRINCIPLE 9 Businesses should engage with and provide value to their consumers in a  
responsible manner.
Essential Indicators
1
Describe the mechanisms in place to receive and respond to consumer complaints and feedback.
	
The Company maintains standardised procedures for handling and investigating product quality complaints 
received from customers. Upon receiving any consumer complaint regarding product quality, the QA team conducts 
a preliminary assessment and initiates Corrective and Preventive Actions (‚ÄúCAPA‚Äù). All complaints are thoroughly 
investigated within 30 working days, and appropriate measures are taken to prevent recurrence.
	
Following the investigation, the QA team sends a ‚ÄòComplaint Reply Form‚Äô and awaits feedback from the complainant 
for 15 working days before closing the complaint. Additionally, Ajanta‚Äôs website (www.ajantapharma.com) features 
a ‚ÄòContact Us‚Äô tab, followed by an ‚ÄòEnquiry‚Äô tab, allowing individuals to register relevant details, including product 
complaints or feedback.
	
Furthermore, the Company has established a dedicated email address, product.complaint@ajantapharma.com, 
enabling consumers and others to submit their grievances and feedback effectively.
2
Turnover of products and/ services as a percentage of turnover from all products/service that carry information 
about 
Particular*
As a percentage to total turnover
Environmental and social parameters relevant to the product
*
Safe and responsible usage
100% 
Recycling and/or safe disposal
- 
* Note: Being pharmaceutical products, the packaging contains all the information and disclosures strictly in accordance with regulatory 
requirements. The company is compliant with applicable laws and regulations regarding product labeling and information.
3
Number of consumer complaints in respect of the following:
Particulars
FY 2023-24
Remark
FY 2022-23
Remarks
Received during 
the year
Pending 
resolution at 
end of year
Received during 
the year
Pending 
resolution at 
end of year
Data privacy
-
-
-
-
-
-
Advertising
-
-
-
-
-
-
Cyber-security
-
-
-
-
-
-
Delivery of essential services
-
-
-
-
-
-
Restrictive Trade Practices
-
-
-
-
-
-
Unfair Trade Practices
-
-
-
-
-
-
Other:
Product quality complaints
188
12
-
168
4
-
Annual Report 2023-24
110
111
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Business Responsibility and Sustainability Report
4
Details of instances of product recalls on account of safety issues:
Particular
Number
Reason for recall
Voluntary recalls
-
Forced recalls
-
5
Does the entity have a framework/ policy on cyber security and risks related to data privacy? (Yes/No)
Yes
If available, provide a web link of the policy
The Policy is available on the intranet of the Company
6
Provide details of any corrective actions taken or underway on issues relating to advertising, and delivery of 
essential services; cyber security and data privacy of customers; re-occurrence of instances of product recalls; 
penalty / action taken by regulatory authorities on safety of products / services.
	
No penalties or regulatory actions have been levied or taken based on the above-mentioned parameters, and 
there have been no instances of product recalls this year.
7
Provide the following information relating to data breaches 
a.	 Number of instances of data breaches along-with impact
-
b.	 Percentage of data breaches involving personally 
identifiable information of customers
-
c.	 Impact, if any, of the data breaches
-
None
Leadership Indicators
1
Channels / platforms where information on products and services of the entity can be accessed (provide web 
link, if available).
	
Our website offers information on our leading products in different segments and markets. Detailed information 
about each product is provided in the product leaflets.
	
Our website can be accessed at - https://www.ajantapharma.com/
2
Steps taken to inform and educate consumers about safe and responsible usage of products and/or services
	
The information label on each product provides consumers with details on pharmacokinetics, safe usage 
instructions, ingredient sourcing, composition, mechanism of action, clinical pharmacology, product interactions, side 
effects, and storage guidelines, among other information.
3
Mechanisms in place to inform consumers of any risk of disruption/discontinuation of essential services.
	
As per the guidelines of National Pharmaceutical Pricing Authority, the Company discloses discontinuation of any 
scheduled formulation by issuing a public notice for relevant stakeholders in addition to informing the Government 
at least six months prior to the intended date of discontinuation.
4
Does the entity display product information on the product over and above what is mandated as per local 
laws? (Yes/No/NA)
Yes
	
a.	
If yes, provide details in brief. 
	
	
The product information displayed complies with local laws/FDA regulations:
	
	
For Drug Category Products: Instructions/warnings/cautions are provided in a red-colored box.
	
	
For Cosmetic Products: Directions for use/ indications/ precautions are provided.
	
	
For Food Licenses: Symbolic indications for Veg/Non-veg sources are included.
	
	
The plastic recycling triangle symbol is displayed on plastic packaging components.
	
	
We offer customer care services to address inquiries related to products and provide solutions.
	
b.	
Did your entity carry out any survey with regard to consumer satisfaction relating to the major products/ 
services of the entity, significant locations of operation of the entity or the entity as a whole? (Yes/No) 
	
	
No
Annual Report 2023-24
112
113
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Annual Report 2023-24
114
115
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Consolidated
Independent Auditor‚Äôs Report
To the Members of 
Ajanta Pharma Limited
REPORT ON THE AUDIT OF THE CONSOLIDATED 
FINANCIAL STATEMENTS
Opinion
We have audited the consolidated financial statements 
of Ajanta Pharma Limited (hereinafter referred to as the 
‚ÄúHolding Company‚Äù and its subsidiaries (Holding Company 
and its subsidiaries together referred to as ‚Äúthe Group‚Äù), which 
comprise the consolidated balance sheet as at 31 March 2024, 
and the consolidated statement of profit and loss (including 
other comprehensive income), consolidated statement 
of changes in equity and consolidated statement of cash 
flows for the year then ended, and notes to the consolidated 
financial statements, including material accounting policies 
and other explanatory information (hereinafter referred to as 
‚Äúthe consolidated financial statements‚Äù).
In our opinion and to the best of our information and 
according to the explanations given to us, and based 
on the consideration of reports of the other auditors on 
separate financial statements of such subsidiaries as were 
audited by the other auditors. the aforesaid consolidated 
financial statements give the information required by the 
Companies Act, 2013 (‚ÄúAct‚Äù) in the manner so required and 
give a true and fair view in conformity with the accounting 
principles generally accepted in India, of the consolidated 
state of affairs of the Group as at 31 March 2024, of its 
consolidated profit and other comprehensive income, 
consolidated changes in equity and consolidated cash 
flows for the year then ended.
Basis for Opinion
We conducted our audit in accordance with the Standards 
on Auditing (SAs) specified under Section 143(10) of 
the Act. Our responsibilities under those SAs are further 
described in the Auditor‚Äôs Responsibilities for the Audit 
of the Consolidated Financial Statements section of our 
report. We are independent of the Group in accordance 
with the ethical requirements that are relevant to our 
audit of the consolidated financial statements in terms 
of the Code of Ethics issued by the Institute of Chartered 
Accountants of India and the relevant provisions of the 
Act, and we have fulfilled our other ethical responsibilities 
in accordance with these requirements. We believe 
that the audit evidence obtained by us along with the 
consideration of reports of the other auditors referred to 
in paragraph (a) of the ‚ÄúOther Matters‚Äù section below, 
is sufficient and appropriate to provide a basis for our 
opinion on the consolidated financial statements.
Key Audit Matter(s)
Key audit matters are those matters that, in our professional 
judgment and based on the consideration of reports of other 
auditors on separate financial statements of components 
audited by them, were of most significance in our audit of 
the consolidated financial statements of the current period. 
These matters were addressed in the context of our audit 
of the consolidated financial statements as a whole, and 
in forming our opinion thereon, and we do not provide a 
separate opinion on these matters.
Revenue Recognition
See Note 7.9 of accounting policies and to note 39 to consolidated financial statements
The key audit matter
	
How the matter was addressed in our audit
The Group has numerous customers operating in multiple 
geographies and sales contracts with these customers have distinct 
terms and conditions relating to the recognition of revenue, the 
right of return and price adjustments. Contractual arrangements 
as well as regulatory requirements in various geographies result in 
adjustments to gross sales price. These adjustments arise from the 
Group‚Äôs obligations to customers towards chargebacks, rebates, 
product recalls, Medicaid, allowances, supply penalties and right 
of return (‚Äúvariable consideration‚Äù). As stated in Note 38 to the 
consolidated financial statements, revenue from the sale of goods 
is measured after adjusting the effects of variable consideration. 
Adjustments are made with respect to variable components which 
requires judgement and estimation by the Group. These are based 
on contractual arrangements, market conditions and accumulated 
experience.
Accordingly we identified recognition of revenue from sale of 
products during the year and at the period end and accruals for 
variable consideration in revenue recognition as a key audit matter.
Our audit procedures in respect of accruals for variable 
components of revenue recognition included the following:
‚Ä¢	
Assessing the Group‚Äôs accounting policies for revenue 
recognition including accounting for variable consideration by 
comparing with applicable accounting standards.
‚Ä¢	
Testing the design, implementation and operating effectiveness 
of the Company‚Äôs manual and automated controls designed 
to ensure recognition of valid revenue transactions in the 
correct period.
‚Ä¢	
Testing key internal controls with respect to accrual for variable 
consideration. These accruals are made using accumulated 
experience, 
contractual 
arrangements 
and 
volume 
of 
transactions with respective customers.
‚Ä¢	
Performing substantive testing of selected samples of revenue 
transactions recorded during the year as well as at year-
end. We used statistical sampling and verified contractual 
terms of sales invoices / contracts, shipping documents and 
acknowledged delivery receipts for those transactions.
The key audit matter
	
How the matter was addressed in our audit
‚Ä¢	
Perform substantive procedures to verify period end accruals 
for adjustment on account of variable consideration.
‚Ä¢	
Examining high risk journal entries and other adjustments that 
contain unusual combinations of credit to revenue with no 
associated debit to cash, debtors, or another revenue account
Other Information
The Holding Company‚Äôs Management and Board of 
Directors are responsible for the other information. The 
other information comprises the information included in the 
Holding Company‚Äôs annual report, but does not include 
the financial statements and auditor‚Äôs reports thereon.
Our opinion on the consolidated financial statements does 
not cover the other information and we do not express any 
form of assurance conclusion thereon.
In connection with our audit of the consolidated financial 
statements, our responsibility is to read the other 
information and, in doing so, consider whether the other 
information is materially inconsistent with the consolidated 
financial statements or our knowledge obtained in the 
audit or otherwise appears to be materially misstated. 
If, based on the work we have performed and based 
on the work done/audit reports of other auditors, we 
conclude that there is a material misstatement of this 
other information, we are required to report that fact. We 
have nothing to report in this regard.
Management‚Äôs and Board of Directors‚Äô Responsibilities 
for the Consolidated Financial Statements
The Holding Company‚Äôs Management and Board 
of Directors are responsible for the preparation and 
presentation of these consolidated financial statements 
in term of the requirements of the Act that give a true and 
fair view of the consolidated state of affairs, consolidated 
profit/ loss and other comprehensive income, consolidated 
statement of changes in equity and consolidated cash 
flows of the Group in accordance with the accounting 
principles generally accepted in India, including the Indian 
Accounting Standards (Ind AS) specified under Section 
133 of the Act. The respective Management and Board 
of Directors of the companies included in the Group are 
responsible for maintenance of adequate accounting 
records in accordance with the provisions of the Act 
for safeguarding the assets of each company and for 
preventing and detecting frauds and other irregularities; 
the selection and application of appropriate accounting 
policies; making judgments and estimates that are 
reasonable and prudent; and the design, implementation 
and maintenance of adequate internal financial controls, 
that were operating effectively for ensuring the accuracy 
and completeness of the accounting records, relevant 
to the preparation and presentation of the consolidated 
financial statements that give a true and fair view and 
are free from material misstatement, whether due to 
fraud or error, which have been used for the purpose of 
preparation of the consolidated financial statements by 
the Management and Board of Directors of the Holding 
Company, as aforesaid.
In preparing the consolidated financial statements, the 
respective Management and Board of Directors of the 
companies included in the Group are responsible for 
assessing the ability of each company to continue as a 
going concern, disclosing, as applicable, matters related 
to going concern and using the going concern basis of 
accounting unless the respective Board of Directors either 
intends to liquidate the Company or to cease operations, 
or has no realistic alternative but to do so.
The respective Board of Directors of the companies 
included in the Group are responsible for overseeing the 
financial reporting process of each company.
Auditor‚Äôs Responsibilities for the Audit of the 
Consolidated Financial Statements
Our objectives are to obtain reasonable assurance about 
whether the consolidated financial statements as a whole 
are free from material misstatement, whether due to fraud 
or error, and to issue an auditor‚Äôs report that includes 
our opinion. Reasonable assurance is a high level of 
assurance, but is not a guarantee that an audit conducted 
in accordance with SAs will always detect a material 
misstatement when it exists. Misstatements can arise from 
fraud or error and are considered material if, individually 
or in the aggregate, they could reasonably be expected 
to influence the economic decisions of users taken on the 
basis of these consolidated financial statements.
As part of an audit in accordance with SAs, we exercise 
professional judgment and maintain professional 
skepticism throughout the audit. We also:
‚Ä¢	 Identify and assess the risks of material misstatement 
of the consolidated financial statements, whether due 
to fraud or error, design and perform audit procedures 
responsive to those risks, and obtain audit evidence 
that is sufficient and appropriate to provide a basis 
for our opinion. The risk of not detecting a material 
misstatement resulting from fraud is higher than for 
one resulting from error, as fraud may involve collusion, 
Annual Report 2023-24
116
117
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Consolidated
forgery, intentional omissions, misrepresentations, or the 
override of internal control.
‚Ä¢	 Obtain an understanding of internal control relevant to 
the audit in order to design audit procedures that are 
appropriate in the circumstances. Under Section 143(3)
(i) of the Act, we are also responsible for expressing 
our opinion on whether the company has adequate 
internal financial controls with reference to financial 
statements in place and the operating effectiveness 
of such controls.
‚Ä¢	 Evaluate the appropriateness of accounting policies 
used and the reasonableness of accounting estimates 
and related disclosures made by the Management and 
Board of Directors.
‚Ä¢	 Conclude on the appropriateness of the Management 
and Board of Directors use of the going concern basis 
of accounting in preparation of consolidated financial 
statements and, based on the audit evidence obtained, 
whether a material uncertainty exists related to events 
or conditions that may cast significant doubt on the 
appropriateness of this assumption. If we conclude that 
a material uncertainty exists, we are required to draw 
attention in our auditor‚Äôs report to the related disclosures 
in the consolidated financial statements or, if such 
disclosures are inadequate, to modify our opinion. Our 
conclusions are based on the audit evidence obtained 
up to the date of our auditor‚Äôs report. However, future 
events or conditions may cause the Group to cease to 
continue as a going concern.
‚Ä¢	 Evaluate the overall presentation, structure and content 
of the consolidated financial statements, including the 
disclosures, and whether the consolidated financial 
statements represent the underlying transactions and 
events in a manner that achieves fair presentation.
‚Ä¢	 Obtain sufficient appropriate audit evidence regarding 
the financial information of such entities or business 
activities within the Group to express an opinion on the 
consolidated financial statements. We are responsible 
for the direction, supervision and performance of 
the audit of the financial information of such entities 
included in the consolidated financial statements 
of which we are the independent auditors. For the 
other entities included in the consolidated financial 
statements, which have been audited by other auditors, 
such other auditors remain responsible for the direction, 
supervision and performance of the audits carried out 
by them. We remain solely responsible for our audit 
opinion. Our responsibilities in this regard are further 
described in paragraph (a) of the section titled ‚ÄúOther 
Matters‚Äù in this audit report.
We communicate with those charged with governance of 
the Holding Company and such other entities included in 
the consolidated financial statements of which we are the 
independent auditors regarding, among other matters, 
the planned scope and timing of the audit and significant 
audit findings, including any significant deficiencies in 
internal control that we identify during our audit.
We also provide those charged with governance with 
a statement that we have complied with relevant 
ethical requirements regarding independence, and 
to communicate with them all relationships and other 
matters that may reasonably be thought to bear on our 
independence, and where applicable, related safeguards.
From the matters communicated with those charged with 
governance, we determine those matters that were of 
most significance in the audit of the consolidated financial 
statements of the current period and are therefore the key 
audit matters. We describe these matters in our auditor‚Äôs 
report unless law or regulation precludes public disclosure 
about the matter or when, in extremely rare circumstances, 
we determine that a matter should not be communicated 
in our report because the adverse consequences of doing 
so would reasonably be expected to outweigh the public 
interest benefits of such communication.
Other Matter(s)
a.	
We did not audit the financial statements / financial 
information of three subsidiaries, whose financial 
statements/financial information reflects total assets 
(before consolidation adjustments) of H 245.71 Crore as 
at 31 March 2024, total revenues (before consolidation 
adjustments) of H 324.91 Crore and net cash flows 
(before consolidation adjustments) amounting to 
H (12.97) Crore for the period ended on that date, as 
considered in the consolidated financial statements. 
These financial statements/This financial information 
have been audited by other auditors whose reports 
have been furnished to us by the Management and 
our opinion on the consolidated financial statements, 
in so far as it relates to the amounts and disclosures 
included in respect of these subsidiaries, and our 
report in terms of sub-section (3) of Section 143 of the 
Act, in so far as it relates to the aforesaid subsidiaries 
is based solely on the reports of the other auditors.
	
Our opinion on the consolidated financial statements, 
and our report on Other Legal and Regulatory 
Requirements below, is not modified in respect of the 
above matter with respect to our reliance on the work 
done and the reports of the other auditors.
Report on Other Legal and Regulatory Requirements
1.	
As required by the Companies (Auditor‚Äôs Report) 
Order, 2020 (‚Äúthe Order‚Äù) issued by the Central 
Government of India in terms of Section 143(11) of 
Independent Auditor‚Äôs Report
the Act, we give in the ‚ÄúAnnexure A‚Äù a statement on 
the matters specified in paragraphs 3 and 4 of the 
Order, to the extent applicable.
2 A.	 As required by Section 143(3) of the Act, based on 
our audit and on the consideration of reports of the 
other auditors on separate financial statements of 
such subsidiaries, as were audited by other auditors, 
as noted in the ‚ÄúOther Matters‚Äù paragraph, we report, 
to the extent applicable, that:
	
a.	
We have sought and obtained all the 
information and explanations which to the best 
of our knowledge and belief were necessary 
for the purposes of our audit of the aforesaid 
consolidated financial statements.
	
b.	
In our opinion, proper books of account as 
required by law relating to preparation of the 
aforesaid consolidated financial statements 
have been kept so far as it appears from our 
examination of those books and the reports of 
the other auditors except for the matters stated 
in the paragraph 2B(f) below on reporting under 
Rule 11(g) of the Companies (Audit and Auditors) 
Rules, 2014.
	
c.	
The consolidated balance sheet, the 
consolidated statement of profit and loss 
(including other comprehensive income), the 
consolidated statement of changes in equity 
and the consolidated statement of cash flows 
dealt with by this Report are in agreement with 
the relevant books of account maintained for 
the purpose of preparation of the consolidated 
financial statements.
	
d.	
In our opinion, the aforesaid consolidated 
financial statements comply with the Ind AS 
specified under Section 133 of the Act.
	
e.	
On the basis of the written representation received 
from the directors of the Holding Company as on 
31 March 2024 taken on record by the Board of 
Directors of the Holding Company, none of the 
directors of the Group Companies incorporated 
in India is disqualified as on 31 March 2023 from 
being appointed as a director in terms of section 
164(2) of the Act.
	
f.	
the modification relating to the maintenance of 
accounts and other matters connected therewith 
are as stated in the paragraph 2A(b) above on 
reporting under Section 143(3)(b) and paragraph 
2B(f) below on reporting under Rule 11(g) of the 
Companies (Audit and Auditors) Rules, 2014.
	
g.	
With respect to the adequacy of the internal 
financial controls with reference to financial 
statements of the Holding Company incorporated 
in India and the operating effectiveness of 
such controls, refer to our separate Report in 
‚ÄúAnnexure B‚Äù.
B.	
With respect to the other matters to be included in 
the Auditor‚Äôs Report in accordance with Rule 11 of 
the Companies (Audit and Auditors) Rules, 2014, in 
our opinion and to the best of our information and 
according to the explanations given to us and based 
on the consideration of the reports of the other auditors 
on separate financial statements of the subsidiaries, 
as noted in the ‚ÄúOther Matters‚Äù paragraph:
	
a.	
The consolidated financial statements disclose 
the impact of pending litigations as at 31 March 
2024 on the consolidated financial position of 
the Group. Refer Note 58 to the consolidated 
financial statements.
	
b.	
The Group did not have any material foreseeable 
losses on long-term contracts including 
derivative contracts during the year ended 
31 March 2024.
	
c.	
There has been no delay in transferring amounts 
to the Investor Education and Protection Fund 
by the Holding Company incorporated in India 
during the year ended 31 March 2024.
	
d	
(i)	
The management has represented that, 
to the best of its knowledge and belief, 
as disclosed in the Note 70I(i) to the 
consolidated financial statements, no 
funds have been advanced or loaned or 
invested (either from borrowed funds or 
share premium or any other sources or kind 
of funds) by the Holding Company to or in 
any other person(s) or entity(ies), including 
foreign entities (‚ÄúIntermediaries‚Äù), with the 
understanding, whether recorded in writing 
or otherwise, that the Intermediary shall 
directly or indirectly lend or invest in other 
persons or entities identified in any manner 
whatsoever by or on behalf of the Holding 
Company (‚ÄúUltimate Beneficiaries‚Äù) or 
provide any guarantee, security or the like 
on behalf of the Ultimate Beneficiaries.
Annual Report 2023-24
118
119
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Consolidated
	
	
(ii)	
The management has represented that, 
to the best of its knowledge and belief, 
as disclosed in the Note 70I(ii) to the 
consolidated financial statements, no 
funds have been received by the Holding 
Company from any person(s) or entity(ies), 
including foreign entities (‚ÄúFunding Parties‚Äù), 
with the understanding, whether recorded 
in writing or otherwise, that the Holding 
Company shall directly or indirectly, lend or 
invest in other persons or entities identified 
in any manner whatsoever by or on behalf of 
the Funding Parties (‚ÄúUltimate Beneficiaries‚Äù) 
or provide any guarantee, security or the like 
on behalf of the Ultimate Beneficiaries.
	
	
(iii)	
Based on the audit procedures performed 
that have been considered reasonable and 
appropriate in the circumstances, nothing 
has come to our notice that has caused 
us to believe that the representations 
under sub-clause (i) and (ii) of Rule 11(e), as 
provided under (i) and (ii) above, contain any 
material misstatement.
	
e.	
The interim dividend declared and paid by the 
Holding Company during the year and until the 
date of this audit report is in accordance with 
Section 123 of the Act.
	
f.	
Based on our examination which included test 
checks, the Company has used an accounting 
software for maintaining its books of account 
which has a feature of audit trail (edit log) 
facility and the same has operated throughout 
the year for all relevant transactions recorded in 
the software except that the audit trail was not 
enabled (i) at the database level to log any direct 
data changes; (ii) at the application level for two 
fields relating to production and inventory and 
(iii) for certain changes at the application level 
which were performed by users having privileged 
access rights. Further, where audit trail (edit log) 
facility was enabled and operated throughout 
the year, we did not come across any instance 
of audit trail feature being tampered with.
C.	
With respect to the matter to be included in the 
Auditor‚Äôs Report under Section 197(16) of the Act:
	
In our opinion and according to the information and 
explanations given to us and based on the reports of 
the statutory auditors of such subsidiary companies 
incorporated in India which were not audited by us, 
the remuneration paid during the current year by the 
Holding Company and its subsidiary companies to 
its directors is in accordance with the provisions of 
Section 197 of the Act. The remuneration paid to any 
director by the Holding Company and its subsidiary 
companies is not in excess of the limit laid down under 
Section 197 of the Act. The Ministry of Corporate Affairs 
has not prescribed other details under Section 197(16) 
of the Act which are required to be commented upon 
by us.
For B S R & Co. LLP
Chartered Accountants
Firm‚Äôs Registration No.: 101248W/W-100022
Sreeja Marar
Partner
	
 Membership No.: 111410
	
ICAI UDIN: 24111410BKGQNY3517
Place: Mumbai
Date: 02 May 2024
Independent Auditor‚Äôs Report
Annexure A to the Independent Auditor‚Äôs Report 
on the Consolidated Financial Statements of Ajanta Pharma Limited for the year ended 31 March 2024
(Referred to in paragraph 1 under ‚ÄòReport on Other Legal and Regulatory Requirements‚Äô section of our report of even 
date)
(xxi)	 According to the information and explanations given to us and based on our examination, there are no companies 
included in the consolidated financial statements of the Holding Company which are companies incorporated in 
India except the Holding Company. The Companies (Auditor‚Äôs Report) Order, 2020 of the Holding Company did 
not include any unfavourable answers or qualifications or adverse remarks.
For B S R & Co. LLP
Chartered Accountants
Firm‚Äôs Registration No.: 101248W/W-100022
Sreeja Marar
Partner
	
 Membership No.: 111410
	
ICAI UDIN: 24111410BKGQNY3517
Place: Mumbai
Date: 02 May 2024
Annual Report 2023-24
120
121
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Consolidated
Annexure B to the Independent Auditor‚Äôs Report 
on the consolidated financial statements of Ajanta Pharma Limited for the year ended 31 March 2024
Report on the internal financial controls with reference to the aforesaid consolidated financial statements under Clause 
(i) of Sub-section 3 of Section 143 of the Act
(Referred to in paragraph 2(A)(g) under ‚ÄòReport on Other Legal and Regulatory Requirements‚Äô section of our report of 
even date)
Opinion
In conjunction with our audit of the consolidated financial 
statements of Ajanta Pharma Limited (hereinafter referred 
to as ‚Äúthe Holding Company‚Äù) as of and for the year ended 
31 March 2024, we have audited the internal financial 
controls with reference to financial statements of the 
Holding Company , as of that date.
In our opinion, the Holding Company, has, in all material 
respects, adequate internal financial controls with 
reference to financial statements and such internal financial 
controls were operating effectively as at 31 March 2024, 
based on the internal financial controls with reference to 
financial statements criteria established by the Holding 
Company considering the essential components of such 
internal controls stated in the Guidance Note on Audit of 
Internal Financial Controls Over Financial Reporting issued 
by the Institute of Chartered Accountants of India (the 
‚ÄúGuidance Note‚Äù).
Management‚Äôs 
and 
Board 
of 
Directors‚Äô 
Responsibilities for Internal Financial Controls
The Company‚Äôs Management and the Board of Directors 
are responsible for establishing and maintaining internal 
financial controls based on the internal financial controls 
with reference to financial statements criteria established 
by the Company considering the essential components 
of internal control stated in the Guidance Note. These 
responsibilities include the design, implementation and 
maintenance of adequate internal financial controls that 
were operating effectively for ensuring the orderly and 
efficient conduct of its business, including adherence to 
the Company‚Äôs policies, the safeguarding of its assets, 
the prevention and detection of frauds and errors, the 
accuracy and completeness of the accounting records, 
and the timely preparation of reliable financial information, 
as required under the Act.
Auditor‚Äôs Responsibility
Our responsibility is to express an opinion on the internal 
financial controls with reference to financial statements 
based on our audit. We conducted our audit in accordance 
with the Guidance Note and the Standards on Auditing, 
prescribed under Section 143(10) of the Act, to the extent 
applicable to an audit of internal financial controls with 
reference to financial statements. Those Standards and 
the Guidance Note require that we comply with ethical 
requirements and plan and perform the audit to obtain 
reasonable assurance about whether adequate internal 
financial controls with reference to financial statements 
were established and maintained and if such controls 
operated effectively in all material respects.
Our audit involves performing procedures to obtain audit 
evidence about the adequacy of the internal financial 
controls with reference to financial statements and their 
operating effectiveness. Our audit of internal financial 
controls with reference to financial statements included 
obtaining an understanding of internal financial controls 
with reference to financial statements, assessing the 
risk that a material weakness exists, and testing and 
evaluating the design and operating effectiveness of 
internal control based on the assessed risk. The procedures 
selected depend on the auditor‚Äôs judgement, including the 
assessment of the risks of material misstatement of the 
consolidated financial statements, whether due to fraud 
or error.
We believe that the audit evidence we have obtained is 
sufficient and appropriate to provide a basis for our audit 
opinion on the internal financial controls with reference to 
financial statements.
Meaning of Internal Financial Controls with 
Reference to Financial Statements
A company‚Äôs internal financial controls with reference to 
financial statements is a process designed to provide 
reasonable assurance regarding the reliability of financial 
reporting and the preparation of financial statements 
for external purposes in accordance with generally 
accepted accounting principles. A company‚Äôs internal 
financial controls with reference to financial statements 
include those policies and procedures that (1) pertain 
to the maintenance of records that, in reasonable 
detail, accurately and fairly reflect the transactions and 
dispositions of the assets of the company; (2) provide 
reasonable assurance that transactions are recorded as 
necessary to permit preparation of financial statements 
in accordance with generally accepted accounting 
principles, and that receipts and expenditures of the 
company are being made only in accordance with 
authorisations of management and directors of the 
company; and (3) provide reasonable assurance regarding 
prevention or timely detection of unauthorised acquisition, 
use, or disposition of the company‚Äôs assets that could 
have a material effect on the financial statements.
Inherent Limitations of Internal Financial Controls 
with Reference to Financial Statements
Because of the inherent limitations of internal financial 
controls with reference to financial statements, including 
the possibility of collusion or improper management 
override of controls, material misstatements due to error 
or fraud may occur and not be detected. Also, projections 
of any evaluation of the internal financial controls with 
reference to financial statements to future periods are 
subject to the risk that the internal financial controls 
with reference to financial statements may become 
inadequate because of changes in conditions, or that 
the degree of compliance with the policies or procedures 
may deteriorate.
For B S R & Co. LLP
Chartered Accountants
Firm‚Äôs Registration No.: 101248W/W-100022
Sreeja Marar
Partner
	
 Membership No.: 111410
	
ICAI UDIN: 24111410BKGQNY3517
Place: Mumbai
Date: 02 May 2024
Annual Report 2023-24
122
123
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Consolidated
Consolidated Balance Sheet
as at 31 March 2024
H in Crore
Particulars
Note
 As at 
31 March 2024 
 As at 
31 March 2023 
ASSETS
Non-current assets
(a)
Property, plant and equipment 
8
 1,384.13 
 1,407.83 
(b)
Capital work-in-progress 
8
 256.45 
 209.47 
(c)
Right-of-use assets 
8
 80.40 
 80.86 
(d)
Other intangible assets (other than self generated) 
8
 14.66 
 7.75 
(e)
Financial assets 
(i)	
Investments
9
 18.58 
 25.10 
(ii)	
Other non-current financial assets
10
 9.36 
 11.09 
(f)
Deferred tax assets (net) 
11
 134.45 
 96.77 
(g)
Income tax assets (net) 
12
 - 
 0.83 
(h)
Other non-current assets 
13
 9.44 
 5.32 
Total non-current assets
 1,907.47 
 1,845.02 
Current assets
(a)
Inventories
14
 828.36 
 815.63 
(b)
Financial assets
(i)	
Investments
15
 330.05 
 510.27 
(ii)	
Trade receivables
16
 1,246.84 
 1,056.90 
(iii)	 Cash and cash equivalents
17
 129.49 
 329.83 
(iv)	 Bank balances other than cash and cash equivalents
18
 1.28 
 1.07 
(v)	 Loans
19
 33.96 
 17.39 
(vi)	 Other financial assets
20
 19.02 
 2.48 
(c)
Other current assets
21
 133.07 
 91.61 
 2,722.07 
 2,825.18 
Assets classified as held for sale
22
 8.85 
 8.82 
Total current assets
 2,730.92 
 2,834.00 
Total assets
 4,638.39 
 4,679.02 
EQUITY AND LIABILITIES
Equity
(a)
Equity share capital
23
 25.27 
 25.27 
(b)
Other equity
24
 3,542.09 
 3,362.72 
Total equity
 3,567.36 
 3,387.99 
Liabilities
Non-current liabilities
(a)
Financial liabilities 
(i)	
Borrowings 
25
 - 
 1.25 
(ii)	
Lease liabilities 
26
 23.52 
 24.95 
(iii)	 Other financial liabilities 
27
 1.37 
 1.01 
(b)
Other non-current liabilities 
28
 2.34 
 2.67 
(c)
Provisions 
29
 39.54 
 24.15 
(c)
Deferred tax liabilities (net) 
30
 108.50 
 97.72 
Total non-current liabilities
 175.27 
 151.75 
Current liabilities
(a)
Financial liabilities
(i)	
Borrowings 
31
 1.49 
 0.18 
(ii)	
Lease liabilities 
32
 10.27 
 9.25 
(iii)	 Trade payables 
	
(a)	 total outstanding dues of micro enterprises and small enterprises
33
 20.64 
 37.94 
	
(b)	 total outstanding dues of creditors other than micro enterprises and  
small enterprises
33
 442.56 
 384.83 
(iii)	 Other financial liabilities
34
 298.03 
 636.84 
(b)
Other current liabilities
35
 59.73 
 23.15 
(c)
Provisions
36
 17.76 
 14.02 
(d)
Current tax liabilities (net)
37
 44.77 
 33.07 
 895.25 
 1,139.28 
Liabilities classified as held for sale
38
 0.51 
 - 
Total current liabilities
 895.76 
 1,139.28 
Total liabilities
 1,071.03 
 1,291.03 
Total equity and liabilities
 4,638.39 
 4,679.02 
Material accounting policies
1 to 7
The notes referred to above form an integral part of the consolidated financial statements
 8 to 70 
As per our report of even date attached 
For B S R & Co. LLP
For and on behalf of Board of Directors of 
Chartered Accountants
Ajanta Pharma Limited
Firm's Registration No.: 101248W/W-100022
Sreeja Marar
Yogesh M. Agrawal
Rajesh M. Agrawal
Partner 
Managing Director
Joint Managing Director
Membership No.: 111410
DIN: 00073673
DIN: 00302467
Arvind K. Agrawal
Gaurang C. Shah
Place: Mumbai
Chief Financial Officer
Company Secretary
Date: 02 May 2024
FCS No.: 6696
Consolidated Statement of Profit and Loss 
for the year ended 31 March 2024
H in Crore
Particulars
Note
 Year ended 
31 March 2024 
 Year ended 
31 March 2023 
INCOME
	
Revenue from operations
39 
 4,208.71 
 3,742.64 
	
Other income
40 
 84.60 
 98.64 
Total income
 4,293.31 
 3,841.28 
EXPENSES
	
Cost of materials consumed 
41 
 939.43 
 878.36 
	
Purchase of stock-in-trade 
42 
 166.35 
 146.28 
	
Changes in inventories of finished goods/ stock-in-trade/ work-in-progress 
43 
 (39.21)
 25.76 
	
Employee benefits expense 
44 
 900.34 
 785.14 
	
Finance costs 
45 
 7.21 
 5.84 
	
Depreciation and amortisation expense 
46 
 135.40 
 130.80 
	
Other expenses 
47 
 1,069.86 
 1,123.85 
Total expenses 
 3,179.38 
 3,096.03 
Profit before tax 
 1,113.93 
 745.25 
Tax expense:
65
	
-	
Current tax (net)
	
	
	
For current year
 298.22 
 175.58 
	
	
	
For earlier years
 23.84 
 21.66 
	
-	
Deferred tax (net)
 (24.30)
 (39.97)
Total tax expense
 297.76 
 157.27 
Profit for the year
 816.17 
 587.98 
Other comprehensive income/(loss)
Items that will not to be reclassified subsequently to profit or loss
Re-measurement of defined benefit liability/(assets)
 (3.88)
 (3.49)
Income tax relating to items that will not be reclassified to profit or loss
 1.36 
 1.22 
Net other comprehensive income/(loss) that will not be reclassified subsequently to 
profit or loss
 (2.52)
 (2.27)
Items that will be reclassified subsequently to profit or loss
Exchange differences in translating the financial statements of foreign operations
 3.33 
 17.12 
Income tax relating to items that will be reclassified to profit or loss
 - 
 - 
Net other comprehensive (loss)/income to be reclassified subsequently to  
profit or loss
 3.33 
 17.12 
Other comprehensive income/(loss) for the year (net of income tax)
 0.81 
 14.85 
Total comprehensive income for the year
 816.98 
 602.83 
Earnings Per Equity Share (Face Value K 2/-)
49
	
Basic (H)
 64.82 
 45.89 
	
Diluted (H)
 64.77 
 45.89 
Material accounting policies
1 to 7
The notes referred to above form an integral part of the consolidated financial 
statements
 8 to 70
As per our report of even date attached 
For B S R & Co. LLP
For and on behalf of Board of Directors of 
Chartered Accountants
Ajanta Pharma Limited
Firm's Registration No.: 101248W/W-100022
Sreeja Marar
Yogesh M. Agrawal
Rajesh M. Agrawal
Partner 
Managing Director
Joint Managing Director
Membership No.: 111410
DIN: 00073673
DIN: 00302467
Arvind K. Agrawal
Gaurang C. Shah
Place: Mumbai
Chief Financial Officer
Company Secretary
Date: 02 May 2024
FCS No.: 6696
Annual Report 2023-24
124
125
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Consolidated
Consolidated Statement of Changes in Equity 
for the year ended 31 March 2024
A. Equity Share Capital (Refer Note 23)
H in Crore
Particulars
Balance as at 
01 April 2023
Changes in Equity 
Share Capital due 
to prior period 
errors
Restated balance 
at the beginning 
of the current 
reporting period
Changes in equity 
share capital 
during the year
Balance as at 
31 March 2024
Authorised
 30.00 
 - 
 30.00 
 - 
 30.00 
Issued, Subscribed & Paid up
 25.27 
 - 
 25.27 
 - 
 25.27 
H in Crore
Particulars
Balance as at 
 01 April 2022
Changes in Equity 
Share Capital due 
to prior period 
errors
Restated balance 
at the beginning 
of the current 
reporting period
Changes in equity 
share capital 
during the year
Balance as at 
31 March 2023
Authorised
 30.00 
 - 
 30.00 
 - 
 30.00 
Issued, Subscribed & Paid up
 17.17 
 - 
 17.17 
 8.10 
 25.27 
B. 
Other Equity (Refer Note 24)
H in Crore
Particulars
Reserves and Surplus
Other Comprehensive Income
Total 
Non-
Controlling 
Interests 
Total 
Equity 
Capital 
Redemption 
Reserve 
Securities 
Premium 
General 
Reserve 
Employee 
Stock 
Options 
Outstanding 
Account 
Retained 
Earnings 
Foreign 
Currency 
Translation 
Reserve 
Other items (Re-
measurement 
gains (losses) on 
defined benefit 
plans) 
Balance as at 01 April 2022
2.63 
- 
531.77 
0.30 
2,717.70 
0.88 
(6.10)
3,247.17 
- 
3,247.17 
Profit for the period
- 
- 
- 
- 
587.98 
- 
- 
587.98 
- 
587.98 
Other comprehensive income
- 
- 
- 
- 
- 
17.12 
(2.27)
14.85 
- 
14.85 
Total comprehensive income
- 
- 
- 
- 
587.98 
17.12 
(2.27)
602.83 
- 
602.83 
Exercised Stock Options
- 
- 
- 
0.22 
- 
- 
- 
0.22 
- 
0.22 
Utilised for buy-back of Equity 
Shares (refer note 23.8)
- 
(0.18)
(320.73)
- 
- 
- 
- 
(320.91)
- 
(320.91)
Expense & Tax on buyback of 
equity shares (refer note 23.8)
- 
- 
- 
- 
(74.72)
- 
- 
(74.72)
- 
(74.72)
Transfer to Capital Redemption 
Reserve for buyback of Equity 
Shares (refer note 23.8)
(2.19)
- 
(0.00)
- 
-
- 
- 
(2.19)
- 
(2.19)
Exercised Stock Options
- 
0.18 
- 
- 
- 
- 
- 
0.18 
0.18 
Share-based payment expenses
- 
- 
- 
(0.18)
- 
- 
- 
(0.18)
- 
(0.18)
Dividend Paid
- 
- 
- 
- 
(89.69)
- 
- 
(89.69)
(89.69)
Dividend Distribution Tax
- 
- 
- 
- 
- 
- 
- 
- 
- 
As at 31 March 2023
0.44 
- 
211.04 
0.34 
3,141.27 
18.00 
(8.37)
3,362.72 
- 
3,362.72 
Balance as at 01 April 2023
0.44 
- 
211.04 
0.34 
3,141.27 
18.00 
(8.37)
3,362.72 
- 
3,362.72 
Profit for the period
-
-
-
-
816.17 
-
-
816.17 
- 
816.17 
Other comprehensive income (net 
of tax)
- 
- 
- 
- 
- 
3.33 
(2.52)
0.81 
- 
0.81 
Total comprehensive income
- 
- 
- 
- 
816.17 
3.33 
(2.52)
816.98 
- 
816.98 
Exercised Stock Options
- 
- 
- 
5.68 
- 
- 
- 
5.68 
- 
5.68 
Utilised for buy-back of Equity 
Shares (refer note 23.8)
- 
- 
- 
- 
- 
-
-
- 
- 
- 
Expense & Tax on buyback of 
equity shares (refer note 23.8)
- 
- 
- 
- 
(0.92)
-
-
(0.92)
- 
(0.92)
Transfer to Capital Redemption 
Reserve for buyback of Equity 
Shares (refer note 23.8)
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
Exercised Stock Options
- 
0.18 
- 
- 
- 
- 
- 
0.18 
- 
0.18 
Share-based payment expenses
- 
- 
- 
(0.37)
- 
- 
- 
(0.37)
- 
(0.37)
Dividend Paid
- 
- 
- 
- 
(642.17)
- 
- 
(642.17)
- 
(642.17)
Dividend Distribution Tax
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
As at 31 March 2024 
0.44 
0.18 
211.04 
5.65 
3,314.35 
21.33 
(10.89)
3,542.09 
- 
3,542.09 
Consolidated Statement of Changes in Equity 
for the year ended 31 March 2024
a)	 Capital Redemption Reserve
	
As per Companies Act, 2013, capital redemption reserve is created on redemption of preference shares and when 
company purchases its own shares out of free reserves or securities premium. A sum equal to the nominal value of 
the shares redeemed or purchased is transferred to capital redemption reserve.
b)	
Securities Premium
	
Securities premium account comprises of premium on issue of shares. The reserve is utilised in accordance with 
the specific provision of the Companies Act, 2013.
c)	
General Reserve
	
The General reserve is used from time to time to transfer profits from retained earnings for appropriation purposes.
d)	 Employee Stock Option Outstanding
	
The fair value of the equity-settled share-based payment transactions are debited to Statement of Profit and Loss 
with corresponding credit to Employee Stock Options Outstanding Account over the vesting period of the options.
e)	
Retained Earnings
	
Retained Earnings are the profits that the Company has earned till date less any transfer to general reserve, 
dividends or other distributions paid to shareholders.
f)	
Foreign Currency Translation Reserve
	
This reserve represents exchange differences arising on account of conversion of foreign operations to Company‚Äôs 
functional currency.
Material accounting policies	
	
	
	
	
	
	
	
	
	
1 to 7
See accompanying notes forming part of the consolidated financial statements	
8 to 70
As per our report of even date attached 
For B S R & Co. LLP
For and on behalf of Board of Directors of 
Chartered Accountants
Ajanta Pharma Limited
Firm's Registration No.: 101248W/W-100022
Sreeja Marar
Yogesh M. Agrawal
Rajesh M. Agrawal
Partner 
Managing Director
Joint Managing Director
Membership No.: 111410
DIN: 00073673
DIN: 00302467
Arvind K. Agrawal
Gaurang C. Shah
Place: Mumbai
Chief Financial Officer
Company Secretary
Date: 02 May 2024
FCS No.: 6696
Annual Report 2023-24
126
127
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Consolidated
Consolidated Statement of Cash Flow 
for the year ended 31 March 2024
H in Crore
 Particulars 
 Year ended 
31 March 2024 
 Year ended 
31 March 2023 
 A. 
CASH FLOW FROM OPERATING ACTIVITIES
Profit before tax 
 1,113.93 
 745.25 
Adjustment for
Depreciation and amortisation expense
 135.40 
 130.80 
Loss on sale/retirement of property, plant and equipment (net)
 (3.49)
 6.19 
Finance costs
 7.21 
 5.84 
Loss/(Gain) on fair value of investment
 9.11 
 2.30 
Loss/(Gain) on fair value of derivative
 (22.82)
 18.82 
Income from investments and deposits
 (38.12)
 (17.64)
Deferred Government grant
 (0.33)
 (0.33)
Equity settled share-based payment
 5.49 
 0.22 
Unrealised Foreign exchange (Gain)
 (9.42)
 (14.08)
Impairment loss on financial assets
 - 
 (0.82)
Operating cash flow before working capital changes
 1,196.96 
 876.55 
Changes in working capital
(Increase) in trade receivables
 (178.88)
 (10.55)
(Increase)/Decrease in other current assets
 (40.94)
 6.93 
Decrease in other current financial assets
 17.40 
 32.33 
Decrease in other non-current financial assets
 1.73 
 0.96 
(Increase)/Decrease in non-current financial assets
 (1.01)
 0.27 
(Increase) in inventories
 (12.30)
 (22.37)
(Increase) in current loans
 (16.57)
 (11.02)
(Decrease) in other non-current financial liabilities
 0.69 
 0.25 
(Decrease)/Increase in other current liabilities
 36.05 
 (44.01)
Increase in other current financial liabilities
 36.09 
 11.38 
Increase in non-current provisions
 15.39 
 4.83 
Liabilities classified as held for sale (Refer Note 68)
 0.51 
 - 
Increase in current provisions
 1.22 
 0.94 
Increase in trade payables
 40.85 
 96.91 
Cash generated from operating activities
 1,097.20 
 943.40 
Net income tax paid
 (312.13)
 (151.29)
Net cash generated from operating activities
 785.07 
 792.11 
 B. 
CASH FLOW FROM INVESTING ACTIVITIES
Capital expenditure on property, plant and equipment & intangible assets including 
capital advances
 (152.41)
 (174.49)
Proceeds from sale of property, plant and equipment
 13.38 
 0.73 
Bank balances not considered as cash and cash equivalents
 (0.21)
 4.35 
Purchase of current investments
 (2,079.76)
 (1,666.86)
Proceeds from sale of current investments
 2,257.39 
 1,276.15 
Income on investments and deposits
 27.00 
 0.52 
Net cash generated/(used) in investing activities
 65.39 
 (559.60)
Consolidated Statement of Cash Flow 
for the year ended 31 March 2024
H in Crore
 Particulars 
 Year ended 
31 March 2024 
 Year ended 
31 March 2023 
 C. 
CASH FLOW FROM FINANCING ACTIVITIES
Proceeds from Issue of Equity Shares (31 March 2024 H 2,000, 31 March 2023 H 2,000)
0.00
0.00
(Repayment)/Proceeds of borrowings (net)
 0.06 
 (0.49)
Interest paid
 (3.53)
 (2.33)
Payment of lease liability (includes interest of H 3.68 Crore in year ending on 31 March 
2024 and H 3.51 Crore in year ending on 31 March 2023)
 (16.23)
 (14.25)
(Payment) for buyback of equity shares (Refer Note 23.8)
 (388.27)
 - 
Income/(Payment) for expenses for buyback of equity shares (Refer Note 23.8)
 (0.92)
 (1.44)
Dividend paid
 (642.17)
 (89.69)
Net cash used in financing activities
 (1,051.06)
 (108.20)
Net (decrease)/increase in cash and cash equivalents (A + B + C)
 (200.60)
 124.31 
Cash and cash equivalents as at the beginning of the year
 329.83 
 206.36 
Cash and cash equivalents as at the end of the year
 129.23 
 330.67 
Reconciliation of cash and cash equivalents with the Balance sheet
Cash and cash equivalents as restated as at the end of the year
 129.23 
 330.67 
Unrealised (loss)/gain on foreign currency cash and cash equivalents
 0.26 
 (0.84)
Cash and cash equivalents as per balance sheet (refer note 17)
 129.49 
 329.83 
Figures in brackets indicates outflow. 
Notes:
1.	
The above Cash Flow Statement has been prepared under the ‚ÄòIndirect Method‚Äô as set out in the Indian Accounting Standard 7 (Ind AS -7) 
‚ÄúStatement of Cash Flow‚Äú under Section 133 of the Companies Act, 2013.
2.	
Cash comprises cash on hand, current accounts and deposits with banks. Cash equivalents are short-term balances (with an original 
maturity of three months or less from the date of acquisition).
3.	
Reconciliation between the opening and closing balances in the balance sheet for liabilities arising from financing activities.
H in Crore
Particulars 
Notes 
31 March 2023
Cash Flows 
 Non-cash changes 
As at 
31 March 2024
 Acquisition 
 Foreign 
exchange 
movement 
 Fair value 
change 
Borrowing 
25 & 31
1.43 
0.06 
 - 
 - 
 - 
 1.49 
4. 	 During the year the Group paid H 17.32 Crore (31 March 2023 H 16.37 Crore) towards corporate social responsibility (CSR) expenditure 
included in corporate social responsibility expenditure Refer note 60).
5. 	 Movement in lease liabilities (refer note 57).
Material accounting policies	
	
	
	
	
	
	
	
	
	
	
1 to 7
The notes referred to above form an integral part of the consolidated financial statements	
8 to 70
As per our report of even date attached 
For B S R & Co. LLP
For and on behalf of Board of Directors of 
Chartered Accountants
Ajanta Pharma Limited
Firm's Registration No.: 101248W/W-100022
Sreeja Marar
Yogesh M. Agrawal
Rajesh M. Agrawal
Partner 
Managing Director
Joint Managing Director
Membership No.: 111410
DIN: 00073673
DIN: 00302467
Arvind K. Agrawal
Gaurang C. Shah
Place: Mumbai
Chief Financial Officer
Company Secretary
Date: 02 May 2024
FCS No.: 6696
Annual Report 2023-24
128
129
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Consolidated
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
1. 
Corporate Information
Ajanta Pharma Limited (‚Äúthe Company‚Äù) is a public 
limited company incorporated and domiciled in India. 
Its shares are listed on Bombay Stock Exchange 
and National Stock Exchange. The registered 
office of Holding Company is located at Ajanta 
House, Charkop, Kandivali (West), Mumbai. These 
Consolidated Financial statements (‚ÄúCFS‚Äù) comprises 
the Company and its wholly-owned subsidiaries 
(referred to collectively as the ‚ÄúGroup‚Äù).
The Group is primarily involved in development, 
manufacturing and marketing of speciality 
pharmaceutical finished dosages.
2. 
Basis of Preparation
	
Statement of Compliance:
These consolidated financial statements have been 
prepared in accordance with the Indian Accounting 
Standards (‚ÄòInd AS‚Äô) as per the Companies (Indian 
Accounting Standards) Rules, 2015, as amended 
from time to time, notified under Section 133 of 
the Companies Act, 2013 (‚ÄòAct‚Äô) and other relevant 
provisions of the Act. These consolidated financial 
statements have been prepared on an accrual 
basis and under the historical cost basis, except 
otherwise stated.
These Consolidated Financial Statements for the year 
ended 31 March 2024 have been reviewed by the 
Audit Committee and subsequently approved by the 
Board of Directors at its meeting held on 02 May 2024.
	
Use Of Estimates and Judgements:
The preparation of consolidated financial statements 
in conformity with Ind AS requires management to 
make judgements, estimates and assumptions that 
affect the application of accounting policies and the 
reported amounts of assets, liabilities, income and 
expenses and the disclosure of contingent liabilities 
on the date of the financial statements. Actual results 
could differ from those estimates. Estimates and under 
lying assumptions are reviewed on an ongoing basis. 
Any revision to accounting estimates is recognised 
prospectively in current and future periods.
	
Judgements:
Information about judgements made in applying 
accounting policies that have the most significant 
effects on the amounts recognised in the financial 
statements is included in the following notes.
 
Classification of Lease as per Ind AS 116:
Ind AS 116 Leases requires a lessee to determine the 
lease term as the non-cancellable period of a lease 
adjusted with any option to extend or terminate the 
lease, if the use of such option is reasonably certain. 
The Group makes an assessment on the expected 
lease term on lease by lease basis and thereby 
assesses whether it is reasonably certain that any 
options to extend or terminate the contract will be 
exercised. In evaluating the lease term, The Group 
considers factors such as any significant leasehold 
improvements undertaken over the lease term, 
costs relating to the termination of lease and the 
importance of the underlying lease to The Group‚Äôs 
operations taking into account the location of the 
underlying asset and the availability of the suitable 
alternatives. The lease term in future periods is 
reassessed to ensure that the lease term reflects the 
current economic circumstances. The discount rate 
is generally based on the incremental borrowing rate 
specific to the lease being evaluated or for a portfolio 
of leases with similar characteristics.
	
Estimates:
Information about assumptions and estimation 
uncertainties at the reporting date that have a 
significant risk of resulting in a material adjustment to 
the carrying amounts of assets and liabilities within the 
next financial year is included in the following notes:
	
Recognition of Current and Deferred Tax 
Assets:
The Group‚Äôs tax charge on ordinary activities is the 
sum of the total current and deferred tax charges. 
The calculation of The Group‚Äôs total tax charge 
necessarily involves a degree of estimation in respect 
of certain items whose tax treatment cannot be finally 
determined until resolution has been reached with the 
relevant tax authority or, as appropriate, through a 
formal legal process. The final resolution of some of 
these items may give rise to material profits/losses 
and/or cash flows.
The complexity of The Group‚Äôs structure makes the 
degree of estimation more challenging. The resolution 
of issues is not always within the control of The Group 
and it is often dependent on the efficiency of the legal 
processes in the relevant taxing jurisdictions in which 
The Group operates. Issues can, and often do, take 
many years to resolve.
Payments in respect of tax liabilities for an accounting 
period result from payments on account and on the 
final resolution of open items. As a result there can 
be substantial differences between the tax charge in 
the Statement of Profit and Loss and tax payments.
The recognition of deferred tax assets is based upon 
whether it is more likely than not that sufficient and 
suitable taxable profits will be available in the future 
against which the reversal of temporary differences 
can be deducted. To determine the future taxable 
profits, reference is made to the latest available 
profit forecasts. Where the temporary differences 
are related to losses, relevant tax law is considered 
to determine the availability of the losses to offset 
against the future taxable profits.
	
Chargebacks, Rebates and Discount:
Provisions for chargeback, rebates, discounts, other 
deductions and Medicaid payments are estimated 
and provided for in the year of sales and recorded as 
reduction of revenue. A chargeback claim is a claim 
made by the wholesaler for the difference between 
the price at which the product is initially invoiced to 
the wholesaler and the net price at which it is agreed 
to be procured from the Group. Provisions for such 
chargebacks, rebates and discounts are accrued and 
estimated based on historical average rate actually 
claimed over a period of time, current contract prices 
with wholesalers/other customers and estimated 
inventory holding by the wholesaler.
	
Property, Plant and Equipment:
Useful lives of tangible assets are based on the life 
prescribed in Schedule II of the Act. In cases, where 
the useful lives are different from that prescribed in 
Schedule II, they are based on technical advice, taking 
into account the nature of the asset, the estimated 
usage of the asset, the operating conditions of the 
asset, past history of replacement, anticipated 
technological changes, manufacturers‚Äô warranties 
and maintenance support.
 
Recognition and Measurement of Defined 
Benefit Obligations:
The obligation arising from the defined benefit plan 
is determined on the basis of actuarial valuation. Key 
actuarial assumptions include discount rate, trends 
in salary escalation and vested future benefits and 
life expectancy. The discount rate is determined with 
reference to market yields at the end of the reporting 
period on the government bonds. The period to 
maturity of the underlying bonds correspond to 
the probable maturity of the post-employment 
benefit obligations.
	
Intangible Assets:
Intangible assets majorly consist software licences 
which are amortised over licence period which 
equates the economic useful life ranging between 
2-5 years on a straight-line basis over the period of 
its economic useful life.
	
Allowance for Uncollected Accounts 
Receivable and Advances:
Trade receivables do not carry any interest and 
are stated at their normal value as reduced by 
appropriate allowances for estimated irrecoverable 
amounts. Individual trade receivables are written 
off when management seems them not collectible. 
Impairment is made using expected credit loss model.
The impairment provisions for financial assets 
are based on assumption about risk of default 
and expected loss rates. Judgement in making 
these assumptions and selecting the inputs to the 
impairment calculation are based on past history, 
existing market condition as well as forward-looking 
estimates at the end of each reporting period.
	
Allowances for Inventories:
Management reviews the inventory age listing on 
a periodic basis. The review involves comparison of 
the carrying value of the aged inventory items. The 
purpose is to ascertain whether an allowance is 
required to be made in the financial statement for 
any obsolete and slow-moving items. Management 
is satisfied that adequate allowance for obsolete 
and slow-moving inventories has been made in the 
group‚Äôs financial statements.
Management also reviews net realisable value for all 
its inventory and is satisfied that adequate allowance 
has been made in the financial statements.
	
Contingencies:
Management judgement is required for estimating 
the possible outflow of resources, if any, in respect of 
contingencies/claim/litigations against the Group as 
it is not possible to predict the outcome of pending 
matters with accuracy.
	
Impairment Reviews:
An impairment exists when the carrying value of 
an asset or cash generating unit (‚ÄòCGU‚Äô) exceeds 
its recoverable amount. Recoverable amount is 
the higher of its fair value less costs to sell and its 
value in use. The value in use calculation is based 
on a discounted cash flow model. In calculating the 
Annual Report 2023-24
130
131
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Consolidated
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
value in use, certain assumptions are required to be 
made in respect of highly uncertain matters, including 
management‚Äôs expectations of growth in EBITDA, 
long-term growth rates; and the selection of discount 
rates to reflect the risks involved.
	
Determination of Functional Currency:
Each entity in the group determines its own functional 
currency (the currency of the primary economic 
environment in which the entity operates) and 
items included in the financial statements of each 
entity are measured using that functional currency. 
Ind AS 21, ‚ÄúThe Effects of Changes in Foreign Exchange 
Rates‚Äù prescribes the factors to be considered for 
the purpose of determination of functional currency. 
Management uses its judgement to determine the 
functional currency that most faithfully represents 
the economic effects of the underlying transactions, 
events and conditions.
	
Provision for Anticipated Sales Return:
In determining the provision for anticipated sales 
returns, estimates for probable saleable and 
non-saleable returns of goods from the customers 
are made on scientific basis after factoring in the 
historical data of such returns and its trend.
3. 
Principles of Consolidation
These consolidated financial statements comprise 
the financial statement of the Company and its 
wholly-owned subsidiaries. A subsidiary is an entity 
over which the Group has control. Control is achieved 
when the Group is exposed, or has rights, to variable 
returns from its involvement with the investee and has 
the ability to affect those returns through its power 
over the investee. Specifically, the Group controls an 
investee if and only if the Group has:
‚Ä¢	 Power over the investee (i.e. existing rights that give 
it the current ability to direct the relevant activities 
of the investee)
‚Ä¢	 Exposure, or rights, to variable returns from its 
involvement with the investee, and
‚Ä¢	 The ability to use its power over the investee to 
affect its returns.
Generally, there is a presumption that a majority 
of voting rights result in control. To support this 
presumption and when the Group has less than 
a majority of the voting or similar rights of an 
investee, the Group considers all relevant facts and 
circumstances in assessing whether it has power over 
an investee, including:
‚Ä¢	 The contractual arrangement with the other vote 
holders of the investee
‚Ä¢	 Rights arising from other contractual arrangements
‚Ä¢	 The Group‚Äôs voting rights and potential voting rights
‚Ä¢	 The size of the Group‚Äôs holding of voting rights 
relative to the size and dispersion of the holdings 
of the other voting rights holders.
The Group re-assesses whether or not it controls 
an investee if facts and circumstances indicate 
that there are changes to one or more of the three 
elements of control.
Consolidated financial statements are prepared using 
uniform accounting policies for like transactions and 
other events in similar circumstances. If a member of 
the Group uses accounting policies other than those 
adopted in the consolidated financial statements for 
like transactions and events in similar circumstances, 
appropriate adjustments are made to that Group 
member‚Äôs financial statements in preparing the 
consolidated financial statements to ensure 
conformity with the Group‚Äôs accounting policies.
	
Consolidation Procedure:
	
(i)	
Subsidiaries
Subsidiaries are entities controlled by the 
Group. The Group controls an entity when it is 
exposed to, or has rights to, variable returns 
from its involvement with the entity and has 
the ability to affect those returns through its 
power over the entity. The financial statements 
of subsidiaries are included in the consolidated 
financial statements from the date on which 
control commences until the date on which 
control ceases.
Items of assets, liabilities, equity, income, 
expenses and cashflows of the parents with 
those of its subsidiaries are combined like to 
like basis. For this purpose, income & expenses 
of the subsidiaries are based on the assets and 
liabilities recognised in consolidated financial 
statements at acquisition date.
	
(ii)	 Non-Controlling Interests (NCI)
NCI are measured at their proportionate share 
of the acquiree‚Äôs net identifiable assets at the 
date of acquisition.
Non-controlling interests in the net assets 
(excluding goodwill) of consolidated subsidiaries 
are identified separately from the Group‚Äôs equity. 
NCI are measured at their proportionate share 
of the acquiree‚Äôs net identifiable assets at the 
date of acquisition. Subsequent to acquisition, 
the carrying amount of non-controlling interests 
is the amount of those interests at initial 
recognition plus the non-controlling interests‚Äô 
share of subsequent changes in equity. 
Total comprehensive income is attributed to 
non-controlling interests even if it results in the 
non-controlling interest having a deficit balance.
	
(iii)	 Loss of Control
When the Group loses control over a subsidiary, 
it derecognises the assets and liabilities of 
the subsidiary, and any related NCI and other 
components of equity. Any interest retained in 
the former subsidiary is measured at fair value at 
the date the control is lost. Any resulting gain or 
loss is recognised in Statement of Profit and Loss.
	
(iv)	 Transaction‚Äôs Eliminated on Consolidation
Intra-group balances and transactions, and 
any unrealised income and expenses arising 
from intra-group transactions, are eliminated. 
Unrealised losses are eliminated in the same way 
as unrealised gains, but only to the extent that 
there is no evidence of impairment.
4. 
Functional and Presentation Currency
Group‚Äôs consolidated financial statements are 
presented in Indian rupees, which is the functional 
currency of the Holding Company. For each entity the 
Group determines the functional currency and items 
included in the financial statements of each entity are 
measured using that functional currency.
	
Initial recognition: 
Currency transactions are recorded by the Group‚Äôs 
entities at their respective functional currency, 
by applying to the foreign currency amount the 
exchange rate between the functional currency and 
foreign currency at the date of the transaction.
	
Conversion:
Foreign currency monetary items are reported at 
functional currency spot rate of exchange at reporting 
date. ‚ÄòNon-monetary items that are measured 
in terms of historical cost in a foreign currency are 
translated using the exchange rates at the dates of 
the initial transactions.
	
Group Companies:
On consolidation, the assets and liabilities of foreign 
operations are translated into Indian rupees at the 
rate of exchange prevailing at the reporting date 
and their statements of profit or loss are translated 
at average exchange rates.
For practical reasons, the Group uses an average rate 
to translate income and expense items, if the average 
rate approximates the exchange rates at the dates 
of the transactions. The exchange differences arising 
on translation for consolidation are recognised in OCI. 
On disposal of a foreign operation, the component 
of OCI relating to that particular foreign operation is 
recognised in profit or loss.
5. 
Rounding of Amounts
All amounts disclosed in the financial statements and 
notes have been rounded off to the nearest Crore.
6. 
Current/Non-Current Classification
An entity shall classify an asset as current when-
(a)	
it expects to realise the asset, or intends to sell 
or consume it, in its normal operating cycle;
(b)	
it holds the asset primarily for the purpose 
of trading;
(c)	
it expects to realise the asset within twelve 
months after the reporting period; or
(d)	
the asset is cash or a cash equivalent unless the 
asset is restricted from being exchanged or used 
to settle a liability for at least twelve months 
after the reporting period.
An entity shall classify all other assets as non-current.
An entity shall classify a liability as current when-
(a)	
it expects to settle the liability in its normal 
operating cycle;
(b)	
it holds the liability primarily for the purpose 
of trading;
(c)	
the liability is due to be settled within twelve 
months after the reporting period; or
(d)	
it does not have an unconditional right to 
defer settlement of the liability for at least 
twelve months after the reporting period. 
Terms of a liability that could, at the option of 
the counterparty, result in its settlement by 
the issue of equity instruments do not affect 
its classification.
Annual Report 2023-24
132
133
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Consolidated
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
An entity shall classify all other liabilities as 
non-current.
	
Operating Cycle:
An operating cycle is the time between the acquisition 
of assets for processing and their realisation in cash 
or cash equivalents.
Based on the nature of products/activities of the group 
and the normal time between acquisition of assets 
and their realisation in cash or cash equivalents, the 
group has determined its operating cycle as twelve 
months for the purpose of classification of its assets 
and liabilities as current and non-current.
7. 
Material Accounting Policies
7.1 Property, Plant and Equipment
	
Recognition and measurement:
Items of PPE are carried at cost less accumulated 
depreciation and impairment losses, if any. The 
cost of an item of PPE comprises its purchase price, 
including import duties and other non-refundable 
taxes or levies and any directly to the attributable 
cost of bringing the assets to its working condition for 
its intended use and any trade discount and rebates 
are deducted in arriving at purchase price. Cost 
of the assets also includes interest on borrowings 
attributable to acquisition of qualifying fixed assets 
up to the date the asset is ready for its intended use 
incurred up to that date.
Such cost includes the cost of replacing part of 
the plant and equipment and borrowing costs for 
long-term construction projects if the recognition 
criteria are met. When significant parts of plant and 
equipment are required to be replaced at intervals, 
the Group depreciates these components separately 
based on their specific useful lives. Likewise, when a 
major inspection is performed, its cost is recognised in 
the carrying amount of the plant and equipment as a 
replacement if the recognition criteria are satisfied. All 
other repair and maintenance costs are recognised in 
the statement of profit or loss as incurred.
Cost of Items of Property, plant and equipment not 
ready for intended use as on the balance sheet date, 
is disclosed as capital work-in-progress. Advances 
given towards acquisition of property, plant and 
equipment outstanding at each balance sheet 
date are disclosed as Capital Advance under Other 
non-current assets.
All identifiable revenue expenses including interest 
incurred in respect of various projects/expansion, 
net of income earned during the project development 
stage prior to its intended use, are considered as pre-
operative expenses and disclosed under Capital 
Work-in-Progress.
Capital expenditure on Property, plant and 
equipment for research and development is 
classified under property, plant and equipment and 
is depreciated on the same basis as other property, 
plant and equipment.
Property, plant and equipment are derecognised 
either on disposal or when the asset retires from 
active use. Losses arising in the case of the retirement 
of property, plant and equipment and gains or 
losses arising from disposal of property, plant and 
equipment are recognised in the statement of profit 
and loss in the year of occurrence.
	
Transition to Ind AS:
The cost property, plant and equipment at 01 April 
2016, the Companies date of transition to Ind AS, 
was determined with reference to its carrying value 
recognised as per the previous GAAP (deemed cost), 
as at the date of transition to Ind AS.
	
Subsequent Expenditure:
Subsequent expenditure is capitalised only if it is 
probable that the future economic benefits associated 
with the expenditure will flow to the Company and the 
cost of the item can be measured reliably.
	
Depreciation:
Depreciation is the systematic allocation of the 
depreciable amount of PPE over its useful life and is 
provided on a straight-line basis over the useful lives 
as prescribed under Schedule II to the Act or as per 
technical assessment. The residual values, useful lives 
and method of depreciation of PPE is reviewed at 
each financial year end and adjusted prospectively, 
if appropriate.
Depreciation on additions/disposals is provided on 
a pro-rata basis i.e. from/up to the date on which is 
asset is ready to use/disposed of. Freehold land is 
not depreciated.
The estimated useful lives of Tangible assets are 
as follows
PPE
Useful Life
Buildings*
5 Years to 60 Years
Plant and Equipment*
3 Years to 25 Years
Furniture and Fixtures*
10 Years
Vehicles
8 Years to 10 Years
Office Equipments*
3 Years to 5 Years
* For these class of assets, the useful life of assets is different than 
the prescribed life as per Part C of Schedule II of the Companies 
Act, 2013. The different useful life is based on internal technical 
evaluation by the Company and historical usage of assets.
Dies & Punches having useful life of 3 years as per 
technical evaluation and management estimate and 
Solar Plants having useful life of 25 years.
Property, plant and equipment which are added/
disposed off during the year, depreciation is provided 
on pro-rata basis.
Building constructed on leasehold land are 
depreciated based on the useful life specified in 
Schedule II to the Companies Act, 2013, where the 
lease period of the land is beyond the life of the 
building. In other cases, building constructed on 
leasehold land are amortised over the primary lease 
period of the land.
	
Depreciation for Subsidiaries:
Depreciation on property, plant and equipment has 
been provided at the rates required/permissible 
by the GAAPs of the respective countries. The 
management believes that these estimated useful 
lives are realistic and reflect fair approximation of 
the period over which the assets are likely to be used.
Vehicles acquired on finance leases are depreciated 
over the period of lease agreement or the useful life, 
whichever is shorter.
7.2 Intangible Assets
Intangible assets are recognised when it is probable 
that the future economic benefits that are attributable 
to the assets will flow to the Group and the cost of the 
assets can be measured reliably.
Intangible assets are carried at cost less accumulated 
amortisation and impairment losses, if any. Internally 
generated intangibles, excluding development 
costs as defined in Ind AS, are not capitalised and 
the related expenditure is reflected in Statement of 
profit and loss in the period in which the expenditure 
is incurred.
Software is amortised over their estimated useful life 
on straight-line basis from the date they are available 
for intended use or the period of the license as 
applicable, subject to impairment test.
The amortisation period and the amortisation method 
for an intangible assets with a finite useful life are 
reviewed at least at the end of each reporting period. 
Changes in the expected useful life or the expected 
pattern of consumption of future economic benefits 
embodied in the asset are considered to modify the 
amortisation period or method, as appropriate, and 
are treated as changes in accounting estimates.
Gains or losses arising from derecognition of an 
intangible asset are measured as the difference 
between the net disposal proceeds and the 
carrying amount of the asset and are recognised 
in the statement of profit and loss when the assets 
are derecognised.
	
Research and Development:
Revenue expenditure on research is recognised in the 
statement of profit and loss in the period in which it 
is incurred.
Development expenditure incurred on an individual 
project is carried forward when its future recoverability 
can reasonably be regarded as assured. Any 
expenditure carried forward is amortised over the 
period of expected future sales from the related 
project. The carrying value of development costs is 
reviewed for impairment annually when the asset is 
not yet in use, and otherwise when events or changes 
in circumstances indicate that the carrying value may 
not be recoverable.
	
Investment Property:
Investment property is property held either to earn 
rental income or for capital appreciation or for both, 
but not for sale in the ordinary course of business, use 
in the production or supply of goods or services or for 
administrative purposes. Upon initial recognition, an 
investment property is measured at cost, including 
related transaction cost. Subsequent to initial 
recognition, investment property is measured at cost 
less accumulated depreciation and accumulated 
impairment losses, if any.
The group depreciates investment property using the 
following useful lives from the date of original purchase.
Investment 
Property
Management estimate 
of useful life
Useful life as per 
Schedule II
Building
21 years
30 and 60 years
Annual Report 2023-24
134
135
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Consolidated
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
Any gain or loss on disposal of an investment property 
is recognised in profit or loss.
The fair values of investment property is disclosed in 
the notes. Fair values are determined on the basis of 
valuation done by registered valuer.
	
Impairment on non-financial assets:
The group‚Äôs non-financial assets other than 
inventories and deferred tax assets, are reviewed at 
each reporting date to determine whether there is any 
indication of impairment. If any such indication exists, 
then the asset‚Äôs recoverable amount is estimated.
For impairment testing, assets that do not generate 
independent cash inflows (i.e. corporate assets) are 
grouped together into cash-generating units (CGUs). 
Each CGU represents the smallest group of assets that 
generates cash inflows that are largely independent 
of the cash inflows of other assets or CGUs.
The recoverable amount of a CGU is the higher of its 
value in use and its fair value less costs to sell. Value 
in use is based on the estimated future cash flows, 
discounted to their present value using a discount 
rate that reflects current market assessments of the 
time value of money and the risks specific to the CGU.
An impairment loss is recognised if the carrying 
amount of an asset or CGU exceeds its estimated 
recoverable amount. Impairment loss recognised 
in respect of a CGU is allocated first to reduce the 
carrying amounts of the assets of the CGU (or group 
of CGUs) on a pro rata basis.
An impairment loss in respect of assets for which 
impairment loss has been recognised in prior periods, 
the Company reviews at each reporting date whether 
there is any indication that the loss has decreased or 
no longer exists. An impairment loss is reversed if there 
has been a change in the estimates used to determine 
the recoverable amount. Such a reversal is made only 
to the extent that the asset‚Äôs carrying amount does 
not exceed the carrying amount that would have 
been determined, net of depreciation or amortisation, 
if no impairment loss had been recognised.
The following intangible assets are tested for 
impairment each financial year even if there is no 
indication that the asset is impaired:
i)	
An intangible asset that is not yet available for 
use; and
ii)	
An intangible asset that is amortised over a 
period exceeding ten years from the date when 
the asset is available for use.
7.3 Non-current assets classified as held for sale
Assets are classified as held for sale and stated at the 
lower of carrying amount and fair value less costs to 
sell if the asset is available for immediate sale and its 
sale is highly probable. Such assets or group of assets 
are presented separately in the Balance Sheet as 
‚ÄúAssets Classified as Held for Sale‚Äù. Once classified as 
held for sale, intangible assets, investment property 
and property, plant and equipment are no longer 
amortised or depreciated.
7.4 Financial Instruments
Trade receivables and debt securities issued are 
initially recognised when they originate. All other 
financial assets and financial liabilities are initially 
recognised when the Company becomes a party to 
the contractual provisions of the instrument.
A financial asset (unless it is a trade receivable without 
a significant financing component) or financial liability 
is initially measured at fair value plus or minus, for 
an item not at FVTPL, transaction costs that are 
directly attributable to its acquisition or issue. A trade 
receivable without a significant financing component 
is initially measured at the transaction price.
A financial instrument is any contract that gives rise to 
a financial asset of one entity and a financial liability 
or equity instrument of another entity.
	
Financial Assets:
	
Classification:
The Group classifies financial assets as subsequently 
measured at amortised cost, fair value through other 
comprehensive income or fair value through profit or 
loss, on the basis of its business model for managing 
the financial assets and the contractual cash flow 
characteristics of the financial asset.
	
Initial recognition and measurement:
All financial assets excluding trade receivable 
(not measured subsequently at fair value through 
profit or loss) are recognised initially at fair value 
plus transaction costs that are attributable to the 
acquisition of the financial asset.
	
Subsequent measurement:
For the purpose of subsequent measurement, financial 
assets are classified in two broad categories:¬†
‚Ä¢	 Financial assets at fair value (FVTPL / FVTOCI)
‚Ä¢	 Financial assets at amortised cost.
When assets are measured at fair value, gains and 
losses are either recognised in the statement of profit 
and loss (i.e. fair value through profit or loss (FVTPL)), 
or recognised in other comprehensive income (i.e. fair 
value through other comprehensive income (FVOCI)).
	
Financial Assets measured at amortised cost (net of 
write down for impairment, if any):
Financial assets are measured at amortised cost 
when asset is held within a business model, whose 
objective is to hold assets for collecting contractual 
cash flows and contractual terms of the asset give 
rise on specified dates to cash flows that are solely 
payments of principal and interest. Such financial 
assets are subsequently measured at amortised 
cost using the effective interest rate (EIR) method less 
impairment, if any. The losses arising from impairment 
are recognised in the Statement of profit and loss.
	
Financial Assets measured at Fair Value through 
Other Comprehensive Income (‚ÄúFVTOCI‚Äù):
Financial assets under this category are measured 
initially as well as at each reporting date at fair 
value, when asset is held within a business model, 
whose objective is to hold assets for both collecting 
contractual cash flows and selling financial assets. 
Fair value movements are recognised in the other 
comprehensive income.
	
Financial Assets measured at Fair Value through 
Profit or Loss (‚ÄúFVTPL‚Äù):
Financial assets under this category are measured 
initially as well as at each reporting date at fair value 
with all changes recognised in profit or loss.
	
Investment in Subsidiary:
Investment in equity instruments of Subsidiaries 
are measured at cost. In the financial statements, 
investment in subsidiaries is carried at cost. The 
carrying amount is reduced to recognise any 
impairment in the value of investment.
	
Investment in Equity Instruments:
Equity instruments which are held for trading are 
classified as at FVTPL. Fair value changes on the 
instrument, excluding dividends, are recognised in 
profit or loss.
	
Investment in Debt Instruments:
A debt instrument is measured at amortised cost 
or at FVTOCI. Any debt instrument, which does not 
meet the criteria for categorisation as at amortised 
cost or as FVOCI, is classified as at FVTPL. Debt 
instruments included within the FVTPL category are 
measured at fair value with all changes recognised 
in the Statement of profit and loss.
	
Derecognition of Financial Assets:
A financial asset is primarily derecognised when 
the rights to receive cash flows from the asset have 
expired or the Group has transferred its rights to 
receive cash flows from the asset.
	
Impairment of Financial Assets:
In accordance with Ind AS 109, the Group applies 
expected credit loss (ECL) model for measurement and 
recognition of impairment loss on the financial assets 
that are debt instruments and trade receivables.
	
Financial Liabilities:
	
Classification:
The Group classifies all financial liabilities as 
subsequently measured at amortised cost or FVTPL.
	
Initial recognition and measurement:
All financial liabilities are recognised initially at fair value 
and, in the case of loans, borrowings and payables, 
net of directly attributable transaction costs.
Financial liabilities include trade and other payables, 
loans and borrowings including bank overdrafts and 
derivative financial instruments.
	
Subsequent measurement:
Financial liabilities at fair value through profit or 
loss include financial liabilities held for trading and 
financial liabilities designated upon initial recognition 
as at fair value through profit or loss. Interest-bearing 
loans and borrowings are subsequently measured at 
amortised cost using the Effective Interest Rate (EIR) 
method. Gains and losses are recognised in profit or 
loss when the liabilities are derecognised as well as 
through EIR amortisation process. Amortised cost is 
calculated by taking into account any discount or 
premium on acquisition and fees or costs that are 
an integral part of the EIR. The EIR amortisation is 
included as finance costs in the Statement of Profit 
and Loss.
	
Derecognition of Financial Liabilities:
A financial liability is derecognised when the obligation 
under the liability is discharged or cancelled or 
expires. When an existing financial liability is replaced 
by another from the same lender on substantially 
Annual Report 2023-24
136
137
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Consolidated
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
different terms, or the terms of an existing liability 
are substantially modified, such an exchange or 
modification is treated as the derecognition of the 
original liability and the recognition of a new liability. 
The difference in the respective carrying amounts is 
recognised in the Statement of Profit and Loss.
	
Derivative Financial Instrument:
The Group uses derivative financial instruments, such 
as forward currency contracts to mitigate its foreign 
currency risks. Such derivative financial instruments 
are initially recognised at fair value on the date on 
which a derivative contract is entered into and are 
subsequently re-measured at fair value. Derivatives 
are carried as financial assets when the fair value 
is positive and as financial liabilities when the fair 
value is negative. Any changes therein are generally 
recognised in the statement of profit and loss.
7.5 Inventories
Raw materials and packing materials are valued at 
lower of cost (on moving weighted average basis) 
and the net realisable value, cost of which includes 
duties and taxes (net off CENVAT and Goods and 
Service Tax wherever applicable). Cost of imported 
raw materials and packing materials lying in bonded 
warehouse includes the amount of customs duty. 
Finished products including traded goods and 
work-in-progress are valued at lower of cost and net 
realisable value.
The cost of finished goods and work-in-progress have 
been computed to include all cost of purchases, cost 
of conversion, appropriate share of fixed production 
overheads based on normal operating capacity and 
other related cost incurred in bringing the inventories 
to their present location and condition.
Net realisable value is the estimated selling price in 
the ordinary course of business, less the estimated 
costs of completion and selling expenses necessary 
to make the sale.
Slow and non-moving material, products nearing 
expiry, defective inventory are fully provided for and 
valued at net realisable value.
Goods and materials in transit are valued at actual 
cost incurred up to the date of balance sheet. 
Materials and other items held for use in production 
of inventories are not written down, if the finished 
products in which they will be used are expected to 
be sold at or above cost.
Consumables and other materials procured for R&D 
purpose are charged off when acquired.
The comparison of cost and Net realisable value is 
made on an item-by-item basis.
7.6 Cash and Cash Equivalents
Cash and Cash Equivalents comprise of cash on 
hand and cash at bank including fixed deposit/highly 
liquid investments with original maturity period of 
three months or less that are readily convertible to 
known amounts of cash and which are subject to an 
insignificant risk of changes in value.
For the purpose of the statement of cash flows, cash 
and cash equivalents consist of cash and short-term 
deposits, as defined above, as they are considered 
an integral part of the group‚Äôs cash management.
7.7 Cash Flow Statement
Cash flows are reported using the indirect method, 
whereby net profit before tax is adjusted for the 
effects of transactions of a non-cash nature, any 
deferrals or accruals of past or future operating cash 
receipts or payments and item of income or expenses 
associated with investing or financing cash flows. The 
cash flow from operating, investing and financing 
activities of the Group are segregated.
7.8 Foreign Currency Transactions
Transactions in foreign currencies are translated into 
the Company‚Äôs functional currency at the exchange 
rates at the dates of the transactions.
Monetary assets and liabilities denominated in 
foreign currencies are translated into the functional 
currency at the exchange rate at the reporting date. 
Non-monetary assets and liabilities that are measured 
at fair value in a foreign currency are translated 
into the functional currency at the exchange rate 
when the fair value was determined. Non-monetary 
assets and liabilities that are measured based on 
historical cost in a foreign currency are not translated. 
Foreign currency exchange differences are generally 
recognised in the statement of profit and loss.
Exchange differences arising on the settlement of 
monetary items or on translating monetary items 
at rates different from those at which they were 
translated on initial recognition during the period or 
in previous Financial Statements are recognised in 
the Standalone Statement of Profit and Loss in the 
period in which they arise. When a gain or loss on a 
non-monetary item is recognised in Other 
Comprehensive Income, any exchange component of 
that gain or loss is recognised in Other Comprehensive 
Income. Conversely, when a gain or loss on a non-
monetary item is recognised in Standalone Statement 
of Profit and Loss, any exchange component of that 
gain or loss is recognised in Standalone Statement 
of Profit and Loss.
In case of foreign operations whose functional 
currency is different from the parent company‚Äôs 
functional currency, the assets and liabilities of such 
foreign operations, The income and expenses of such 
foreign operations are translated to the reporting 
currency at the monthly average exchange rates 
prevailing during the year. Resulting foreign currency 
differences are recognised in other comprehensive 
income/(loss) and presented within equity as part 
of FCTR. When a foreign operation is disposed of, 
in part or in full, the relevant amount in the FCTR is 
reclassified to the Consolidated Statement of Profit 
and Loss as a part of gain or loss on disposal.
7.9 Revenue Recognition
	
Sale of Goods:
Revenue is measured based on the transaction 
price adjusted for discounts, rebates, chargebacks, 
medicaids, product recalls & supply penalties, which 
is specified in a contract with customer. Revenue 
are net of estimated returns and taxes collected 
from customers.
Revenue from sale of goods is recognised at point 
in time when control is transferred to the customer 
and it is probable that consideration will be collected. 
Control of goods is transferred upon the shipment of 
the goods to the customer or when goods is made 
available to the customer as per terms agreed.
The transaction price is documented on the sales 
invoice and payment is generally due as per agreed 
credit terms with customer.
The consideration can be fixed or variable. Variable 
consideration is only recognised when it is highly 
probable that a significant reversal will not occur.
Sales return is variable consideration that is recognised 
and recorded based on historical experience, market 
conditions and provided for in the year of sale as 
reduction from revenue. The methodology and 
assumptions used to estimate returns are monitored 
and adjusted regularly in line with trade practices, 
historical trends, past experience and projected 
market conditions.
	
Interest income:
Interest income is recognised with reference to the 
Effective Interest Rate method.
	
Dividend income:
Dividend from investment is recognised as revenue 
when right to receive is established.
	
Income from Export Benefits and Other Incentives:
Export benefits available under prevalent schemes 
are accrued as revenue in the year in which the goods 
are exported and/or services are rendered only when 
their reasonable assurance that the conditions 
attached to them will be complied with, and the 
amounts will be received. Export benefit receivables 
are carried at net realisable value.
7.10 Employee Benefits
	
In case of Holding Company:
All employee benefits payable wholly within twelve 
months of rendering service are classified as short-
term employee benefits. Benefits such as salaries, 
wages, short-term compensated absences, 
performance incentives etc., and the expected cost 
of bonus, ex-gratia are recognised during the period 
in which the employee renders related service.
	
(i)	
Defined benefit plans
The Company provides for gratuity, a defined 
benefit retirement plan (‚Äòthe Gratuity Plan‚Äô) 
covering eligible employees. The Gratuity 
Plan provides a lump-sum payment to vested 
employees at retirement, death, incapacitation 
or termination of employment, of an amount 
based on the respective employee‚Äôs salary and 
the tenure of employment with the Company.
Liabilities with regard to Gratuity Plan are 
determined by actuarial valuation, performed by 
an independent actuary, at each balance sheet 
date using the Projected Unit Credit Method.
The Company fully contributes all ascertained 
liabilities to the Ajanta Pharma Limited Group 
Gratuity Trust (the Trust). Trustees administer 
contributions made to the Trust and contributions 
are invested in a scheme with Life Insurance 
Corporation of India as permitted by laws 
of India.
The retirement benefit obligations recognised 
in the balance sheet represents the present 
value of the defined benefit obligations 
reduced by the fair value of scheme assets. 
Annual Report 2023-24
138
139
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Consolidated
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
Any asset resulting from this calculation is limited 
to the present value of available refunds and 
reductions in future contributions to the scheme. 
The Company recognises the net obligation of 
a defined benefit plan in its balance sheet as 
an asset or liability. Actuarial gains and losses 
are recognised in full in the other comprehensive 
income for the period in which they occur. The 
effect of any plan amendments are recognised 
in the Statement of Profit and Loss.
	
(ii)	 Defined contribution plans
Contributions to defined contribution plans are 
recognised as expense when employees have 
rendered services entitling them to such benefits.
The Company pays provident fund contributions 
to publicly administered provident funds as per 
local regulations. The Company has no further 
payment obligations once the contributions 
have been paid. The contributions are 
accounted for as defined contribution plans and 
the contributions are recognised as employee 
benefit expense when they are due. Prepaid 
contributions are recognised as an asset to the 
extent that a cash refund or a reduction in the 
future payments is available.
	
(iii)	 Compensated absences
The Company has a policy on compensated 
absences which are both accumulating and 
non-accumulating in nature. The expected 
cost of accumulating compensated absences 
is determined by actuarial valuation performed 
by an independent actuary at each balance 
sheet date using projected unit credit method 
on the additional amount expected to be paid/
availed within twelve months as a result of the 
unused entitlement that has accumulated at the 
balance sheet date.
Compensated absences which are not expected 
to occur within twelve months after the end of 
the period in which the employee renders the 
related services are recognised as a liability 
at the present value of the defined benefit 
obligation at the balance sheet date.
Expense on non-accumulating compensated 
absences is recognised in the period in which 
the absences occur.
	
(iv)	 Share-based compensation
Employees Stock Options Plans (‚ÄúESOPs‚Äù): 
The grant date fair value of options granted 
to employees is recognised as an employee 
expense, over the period that the employees 
become unconditionally entitled to the options. 
The expense is recorded for each separately 
vesting portion of the award as if the award 
was, in substance, multiple awards. The increase 
in equity recognised in connection with share-
based payment transaction is presented as a 
separate component in equity under ‚ÄúEmployee 
Stock Options Outstanding Reserve‚Äù. The amount 
recognised as an expense is adjusted to reflect 
the actual number of stock options that vest. 
The options granted to employees of subsidiary 
is recognised as an equity investment.
The Company recognises compensation 
expense relating to share-based payments in 
net profit using fair-value in accordance with Ind 
AS 102, Share-Based Payment.
	
In case of Subsidiary at Mauritius:
For employees who are not covered by a pension 
plan, the net present value of severance allowances 
payable under the Employment Rights Act, 2008 is 
provided for. The obligations arising under this item 
are not funded.
	
In case of Subsidiary at Philippines:
	
Short-term benefits:
The Company recognises a liability net of amounts 
already paid and an expense for services rendered 
by employees during the accounting period. Short-
term benefits given by the Company to its employees 
include salaries and wages, social security 
contributions, short-term compensated absences, 
bonuses and other non-monetary benefits.
	
Post-employment benefits:
The Company does not have a formal retirement 
benefit plan. However, the Company is subject to the 
provisions of Republic Act No. 7641, retirement law.
	
Compensated Absences:
Compensated absences are recognised for the 
number of paid leave days remaining at the end 
of the reporting period. Those are included in the 
salaries and wages account and are recognised 
when availed of by the employees.
	
In case of Subsidiary at USA:
	
Short-term benefits:
The Company recognises a liability net of amounts 
already paid and an expense for services rendered 
by employees during the accounting period. 
Short-term benefits given by the Company to its 
employees include salaries and wages, social 
security contributions, Medicare contributions, and 
other non-monetary benefits. A liability is recognised 
for the amount expected to be paid, if the Company 
has a present legal or constructive obligation to pay 
this amount as a result of past service provided by 
the employee, and the amount of obligation can be 
estimated reliably
	
Post-employment benefits:
The Company provides a 401(k) retirement programme 
for full-time employees who are 21 years of age or 
older. Eligible employees are entitled to participate 
in the Company offered plan with an option to 
contribute up to maximum 3% of annual base salary. 
For employees with an annual base salary above the 
annual compensation limits, as determined by the 
Federal Internal Revenue Service (Federal), the annual 
APUI contribution will be capped at 3% of the Federal 
allowed annual compensation limits. All contributions 
are 100% vested immediately to the employee.
7.11 Borrowing Costs
Borrowing costs directly attributable to the 
acquisition, construction or production of an asset 
that necessarily takes a substantial period of time to 
get ready for its intended use or sale are capitalised 
as part of the cost of the asset. All other borrowing 
costs are expensed in the period in which they occur. 
Borrowing costs consist of interest and other costs 
that an entity incurs in connection with the borrowing 
of funds. Borrowing cost also includes exchange 
differences to the extent regarded as an adjustment 
to the borrowing costs.
7.12 Leases
The Group‚Äôs lease asset classes primarily consist of 
leases for land and buildings. The Group assesses 
whether a contract contains a lease, at inception of 
a contract. A contract is, or contains, a lease if the 
contract conveys the right to control the use of an 
identified asset for a period of time in exchange for 
consideration. To assess whether a contract conveys 
the right to control the use of an identified asset, the 
Group assesses whether: (1) the contract involves 
the use of an identified asset (2) the Group has 
substantially all of the economic benefits from use 
of the asset through the period of the lease and (3) 
the Group has the right to direct the use of the asset.
At the date of commencement of the lease, the 
Group recognises a right-of-use asset (‚ÄúROU‚Äù) and a 
corresponding lease liability for all lease arrangements 
in which it is a lessee, except for leases with a term 
of twelve months or less (short-term leases) and low 
value leases. For these short-term and low value 
leases, the Group recognises the lease payments as 
an operating expense on a straight-line basis over 
the term of the lease.
Certain lease arrangements includes the options to 
extend or terminate the lease before the end of the 
lease term. ROU assets and lease liabilities includes 
these options when it is reasonably certain that they 
will be exercised.
The right-of-use assets are initially recognised at 
cost, which comprises the initial amount of the lease 
liability adjusted for any lease payments made at or 
prior to the commencement date of the lease plus 
any initial direct costs less any lease incentives. They 
are subsequently measured at cost less accumulated 
depreciation and impairment losses.
Right-of-use assets are depreciated from the 
commencement date on a straight-line basis over 
the shorter of the lease term and useful life of the 
underlying asset. Right of use assets are evaluated 
for recoverability whenever events or changes in 
circumstances indicate that their carrying amounts 
may not be recoverable. For the purpose of 
impairment testing, the recoverable amount (i.e. the 
higher of the fair value less cost to sell and the value-
in-use) is determined on an individual asset basis 
unless the asset does not generate cash flows that 
are largely independent of those from other assets. 
In such cases, the recoverable amount is determined 
for the Cash Generating Unit (CGU) to which the 
asset belongs.
The lease liability is initially measured at amortised 
cost at the present value of the future lease 
payments. The lease payments are discounted using 
the generally accepted interest rate. Lease liabilities 
are remeasured with a corresponding adjustment to 
the related right of use asset if the Company changes 
its assessment if whether it will exercise an extension 
or a termination option.
Lease liability and ROU asset have been separately 
presented in the Balance Sheet and lease payments 
have been classified as financing cash flows.
Annual Report 2023-24
140
141
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Consolidated
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
Leases for which the Group is a lessor is classified as a 
finance or operating lease. Whenever the terms of the 
lease transfer substantially all the risks and rewards 
of ownership to the lessee, the contract is classified 
as a finance lease. All other leases are classified as 
operating leases.
In respect of assets given on operating lease, lease 
rentals are accounted in the Statement of Profit 
and Loss, on accrual basis in accordance with the 
respective lease agreements.
7.13 Government Grants
Government grants are initially recognised as deferred 
income at fair value if there is reasonable assurance 
that they will be received and the Company will 
comply with the conditions associated with the grant;
‚Ä¢	 In case of capital grants, they are then recognised 
in Statement of Profit and Loss as other income on 
a systematic basis over the useful life of the asset.
‚Ä¢	 In case of grants that compensate the Company 
for expenses incurred are recognised in Statement 
of Profit and Loss on a systematic basis in the 
periods in which the expenses are recognised.
7.14 Earnings Per Share
Basic earnings per equity share is computed by 
dividing the net profit attributable to the equity 
holders of the Company by the weighted average 
number of equity shares outstanding during the 
period. Diluted earnings per equity share is computed 
by dividing the net profit attributable to the equity 
holders of the Company by the weighted average 
number of equity shares considered for deriving basic 
earnings per equity share and also the weighted 
average number of equity shares that could have 
been issued upon conversion of all dilutive potential 
equity shares. The dilutive potential equity shares are 
adjusted for the proceeds receivable had the equity 
shares been actually issued at fair value. Dilutive 
potential equity shares are deemed converted as of 
the beginning of the period, unless issued at a later 
date. Dilutive potential equity shares are determined 
independently for each period presented.
7.15 Income Taxes
Income tax expense comprises current and deferred 
income tax.
Current tax is recognised in statement of profit or loss, 
except when they relate to items that are recognised 
in other comprehensive income or directly in equity, 
in which case, the current tax is also recognised in 
other comprehensive income or directly in equity 
respectively. Current income tax for current and prior 
periods is recognised at the amount expected to be 
paid to or recovered from the tax authorities, using 
the tax rates and tax laws that have been enacted 
by the balance sheet date. Deferred income tax 
assets and liabilities are recognised for all temporary 
differences arising between the tax bases of assets 
and liabilities and their carrying amounts in the 
financial statements.
Deferred tax assets are reviewed at each reporting 
date and are reduced to the extent that it is no longer 
probable that the related tax benefit will be realised.
Deferred income tax assets and liabilities are 
measured using tax rates and tax laws that have 
been enacted or substantively enacted by the 
balance sheet date and are expected to apply to 
taxable income in the years in which those temporary 
differences are expected to be recovered or settled. 
The effect of changes in tax rates on deferred 
income tax assets and liabilities is recognised as 
income or expense in the period that includes the 
enactment or the substantive enactment date. A 
deferred income tax asset is recognised to the extent 
that it is probable that future taxable profit will be 
available against which the deductible temporary 
differences and tax losses can be utilised. The Group 
offsets current tax assets and current tax liabilities, 
where it has a legally enforceable right to set off the 
recognised amounts and where it intends either to 
settle on a net basis, or to realise the asset and settle 
the liability simultaneously.
Deferred income taxes are not provided on the 
undistributed earnings of subsidiaries where it is 
expected that the earnings of the subsidiary will not 
be distributed in the foreseeable future.
Management periodically evaluates positions taken 
in the tax returns with respect to situations in which 
applicable tax regulations are subject to interpretation 
and establishes provisions where appropriate.
7.16 Dividends to Shareholders
Annual dividend distribution to the shareholders is 
recognised as a liability in the period in which the 
dividends are approved by the shareholders. Any 
interim dividend paid is recognised on approval by 
Board of Directors. Dividend payable is recognised 
directly in equity.
7.17 Provisions, Contingent Liabilities, Contingent 
Assets and Commitments
	
General:
Provisions (legal and constructive) are recognised 
when the Group has a present obligation (legal or 
constructive) as a result of a past event and it is 
probable that an outflow of resources will be required 
to settle the obligation, in respect of which a reliable 
estimate can be made.
Provisions (excluding retirement benefits and 
compensated absences) are not discounted to its 
present value and are determined based on best 
estimate required to settle the obligation at the 
balance sheet date. These are reviewed at each 
balance sheet date and adjusted to reflect the 
current best estimates.
If there is any expectation that some or all of the 
provision will be reimbursed, the reimbursement is 
recognised as a separate asset but only when the 
reimbursement is virtually certain. The expense relating 
to a provision is presented in the statement of profit 
and loss net of any virtually certain reimbursement.
If the effect of the time value of money is material, 
provisions are discounted using a current pre-tax rate 
that reflects, when appropriate, the risk specific to the 
liability. When discounting is used, the increase in the 
provision due to the passage of time is recognised 
as a finance cost.
Contingent liability is disclosed in the case of:
‚Ä¢	 A present obligation arising from past events, when 
it is not probable that an outflow of resources will 
be required to settle the obligation;
‚Ä¢	 A present obligation arising from past events, when 
no reliable estimates is possible;
‚Ä¢	 A possible obligation arising from past events, 
unless the probability of outflow of resources 
is remote.
Contingent liabilities are not recognised but disclosed 
in the Consolidated Financial Statements. Contingent 
assets are neither recognised nor disclosed in the 
Financial Statements.
Commitments include the amount of purchase order 
(net of advances) issued to parties for completion of 
assets and Non-cancellable operating lease.
Provisions, contingent liabilities, contingent assets 
and commitments are reviewed at each balance 
sheet date.
7.18 Fair value measurement
The Group measures financial instruments, such as, 
derivatives at fair value at each balance sheet date 
in accordance with Ind AS 113.
Financials Statements have been prepared on the 
historical cost basis except for the following material 
items in the statement of financial position:
‚Ä¢	 Derivative financial instruments (mainly forward 
currency contracts) are measured at fair value 
received from Bank.
‚Ä¢	 Mutual Funds are measured at fair values as per 
Net Asset Value (NAV).
‚Ä¢	 Employee Stock Option Plan (ESOP) at fair values 
as per Black Scholes option pricing model.
Fair value is the price that would be received 
to sell an asset or settle a liability in an ordinary 
transaction between market participants at the 
measurement date.
The fair value of an asset or a liability is measured 
using the assumptions that market participants 
would use when pricing the asset or liability, assuming 
that market participants act in their economic 
best interest.
A fair value measurement of a non-financial asset 
takes into account a market participant‚Äôs ability to 
generate economic benefits by using the asset in its 
highest and best use or by selling it to another market 
participant that would use the asset in its highest and 
best use.
The Group uses valuation techniques that are 
appropriate in the circumstances and for which 
sufficient data are available to measure fair value, 
maximising the use of relevant observable inputs and 
minimising the use of unobservable inputs.
All assets and liabilities for which fair value is 
measured or disclosed in the financial statements are 
categorised within the fair value hierarchy, described 
as follows, based on the lowest level input that is 
significant to the fair value measurement as a whole:
Annual Report 2023-24
142
143
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Consolidated
Notes to the Consolidated Financial Statements
as at 31 March 2024
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
‚Ä¢	 Level 1 ‚Äî Quoted (unadjusted) market prices in 
active markets for identical assets or liabilities.
‚Ä¢	 Level 2 ‚Äî Valuation techniques for which the 
lowest level input that is significant to the fair value 
measurement is directly or indirectly observable.
‚Ä¢	 Level 3 ‚Äî Valuation techniques for which the 
lowest level input that is significant to the fair value 
measurement is unobservable.
For assets and liabilities that are recognised in the 
financial statements on a recurring basis, the Group 
determines whether transfers have occurred between 
levels in the hierarchy by re-assessing categorisation 
(based on the lowest level input that is significant to 
the fair value measurement as a whole) at the end of 
each reporting period.
For the purpose of fair value disclosures, the Company 
has determined classes of assets and liabilities on 
the basis of the nature, characteristics and risks of 
the asset or liability and the level of the fair value 
hierarchy as explained above.
7.19 Recent accounting pronouncements
Ministry of Corporate Affairs (‚ÄúMCA‚Äù) notifies new 
standard or amendments to the existing standards 
under Companies (Indian Accounting Standards) 
Rules as issued from time to time. For the year 
ended 31 March 2024, MCA has not notified any new 
standards or amendments to the existing standards 
applicable to the Group.
8.  Property, Plant and Equipment, Capital Work-In-Progress, Investment Properties and Other 
Intangible Assets (other than self generated)
8.1 As at 31 March 2024 
H in Crore
Particulars 
Gross Block (Cost or Deemed Cost) 
Accumulated Depreciation/Amortisation 
Net Block 
As at 
01 April 
2023 
 Exchange 
 Difference 
Additions 
Disposals 
As at 
31 March 
2024 
01 April 
2023 
 Exchange 
 Difference 
 For the 
year
Disposals 
As at 
31 March 
2024 
As at 
31 March 
2024 
(A) Property, plant and 
equipment 
Freehold land** 
 157.66 
 0.03 
 - 
 8.85 
 148.84 
 - 
 - 
 - 
 - 
 - 
 148.84 
Leasehold improvement 
 0.00 
 (0.00)
 - 
 - 
 0.00 
 0.00 
 (0.00)
 - 
 - 
 0.00 
 0.00 
Buildings 
 605.66 
 (0.05)
 11.79 
 - 
 617.40 
 153.13 
 (0.03)
 16.25 
 - 
 169.35 
 448.05 
Plant and equipments 
 1,223.26 
 - 
 80.15 
 2.87 
 1,300.54 
 481.72 
 - 
 88.70 
 2.39 
 568.03 
 732.51 
Furniture and fixtures 
 92.37 
 0.02 
 1.96 
 0.01 
 94.34 
 55.95 
 0.01 
 5.78 
 0.01 
 61.73 
 32.61 
Vehicles 
 11.46 
 (0.21)
 0.04 
 7.09 
 4.20 
 9.70 
 (0.19)
 0.33 
 6.86 
 2.98 
 1.22 
Office equipments 
 26.65 
 (0.02)
 2.14 
 0.21 
 28.56 
 19.47 
 (0.02)
 2.38 
 0.20 
 21.63 
 6.93 
Computers 
 34.18 
 (0.00)
 7.96 
 0.57 
 41.57 
 23.44 
 (0.00)
 4.69 
 0.53 
 27.60 
 13.97 
Total 
 2,151.25 
 (0.24)
 104.04 
 19.60 
 2,235.45 
 743.41 
 (0.23)
 118.13 
 9.99 
 851.32 
 1,384.13 
(B) Other intangible assets 
Computer Software 
 31.88 
 0.07 
 11.89 
 - 
 43.84 
 24.13 
 0.04 
 5.01 
 - 
 29.18 
 14.66 
Total 
 31.88 
 0.07 
 11.89 
 - 
 43.84 
 24.13 
 0.04 
 5.01 
 - 
 29.18 
 14.66 
Total (A+B) 
 2,183.13 
 (0.16)
 *115.93 
 19.60 
 2,279.29 
 767.55 
 (0.19)
 123.14 
 9.99 
 880.50 
 1,398.79 
(C) Capital work-in-progress#  209.47 
 - 
 169.63 
 122.65 
 256.45 
 - 
 - 
 - 
 - 
 - 
 256.45 
(D) Investment properties 
 - 
 - 
 - 
 - 
 - 
-
-
 - 
 - 
 - 
 - 
Total (A)+(B)+(C)+(D) 
 1,655.24 
* Addition includes H 4.83 Crore used for Research and Development.
** Freehold land of H 8.85 Crore classified as held for sale (refer note 22 & 68). 
# Capital-Work-in Progress ageing schedule.
H in Crore
Particulars
Amount in Capital Work-In-Progress for a period of
Total 
Less than 
1 year 
1-2 years 
2-3 years 
More than 
3 years 
 Projects in progress (*) 
 121.75 
 36.65 
 38.86 
 59.19 
 256.45 
* Project execution plans are assessed on an annual basis and all the projects are executed as per rolling annual plan. 
CWIP includes cost incurred on corporate house under construction and is schedule to meet the annual rolling plan 
though there is delay as compared to the original plan due to delays in Government approval, pandemic and various 
other pediments outside of management control at various stages. There are no identified overruns from budgeted cost.
Annual Report 2023-24
144
145
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Consolidated
Notes to the Consolidated Financial Statements
as at 31 March 2024
Notes to the Consolidated Financial Statements
as at 31 March 2024
8.2  As at 31 March 2023 
H in Crore
Particulars 
Gross Block (Cost or Deemed Cost) 
Accumulated Depreciation/Amortisation 
Net Block 
As at 
01 April 
2022
 Exchange 
 Difference 
Additions 
Disposals 
As at 
31 March 
2023
As at 
01 April 
2022 
 Exchange 
 Difference 
 For the 
year
Disposals 
As at 
31 March 
2023
As at 
31 March 
2023
(A) Property, plant and 
equipment 
Freehold land 
 157.66 
 - 
 - 
 - 
 157.66 
 - 
 - 
 - 
 - 
 - 
 157.66 
Leasehold improvement 
 1.13 
 - 
 - 
 1.13 
 0.00 
 0.78 
 - 
 0.00 
 0.78 
 0.00 
 0.00 
Buildings 
 587.42 
 - 
 18.87 
 0.63 
 605.66 
 136.88 
 - 
 16.37 
 0.12 
 153.13 
 452.53 
Plant and equipments 
 1,173.22 
 - 
 70.84 
 20.81  1,223.26 
 410.71 
 - 
 85.64 
 14.63 
 481.72 
 741.54 
Furniture and fixtures 
 87.33 
 - 
 6.44 
 1.40 
 92.37 
 51.53 
 - 
 5.54 
 1.12 
 55.95 
 36.42 
Vehicles 
 12.21 
 - 
 - 
 0.75 
 11.46 
 9.46 
 - 
 0.94 
 0.70 
 9.70 
 1.76 
Office equipments 
 27.86 
 - 
 2.39 
 3.61 
 26.65 
 20.54 
 - 
 2.29 
 3.36 
 19.47 
 7.18 
Computers 
 28.26 
 - 
 6.94 
 1.01 
 34.18 
 20.13 
 - 
 4.17 
 0.86 
 23.44 
 10.74 
Total (A) 
 2,075.10 
 - 
 105.48 
 29.34  2,151.25 
 650.03 
 - 
 114.95 
 21.57 
 743.41 
 1,407.83 
(B) Other intangible assets 
Computer Software 
 29.30 
 - 
 2.58 
 - 
 31.88 
 20.03 
 - 
 4.10 
 - 
 24.13 
 7.75 
Total (B) 
 29.30 
 - 
 2.58 
 - 
 31.88 
 20.03 
 - 
 4.10 
 - 
 24.13 
 7.75 
Total (A+B) 
 2,104.40 
 - 
 * 108.05 
 29.34  2,183.13 
 670.06 
 - 
 119.05 
 21.57 
 767.55 
 1,415.58 
(C) Capital work-in-progress#  152.86 
 - 
 164.08 
 107.47 
 209.47 
 - 
 - 
 - 
 - 
 - 
 209.47 
(D) Investment properties ** 
 10.93 
 - 
 - 
 10.93 
 - 
 2.52 
 - 
 0.49 
 3.01 
 (0.00)
 0.00 
Total (A)+(B)+(C)+(D) 
 1,625.05 
* Addition includes H 18.20 Crore used for Research and Development.
** Investment property classified as held for sale (refer note 22 & 68). 
# Capital work-in-progress ageing schedule.
H in Crore
Particulars
Amount in Capital Work-In-Progress for a period of
Total 
Less than 1 year 
1-2 years 
2-3 years 
More than 
3 years 
 Projects in progress (*) 
 97.81 
 51.86 
 29.37 
 30.43 
 209.47 
* Project execution plans are assessed on an annual basis and all the projects are executed as per rolling annual plan. 
8.3 Right-of-Use Assets (refer note 57)
As at 31 March 2024
Particulars 
Gross Block (Cost or Deemed Cost) 
Accumulated Depreciation/Amortisation 
Net Block 
As at 
01 April 
2023 
 Exchange 
 Difference 
Additions 
Disposals 
As at 
31 March 
2024 
As at 
01 April 
2023 
 Exchange 
 Difference 
 For the 
year
Disposals 
As at 
31 March 
2024 
As at 
31 March 
2024 
Leasehold land 
 62.59 
 - 
 - 
 - 
 62.59 
 2.82 
 - 
 0.95 
 - 
 3.77 
 58.82 
Leasehold properties 
 37.11 
 (0.10)
 12.15 
 1.63 
 47.53 
 16.02 
 (0.06)
 11.30 
 1.31 
 25.95 
 21.58 
Total 
 99.70 
 (0.10)
 12.15 
 1.63 
 110.12 
 18.84 
 (0.06)
 12.25 
 1.31 
 29.72 
 80.40 
As at 31 March 2023
Particulars 
Gross Block (Cost or Deemed Cost) 
Accumulated Depreciation/Amortisation 
Net Block 
As at 
01 April 
2022
 Exchange 
 Difference 
Additions 
Disposals 
As at 
31 March 
2023
As at 
01 April 
2022 
 Exchange 
 Difference 
 For the 
year
Disposals 
As at 
31 March 
2023
As at 
31 March 
2023
Leasehold land 
 62.59 
 - 
 - 
 - 
 62.59 
 1.87 
 - 
 0.95 
 - 
 2.82 
 59.77 
Leasehold properties 
 42.84 
 - 
 21.82 
 27.55 
 37.11 
 33.18 
 - 
 10.32 
 27.48 
 16.02 
 21.09 
Total 
 105.43 
 - 
 21.82 
 27.55 
 99.70 
 35.06 
 - 
 11.27 
 27.48 
 18.84 
 80.86 
9. 
Investments (Non-Current) 
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Long-term trade investments
Unquoted investments
in Joint Venture
Turkmenderman Ajanta Pharma Ltd. (Refer Note below #)
2,00,000 (31 March 2023 2,00,000) Shares of US $ 10 each fully paid-up
 - 
 - 
In Membership Share in LLP (at Fair Value through Profit or Loss)
ABCD Technologies LLP, India (Percentage share 4.03%)
 18.58 
 25.10 
In others at fair value
OPGS Power Gujarat Private Limited
1,95,000 (31 March 2023 1,95,000) Shares of H 0.19 each 
0.00
0.00
(31 March 2024 H 37,050, 31 March 2023 H 37,050)
Total
 18.58 
 25.10 
# Note: The Company has made full provision for investment in aggregate value of unquoted 
investments in Turkmenderman Ajanta Pharma Limited in year 2014-15 and the carrying value of 
investment is considered as Nil. 
Aggregate value of unquoted investments
 25.53 
 32.05 
Aggregate value of unquoted investments (net of impairment)
 18.58 
 25.10 
Aggregate market value of quoted investments
 - 
 - 
Aggregate amount of impairment in value of non-current investment
 6.95 
 6.95 
* Figures in Brackets are for Previous Years
10. Other Non-Current Financial Assets
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Unsecured, considered good unless otherwise stated
Security deposits
 4.99 
 6.24 
Financial asset at amortised cost
 4.16 
 3.90 
In deposit accounts with banks with maturity of more than 12 months from the balance sheet 
date
-	
Under lien 
 0.19 
 0.84 
Interest accrued on fixed deposits with banks
 0.02 
 0.11 
 9.36 
 11.09 
11. Deferred Tax Assets (Net)
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Others
 134.45 
 96.77 
 134.45 
 96.77 
12. Non-Current Tax Assets (Net)
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Income tax paid (net provision (31 March 2023 H 122.40 Crore))
 - 
 0.83 
 - 
 0.83 
Annual Report 2023-24
146
147
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Consolidated
Notes to the Consolidated Financial Statements
as at 31 March 2024
Notes to the Consolidated Financial Statements
as at 31 March 2024
13. Other Non-Current Assets
(Unsecured, considered good unless otherwise stated)
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Capital advances
 7.88 
 4.77 
VAT receivable
 1.04 
 0.03 
Octroi refund receivable
 0.52 
 0.52 
 9.44 
 5.32 
14. Inventories
(At lower of cost and net realisable value)
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Raw materials
 233.25 
 264.40 
Packing materials
 54.71 
 51.71 
Work-in-progress
 54.35 
 52.46 
Finished goods (including in transit H 120.57 Crore, 31 March 2023 H 90.05 Crore)
 291.31 
 278.69 
Stock-in-trade (including in transit H 8.01 Crore, 31 March 2023 H 6.07 Crore)
 194.74 
 168.37 
 828.36 
 815.63 
During the year, the group recorded inventory write downs of H 5.95 Crore (31 March 2023 H 5.64 Crore). These adjustments were included in 
cost of material consumed and changes in inventories.
15. Current Investments
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Measured at Fair Value through Profit or Loss
Quoted
Investments in Market Linked Non Convertible Debentures
 37.12 
 161.56 
Investment in Mutual Funds
 10.24 
 178.32 
Measured at Amortised Cost
Quoted
Investments in Non Convertible Debentures
 251.79 
 46.18 
Unquoted
Investment in Commercial Papers
 30.90 
 124.21 
 330.05 
 510.27 
Aggregate book value of quoted investments
 299.15 
 386.06 
Aggregate market value of quoted investments
 299.15 
 386.06 
Aggregate book value of unquoted investments (net of impairment)
 30.90 
 124.21 
Aggregate amount of impairment in value of investments
 - 
 - 
16. Trade Receivables
(Unsecured, considered good unless otherwise stated)
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Trade receivables considered good
 1,246.84 
 1,056.90 
Trade receivables which have significant increase in credit risk
 2.70 
 2.82 
Trade receivables credit impaired
 6.13 
 8.22 
 1,255.67 
 1,067.94 
Less: Loss allowance
 (8.83)
 (11.04)
Total Receivables
 1,246.84 
 1,056.90 
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Break-up of Security Details
(i)	 Trade receivables considered good- Secured
 - 
 - 
(ii)	 Trade receivables considered good- Unsecured
 1,246.84 
 1,056.90 
(iii)	 Trade receivables which have significant increase in Credit Risk
 2.70 
 2.82 
(iv)	 Trade receivables - credit impaired
 6.13 
 8.22 
Total
 1,255.67 
 1,067.94 
Loss Allowance
 (8.83)
 (11.04)
Total Trade Receivables
 1,246.84 
 1,056.90 
Ageing Schedule for Trade Receivables as on 31 March 2024
 H in Crore 
Particulars
 Not Due 
 Outstanding for following period from due date of payment
 Total 
 < 6 
Months 
 6 -12 
months 
 1 -2 year 
 2-3 years  More than 
3 years 
(i)	 Undisputed Trade receivables ‚Äì 
considered good
 1,113.82 
 109.30 
 23.14 
 0.58 
 -  
 -  
 1,246.84 
(ii)	 Undisputed Trade Receivables ‚Äì which 
have significant increase in credit risk
 -  
 -  
 -  
 -  
 - 
 - 
 - 
(iii)	 Undisputed Trade Receivables ‚Äì credit 
impaired
 - 
 1.71 
 1.13 
 0.10 
 2.28 
 0.91 
 6.13 
(iv)	 Disputed Trade Receivables‚Äì
considered good
 - 
 - 
 - 
 - 
 - 
 - 
 - 
(v)	 Disputed Trade Receivables ‚Äì which 
have significant increase in credit risk
 - 
 - 
 - 
 - 
 2.70 
 - 
 2.70 
(vi)	 Disputed Trade Receivables ‚Äì credit 
impaired
 - 
 - 
 - 
 - 
 - 
 - 
 - 
Total
 1,113.82 
 111.01 
 24.27 
 0.68 
 4.98 
 0.91 
 1,255.67 
Less: Loss Allowance
 (8.83)
Total Trade Receivable
 1,246.84 
Ageing Schedule for Trade Receivables as on 31 March 2023
 H in Crore 
Particulars
Not Due
 Outstanding for following period from due date of payment 
 Total 
 < 6 Months 
 6-12 
Months 
 1 -2 year 
 2-3 years 
 More than 
3 years 
(i)	 Undisputed Trade receivables ‚Äì 
considered good
 942.48 
 98.04 
 13.98 
 2.40 
 - 
 - 
 1,056.90 
(ii)	 Undisputed Trade Receivables ‚Äì which 
have significant increase in credit risk
 - 
 - 
 - 
 - 
 - 
 - 
 - 
(iii)	 Undisputed Trade Receivables ‚Äì credit 
impaired
 - 
 0.80 
 0.59 
 6.50 
 0.06 
 0.27 
 8.22 
(iv)	 Disputed Trade Receivables‚Äì
considered good
 - 
 - 
 - 
 - 
 - 
 - 
 - 
(v)	 Disputed Trade Receivables ‚Äì which 
have significant increase in credit risk
 - 
 - 
 - 
 - 
 - 
 2.82 
 2.82 
(vi)	 Disputed Trade Receivables ‚Äì credit 
impaired
 - 
 - 
 - 
 - 
 - 
 - 
 - 
Total
 942.48 
 98.84 
 14.57 
 8.90 
 0.06 
 3.09 
 1,067.94 
Less: Loss Allowance
 (11.04)
Total Trade Receivable
 1,056.90 
There are no unbilled receivables, hence the same is not disclosed in the ageing schedule. 
Annual Report 2023-24
148
149
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Consolidated
Notes to the Consolidated Financial Statements
as at 31 March 2024
Notes to the Consolidated Financial Statements
as at 31 March 2024
(There are no other trade receivables which have significant increase in credit risk, Refer note 53 for information about 
credit risk and market risk of trade receivables).
The loss allowance on trade receivable has been computed on the basis of Ind AS 109, Financial Instruments which 
require such allowance to be made even for trade receivable considered good on the basis that credit risk exists even 
though it may be very low. The Company exposure to credit and currency risk and loss allowance related to trade 
receivable are disclosed in note 53.
17. Cash and Cash Equivalents
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Cash and cash equivalents (as per Ind AS-7 - "Statement of cash flows")
Bank Balances 
-	
In current accounts
 90.55 
 98.16 
-	
In EEFC Accounts
 38.93 
 185.16 
In Deposit Accounts (with original maturity of 3 months or less)
-	
Under Lien
 - 
 46.50 
Cash on Hand
 0.01 
 0.01 
 129.49 
 329.83 
Balance of H Nil (31 March 2023 H 46.50 Crore) includes deposits account is subject to restrictions on account of share bought back.
18. Bank Balances Other than Cash and Cash Equivalents
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Earmarked balances with banks
-	
Unpaid dividend
 0.72 
 0.82 
	
Unpaid Sale Proceeds of Fractional Shares (31 March 2024 H 24,226 {including deposit of H 
8,935}, 31 March 2023 H 25,289 {including deposit of H 9,998})
0.00
 - 
In Deposit Accounts (original maturity of more than 3 months but less than 12 months)
-	
Under lien
 0.56 
 0.25 
 1.28 
 1.07 
19. Loans
(Unsecured, considered good unless otherwise stated)
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Advances to employees
 31.77 
 15.31 
Loan to employees
 2.19 
 2.08 
 33.96 
 17.39 
 H in Crore 
Particulars
 As at 
31 March 2024 
 As at 
31 March 2023 
Loans to Employees
Secured, considered good 
 - 
 - 
Unsecured, considered good 
 2.19 
 2.08 
Significant increase in Credit Risk 
 - 
 - 
Credit impaired 
 - 
 - 
 2.19 
 2.08 
20. Other Current Financial Assets
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Interest receivable
 6.54 
 2.48 
Forward exchange contracts used for hedging
 12.48 
 - 
 19.02 
 2.48 
21. Other Current Assets
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Advances other than capital advances
Advances to vendors
-	
considered good
 38.24 
 26.88 
Prepaid expenses
 25.92 
 16.44 
Other advances recoverable
 5.79 
 4.85 
Balance with Statutory/Govt. Authorities
-	
GST receivable
 54.30 
 40.27 
Export benefits receivable
 8.82 
 3.17 
 133.07 
 91.61 
22. Asset Held for Sale (Refer note 68)
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Investment Properties 
 8.85 
 7.92 
Property, Plant & Equipment 
 - 
 0.90 
 8.85 
 8.82 
23. Equity Share Capital
Particulars
As at 31 March 2024
As at 31 March 2023
 Number of 
Shares 
D in Crore
 Number of 
Shares 
K in Crore
Authorised
Equity shares of H 2 each
 15,00,00,000 
 30.00 
 15,00,00,000 
 30.00 
Issued, subscribed and paid-up:
Issued, subscribed and fully paid up Equity shares of  
H 2 each
 12,59,15,655 
 25.18 
 12,59,14,655 
 25.18 
Add: Share Forfeited (on account of Buyback)
 7,66,500 
 0.09 
 7,66,500 
 0.09 
Total
 12,66,82,155 
 25.27 
 12,66,81,155 
 25.27 
Annual Report 2023-24
150
151
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Consolidated
Notes to the Consolidated Financial Statements
as at 31 March 2024
Notes to the Consolidated Financial Statements
as at 31 March 2024
23.1 Movements in equity share capital
Particulars
As at 31 March 2024
As at 31 March 2023
 Number of 
Shares 
K in Crore
 Number of 
Shares 
K in Crore
Equity shares outstanding as at the beginning of the year
 12,59,14,655 
 25.18 
 8,54,15,770 
 17.08 
Add: Equity shares allotted during the year against option's 
exercised under Employee Stock Option Plan/Scheme 
(ESOP)
 1,000 
 0.00# 
 1,000 
 0.00* 
Add: Equity shares allotted during the year as Bonus on 
ESOP@
 - 
 - 
 4,27,07,885 
 8.54 
Add: Equity shares allotted during the year as Bonus on 
ESOP (31 March 2024 Nil, 31 March 2023 500)
 - 
 0.00** 
 500 
 0.00** 
Less: Equity shares extinguished on buy back 
(Refer note 23.8)
 - 
 - 
 (22,10,500)
 (0.44)
Equity shares outstanding as at the end of the year
 12,59,15,655 
 25.18 
 12,59,14,655 
 25.18 
# H 2,000 * H 2,000 ** H 1,000
@ In the previous year, the Company has allotted the bonus shares at a ratio of 1:2 in it‚Äôs Board Meeting held on 24 June 2022. Accordingly, 
the number of shares increased from 8,54,16,770 to 12,81,25,155. The paid-up capital on account of Bonus issue of H 2.62 Crore has been 
appropriated from Capital Redemption Reserve, H 0.18 Crore has been appropriated from Securities Premium and H 5.73 Crore has been 
appropriated from General Reserve.
23.2 Rights Attached to Equity Shares 
The Company has only one class of Equity shares with voting rights having a par value of H 2 per share. The Company 
declares & pays dividend in Indian Rupees. Any interim dividend paid is recognised on the approval by Board of Directors.
The following dividends were declared and paid by the Company during the year ended:
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Interim and final equity dividend were declared and paid for financial year 2022-23 at H 7 per 
equity share
 - 
 89.69 
Interim and final equity dividend were declared and paid for financial year 2023-24 at H 51 per 
equity share
 642.17 
 - 
Total
 642.17 
 89.69 
In the event of liquidation of the Company, the holders of Equity shares will be entitled to receive remaining assets 
of the Company, after distribution of all preferential amounts. The distribution will be in proportion to the numbers of 
Equity shares held by shareholders.
Dividends and tax thereon have not been recognised as liabilities in the year to which they pertain to and is recorded 
in the year in which they have been approved in the Annual General Meeting.
23.3 Details of shareholders holding more than 5% Equity shares 
Name of Shareholders
As at 31 March 2024
As at 31 March 2023
 Number of 
Shares 
% holding
 Number of 
Shares 
% holding
Yogesh M. Agrawal, Trustee Yogesh Agrawal Trust 
 1,82,33,038 
 14.48 
 1,82,33,038 
 14.48 
Rajesh M. Agrawal, Trustee Rajesh Agrawal Trust 
 1,82,33,039 
 14.48 
 1,82,33,039 
 14.48 
Ravi Purushottam Agrawal, Trustee Ravi Agrawal Trust 
 1,63,86,623 
 13.01 
 1,63,86,623 
 13.01 
Aayush Madhusudan Agrawal, Trustee Aayush Agrawal 
Trust 
 1,42,37,664 
 11.31 
 1,42,37,664 
 11.31 
Gabs Investments Private Limited 
 1,25,88,393 
 10.00 
 1,25,88,393 
 10.00 
23.4 Equity shares reserved for issuance under Employees Stock Options Scheme 2011 of the Company 
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
 Number of 
Shares 
 Number of 
Shares 
Equity shares* 
 - 
 10,95,250 
* During the year, the Company made the decision to withdraw the Employee Stock Options Scheme 2011 in the Nomination & Remuneration 
Committee meeting held on 31 January 2024, with immediate effect. 
23.5 Equity shares reserved for issuance under Share-based Incentive Plan 2019 of the Company 
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
 Number of 
Shares 
 Number of 
Shares 
Equity shares 
 4,94,500 
 4,95,500 
23.6 Aggregate number of Equity shares issued during last five years pursuant to Employees Stock 
Options Scheme 2011 & Share-based Incentive Plan 2019 
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
 Number of 
Shares 
 Number of 
Shares 
Equity shares 
 2,28,250 
 2,27,250 
23.7 Equity shares allotted as fully paid up bonus Shares for the period of five years immediately 
preceding the balance sheet date 
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
 Number of 
Shares 
 Number of 
Shares 
Bonus Shares on allotment of ESOP in FY 2022-23 
 500 
 500 
Bonus Shares issued in FY 2022-23 
 4,27,07,885 
 4,27,07,885 
23.8 Equity Shares Extinguished on Buy-Back
31 March 2024 
Board of Directors have approved buy back of its 10,28,881 equity shares, being 0.82% of the total paid up equity 
share capital (prior buyback) at H 2,770 per equity share for an aggregate amount of H 285.00 Crore on 02 May 2024.
31 March 2023
The Board of Directors of the Company, at its meeting held on 10 March 2023 has approved the proposal of Buy-back 
of 22,10,500 fully paid-up equity shares of the Company of face value of H 2 each at a price of H 1,425/- per equity 
share, on a proportionate basis, for an aggregate amount not exceeding H 315.00 Crore through the tender offer 
process (‚ÄúBuyback‚Äù), in accordance with the provisions of the Companies Act, 2013, and rules made thereunder, and 
the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018 (the ‚ÄúSEBI Buyback Regulations‚Äù). 
The buyback issue opened on 31 March 2023 and closed on 10 April 2023.
The Company has taken the impact of buyback in previous financial year and paid in current financial year, for this 
Company has utilised its General Reserve (H 315.00 Crore) for the buyback of its equity shares. Total transaction cost 
of H 2.36 Crore (current year H 0.92 Crore and previous year H 1.44 Crore) incurred towards buyback and tax of H 73.28 
Crore was offset from retained earnings. In accordance with Section 69 of the Companies Act, 2013, the Company 
Annual Report 2023-24
152
153
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Consolidated
Notes to the Consolidated Financial Statements
as at 31 March 2024
Notes to the Consolidated Financial Statements
as at 31 March 2024
has created Capital Redemption Reserve of H 0.44 Crore equal to the nominal value of the shares bought back as an 
appropriation from the General Reserve.
31 March 2022
The Company bought back 11,20,000 equity shares for an aggregate amount not exceeding of H 285.60 Crore being 
1.29% of the total paid up equity share capital (prior buyback) at H 2,550 per equity share. The equity shares bought 
back were extinguished on 28 February 2022.
31 March 2021
The Company bought back 7,35,000 equity shares for an aggregate amount not exceeding of H 136 Crore being 0.84% 
of the total paid up equity share capital (prior buyback) at H 1,850 per equity share. The equity shares bought back 
were extinguished on 30 December 2020.
31 March 2019
The Company bought back 7,69,230 equity shares for an aggregate amount not exceeding of H 100 Crore being 0.87% 
of the total paid up equity share capital (prior buyback) at H 1,300 per equity share. The equity shares bought back 
were extinguished on 26 March 2019.
23.9 Details of Equity Shares held by promoters at the end of the year 
Name of Promoter
As at 31 March 2024
As at 31 March 2023
 Number of 
Shares 
 % of total 
shares 
 % Change 
during the 
year 
 Number of 
Shares 
 % of total 
shares 
 % Change 
during the 
year 
Yogesh M. Agrawal, trustee Yogesh Agrawal Trust
 1,82,33,038 
 14.48 
 - 
 1,82,33,038 
 14.48 
 47.28 
Rajesh M. Agrawal, trustee Rajesh Agrawal Trust
 1,82,33,039 
 14.48 
 - 
 1,82,33,039 
 14.48 
 47.28 
Ravi Purushottam Agrawal, trustee Ravi Agrawal 
Trust
 1,63,86,623 
 13.01 
 - 
 1,63,86,623 
 13.01 
 33.48 
Aayush Madhusudan Agrawal, trustee Aayush 
Agrawal Trust
 1,42,37,664 
 11.31 
 - 
 1,42,37,664 
 11.31 
 16.11 
Gabs Investments Private Limited
 1,25,88,393 
 10.00 
 - 
 1,25,88,393 
 10.00 
 50.00 
Ganga Exports being represented by Mr. Yogesh 
Agrawal, Mr. Rajesh Agrawal & Mr. Ravi Agrawal
 33,79,297 
 2.68 
 - 
 33,79,297 
 2.68 
 46.94 
Ravi P. Agrawal
 2,85,000 
 0.23 
 - 
 2,85,000 
 0.23 
 50.00 
Aayush M. Agrawal
 30,000 
 0.02 
 - 
 30,000 
 0.02 
 50.00 
24. Other Equity
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Capital redemption reserve
Balance at the beginning of the year
 0.44 
 2.63 
Add/(less): utilised for buyback & allotment of Bonus shares
 - 
 (2.19)
Balance as at the year end
 0.44 
 0.44 
Securities premium account
Balance at the beginning of the year
 - 
 - 
Add: addition during the year
 0.18 
 0.18 
Less: utilisation for buyback of shares
 - 
 (0.18)
Balance as at the year end
 0.18 
 - 
Foreign Currency Translation Reserve
Balance at the beginning of the year
 18.00 
 0.88 
Add: Addition during the year
 3.33 
 17.12 
Balance as at the year end
 21.33 
 18.00 
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
General reserve
Balance at the beginning and at the end of the year
 211.04 
 531.77 
Less: transferred to capital redemption reserve
 - 
 - 
Less: utilised for buyback & allotment of Bonus shares
 - 
 (320.73)
Balance as at the year end
 211.04 
 211.04 
Employee stock option outstanding
Balance at the beginning of the year
 0.34 
 0.30 
Add: share-based payment expenses
 (0.37)
 (0.18)
Less: exercised during the year
 (5.68)
 (0.22)
Balance as at the year end
 5.65 
 0.34 
Other items of other comprehensive income  
(Re-measurement gains (losses) on defined benefit plans)
Balance at the beginning of the year
 (8.37)
 (6.10)
Add: amount transferred
 (2.52)
 (2.27)
Balance as at the year end
 (10.89)
 (8.37)
Retained earnings
Balance at the beginning of the year
 3,141.27 
 2,717.70 
Profit for the year
 816.17 
 587.98 
Less: Appropriations
-	
Interim Dividend on Equity shares
 642.17 
 89.69 
-	
Expense relating to buyback of Equity shares
 0.92 
 74.72 
Balance at the year end 
 3,314.35 
 3,141.27 
Total Other equity 
 3,542.09 
 3,362.72 
25. Non-Current Borrowings
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Vehicle loans (secured)
From banks (foreign currency) 
 - 
 1.25 
 - 
 1.25 
25.1	Vehicle loans are secured against vehicles acquired under the scheme & are repayable in equal monthly instalment 
up to 31 December 2023 & rate of interest is 5.17% to 10% p.a.
26. Lease Liabilities
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Lease liabilities (refer note 57)
 23.52 
 24.95 
 23.52 
 24.95 
27. Other Financial Liabilities (Non-Current)
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Security Deposits payable
 1.37 
 1.01 
 1.37 
 1.01 
Annual Report 2023-24
154
155
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Consolidated
Notes to the Consolidated Financial Statements
as at 31 March 2024
Notes to the Consolidated Financial Statements
as at 31 March 2024
28. Other Non-Current Liabilities
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Deferred Government Grant
 2.34 
 2.67 
 2.34 
 2.67 
29. Provisions (Non-Current)
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Provision for employee benefits (Net)
Gratuity (Refer Note 51.2)
 13.50 
 2.32 
Compensated absences (Refer Note 51.3)
 26.04 
 21.83 
 39.54 
 24.15 
30. Deferred Tax Liabilities (Net)
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Tax effect of items constituting - Deferred tax liabilities
Difference in tax base of property, plant and equipment
 (A) 
 143.50 
 132.02 
Unrealised gain/loss on securities carried at FVOCI/FVTPL
 (B) 
 (0.91)
 (0.80)
Tax effect of items constituting - Deferred tax assets
MAT credit entitlement
 (C) 
 - 
 2.98 
Disallowance under income tax
 (D) 
 34.09 
 30.52 
Deferred tax liabilities (net)
 (A+B)-(C+D) 
 108.50 
 97.72 
31. Borrowings (Current) 
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Current Maturities of long-term borrowing
Vehicle loans (secured)
 1.49 
 0.18 
 1.49 
 0.18 
32. Lease Liabilities
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Lease liabilities (refer note 57)
 10.27 
 9.25 
 10.27 
 9.25 
33. Trade Payables 
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Total outstanding dues of micro enterprises and small enterprises 
 20.64 
 37.94 
Total outstanding dues of creditors other than micro enterprises and small enterprises 
 442.56 
 384.83 
 463.20 
 422.77 
(Refer Note 63 for disclosure relating to Micro & Small Enterprises) 
34. Other Financial Liabilities (Current)
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Unpaid dividend*
 0.72 
 0.82 
Unpaid sale proceeds of fractional shares* (31 March 2024 H 15,291 and 31 March 2023 H 15,291)
0.00
0.00
Capital creditors
 43.18 
 29.81 
Book overdraft
 1.56 
 3.84 
Employee benefits payable
 29.29 
 8.85 
Forward exchange contracts used for hedging
 - 
 18.82 
Provision for anticipated sales return (Refer note 56)
 223.27 
 186.43 
Other payables
 0.01 
 - 
Liability on account of share buy back
 - 
 388.27 
 298.03 
 636.84 
* There are no amounts due and outstanding to be credited to Investor Education & Protection Fund as at 31 March 2024.. 
35. Other Current Liabilities
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Advances from customers
 39.32 
 10.01 
Statutory dues payable
 20.08 
 12.81 
Deferred government grant
 0.33 
 0.33 
 59.73 
 23.15 
36. Provisions (Current)
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Provision for employee benefits (net)
Gratuity (Refer Note 51.2)
 10.73 
 8.71 
Compensated absences (Refer Note 51.3)
 7.03 
 5.31 
 17.76 
 14.02 
37. Current Tax Liabilities (Net)
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Provision for tax (net of income tax assets)
 44.77 
 33.07 
 44.77 
 33.07 
38. Liabilities Classified as Held for Sale
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Liability against Assets held for sale (Refer note 68)
 0.51 
 - 
 0.51 
 - 
Annual Report 2023-24
156
157
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Consolidated
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
39. Revenue from Operations
 H in Crore 
Particulars 
 Year ended 
31 March 2024 
 Year ended 
31 March 2023 
Sale of products (Refer note 55)
Finished goods
 3,448.59 
 3,004.22 
Stock-in-trade
 713.00 
 703.30 
Other operating revenues
Export incentives
 27.16 
 14.85 
Others
 19.96 
 20.27 
 4,208.71 
 3,742.64 
40. Other Income
 H in Crore 
Particulars 
 Year ended 
31 March 2024 
 Year ended 
31 March 2023 
Net gain on disposal of Property, Plant and Equipment
 3.49 
 0.84 
Income from financial assets carried at FVTPL
	
Gain on sale/redemption of Current Investments
 11.12 
 17.12 
	
Gain on financial instrument at FVTPL
 22.82 
 - 
Income on financial assets carried at amortised cost
	
Interest on deposits with banks
 0.15 
 0.52 
	
Interest from others
 27.56 
 7.94 
Exchange difference (net)
 15.87 
 66.07 
Miscellaneous income 
 3.59 
 6.15 
 84.60 
 98.64 
41. Cost of Material Consumed
 H in Crore 
Particulars 
 Year ended 
31 March 2024 
 Year ended 
31 March 2023 
Raw material consumed
 752.99 
 697.27 
Packing material consumed
 186.44 
 181.09 
 939.43 
 878.36 
42. Purchase of Stock-In-Trade
 H in Crore 
Particulars 
 Year ended 
31 March 2024 
 Year ended 
31 March 2023 
Purchases of stock-in-trade
 166.35 
 146.28 
 166.35 
 146.28 
43. Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade
 H in Crore 
Particulars 
 Year ended 
31 March 2024 
 Year ended 
31 March 2023 
Inventories at the beginning of the year:
Work-in-progress
 52.46 
 46.50 
Finished goods 
 278.69 
 262.82 
Stock-in-trade
 168.37 
 192.29 
(A)
 499.52 
 501.61 
Inventories at the end of the year:
Work-in-progress
 54.35 
 52.46 
Finished goods 
 291.31 
 278.69 
Stock-in-trade
 194.75 
 168.38 
(B)
 540.41 
 499.53 
Effect of foreign exchange translation
(C)
 1.68 
 23.67 
Total changes in inventories of finished goods, work-in-progress and 
stock-in-trade:
Work-in-progress
 (1.89)
 (5.96)
Finished goods 
 (12.62)
 (15.77)
Stock-in-trade
 (24.70)
 47.49 
Total changes in inventories of finished goods, work-in-progress and  
stock-in-trade:
(A) - (B) + (C)
 (39.21)
 25.76 
44. Employee Benefit Expenses
 H in Crore 
Particulars 
 Year ended 
31 March 2024 
 Year ended 
31 March 2023 
Salaries, wages and bonus
 825.67 
 731.16 
Share-based payment expense (refer note 52)
 5.49 
 0.22 
Contribution to provident and other funds 
 36.41 
 33.83 
Gratuity expenses (refer note 51)
 20.35 
 7.76 
Staff welfare expenses
 12.42 
 12.17 
 900.34 
 785.14 
45. Finance Cost
 H in Crore 
Particulars 
 Year ended 
31 March 2024 
 Year ended 
31 March 2023 
Interest expenses
 7.21 
 5.84 
 7.21 
 5.84 
46. Depreciation and Amortisation Expense
 H in Crore 
Particulars 
 Year ended 
31 March 2024 
 Year ended 
31 March 2023 
Depreciation on property, plant and equipment (refer note 8)
 118.14 
 114.94 
Amortisation on intangible assets (refer note 8)
 5.01 
 4.10 
Depreciation on right-of-use assets (Refer note 8)
 12.25 
 11.27 
Amortisation on investment property (Refer note 8)
 - 
 0.49 
 135.40 
 130.80 
Annual Report 2023-24
158
159
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Consolidated
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
47. Other expenses
 H in Crore 
Particulars 
 Year ended 
31 March 2024 
 Year ended 
31 March 2023 
Selling expenses
 248.63 
 221.69 
Clearing and forwarding
 164.42 
 237.23 
Medical Literature Expenses
 11.79 
 15.58 
Field Travelling Expenses
 42.96 
 38.92 
Consultancy Charges
 58.77 
 44.90 
Travelling expenses
 99.78 
 77.69 
Processing charges
 13.63 
 13.59 
Power and fuel
 66.57 
 65.71 
Advertisement and publicity
 4.49 
 5.02 
Consumption of stores & spare parts
 48.75 
 66.33 
Product registration expenses
 51.30 
 45.90 
Rent (refer note 57)
 7.38 
 7.59 
Rates and taxes
 1.43 
 1.62 
Legal and professional fees
 42.44 
 42.65 
Postage, telephone and stationery expenses
 12.78 
 12.62 
Repairs & maintenance
	
Buildings
 4.10 
 5.39 
	
Plant and machinery
 38.42 
 41.86 
	
Computers & others
 11.95 
 12.55 
Insurance
 15.55 
 15.80 
Loss on Investment at FVTPL
 9.11 
 2.30 
Donation (refer note 67)
 5.57 
 4.79 
Bad debts written off, allowance for doubtful trade receivables (net)
 0.06 
 0.02 
Loss on financial instrument at FVTPL
 - 
 18.82 
Loss on sale/discard of property, plant and equipment (net)
 - 
 6.19 
Clinical and analytical charges
 37.59 
 55.55 
Director sitting fees
 0.37 
 0.32 
Corporate social responsibility expenses (refer note 60)
 17.32 
 16.37 
Commission to directors
 0.12 
 6.72 
Miscellaneous expenses
 54.59 
 40.13 
 1,069.87 
 1,123.85 
48. Capital Management
Group‚Äôs policy is to maintain a strong capital base so as to maintain investor, creditor and market confidence and to 
sustain future development of the business. Management monitors the return (EBIT) on capital, as well as the level of 
dividends to equity shareholders. The Group‚Äôs objective for capital management is to maximise shareholder value, 
safeguard business continuity and support the growth of the Group. The Group determines the capital requirement 
based on annual operating plans and long-term and other strategic investment plans. 
Group monitors capital using a ratio of ‚Äòadjusted net debt‚Äô to ‚Äòadjusted equity‚Äô. For this purpose, adjusted net debt is 
defined as debt less cash and cash equivalents and current investments. Adjusted equity comprises all components 
of equity. 
Group‚Äôs policy is to keep the Net Debt Equity ratio below 1.00 and its adjusted net debt to equity ratio at 31 March 
2024 was as follows. 
 H in Crore 
Particulars 
As at 
31 March 2024 
As at 
31 March 2023 
Borrowings
1.49
1.43
Less: Cash and Cash Equivalents and current investments
(459.54)
(840.10)
Adjusted net debt
A
(458.05)
(838.67)
Equity
B
3,567.36
3,387.99
Adjusted net debt to equity ratio
A/B
(0.13)
(0.25)
49. Basic and Diluted Earnings per Share is Calculated as under
The numerator and denominator used to calculate Basic and diluted earnings per share:
Particulars 
As at 
31 March 2024 
As at 
31 March 2023 
Profit after non-controlling interest attributable to Equity shareholders- for 
Basic EPS (H in Crore)
A
816.17
587.98
Add: Dilutive effect on profit (H in Crore)*
B
-
-
Numerator for calculating dilutive earning per share (H in Crore)
C=A-B
816.17
587.98
Weighted Average Number of Equity Shares outstanding - for Basic EPS
D
12,59,15,562
12,81,18,877
Add: Dilutive effect of ESOP outstanding- Number of Equity Shares*
E
90,479
3,994
Weighted Average Number of Equity Shares for Diluted EPS 
F=D+E
12,60,06,041
12,81,22,871
Face Value per Equity Share (H)
2
2
Basic Earnings Per Share (H)**
A/D
64.82
45.89
Diluted Earnings Per Shares (H)**
C/F
64.77
45.89
 * On account of Employee Stock Option Scheme 2011 (ESOS) and Share-based Incentive Plan 2019 - (Refer note 52). 
** Earning per share has been computed after given effect of the share buyback.
50.	 Consolidated Financial Statements present the consolidated accounts of the Holding Company and following 
subsidiary companies.
50.1 Details of subsidiaries of the Group are as under
Name of the Company
Country of 
Incorporation
% voting power 
held as at 
31 March 2024
Ajanta Pharma (Mauritius) Ltd. (‚ÄúAPML‚Äù)
Mauritius
100%
Ajanta Pharma USA Inc. (‚ÄúAPUI‚Äù)
U.S.A.
100%
Ajanta Pharma Philippines Inc. (‚ÄúAPPI‚Äù)
Philippines
100%
Ajanta Pharma Nigeria Ltd. (‚ÄúAPNL‚Äù)
Nigeria
100%
50.2 Ajanta Pharma (Mauritius) International Ltd., a wholly-owned subsidiary of APML, was removed from register of 
companies u/s 308 of the Companies Act, 2001 (Mauritius) by Business registration department vide its letter 
dated 27 September 2022.
50.3 The financial statements of the subsidiaries used for consolidation are for the period from 01 April 2023 to 
31 March 2024.
Annual Report 2023-24
160
161
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Consolidated
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
51. Employee Benefits in Respect of the Holding Company
As required by Ind AS 19 ‚ÄòEmployee Benefits‚Äô the disclosures are as under: 
51.1 Defined Contribution Plans
The Company offers its employees defined contribution plans in the form of Provident Fund (PF) and Employees‚Äô Pension 
Scheme (EPS) with the government, and certain state plans such as Employees‚Äô State Insurance (ESI). PF and EPS cover 
substantially all regular employees and the ESI covers certain employees. Contributions are made to the Government‚Äôs 
administered funds. While both the employees and the Company pay predetermined contributions into the Provident 
Fund and the ESI Scheme, contributions into the Pension fund is made only by the Company. The contributions are 
normally based on a certain proportion of the employee‚Äôs salary. The Company does not have any liability beyond 
depositing these amounts in to the government administered fund. During the year, the Company has made the 
following contributions:
 H in Crore 
Particulars 
 Year ended 
31 March 2024 
 Year ended 
31 March 2023 
Provident Fund and Employee‚Äôs Pension Scheme
32.93
29.75
Employees State Insurance and others
3.48
4.05
Total
36.41
33.80
51.2 Defined Benefit Plans
Gratuity: 
The Company makes annual contributions to Employees‚Äô Group Gratuity-cum Life Assurance (Cash Accumulation) 
Scheme of LIC, a funded defined benefit plan for qualifying employees. The Companies scheme provides for payment 
to vested employees as under:
51.2.1 On normal retirement/ early retirement/ withdrawal/ resignation
As per the provisions of Payments of Gratuity Act, 1972 with vesting period of 5 years of service. A benefit ceiling of 
H 0.20 Crore is applied only for Director.
51.2.2 On the death in service
As per the provisions of Payment of Gratuity Act, 1972 without any vesting period.
The most recent actuarial valuation of plan assets and the present value of the defined benefit obligation for gratuity 
were carried out as at 31 March 2024. The present value of the defined benefit obligations and the related current 
service cost and past service cost, were measured using the Projected Unit Credit Method.
Based on the actuarial valuation obtained in this respect, the following table sets out the status of the gratuity plan 
and the amounts recognised in the Company‚Äôs financial statements as at the Balance Sheet date:
 H in Crore 
Particulars 
As at 
31 March 2024
As at 
31 March 2023
i)
Changes in Defined Benefit Obligation
Opening defined benefit obligation
58.78
48.19
Current service cost
9.59
7.59
Interest cost
3.93
2.99
Actuarial loss/(gain)
-	
Changes in financial assumptions
0.67
(1.53)
-	
Changes in demographic assumptions
-
-
-	
Experience adjustments
2.68
5.21
Past service cost
10.27
-
 H in Crore 
Particulars 
As at 
31 March 2024
As at 
31 March 2023
Benefit (paid)
(4.59)
(3.67)
Closing defined benefit obligation
81.33
58.78
ii)
Changes in value of Plan Assets
Opening value of plan assets
47.75
41.92
Interest Income
3.43
2.82
Return on plan assets excluding amount included in Interest Income
(0.53)
(0.18)
Contributions by employer
11.04
6.49
Benefits (paid)
(4.59)
(3.66)
Closing value of plan assets
57.10
47.75
iii)
Amount recognised in the Balance Sheet
Present value of funded obligations as at year end
81.33
58.78
Fair value of the plan assets as at year end
(57.10)
(47.75)
Net liability recognised as at the year end
24.23
11.03
iv)
Expenses recognised in the Statement of Profit and Loss
Current Service Cost
9.59
7.59
Past Service cost
10.27
-
Net Interest cost
0.49
0.17
Net expenses recognised in the Statement of Profit and Loss
20.35
7.76
Expenses recognised in the Statement of Other comprehensive income
Net actuarial loss/(gain) recognised in the current year
-	
Changes in financial assumptions
0.67
(1.53)
-	
Changes in demographic assumptions
-
-
-	
Experience adjustments
2.68
5.20
Return on plan assets excluding amounts included in interest income
0.53
(0.18)
Net (Expenses)/Income recognised in the Statement of Other comprehensive income
3.88
3.49
v)
Asset information
Insurer Managed Funds (100%)
(Fund is Managed by LIC as per IRDA guidelines, category-wise composition of the plan 
assets is not available)
100%
100%
vi)
Principal actuarial assumptions used
Discount rate (p.a.)
7.20%
7.35%
Mortality Rate
Indian Assured 
Lives Mortality 
(2012-14)
Indian Assured 
Lives Mortality 
(2012-14)
Salary growth rate (p.a.)
9.00% for next 
1 year and 7.00% 
thereafter
9.00% for next 
1 year and 7.00% 
thereafter
Weighted average duration of defined benefit obligation (Years)
5.83
6.33
Withdrawal Rate (%): 
Age Band
25 and below
40%
40%
26 to 35
24%
24%
36 to 45
12%
12%
46 to 55
8%
8%
56 and above
8%
8%
vii)
Estimate of amount of contribution in immediate next year
10.73
8.72
Annual Report 2023-24
162
163
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Consolidated
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
Sensitivity Analysis
Reasonably possible changes at the reporting date to one of the relevant actuarial assumptions, holding other 
assumptions constant, would have affected the defined benefit obligation as shown below.
H in Crore
Particulars
As at 31 March 2024
As at 31 March 2023
Increase
Decrease
Increase
Decrease
Discount rate (0.5% movement)
79.15
83.64
57.13
60.54
Salary growth rate (0.5% movement)
83.70
79.06
60.28
57.32
Withdrawal rate (W.R.) Sensitivity (10% movement)
81.09
81.55
58.74
58.80
Although the analysis does not take in to account full distribution of cash flows expected under the plan, it does provide 
an approximation of sensitivity of assumptions. The estimate of future increase in compensation levels, considered in 
the actuarial valuation, have been taken on account of inflation, seniority, promotion and other relevant factors such 
as supply and demand in the employment market.
51.3 Leave Encashment
The Holding Company‚Äôs employees are entitled for compensated absences which are allowed to be accumulated 
and encashed as per the Company‚Äôs policies. The liability of compensated absences, which is non-funded, has been 
provided based on report of independent actuary using ‚ÄúProjected Unit Credit Method‚Äù.
Accordingly, H 33.07 Crore (31 March 2023 H 27.14 Crore) being liability as at the year-end for compensated absences 
as per actuarial valuation has been provided in the accounts.
Employee retirement and other benefit obligations in respect of the subsidiary at Mauritius:
For employees who are not covered by a pension plan, the net present value of severance allowances payable is 
provided for aggregating H Nil (31 March 2023 H Nil).
Employee retirement and other benefit obligations in respect of the subsidiary at Philippines:
Short-term benefits include salaries and wages and other government contributions which are due within 12 months 
after the end of the period in which employee renders the related service. The Company‚Äôs short-term employee benefits 
amounted to H Nil (31 March 2023 H Nil). The Company did not yet set up a retirement plan since it does not have more 
than ten employees who had served at least five years.
Employee retirement and other benefit obligations in respect of the subsidiary at USA:
Short-term benefits include salaries and wages and other government contributions which are due within 12 months 
after the end of the period in which employee renders the related service. The Company‚Äôs short-term employee benefits 
amounted to H 2.96 Crore (31 March 2023 H 3.28 Crore).
52. Share-Based Payments 
The Holding Company has established ‚ÄúEmployee Stock Options Scheme 2011‚Äù (‚ÄòESOP-2011‚Äô) and ‚ÄúShare-based 
Incentive Plan 2019‚Äù as approved in earlier year by the shareholders of the Company and Compensation committee 
of Board of Directors for the key employees of the Company. The options issued under the above scheme vest in a 
phased manner.
During the year, the Company made the decision to withdraw the Employee Stock Options Scheme 2011 in the 
Nomination & Remuneration committee meeting held on 31 January 2024, with immediate effect.
During the year 91,350 option have been granted and 3,750 option cancelled by the Company under the aforesaid 
Share-based Incentive Plan 2019 to the employees (including KMP‚Äôs) of the Group.
Grant Date
No. of option Granted
No. of Option Cancelled
Exercise Price
Vesting Period
10 May 2022
-
2,000
-
-
05 May 2022
11,600
1,750
H 2/-
05 May 2024 to 05 May 2026
27 July 2023
79,750
-
H 2/-
27 July 2024 to 01 January 2027
Details of options granted during the year to Key Managerial Personnel are as below:
Name of the Employee
Designation
Number of options
Grant/exercise price
Mr. Arvind K. Agrawal
Chief Financial Officer
3,000
H 2/-
Mr. Gaurang C. Shah
Company Secretary
1,500
H 2/-
The options are granted at an exercise price which is in accordance with the relevant SEBI guidelines in force, at the 
time of such grants. Each option entitles the holder to exercise the right to apply for and seek allotment of one equity 
share of H 2‚ÅÑ- each. 
The particulars of the options under Share-based Incentive Plan 2019 are as under:
Particulars 
As at 
31 March 2024
 Nos.
As at 
31 March 2024
 Nos.
Option outstanding as at the beginning of the year
4,000
3,000
Add: Option granted during the year
91,350
2,000
Less: Option exercised during the year 
1,000
1,000
Less: Option lapsed/cancelled during the year
3,750
-
Option outstanding as at the year End
90,600
4,000
Particulars
As at 
31 March 2024 
Nos.
Range of 
Exercise Prices 
(D)
Weighted 
Average 
Exercise Prices 
(D)
Weighted 
Average 
share price 
at the date of 
exercise (D)
Weighted 
Average 
Contractual 
life (Years)
Options outstanding as at the beginning of the 
year
4,000
2.00
2.00
-
1.60
Add: Options granted during the year 
91,350
2.00
2.00
-
1.36
Less: Options exercised during the year 
1,000
2.00
2.00
1,312.60
-
Less: Options lapsed/cancelled during the year
3,750
-
-
-
-
Options outstanding as at the year end 
90,600
2.00
2.00
-
1.37
Particulars
As at 
31 March 2023 
Nos.
Range of 
Exercise Prices 
(D)
Weighted 
Average 
Exercise Prices 
(D)
Weighted 
Average share 
price at the 
date of exercise 
(D)
Weighted 
Average 
Contractual life 
(Years)
Options outstanding as at the beginning of the 
year
3,000
2.00
2.00
-
1.08
Add: Options granted during the year 
2,000
2.00
2.00
-
1.31
Less: Options exercised during the year 
1,000
2.00
2.00
1,147.41
-
Less: Options lapsed/cancelled during the year
-
-
-
-
-
Options outstanding as at the year end 
4,000
2.00
2.00
-
1.60
Annual Report 2023-24
164
165
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Consolidated
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
Effect of Share-Based Plan in Profit & Loss: 
For details of the related employee benefits expense, refer note 44.
Description of the method and significant assumptions used during the year to estimate the fair values of the options, 
including the following weighted average information:
Variables 
Weighted Average Information
Plan 
Share Based Incentive Plan 2019
Particulars 
500 
option
3,000 
option
3,000 
option
2,000 
option
11,600 
option
79,750 
option
Grant date 
27 September 
2019
20 May 2020
30 April 2021
10 May 2022
05 May 2023
27 July 2023
Last date for acceptance 
27 October 
2019
19 June 2020
30 May 2021
09 June 2022
03 June 2023
25 August 2023
Risk free rate (%) 
5.20
5.20
4.53
7.06
7.05
7.14
Expected Life (years) 
2
1
1 to 3
3 to 4
1 to 3
1 to 4
Volatility (%) 
13.74
14.67
14.57
13.12
13.12
13.12
Dividend yield (%) 
0.55
0.71
0.76
0.68
0.86
0.86
Price of the underlying share in 
the market at the time of option 
grant (H)
1,055
1,439
1,842
1,105
1,298
1,553
Fair value of options (H)
1,041
1,425
1,792
1,078
1,273
1,522
Exercise price (H)
2
2
2
2
2
2
The particulars of the options Share Based Incentive Plan 2019 granted to Employees of Subsidiary are as below:
Variables 
Weighted Average Information
Plan 
Share Based Incentive Plan 2019
Particulars 
500 
option
3,000 
option
13,000 
option
Grant date 
27 September 2019
20 May 2020
27 July 2023
Last date for acceptance 
27 October 2019
19 June 2020
25 August 2023
Risk free rate (%) 
5.20
5.20
7.14
Expected Life (years) 
2
1
1 to 4
Volatility (%) 
13.74
14.67
13.12
Dividend yield (%) 
0.55
0.71
0.86
Price of the underlying share in the market at the time of option grant (H)
1,055
1,439
1,553
Fair value of options (H)
1,041
1,425
1,522
Exercise price (H)
2
2
2
Valuation of Stock Options
The fair value of stock options granted during the period has been measured using the Black‚ÄìScholes option pricing 
model at the date of the grant. The Black-Scholes option pricing model includes assumptions regarding dividend yields, 
expected volatility, expected terms and risk-free interest rates. They key inputs and assumptions used are as follows:
Share price: The closing price on NSE as on the date of grant has been considered for valuing the options granted.
Exercise Price: Exercise Price is the market price or face value or such other price as determined by the Remuneration 
and Compensation Committee.
Expected Volatility: The historical volatility of the stock till the date of grant has been considered to calculate the fair 
value of the options.
Expected Option Life: Expected Life of option is the period for which the Company expects the options to be live. The 
minimum life of a stock option is the minimum period before which the options cannot be exercised and the maximum 
life is the period after which the options cannot be exercised.
Expected dividends: Expected dividend yield has been calculated as an average of dividend yields for four years 
preceding the date of the grant.
Risk free interest rate: The risk-free interest rate on the date of grant considered for the calculation is the interest 
rate applicable for a maturity equal to the expected life of the options based on the zero-coupon yield curve for 
Government Securities.
These assumptions reflect management‚Äôs best estimates, but these assumptions involve inherent market uncertainties 
based on market conditions generally outside of the Company‚Äôs control. As a result, if other assumptions had been 
used in the current period, stock-based compensation expense could have been materially impacted. Further, if 
management uses different assumptions in future periods, stock-based compensation expense could be materially 
impacted in future years. The Company has granted stock options to employees of a subsidiary, the estimated fair 
value of stock options issued are included in the carrying value of the investment in the said subsidiary on a straight-
line basis over the requisite service period of each separately vesting portion of the award.
53. Financial Instrument ‚Äì Fair Values and Risk Management
A.	 Fair Value Measurements 
H in Crore
Financial instruments by category
As at 31 March 2024
As at 31 March 2023
FVTPL
Amortised cost
FVTPL
Amortised cost
Financial assets
Investment in Limited Liability Partnership
18.58
-
25.10
-
Forward exchange contracts used for hedging
12.48
-
-
-
Investments in NCDs/NC MLDs
37.12
251.79
161.56
46.18
Investments in CPs
-
30.90
-
124.21
Investments in mutual funds
10.24
-
178.32
-
Investment in unquoted equity shares (31 March 2024  
H 37,050, 31 March 2023 H 37,050)
-
0.00
-
0.00
Trade receivables
-
1,246.84
-
1,056.90
Other non-current financial assets
-
9.36
-
11.09
Cash and cash equivalents
-
129.49
-
329.83
Bank balances other than cash and cash equivalents
-
1.28
-
1.07
Current loans
-
33.96
-
17.39
Interest receivable
-
6.54
-
2.48
Total Financial assets
78.42
1,710.16
364.98
1,589.15
Financial Liabilities
Borrowings and book overdraft
-
3.05
-
5.27
Other non-current financial liabilities
-
1.37
-
1.01
Non-current lease liabilities
-
23.52
-
24.95
Capital creditors
-
43.18
-
29.81
Other current financial liabilities
-
224.00
-
575.52
Unpaid sale proceeds if fractional shares (31 March 2024  
H 15,291, 31 March 2023 H 15,291)
-
0.00*
-
0.00#
Employee benefits payable
-
29.29
-
8.85
Current lease liabilities
-
10.27
-
9.25
Forward exchange contracts used for hedging
-
-
18.82
-
Trade payables
-
463.20
-
422.77
Total Financial liabilities
-
797.88
18.82
1,077.43
Fair value measurement of lease liabilities is not required.
Annual Report 2023-24
166
167
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Consolidated
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
Fair Value Hierarchy
This section explains the judgements and estimates made in determining the fair values of the financial instruments 
that are (a) recognised and measured at fair value and (b) measured at amortised cost and for which fair values are 
disclosed in the financial statements. To provide an indication about the reliability of the inputs used in determining 
fair value, the Company has classified its financial instruments into the three levels prescribed under the accounting 
standard. An explanation of each level follows underneath the table.
H in Crore
Financial assets and liabilities measured at fair value
As at 31 March 2024
As at 31 March 2023
Level
Level
I
II
III
I
II
III
Financial assets
Recurring fair value measurement
Investment in Limited liability partnership
-
-
18.58
-
-
25.10
Forward exchange contracts used for hedging
-
12.48
-
-
-
-
Investments in NCDs/NC MLDs
-
37.12
-
-
161.56
-
Investments in mutual funds
10.24
-
-
178.32
-
-
Total Financial assets
10.24
49.60
18.58
178.32
161.56
25.10
Financial Liabilities
Forward exchange contracts used for hedging
-
-
-
-
18.82
-
Total Financial Liabilities
-
-
-
-
18.82
-
Level 1 ‚Äì Level 1 Hierarchy includes financial instruments measured using quoted prices. This includes mutual funds that 
have declared buyback NAV. The mutual funds are valued using the closing NAV.
Level 2 ‚Äì The fair value of financial instruments that are not traded in an active market (like Mark to Market Derivatives, 
and Non-convertible market link Debentures) is determined using valuation techniques which maximise the use of 
observable market data and rely as little as possible on entity-specific estimates. If all significant inputs required to 
fair value as instrument are observable, the instrument is included in level 2.
Level 3 ‚Äì If one or more of the significant inputs is not based on observable market data, the instrument is included in 
level 3. 
Measurement of Fair Values:
Valuation techniques and significant unobservable inputs:
The following tables show the valuation techniques used in measuring Level 2 & Level 3 fair values, for financial instruments 
measured at fair value in the statement of financial position, as well as the significant unobservable inputs used:
Type
Valuation Technique
Significant unobservable  
Inputs
Inter-relationship between 
significant unobservable inputs and 
fair value measurement
Derivative instruments
Forward pricing: The fair value is determined 
using quoted forward exchange rates at the 
reporting date.
Not applicable
Not applicable
Non-Current Financial 
assets (Investment)
Discounted Cash flow: The valuation model 
considers the present value of expected 
receipts/payment 
discounted 
using 
appropriate discounting rates.
Not applicable
Not applicable
B.	
Financial Risk Management 
Group has exposure to following risks arising from financial instruments:
i.	
Credit risk
ii.	
Liquidity risk
iii.	
Market risk
iv.	
Currency risk
Risk Management Framework
Group‚Äôs board of directors has overall responsibility for the establishment and oversight of the Company‚Äôs risk 
management framework. Management is responsible for developing and monitoring the Company‚Äôs risk management 
policies, under the guidance of Audit Committee.
Group‚Äôs risk management policies are established to identify and analyse the risks faced by it, to set appropriate risk 
limits and controls and to monitor risks and adherence to limits. Risk management policies and systems are reviewed 
regularly to reflect changes in market conditions and the Group‚Äôs activities. Group, through its training and procedures 
aims to maintain a disciplined and constructive control environment in which all employees understand their roles 
and obligations.
Group‚Äôs Audit committee oversees how management monitors compliance with the Group‚Äôs risk management policies 
and procedures, and reviews the adequacy of the risk management framework in relation to the risks faced by the 
Group. The audit committee is assisted in its oversight role by internal audit. Internal audit undertakes both regular and 
ad hoc reviews of risk management controls and procedures, the results of which are reported to the Audit committee. 
i.	
Credit Risk 
	
Credit risk is the risk that a counter party will not meet its obligations under a financial instrument or customer 
contract, leading to a financial loss. The Group is exposed to credit risk from its operating activities (primarily trade 
receivables) and from its financing activities, including deposits with banks and mutual funds, foreign exchange 
transactions and other financial instruments.
	
Impairment: 
	
The following table provides information about the exposure to credit risk and expected credit loss for 
trade receivables:
H in Crore
Particulars
As at 31 March 2024
Carrying amount
Weighted 
average loss rate
Loss allowance
Not due
1,113.82
0.00%
-
Past due up to 180 days
111.00
1.52%
1.69
Past due 181 - 365 days
24.27
4.70%
1.14
Past dues 366 - 730 days
0.69
15.94%
0.11
Past dues 731 - 1096 days
4.98
100.00%
4.98
More than 1096 days
0.91
100.00%
0.91
1,255.67
8.83
Annual Report 2023-24
168
169
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Consolidated
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
H in Crore
Particulars
As at 31 March 2023
Carrying amount
Weighted average 
loss rate
Loss allowance
Not due
942.48
0.00%
 - 
Past due up to 180 days
98.84
0.82%
0.80
Past due 181 - 365 days
14.57
4.05%
0.59
Past dues 366 - 730 days
8.90
73.03%
6.50
Past dues 731 - 1096 days
0.06
100.00%
0.06
More than 1096 days
3.09
100.00%
3.09
1,067.94
11.04
a)	
Trade Receivables 
Customer credit risk is managed by each business unit subject to the Group‚Äôs established policy, procedures and 
control relating to customer credit risk management. Trade receivables, which are non-interest bearing, are mainly 
from stockists, distributors and customers and are generally on 14 days to 270 days credit term. Outstanding 
customer receivables are regularly monitored. The Company has no concentration of credit risk as the customer 
base is widely distributed both economically and geographically.
As at 31 March 2024, Group had 76 customers (31 March 2023: 83 customers) that owed the Company more than 
H 0.50 Crore each and accounted for approximately 91% and 91% of the total outstanding as at 31 March 2024 
and 31 March 2023.
	
Expected Credit Loss Assessment
As per simplified approach, the Group makes provision of expected credit losses on trade receivable using a 
provision matrix to mitigate the risk of default payment and make appropriate provision at each reporting date 
wherever required. The trend of the bad debts is negligible.
 H in Crore 
Particulars 
As at 
31 March 2024
As at 
31 March 2023
Gross Carrying amount
1,255.67
1,067.94
Average Expected loss rate
0.70%
1.03%
Carrying amount of trade receivables (net of impairment)
1,246.84
1,056.90
The movement in the allowance for impairment in respect of trade receivables during the year was as follows: 
 H in Crore 
Particulars 
As at 
31 March 2024
As at 
31 March 2023
Balance as at the beginning of the year
11.04
14.74
Impairment loss recognised (net)
-
(0.84)
Amounts written off
(2.21)
(2.86)
Balance as at the year end
8.83
11.04
During the year impairment gain has been recognised due to writeback of allowance of trade receivable.
b)	
Financial Instruments
Group limits its exposure to credit risk by investing in liquid securities issued by mutual funds having a credit ranking 
of at least 3 and above from CRISIL or equivalent rating agency. Group monitors changes in credit risk by tracking 
published external credit ranking. Based on its on-going assessment of counterparty risk, the Group adjusts its 
exposure to various counterparties.
ii.	
Liquidity Risk
Liquidity risk is the risk that the Group may not be able to meet its present and future cash and collateral obligations 
without incurring unacceptable losses. The Group‚Äôs objective is to, at all times maintain optimum levels of liquidity 
to meet its cash and collateral requirements. The Group closely monitors its liquidity position and deploys a robust 
cash management system. It maintains adequate sources of financing including bilateral loans, debt and overdraft 
from banks at an optimised cost. Working capital requirements are adequately addressed by internally generated 
funds. Trade receivables are kept within manageable levels. 
Group aims to maintain the level of its cash and cash equivalents and other highly marketable debt investments 
at an amount in excess of expected cash outflows on financial liabilities over the next six months. The ratio of cash 
and cash equivalents and other highly marketable debt investments to outflows is 0.55 at 31 March 2024 (1.18 at 
31 March 2023)
	
Exposure to Liquidity Risk
The following are the remaining contractual maturities of financial liabilities at the reporting date. The amounts are 
gross and undiscounted, and include estimated interest payments and exclude the impact of netting agreements.
	
As at 31 March 2024
H in Crore
Particulars
Carrying 
Amount
Contractual Cash Flows
Total
0-12 months
1-2 years
2-5 years
More than 
5 years
Trade payables 
463.20
463.20
463.04
0.16
-
-
Other financial 
liabilities
299.40
299.40
298.03
1.37
-
-
Lease liabilities
33.79
33.79
10.27
6.09
3.29
14.14
Borrowings
1.49
1.49
1.49
-
-
-
Total
797.88
797.88
772.83
7.62
3.29
14.14
	
As at 31 March 2023
H in Crore
Particulars
Carrying 
Amount
Contractual Cash Flows
Total
0-12 months
1-2 years
2-5 years
More than 
5 years
Trade payables 
422.77
422.77
422.77
-
-
-
Other financial 
liabilities
637.85
637.85
636.84
1.01
-
-
Lease liabilities
34.20
34.20
9.25
7.95
4.58
12.42
Borrowings
1.43
1.43
0.18
1.25
-
-
Total
1,096.25
1,096.25
1,096.25
10.21
4.58
12.42
iii.	
Market Risk
Market risk is the risk that changes in market prices ‚Äì such as foreign exchange rates, interest rates and equity 
prices ‚Äì will affect the Group‚Äôs income or the value of its holdings of financial instruments. The objective of market 
risk management is to manage and control market risk exposures within acceptable parameters, while optimising 
the return. Financial instruments affected by market risk include loans and borrowings, deposits, investments, and 
derivative financial instruments. 
Group‚Äôs activities expose it to a variety of financial risks, including the effects of changes in foreign currency 
exchange rates and interest rates. The Group uses derivative financial instruments such as foreign exchange 
contracts to manage its exposures to foreign exchange fluctuations. All such transactions are carried out within 
the guidelines set by the risk management committee.
Annual Report 2023-24
170
171
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Consolidated
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
	
Sensitivity Analysis on Interest Rate
The Company‚Äôs fixed rate bank deposits and securities are carried at amortised cost. They are therefore not 
subject to interest rate risk as defined in Ind AS 107, since neither the carrying amount nor the future cash flow will 
fluctuate because of a change in market interest rates.
	
Sensitivity Analysis on Equity Prices
The Group has invested its surplus funds primarily in debt based mutual funds. The value of investment in these 
mutual fund schemes is reflected though Net Asset Value (NAV) declared by the Asset Management Company 
on daily basis. The Company has not performed a sensitivity analysis on these mutual funds based on estimated 
fluctuations in their NAV as in management‚Äôs opinion, such analysis would not display a correct picture.
iv.	 Currency Risk
The Group is exposed to currency risk to the extent that there is a mismatch between the currencies in which sales, 
purchases and borrowings are denominated and the respective functional currencies of the Group. The currencies 
in which these transactions are primarily denominated are US Dollars, Euro, Mauritian Rupee, Philippine Peso and 
Nigerian Naira.
At any point in time, the Group covers foreign currency risk by taking appropriate percentage of its foreign currency 
exposure, as approved by risk management committee in line with the laid down policy approved by the Board. 
The Group uses forward exchange contracts to mitigate its currency risk, most with a maturity of less than one year 
from the reporting date. In respect of other monetary assets and liabilities denominated in foreign currencies, the 
Group‚Äôs policy is to ensure that its net exposure is kept to an acceptable level by buying or selling foreign currencies 
at spot rates when necessary to address short-term imbalances.
The following table analyses foreign currency risk as of 31 March 2024: 
H in Crore
Particulars
US Dollars
Euro
Mauritian 
Rupee
Philippine 
Peso
Nigerian 
Naira
Total
Bank balances
80.97
4.32
12.24
9.00
0.10
106.63
Trade receivables
1,007.33
4.74
31.15
82.17
-
1,125.39
Payables
(46.69)
(1.81)
(0.92)
(10.84)
(0.22)
(60.48)
Borrowings
-
-
-
(1.49)
-
(1.49)
Net assets/(liabilities)
1,041.61
7.25
42.47
78.84
(0.12)
1,170.05
The following table analyses foreign currency risk as of 31 March 2023: 
H in Crore
Particulars
US Dollars
Euro
Mauritian 
Rupee
Philippine 
Peso
Nigerian 
Naira
Australian 
Dollar
Sterling 
Pound
Total
Bank balances
208.22
3.60
24.49
9.76
0.06
-
-
246.13
Trade receivables
838.02
3.78
40.74
76.43
-
-
-
958.97
Payables
(99.27)
(3.26)
(2.85)
(12.08)
(0.41)
(0.01)
(0.01)
(117.89)
Borrowings
-
-
-
(1.43)
-
-
-
(1.43)
Net assets/(liabilities)
946.97
4.12
62.38
72.68
(0.35)
(0.01)
(0.01)
1,085.78
For the year ended 31 March 2024 every percentage point depreciation/appreciation in the exchange rate for 
the closing balances between the Indian Rupee and respective currencies would affect the Group‚Äôs incremental 
profit before tax as per below:
H in Crore
Particulars
Change in currency 
exchange rate
Effect on profit 
before tax
US Dollars (USD)
+1%/(-1%)
10.41/(10.41)
Euro (EUR)
+1%/(-1%)
0.07/(0.07)
Mauritian Rupee (MUR)
+1%/(-1%)
0.42/(0.42)
Philippine Peso (PHP)
+1%/(-1%)
0.79/(0.79)
Nigerian Naira (NN)
+1%/(-1%)
0.00/(0.00)
For the year ended 31 March 2023 every percentage point depreciation/appreciation in the exchange rate 
between the Indian Rupee and respective currencies has affected the Company‚Äôs incremental profit before tax 
as per below:
H in Crore
Particulars
Change in currency 
exchange rate
Effect on profit 
before tax
US Dollars (USD)
+1%/(-1%)
9.47/(9.47)
Euro
+1%/(-1%)
0.04/(0.04)
Mauritian Rupee (MUR)
+1%/(-1%)
0.62/(0.62)
Philippine Peso (PHP)
+1%/(-1%)
0.73/(0.73)
Nigerian Naira (NN)
+1%/(-1%)
0.00/(0.00)
Australian Dollar (AUD)
+1%/(-1%)
0.00/(0.00)
Sterling Pound (GBP)
+1%/(-1%)
0.00/(0.00)
54. Note on foreign Currency Exposures on Assets and Liabilities
During the year, the Group has entered into forward exchange contract, being derivative instruments to mitigate 
foreign currency risk, to establish the amount of currency in Indian Rupees required or available at the settlement date 
of certain payables and receivables. The following are the outstanding foreign currency forward contracts entered 
into by the Group:
Particulars
As at 
31 March 2024
As at 
31 March 2023
Buy or Sell
Cross Currency
Foreign Currency 
Amount in Crore
Foreign Currency 
Amount in Crore
Euro
5.00
5.80
SELL
INR
USD
13.20
8.05
SELL
INR
The year-end foreign currency exposures that have not been mitigated by a derivative instrument or otherwise are 
as below:
Particulars
D in Crore 
D in Crore 
Foreign Currency 
Amount in Crore
Foreign Currency 
Amount in Crore
Foreign Currency
As at 
31 March 2024
As at 
31 March 2023
As at 
31 March 2024
As at 
31 March 2023
Amount Receivable
74.44
-
0.89
-
USD
-
34.09
-
0.38
EURO
0.04
-
#
-
GBP
Amount Payable
234.31
171.03
2.81
2.08
USD
4.08
1.06
0.05
0.01
EURO
-
0.01
-
@
GBP
-
0.00
-
*
AUD
#4,084 @GBP 693 *AUD 1,800
Annual Report 2023-24
172
173
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Consolidated
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
a)	 Interest Rate Risk 
Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of 
changes in market interest rates. The Group‚Äôs exposure to the risk of changes in market interest rates relates primarily 
to the Group‚Äôs debt interest obligations. Further, the Group engages in financing activities at market linked rates, any 
changes in the interest rates environment may impact future rates of borrowing.
The interest rate profile of the Group‚Äôs interest-bearing financial instruments as reported to management is as follows.
 H in Crore 
Particulars
As at 
31 March 2024
As at 
31 March 2023
Foreign Currency Term Loan
1.49
1.43
A reasonably possible change of 100 basis points in interest rates at the reporting date would have impacted profit 
before tax as per below. This analysis assumes that all other variables, in particular foreign currency exchange rates, 
remain constant.
 H in Crore 
Particulars
As at 
31 March 2024
As at 
31 March 2023
Increase in interest rate by 100 basis points
(0.01)
(0.01)
Decrease in interest rate by 100 basis points
0.01
0.01
55. Disaggregation of Revenue
The operations of the Group are limited to only one segment viz. pharmaceuticals and related products. Revenue from 
contract with customers is from sale of manufactured goods. Sale of goods are made at a point in time and revenue 
is recognised upon satisfaction of the performance obligations which is typically upon dispatch/delivery. The Group 
has a credit evaluation policy based on which the credit limits for the trade receivables are established. There is no 
significant financing component as the credit period provided by the Group is not significant.
Primary Geographical Markets
 H in Crore 
Particulars 
Year ended 
31 March 2024
Year ended 
31 March 2023
India
1,307.76
1,174.00
Emerging Market
1,641.70
1,515.51
Africa Institution
248.60
190.23
USA
963.53
827.78
Total revenue from contract with customers
4,161.59
3,707.52
Timing of revenue recognition
Goods transferred at a point in time
4,161.59
3,707.52
Variable components such as discounts, late delivery charges etc. continues to be recognised as revenue deductions 
in compliance with Ind AS 115. One customer who contributes more than 10% of the Group‚Äôs revenue.
 H in Crore 
Revenue Break-up
Year ended 
31 March 2024
Year ended 
31 March 2023
Revenue as per contracted price
8,067.32
7,265.65
Adjusted for:
Sales Return (including provisions)
95.15
86.61
Chargeback, rebates and discounts
3,674.94
3,338.97
Others (Price adjustment, anticipated sales return)
135.64
132.55
Total
3,905.73
3,558.13
Net Sale
4,161.59
3,707.52
The Company normally sells goods on credit which varies from 14 to 21 days for domestic sales and 30 to 270 days in 
case of export sales. This does not involve any significant financing element.
We have one customer having more than 10% of Group‚Äôs Revenue amounting to H 487.11 Crore.
Contract Liability (Advances from Customers):
 H in Crore 
Particulars 
As at 
31 March 2024
As at 
31 March 2023
Contract Liabilities
39.32
10.01
The Contract liability outstanding at the beginning of the year has been recognised as revenue during the year ended 
31 March 2024.
56. Provision for Anticipated Sales Return 
Provision has been made towards probable return of goods from customers, as per Indian Accounting Standard 
(Ind AS) 115 estimated by management based on past trends.
 H in Crore 
Particulars 
As at 
31 March 2024
As at 
31 March 2023
Balance at the beginning of the year
186.43
163.13
Add: Provisions made during the year
36.84
23.30
Less: Amount written back/utilised during the year
-
-
Balance at the end of the year
223.27
186.43
57. Disclosure for Leases under Ind AS 116 - ‚ÄúLeases‚Äù
The Group have taken various premises under operating lease. These are generally cancellable and ranges from 11 
months to 5 years and are renewable by mutual consent on mutually agreeable terms. Some of these lease agreements 
have price escalation clauses. There are no restrictions imposed by these lease arrangements and there are no sub 
leases. There are no contingent rents. A Single discount rate has been applied to a portfolio of leases with reasonably 
similar characteristics.
Right-Of-Use Assets
As at 31 March 2024
 H in Crore
Particulars
Buildings
Land
Total
Cost
As at 01 April 2023
37.11
62.59
99.70
Additions to ROU assets
12.05
-
12.05
De-recognition of ROU assets
(1.63)
-
(1.63)
Balance at 31 March 2024
47.53
62.59
110.12
Accumulated depreciation and impairment
As at 01 April 2023
16.02
2.82
18.84
Depreciation
11.24
0.95
12.19
Eliminated on disposals of assets
(1.31)
-
(1.31)
Balance at 31 March 2024
25.95
3.77
29.72
Annual Report 2023-24
174
175
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Consolidated
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
As at 31 March 2023
 H in Crore
Particulars
Buildings
Land
Total
Cost
As at 01 April 2022
42.23
62.59
104.82
Additions to ROU assets
22.43
-
22.43
De-recognition of ROU assets
(27.55)
-
(27.55)
Balance at 31 March 2023
37.11
62.59
99.70
Accumulated depreciation and impairment
As at 01 April 2022
32.70
1.87
34.57
Depreciation
10.80
0.95
11.75
Eliminated on disposals of assets
(27.48)
-
(27.48)
Balance at 31 March 2023
16.02
2.82
18.84
 H in Crore
Carrying amounts
As at 01 April 2023
80.85
Balance at 31 March 2024
80.40
As at 01 April 2022
70.25
Balance at 31 March 2023
80.85
Lease Expenses Recognised in Statement of Profit and Loss not included in the measurement of lease 
liabilities:
 H in Crore 
Particulars
Year ended 
31 March 2024
Year ended 
31 March 2023
Short-term lease expense
7.38
7.59
Total lease expense
7.38
7.59
Cash Outflow on Leases 
 H in Crore 
Particulars
Year ended 
31 March 2024
Year ended 
31 March 2023
Repayment of lease liabilities  
(includes interest of H 3.68 Crore for year ending 31 March 2024  
and H 3.51 Crore for year ending 31 March 2023)
(16.24)
(14.25)
Total cash outflow on leases
(16.24)
(14.25)
Movement in Lease Liabilities
 H in Crore 
Particulars
Year ended 
31 March 2024
Year ended 
31 March 2023
Opening Lease liabilities
34.20
23.12
Addition during the year
12.15
21.82
Interest accrued during the year
3.68
3.51
Payment of Lease liabilities (including interest)
(16.24)
(14.25)
Closing Lease liabilities
33.79
34.20
Non-Current
23.52
24.95
Current
10.27
9.25
Maturity Analysis of Lease Liabilities ‚Äì Contractual Undiscounted Cash Flows
 H in Crore 
Particulars 
Year ended 
31 March 2024
Year ended 
31 March 2023
Less than 1 year
13.35
11.32
1 to 5 years
18.96
15.92
More than 5 years
93.69
94.10
58. Contingent Liabilities and Commitments
 H in Crore 
Particulars 
As at 
31 March 2024
As at 
31 March 2023
Claims against the Company not acknowledged as debt
i.
Customs Duty on import under Advance License Scheme, pending fulfilment of Exports 
obligation
5.10
2.32
ii.
Disputed Octroi. 
Amount paid under protest and included under ‚ÄúOther Current Assets‚Äù H 0.52 Crore (31 March 
2023 H 0.52 Crore)
0.52
0.52
iii.
Excise duty, Service Tax, VAT and GST disputed by the Company 
3.81
1.10
iv.
Other matter 
0.61
0.61
The Company has two ongoing patent litigations as on 31 March 2024. No liability is expected to arise from 
these litigations.
The Company does not expect the outcome of the matters stated above to have a material adverse impact on the 
Company‚Äôs financial condition, results of operations or cash flows.
Future cash outflows in respect of liability under clause (i) is dependent on terms agreed upon with the parties, in respect 
of clauses (ii) to (iv) is dependent on decisions by relevant authorities of respective disputes, clause (v) financial guarantee.
Code on Social Security, 2020
The new Code on Social Security, 2020 (Code) has been enacted, which could impact the contributions by the Company 
towards Provident Fund and Gratuity. The effective date from which the changes are applicable is yet to be notified 
and the rules are yet to be framed. The Company will complete its evaluation and will give appropriate impact in its 
financial statements in the period in which the Code becomes effective and the related rules are published.
Commitments:
Estimated amounts of contracts remaining to be executed on capital account and not provided for, net of advances 
H 151.35 Crore (31 March 2023 H 86.97 Crore).
59. Related party Disclosure as Required by Ind AS 24 are given below: 
A)	 Relationships where control exist
	
Category I - Directors, Key Management Personnel:
	
Mr. Mannalal B. Agrawal	
	
	
Chairman
	
Mr. Madhusudan B. Agrawal		
	
Executive Vice Chairman
	
Mr. Yogesh M. Agrawal	 	
	
	
Managing Director
	
Mr. Rajesh M. Agrawal	 	
	
	
Joint Managing Director
	
Mr. Chandrakant M Khetan	 	
	
Independent Director
	
Mr. K. H. Viswanathan	
	
	
	
Independent Director
	
Mr. Prabhakar Dalal	
	
	
	
Independent Director
Annual Report 2023-24
176
177
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Consolidated
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
	
Dr. Anjana Grewal		
	
	
	
Independent Director
	
Mr. Arvind K. Agrawal	
	
	
	
Chief Financial Officer
	
Mr. Gaurang C. Shah	
	
	
	
Company Secretary
	
Category II - Enterprise over which persons covered under category I above are able to exercise significant 
control:
	
Gabs Investment Private Limited
	
Seth Bhagwandas Agrawal Charitable Trust
	
Ganga Exports being represented by Mr. Yogesh M. Agrawal, Mr. Rajesh M. Agrawal & Mr. Ravi P. Agrawal
	
Mannalal Agrawal Trust, Trustee ‚Äì Mr. Mannalal B. Agrawal
	
Yogesh Agrawal Trust, Trustee - Mr. Yogesh M. Agrawal
	
Rajesh Agrawal Trust, Trustee - Mr. Rajesh M. Agrawal
	
Ravi Agrawal Trust, Trustee - Mr. Ravi P. Agrawal
	
Aayush Agrawal Trust, Trustee - Mr. Aayush M. Agrawal
	
Ajanta Pharma Limited Group Gratuity Trust
	
Samta Purushottam Agrawal Memorial Foundation
	
Mamta and Madhusudan Agrawal Memorial Foundation
	
Manisha Yogesh Agrawal Foundation
	
Smriti Rajesh Agrawal Foundation
	
Ajanta Foundation
	
A.I. Printers
	
Category III - Others (Close Member of Key Management Personnel):
	
Ms. Tanya Agrawal
	
Mr. Yash Agrawal
	
Mr. Aayush M. Agrawal
	
Mr. Ravi P. Agrawal
B)	
Following Transactions were Carried out with Related Parties
 H in Crore 
Sr. 
No
Particulars
Category
Year ended 
31 March 2024
Year ended 
31 March 2023
1.
Purchase of Packing Material
A.I. Printers
II
0.05
-
2.
Compensation to Key Management & Others
2.1
Short-Term Employee Benefits
Remuneration
Mr. Madhusudan B. Agrawal
I
4.21
3.62
Mr. Yogesh M. Agrawal
I
13.60
12.33
Mr. Rajesh M. Agrawal
I
13.60
12.33
Mr. Arvind Agrawal
I
1.84
1.57
Mr. Gaurang Shah
I
0.97
0.88
Ms. Tanya Agrawal
III
0.11
0.10
Mr. Yash Agrawal
III
0.04
-
Commission to Executive Director
 H in Crore 
Sr. 
No
Particulars
Category
Year ended 
31 March 2024
Year ended 
31 March 2023
Mr. Yogesh M. Agrawal
I
8.00
3.30
Mr. Rajesh M. Agrawal
I
8.00
3.30
Commission and Sitting Fees to Non-Executive Director
Mr. Mannalal B. Agrawal
I
0.08
0.07
Mr. Chandrakant M Khetan
I
0.14
0.12
Mr. K. H. Viswanathan
I
0.11
0.09
Mr. Prabhakar Dalal
I
0.10
0.08
Dr. Anjana Grewal
I
0.09
0.07
2.2
Post-employment benefits
I & III
2.38
0.44
2.3
Share-based payment
Mr. Arvind K. Agrawal
I
0.11
-
Mr. Gaurang C. Shah
I
0.05
-
3.
Dividend Paid
Key Management Personnel
I
0.20
0.03
Others
II & III
425.20
63.21
4.
Corporate Social Responsibility Expense
Seth Bhagwandas Agrawal Charitable Trust
II
-
0.90
Samta Purushottam Agrawal Memorial Foundation
II
5.35
5.86
Ajanta Foundation
II
0.31
0.20
Mamta and Madhusudan Agrawal Memorial Foundation
II
3.75
4.45
Manisha Yogesh Agrawal Foundation
II
0.73
0.25
5.
Contribution made to Group gratuity trust paid to LIC
Ajanta Pharma Limited Group Gratuity Trust
II
11.04
6.85
6.
Buyback of Equity Share
Yogesh M. Agrawal, Trustee Yogesh Agrawal Trust
III
-
48.07
Rajesh M. Agrawal, Trustee Rajesh Agrawal Trust
III
-
48.07
Ravi P. Agrawal, Trustee Ravi Agrawal Trust
III
-
43.28
Aayush M Agrawal, Trustee Aayush Agrawal Trust
III
-
39.34
Ganga Exports being represented by Mr. Yogesh M. Agrawal, Mr. Rajesh 
M. Agrawal & Mr. Ravi P. Agrawal
III
-
10.04
Mr. Arvind K. Agrawal
I
-
0.11
Mr. Gaurang C. Shah (* H 45,600)
I
-
0.00*
Mr. Chandrakant M. Khetan (# H 21,375)
I
-
0.00#
C) Amount Outstanding as on 31 March 2024
 H in Crore 
Sr. 
No
Particulars
Category
As at 
31 March 2024
As at 
31 March 2023
1.
Trade Payables
A.I. Printers
II
0.05
-
2.
Other Advances
Ajanta Foundation
II
0.01
-
Manisha Yogesh Agrawal Foundation
II
0.02
-
3.
Commission Payable to Executive Director
Yogesh M. Agrawal
I
8.00
3.30
Rajesh M. Agrawal
I
8.00
3.30
4.
Commission Payable to Non-Executive Director
Mr. Chandrakant M. Khetan
I
0.05
0.04
Mr. K. H. Viswanathan
I
0.03
0.03
Mr. Prabhakar Dalal
I
0.03
0.03
Annual Report 2023-24
178
179
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Consolidated
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
 H in Crore 
Sr. 
No
Particulars
Category
As at 
31 March 2024
As at 
31 March 2023
Dr. Anjana Grewal
I
0.03
0.03
5.
Buyback of Equity Share
Yogesh M. Agrawal, Trustee Yogesh Agrawal Trust
III
-
48.07
Rajesh M. Agrawal, Trustee Rajesh Agrawal Trust
III
-
48.07
Ravi P. Agrawal, Trustee Ravi Agrawal Trust
III
-
43.28
Aayush M. Agrawal, Trustee Aayush Agrawal Trust
III
-
39.34
Ganga Exports being represented by Mr. Yogesh M. Agrawal, Mr. Rajesh 
M. Agrawal & Mr. Ravi P. Agrawal
III
-
10.04
Mr. Arvind K. Agrawal
I
-
0.11
Mr. Gaurang C. Shah (*H 45,600)
I
-
0.00*
Mr. Chandrakant M. Khetan (#H 21,375)
I
-
0.00#
Based on the internal and external transfer pricing review and validation, the Group believes that all transactions 
with associated enterprises are undertaken on the basis of arm‚Äôs length principle. Outstanding balances at the 
year-end are unsecured and interest free and settlement occurs in cash. Details related to ESOP given to Employees 
of Subsidiary provided in note 52. 
60. Contribution towards Corporate Social Responsibility (‚ÄúCSR‚Äù)
As per Section 135 of the Act, a CSR committee has been formed by the Company. The funds are utilised during the 
year on the activities which are specified in schedule VII of the Act. The utilisation is done by way of direct and indirect 
contribution towards various activities. 
The particulars of CSR expenditure are as follows:
 H in Crore 
Sr.  
No. 
Particulars
Year ended 
31 March 2024
Year ended 
31 March 2023
(a)
Amount required to be spent by the Company during the year
16.43
15.54
(b)
Amount approved by the Board to be spent during the year
16.43
15.54
(c)
Amount spent during the year
(i) 	 Construction/acquisition of asset
-
-
(ii) 	 On purposes other than (i) above
17.32
16.37
(iii) 	Shortfall at the end of the year
-
-
(iv) 	Total of previous year shortfall 
-
-
(v) 	 Nature of CSR activities
Promoting education, Medical 
assistance, Community development 
& promoting of sports
(d)
Details of related party transactions (refer note 59)
10.14
11.66
61. Operating Segments
A.	 Basis for Segmentation
The operations of the Group are limited to one segment viz. Pharmaceutical and related products. The products 
being sold under this segment are of similar nature and comprise of pharmaceutical products only.
The Company‚Äôs Chief Operating Decision Maker (CODM) reviews the internal management reports prepared based 
on an aggregation of financial information for all entities in the Group (adjusted for intercompany eliminations, 
adjustments, etc.) on a periodic basis.
B.	
Geographic Information
The geographic information analyses the Group‚Äôs revenues and non-current assets by the Company‚Äôs country 
of domicile and other countries. In presenting geographic information, segment revenue has been based on the 
selling location in relation to sales to customers and segment assets are based on geographical location of assets.
	
a)	
Revenue from External Customers
 H in Crore 
Year ended 
31 March 2024
Year ended 
31 March 2023
India
1,307.76
1,174.00
Emerging Market
1,641.70
1,515.51
Africa Institution
248.60
190.23
USA
963.53
827.78
4,161.59
3,707.52
	
b)	
Non-Current Assets (other than Financial Instruments and Deferred Tax Assets)
 H in Crore 
Year ended 
31 March 2024
Year ended 
31 March 2023
India
1,766.10
1,745.82
Africa
1.50
1.60
Asia
5.25
4.07
USA
9.03
7.79
1,781.88
1,759.28
62. Remuneration to Auditors of the Company and its Subsidiaries (Excluding GST)
 H in Crore 
Particulars
Year ended 
31 March 2024
Year ended 
31 March 2023
-	
Audit Fees
0.29
0.25
-	
Limited Review
0.32
0.28
-	
For Certification and other matters (including OPE)
0.25
0.22
Local Statutory of Subsidiaries 
-	
For audit
0.33
0.28
-	
For Certification and other matters (including OPE)
0.02
0.04
63. Details of dues to Micro and Small Enterprises as defined under the Micro, Small and Medium 
Enterprises Development Act, 2006
This information has been determined to the extent such parties have been identified on the basis of information 
available with the Company.
 H in Crore 
Particulars
Year ended 
31 March 2024
Year ended 
31 March 2023
i.
The principle amount and the interest due thereon remaining unpaid to any supplier as at 
the end of each accounting year
	
Principle amount due to micro and small enterprises
20.64
37.94
	
Interest due on above
-
-
ii.
The amount of interest paid by the buyer as per Section 16 of the Micro, Small and Medium 
Enterprises Development Act, 2006, along with the amounts of the payment made to the 
supplier beyond the appointed day during each accounting year.
-
-
iii.
The amount of interest due and payable for the period of delay in making payment (which 
have been paid but beyond the appointed day during the year) but without adding the 
interest specified under Micro, Small and Medium Enterprises Development Act, 2006.
-
-
iv.
The amount of interest accrued and remaining unpaid at the end of each accounting year.
-
-
v.
The amount of further interest remaining due and payable even in the succeeding years, until 
such date when the interest dues as above are actually paid to the small enterprise for the 
purpose of disallowance as a deductible expenditure under Section 23 of Micro, Small and 
Medium Enterprises Development Act, 2006.
-
-
Annual Report 2023-24
180
181
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Consolidated
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
The following is ageing schedule for Trade payables for the year ended 31 March 2024:
 H in Crore
Particulars
Unbilled
Not due
Less than 1 year
1-2 years
Total
(i)	 MSME
-
20.64
-
-
20.64
(ii)	 Others
1.19
411.03
30.18
0.16
442.56
(iii)	 Disputed dues ‚Äì MSME
-
-
-
-
-
(iv)	 Disputed dues ‚Äì Others
-
-
-
-
-
Total
1.19
431.67
30.18
0.16
463.20
The following is ageing schedule for Trade payables for the year ended 31 March 2023:
 H in Crore
Particulars
Unbilled
Not due
Less than 1 year
1-2 years
Total
(i)	 MSME
-
37.94
-
-
37.94
(ii)	 Others
11.93
336.97
35.86
0.07
384.83
(iii)	 Disputed dues ‚Äì MSME
-
-
-
-
-
(iv)	 Disputed dues ‚Äì Others
-
-
-
-
-
Total
11.93
374.91
35.86
0.07
422.77
64. Analytical Ratios
Ratio
Numerator
Denominator
As at 
31 March 2024
As at 
31 March 2023
Variance (%)
Current Ratio (in times)
Total current assets
Total current liabilities
3.04
2.48
22.61
Debt - Equity Ratio (in times)
Total Debt (Lease 
liability)
Total equity
0.01
0.01
(5.93)
Debt Service Coverage Ratio 
(in times)
Earnings available for 
debt service
Debt Service
132.41
125.16
5.79
Return on Equity (%)*
Profit for the year less 
preference dividend 
(if any)
Average total equity
23.47%
17.68%
32.76
Inventory Turnover Ratio 
(in times)
Sale of products
Average Inventory
5.06
4.62
9.70
Trade receivables turnover 
ratio (in times)
Revenue from 
Operations
Average Trade 
Receivable
3.65
3.60
1.37
Trade payables turnover ratio 
(in times)
Net Credit Purchases 
(Raw material, packing 
material and purchase 
of traded goods)
Average Trade 
Payables
2.42
2.82
(14.05)
Net capital turnover ratio 
(in times)
Revenue from 
operations
Working Capital (Total 
current assets less 
Total current liabilities)
2.30
2.21
3.78
Net profit ratio (%)
Profit for the year
 Revenue from 
operations
19.39%
15.71%
23.44
Return on capital employed 
(ROCE) (%)*
Profit before tax and 
finance costs
Capital Employed (Net 
worth + Lease liability 
+ Deferred tax liability)
30.21%
21.33%
41.63
Return on investment (%)#
Income generated from 
invested funds
Average invested 
funds
8.87%
6.13%
44.70
* Increase in profit due to combined benefits of reduction in API prices, reduced logistics cost and stabilisation in US price erosion.
# During the year investment made for longer period with higher interest rate.
65. Research and Development Expenditure
A unit of the Company has been recognised by Department of Scientific and Industrial Research (DSIR) as in-house 
research and development unit. The amount of capital and revenue are as below.
 H in Crore 
Particulars
Year ended 
31 March 2024
Year ended 
31 March 2023
Amount in respect to 
	
Capital Expenditure
4.83
18.20
	
Revenue Expenditure
207.73
237.01
Total
212.56
255.21
66 Additional information, as required under Schedule III of the Companies Act, 2013, of enterprises 
consolidated as Subsidiary
As of 31 March 2024
Name of Enterprise
Net assets i.e. total 
assets minus total 
liabilities
Share in profit (loss)
Share in Other 
Comprehensive 
Income
Share in Total 
Comprehensive 
Income
As % of 
total
Amount 
D in Crore
As % of 
total
Amount 
D in Crore
As % of 
total
Amount 
D in Crore
As % of 
total
Amount 
D in Crore
Holding Company
Ajanta Pharma Ltd.
95.7%
 3,413.57 
98.9%
 807.24 
-311.8%
 (2.52)
98.5%
 804.72 
Foreign Subsidiaries
 
 
 
 
 
 
 
 
APML
2.5%
 88.30 
-2.2%
 (17.76)
-66.2%
 (0.53)
-2.2%
 (18.29)
APPI
2.3%
 81.66 
2.3%
 18.99 
236.8%
 1.91 
2.6%
 20.90 
APUI
3.6%
 129.02 
3.0%
 24.89 
211.4%
 1.71 
3.3%
 26.60 
APNL
0.0%
 (0.12)
0.0%
 (0.00)
29.7%
 0.24 
0.0%
 0.24 
Total Eliminations/Adjustments
-3.5%
 (123.74)
-2.1%
 (17.19)
0.0%
 - 
-2.1%
 (17.19)
Exchange difference on 
translation of foreign 
operations
-0.6%
 (21.32)
0.0%
 - 
0.0%
 - 
0.0%
 - 
Total
 
 3,567.36 
 
 816.17 
 
 0.81 
 
 816.98 
As of 31 March 2023
Name of Enterprise
Net assets i.e. total assets 
minus total liabilities
Share in profit (loss)
Share in Other 
Comprehensive Income
Share in Total 
Comprehensive Income
As % of 
total
Amount 
D in Crore
As % of 
total
Amount 
D in Crore
As % of 
total
Amount 
D in Crore
As % of 
total
Amount 
D in Crore
Holding Company
Ajanta Pharma Ltd.
95.8%
 3,246.45 
95.0%
 558.72 
-15.3%
 (2.27)
92.3%
 556.45 
Foreign Subsidiaries
APML
3.1%
 106.59 
-1.2%
 (7.14)
56.2%
 8.34 
0.2%
 1.20 
APPI
2.7%
 89.89 
4.1%
 24.24 
8.9%
 1.32 
4.2%
 25.56 
APUI
3.0%
 101.79 
1.9%
 11.35 
50.2%
 7.46 
3.1%
 18.81 
APNL
0.0%
 (0.36)
0.0%
 (0.09)
0.0%
 0.01 
0.0%
 (0.08)
Total Eliminations/Adjustments
-4.1%
 (138.38)
0.2%
 0.89 
0.0%
 - 
0.1%
 0.89 
Exchange difference on 
translation of foreign 
operations
-0.5%
 (18.00)
0.0%
 - 
0.0%
 - 
0.0%
 - 
Total
 3,387.99 
 587.98 
 14.85 
 602.83 
Refer Annexure ‚ÄúB‚Äù of Director‚Äôs Report for salient features of the financial statements of subsidiaries.
Annual Report 2023-24
182
183
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Consolidated
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
67. Donation
Donation includes political contribution to Bharatiya Janata Party of H 5.00 Crore in year ending 31 March 2024 and 
H 4.00 Crore in year ending 31 March 2023 (through electoral bond).
68. Asset Held for Sale
a)	
During the year, the Parent Company has entered into agreement for sale of its one of the freehold land assets, 
for which H 0.51 Crore advance has been received and recognised as Liability against Assets held for sale, subject 
to fulfilment of certain condition. Transaction is expected to be completed in the next year the said freehold land 
assets aggregating to H 8.85 Crore has been reclassified from Property, plant and equipment to assets held for sale.
b)	
In the previous year, the Parent Company has entered into agreement for sale of its investment properties and 
the said properties aggregating to H 7.92 Crore has been reclassified from investment properties to assets held 
for sale.
c)	
In the previous year, Ajanta Pharma Mauritius Limited (APML), a wholly-owned subsidiary, has entered into an 
arrangement for sale of its Leasehold improvements, Plant & Machinery, Furniture & Fixtures, Office equipment at 
BPML Building, Royal Road, Goodlands, Mauritius for a value of MUR 5 million, and the said properties has been 
reclassified as asset held for sale.
d)	
Rental income recognised in profit or loss for investment properties aggregates to H 0.01 Crore (31 March 2023 
H 0.35 Crore). Maintenance and other expenses aggregating to H 0.01 Crore (31 March 2023 H 0.04 Crore).
69. Income Tax
Amount recognised in statement of profit and loss
a)	 Current Tax
 H in Crore 
Particulars
Year ended 
31 March 2024
Year ended 
31 March 2023
Current tax on profit for the year
298.22
175.58
Adjustment for current tax of earlier periods*
23.84
21.66
Total Current Tax expenses
322.06
197.24
Deferred tax expense/(benefit)
Origination and reversal of timing difference 
(27.28)
(36.99)
Adjustment for earlier periods
-
-
MAT Credit Entitlement
2.98
(2.98)
Total Deferred Tax expenses
(24.30)
(39.97)
Total income tax recognised in the income statement
297.76
157.27
* Tax expenses for earlier periods amounting to H 23.84 Crore (31 March 2023 tax credit H 21.66 Crore) comprises short tax provision for 
FY 2022-23 and reversal of certain deduction which were non-deductible based on subsequent judicial rulings. 
b) 
Reconciliation of Effective Tax Rate
	
The following is a reconciliation of the Group‚Äôs effective tax rate
 H in Crore 
Particulars
Year ended 
31 March 2024
Year ended 
31 March 2023
Accounting profit before income taxes
1,113.93
745.25
Enacted tax rate in India (%)
34.94%
34.94%
Computed expected tax (benefit)/expenses
389.26
260.42
Tax effect due to non-taxable income for India tax purpose
(5.93)
(15.87)
Overseas taxes
14.00
11.15
Effect of non-deductible expenses
42.18
15.19
 H in Crore 
Particulars
Year ended 
31 March 2024
Year ended 
31 March 2023
Temporary difference which is reversed during the Tax Holiday period
(0.49)
(1.76)
Tax effect which is chargeable at different rate
-
(9.62)
Other deductible expenses
(18.96)
(13.05)
Adjustment for current tax of prior periods
23.84
21.66
MAT Credit entitlement
2.98
(2.98)
Deduction for Tax Holiday Unit
(149.12)
(107.87)
Income tax expenses
297.76
157.27
Effective tax rate
26.73%
21.10%
c)	
Recognised Deferred Asset and Liability
H in Crore
Particulars
Deferred tax asset 
Deferred tax liabilities
Net deferred tax asset/
(liabilities)
As at 
31 March 
2024
As at 
31 March 
 2023
As at 
31 March 
2024
As at 
31 March 
 2023
As at 
31 March 
2024
As at 
31 March 
 2023
Property, Plant and equipment
-
-
143.50
132.02
(143.50)
(132.02)
Gain on Investment at FVTPL
0.91
0.80
-
-
0.91
0.80
Leave Encashment
11.56
9.48
-
-
11.56
9.48
Provision for return of Expired 
Goods
16.70
16.70
-
-
16.70
16.70
Diminution in the value of 
investments
2.76
0.48
-
-
2.76
0.48
MAT Credit Entitlement
-
2.98
-
-
-
2.98
Provision for Loss Allowance
3.08
3.86
-
-
3.08
3.86
Temporary difference related to 
subsidiaries
27.26
21.30
-
-
27.26
21.30
Others
107.18
75.47
-
-
107.18
75.47
Net deferred tax asset/(liabilities)
169.45
131.07
143.50
132.02
25.95
(0.95)
d) Movement in Deferred Tax Balances 31 March 2024
H in Crore
Particulars
Net balance 
as at 01 April 
2023
Recognised 
in Profit and 
loss
Net
Deferred tax 
asset
Deferred tax 
liabilities
Property, Plant and equipment
 (132.02)
 (11.48)
 (143.50)
 - 
 (143.50)
Gain on Investment at FVTPL
 0.80 
 0.10 
 0.91 
 0.91 
 - 
Leave Encashment
 9.48 
 2.08 
 11.56 
 11.56 
 - 
Provision for return of Expired Goods
 16.70 
 0.00 
 16.70 
 16.70 
 - 
Diminution in the value of investments
 0.48 
 2.28 
 2.76 
 2.76 
 - 
MAT Credit Entitlement
 2.98 
 (2.98)
 - 
 - 
 - 
Provision for Loss Allowance
 3.86 
 (0.78)
 3.08 
 3.08 
 - 
Temporary difference related to subsidiaries
 21.30 
 5.95 
 27.26 
 27.26 
 - 
Others
 75.47 
31.71 
107.18 
107.18
 - 
Net deferred tax asset/(liabilities)
 (0.94)
26.90 
25.95
169.45 
 (143.50)
Annual Report 2023-24
184
185
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Consolidated
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
Notes to the Consolidated Financial Statements
for the year ended 31 March 2024
 
Movement in Deferred Tax Balances 31 March 2023
H in Crore
Particulars
Net balance 
as at 01 April 
2022
Recognised in 
Profit and loss
Net
Deferred tax 
asset
Deferred tax 
liabilities
Property, Plant and equipment
(126.89)
(5.13)
(132.02)
-
(132.02)
Gain on Investment at FVTPL
(3.13)
3.93
0.80
0.80
-
Leave Encashment
8.34
1.14
9.48
9.48
-
Provision for return of Expired Goods
14.19
2.51
16.70
16.70
-
Diminution in the value of investments
0.48
-
0.48
0.48
-
MAT Credit Entitlement
-
2.98
2.98
2.98
-
Provision for Loss Allowance
5.15
(1.29)
3.86
3.86
-
Temporary difference related to subsidiaries
26.29
(4.99)
21.30
21.30
-
Others
29.26
46.21
75.47
75.47
-
Net deferred tax asset/(liabilities)
(46.31)
45.36
(0.95)
131.07
(132.02)
The charge relating to temporary differences during the year ended 31 March 2024 are primarily on account of 
property plant and equipment and gain on investment at FVTPL partially offset by provision for expired goods, 
provision for loss allowance, compensated absences, MAT credit entitlement. The credit to temporary differences 
during the year ended 31 March 2023 are primarily on account of property plant and equipment and gain on 
investment at FVTPL partially offset by provision for expired goods, provision for loss allowance, compensated 
absences, MAT credit entitlement. Current tax assets and current tax liabilities and the deferred tax assets and 
deferred tax liabilities relate to income taxes levied by the same authority.
70. Additional Disclosures Required by Schedule III (amendments dated 24 March 2021) to the 
Companies Act, 2013
 
A. Relationship with Struck Off Company
	
	
There is no such transaction with the companies struck off under Companies Act, 2013 or Companies Act,1956.
	
B.	
Undisclosed Income
	
There is no income surrendered or disclosed as income during the current or previous year in the tax assessments 
under the Income Tax Act, 1961, that has not been recorded in the books of account.
	
C.	 Utilisation of Borrowings Availed from Banks
	
The borrowings obtained by The Group from banks have been applied for the purposes for which such loans 
were taken.
 
D. Details of Benami Property Held
	
No proceedings have been initiated on or are pending against The Group for holding benami property under 
the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and Rules made thereunder.
 
E. 
Wilful Defaulter
	
The Group has not been declared wilful defaulter by any bank or financial institution or government or any 
government authority.
	
F.	
Compliance with Number of Layers of Companies
	
The Group has complied with the number of layers prescribed under the Companies Act, 2013.
	
G.	 Compliance with Approved Scheme(s) of Arrangements
	
The Group has not entered into any scheme of arrangement which has an accounting impact on current or 
previous financial year.
 
H. Details of Crypto Currency or Virtual Currency
	
The Group has not traded or invested in crypto currency or virtual currency during the current or previous year.
	
I.	
Utilisation of Borrowed Funds and Share Premium
	
i.	
The Group has not advanced or loaned or invested funds to any other person(s) or entity(ies), including 
foreign entities (Intermediaries) with the understanding that the Intermediary shall:
	
	
a)	
directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever 
by or on behalf of the Group (Ultimate Beneficiaries) or
	
	
b)	
provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.
	
ii.	
The Group has not received any fund from any person(s) or entity(ies), including foreign entities (Funding 
Party) with the understanding (whether recorded in writing or otherwise) that the Group shall:
	
	
a)	
directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever 
by or on behalf of the Funding Party (Ultimate Beneficiaries) or
	
	
b)	
provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
In terms of our report attached.
For B S R & Co. LLP
For and on behalf of Board of Directors of 
Chartered Accountants
Ajanta Pharma Limited
Firm's Registration No.: 101248W/W-100022
Sreeja Marar
Yogesh M. Agrawal
Rajesh M. Agrawal
Partner 
Managing Director
Joint Managing Director
Membership No.: 111410
DIN: 00073673
DIN: 00302467
Arvind K. Agrawal
Gaurang C. Shah
Place: Mumbai
Chief Financial Officer
Company Secretary
Date: 02 May 2024
FCS No.: 6696
Annual Report 2023-24
186
187
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Standalone
Independent Auditor‚Äôs Report
To the Members of 
Ajanta Pharma Limited
REPORT ON THE AUDIT OF THE STANDALONE 
FINANCIAL STATEMENTS
Opinion
We have audited the standalone financial statements of 
Ajanta Pharma Limited (the ‚ÄúCompany‚Äù) which comprise 
the standalone balance sheet as at 31 March 2024, and 
the standalone statement of profit and loss (including 
other comprehensive income), standalone statement of 
changes in equity and standalone statement of cash flows 
for the year then ended, and notes to the standalone 
financial statements, including material accounting 
policies and other explanatory information
In our opinion and to the best of our information and 
according to the explanations given to us, the aforesaid 
standalone financial statements give the information 
required by the Companies Act, 2013 (‚ÄúAct‚Äù) in the manner 
so required and give a true and fair view in conformity with 
the accounting principles generally accepted in India, of 
the state of affairs of the Company as at 31 March 2024, 
and its profit and other comprehensive loss, changes in 
equity and its cash flows for the year ended on that date.
Basis for Opinion
We conducted our audit in accordance with the 
Standards on Auditing (SAs) specified under Section 
143(10) of the Act. Our responsibilities under those SAs 
are further described in the Auditor‚Äôs Responsibilities for 
the Audit of the Standalone Financial Statements section 
of our report. We are independent of the Company in 
accordance with the Code of Ethics issued by the Institute 
of Chartered Accountants of India together with the 
ethical requirements that are relevant to our audit of the 
standalone financial statements under the provisions of 
the Act and the Rules thereunder, and we have fulfilled 
our other ethical responsibilities in accordance with these 
requirements and the Code of Ethics. We believe that 
the audit evidence we have obtained is sufficient and 
appropriate to provide a basis for our opinion on the 
standalone financial statements.
Key Audit Matter(s)
Key audit matters are those matters that, in our professional 
judgment, were of most significance in our audit of the 
standalone financial statements of the current period. 
These matters were addressed in the context of our audit 
of the standalone financial statements as a whole, and 
in forming our opinion thereon, and we do not provide a 
separate opinion on these matters.
Revenue Recognition
See Note 6.10 of accounting policies and note 36 to standalone financial statements
The key audit matter
	
How the matter was addressed in our audit
As stated in Note 6.10 to the standalone financial statements, 
revenue from sale of products is recognised at a point in time when 
control of the products is transferred to the customer. Revenue 
from the sale of goods is measured based on the transaction price 
adjusted for discounts and rebates, which is specified in contract 
with customers.
The actual point in time when revenue is recognised varies 
depending on the specific terms and conditions of the sales 
contracts entered into with customers. The Company has a large 
number of customers operating in various geographies and sales 
contracts with these customers have distinct terms and conditions 
relating to the recognition of revenue and right of return.
Revenue is a key performance indicator for the Company. 
Accordingly, there could be pressure to meet the expectations of 
investors / other stakeholders and / or to meet revenue targets 
stipulated in performance incentive schemes for a reporting 
period. We have considered that there is a risk of fraud related to 
revenue being overstated by recognition in the wrong period or 
before control has passed to a valid customer.
Accordingly, we identified recognition of revenue from sale of 
products during the year and at the period end as a key audit 
matter.
Our procedures in respect of recognition of revenue included the 
following:
‚Ä¢	
Verifying the accounting policies adopted by the Company 
with respect to recognition of revenue by comparing with the 
applicable accounting standards.
‚Ä¢	
Testing 
the 
design, 
implementation 
and 
operating 
effectiveness of the Company‚Äôs manual and automated 
controls designed to ensure recognition of valid revenue 
transactions in the correct period.
‚Ä¢	
Performing substantive testing of selected samples of revenue 
transactions recorded during the year as well as at year-
end. We used statistical sampling and verified contractual 
terms of sales invoices / contracts, shipping documents and 
acknowledged delivery receipts for those transactions.
‚Ä¢	
Analysing and testing high risk journal entries that contain 
unusual combinations of credit to revenue with no associated 
debit to cash, debtors or another revenue account.
Other Information
The Company‚Äôs Management and Board of Directors are 
responsible for the other information. The other information 
comprises the information included in the Company‚Äôs 
annual report, but does not include the financial 
statements and auditor‚Äôs report thereon.
Our opinion on the standalone financial statements does 
not cover the other information and we do not express any 
form of assurance conclusion thereon.
In connection with our audit of the standalone financial 
statements, our responsibility is to read the other 
information and, in doing so, consider whether the other 
information is materially inconsistent with the standalone 
financial statements or our knowledge obtained in the 
audit or otherwise appears to be materially misstated. If, 
based on the work we have performed, we conclude that 
there is a material misstatement of this other information, 
we are required to report that fact. We have nothing to 
report in this regard.
Management‚Äôs 
and 
Board 
of 
Directors 
Responsibilities for the Standalone Financial 
Statements
The Company‚Äôs Management and Board of Directors are 
responsible for the matters stated in Section 134(5) of the 
Act with respect to the preparation of these standalone 
financial statements that give a true and fair view of the 
state of affairs, profit/ loss and other comprehensive 
income, changes in equity and cash flows of the Company 
in accordance with the accounting principles generally 
accepted in India, including the Indian Accounting 
Standards (Ind AS) specified under Section 133 of the Act. 
This responsibility also includes maintenance of adequate 
accounting records in accordance with the provisions of 
the Act for safeguarding of the assets of the Company 
and for preventing and detecting frauds and other 
irregularities; selection and application of appropriate 
accounting policies; making judgments and estimates that 
are reasonable and prudent; and design, implementation 
and maintenance of adequate internal financial controls, 
that were operating effectively for ensuring the accuracy 
and completeness of the accounting records, relevant 
to the preparation and presentation of the standalone 
financial statements that give a true and fair view and 
are free from material misstatement, whether due to fraud 
or error.
In preparing the standalone financial statements, the 
Management and Board of Directors are responsible for 
assessing the Company‚Äôs ability to continue as a going 
concern, disclosing, as applicable, matters related to 
going concern and using the going concern basis of 
accounting unless the Board of Directors either intends to 
liquidate the Company or to cease operations, or has no 
realistic alternative but to do so.
The Board of Directors is also responsible for overseeing 
the Company‚Äôs financial reporting process.
Auditor‚Äôs Responsibilities for the Audit of the 
Standalone Financial Statements
Our objectives are to obtain reasonable assurance about 
whether the standalone financial statements as a whole 
are free from material misstatement, whether due to fraud 
or error, and to issue an auditor‚Äôs report that includes 
our opinion. Reasonable assurance is a high level of 
assurance, but is not a guarantee that an audit conducted 
in accordance with SAs will always detect a material 
misstatement when it exists. Misstatements can arise from 
fraud or error and are considered material if, individually 
or in the aggregate, they could reasonably be expected 
to influence the economic decisions of users taken on the 
basis of these standalone financial statements.
As part of an audit in accordance with SAs, we exercise 
professional judgment and maintain professional 
skepticism throughout the audit. We also:
‚Ä¢	 Identify and assess the risks of material misstatement 
of the standalone financial statements, whether due 
to fraud or error, design and perform audit procedures 
responsive to those risks, and obtain audit evidence 
that is sufficient and appropriate to provide a basis 
for our opinion. The risk of not detecting a material 
misstatement resulting from fraud is higher than for 
one resulting from error, as fraud may involve collusion, 
forgery, intentional omissions, misrepresentations, or the 
override of internal control.
‚Ä¢	 Obtain an understanding of internal control relevant to 
the audit in order to design audit procedures that are 
appropriate in the circumstances. Under Section 143(3)
(i) of the Act, we are also responsible for expressing 
our opinion on whether the company has adequate 
internal financial controls with reference to financial 
statements in place and the operating effectiveness 
of such controls.
‚Ä¢	 Evaluate the appropriateness of accounting policies 
used and the reasonableness of accounting estimates 
and related disclosures made by the Management and 
Board of Directors.
‚Ä¢	 Conclude on the appropriateness of the Management 
and Board of Directors use of the going concern basis 
of accounting in preparation of standalone financial 
statements and, based on the audit evidence obtained, 
whether a material uncertainty exists related to events 
or conditions that may cast significant doubt on the 
Annual Report 2023-24
188
189
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Standalone
Company‚Äôs ability to continue as a going concern. If 
we conclude that a material uncertainty exists, we 
are required to draw attention in our auditor‚Äôs report 
to the related disclosures in the standalone financial 
statements or, if such disclosures are inadequate, to 
modify our opinion. Our conclusions are based on the 
audit evidence obtained up to the date of our auditor‚Äôs 
report. However, future events or conditions may cause 
the Company to cease to continue as a going concern.
‚Ä¢	 Evaluate the overall presentation, structure and content 
of the standalone financial statements, including the 
disclosures, and whether the standalone financial 
statements represent the underlying transactions and 
events in a manner that achieves fair presentation.
We communicate with those charged with governance 
regarding, among other matters, the planned scope and 
timing of the audit and significant audit findings, including 
any significant deficiencies in internal control that we 
identify during our audit.
We also provide those charged with governance with 
a statement that we have complied with relevant 
ethical requirements regarding independence, and 
to communicate with them all relationships and other 
matters that may reasonably be thought to bear on our 
independence, and where applicable, related safeguards.
From the matters communicated with those charged with 
governance, we determine those matters that were of 
most significance in the audit of the standalone financial 
statements of the current period and are therefore the key 
audit matters. We describe these matters in our auditor‚Äôs 
report unless law or regulation precludes public disclosure 
about the matter or when, in extremely rare circumstances, 
we determine that a matter should not be communicated 
in our report because the adverse consequences of doing 
so would reasonably be expected to outweigh the public 
interest benefits of such communication.
Report on Other Legal and Regulatory Requirements
1.	
As required by the Companies (Auditor‚Äôs Report) 
Order, 2020 (‚Äúthe Order‚Äù) issued by the Central 
Government of India in terms of Section 143(11) of 
the Act, we give in the ‚ÄúAnnexure A‚Äù a statement on 
the matters specified in paragraphs 3 and 4 of the 
Order, to the extent applicable.
2 A. 	As required by Section 143(3) of the Act, we report that:
	
a.	
We have sought and obtained all the information 
and explanations which to the best of our 
knowledge and belief were necessary for the 
purposes of our audit.
	
b.	
In our opinion, proper books of account as 
required by law have been kept by the Company 
so far as it appears from our examination of 
those books except for the matters stated in 
the paragraph 2B(f) below on reporting under 
Rule 11(g) of the Companies (Audit and Auditors) 
Rules, 2014.
	
c.	
The standalone balance sheet, the standalone 
statement of profit and loss (including other 
comprehensive income), the standalone 
statement of changes in equity and the 
standalone statement of cash flows dealt with 
by this Report are in agreement with the books 
of account.
	
d.	
In our opinion, the aforesaid standalone financial 
statements comply with the Ind AS specified 
under Section 133 of the Act.
	
e.	
On the basis of the written representations 
received from the directors as on 31 March 2024 
taken on record by the Board of Directors, none 
of the directors is disqualified as on 31 March 
2024 from being appointed as a director in terms 
of Section 164(2) of the Act.
	
f.	
the modification relating to the maintenance of 
accounts and other matters connected therewith 
are as stated in the paragraph 2A(b) above on 
reporting under Section 143(3)(b) and paragraph 
[2B(f)] below on reporting under Rule 11(g) of the 
Companies (Audit and Auditors) Rules, 2014.
	
g.	
With respect to the adequacy of the internal 
financial controls with reference to financial 
statements of the Company and the operating 
effectiveness of such controls, refer to our 
separate Report in ‚ÄúAnnexure B‚Äù.
B.	
With respect to the other matters to be included in 
the Auditor‚Äôs Report in accordance with Rule 11 of 
the Companies (Audit and Auditors) Rules, 2014, in 
our opinion and to the best of our information and 
according to the explanations given to us:
	
a.	
The Company has disclosed the impact of 
pending litigations as at 31 March 2024 on its 
financial position in its standalone financial 
statements - Refer Note 53 to the standalone 
financial statements.
	
b.	
The Company did not have any long-term 
contracts including derivative contracts for which 
there were any material foreseeable losses.
Independent Auditor‚Äôs Report
	
c.	
There has been no delay in transferring amounts, 
required to be transferred, to the Investor 
Education and Protection Fund by the Company.
	
d 	
(i) 	
The management has represented 
that, to the best of its knowledge and 
belief, as disclosed in the Note 61(A) to 
the standalone financial statements, no 
funds have been advanced or loaned 
or invested (either from borrowed funds 
or share premium or any other sources 
or kind of funds) by the Company to or in 
any other person(s) or entity(ies), including 
foreign entities (‚ÄúIntermediaries‚Äù), with the 
understanding, whether recorded in writing 
or otherwise, that the Intermediary shall 
directly or indirectly lend or invest in other 
persons or entities identified in any manner 
whatsoever by or on behalf of the Company 
(‚ÄúUltimate Beneficiaries‚Äù) or provide any 
guarantee, security or the like on behalf of 
the Ultimate Beneficiaries.
	
	
(ii)	
The management has represented that, 
to the best of its knowledge and belief, 
as disclosed in the Note 61(B) to the 
standalone financial statements, no funds 
have been received by the Company 
from any person(s) or entity(ies), including 
foreign entities (‚ÄúFunding Parties‚Äù), with 
the understanding, whether recorded in 
writing or otherwise, that the Company shall 
directly or indirectly, lend or invest in other 
persons or entities identified in any manner 
whatsoever by or on behalf of the Funding 
Parties (‚ÄúUltimate Beneficiaries‚Äù) or provide 
any guarantee, security or the like on behalf 
of the Ultimate Beneficiaries.
	
	
(iii)	
Based on the audit procedures performed 
that have been considered reasonable and 
appropriate in the circumstances, nothing 
has come to our notice that has caused 
us to believe that the representations 
under sub-clause (i) and (ii) of Rule 11(e), as 
provided under (i) and (ii) above, contain any 
material misstatement.
	
e.	
The interim dividend declared and paid by the 
Company during the year and until the date of 
this audit report is in accordance with Section 
123 of the Act.
	
f.	
Based on our examination which included test 
checks, the Company has used an accounting 
software for maintaining its books of account 
which has a feature of audit trail (edit log) 
facility and the same has operated throughout 
the year for all relevant transactions recorded in 
the software except that the audit trail was not 
enabled (i) at the database level to log any direct 
data changes; (ii) at the application level for two 
fields relating to production and inventory and 
(iii) for certain changes at the application level 
which were performed by users having privileged 
access rights. Further, where audit trail (edit log) 
facility was enabled and operated throughout 
the year, we did not come across any instance 
of audit trail feature being tampered with.
C.	
With respect to the matter to be included in the 
Auditor‚Äôs Report under Section 197(16) of the Act:
	
In our opinion and according to the information and 
explanations given to us, the remuneration paid by 
the Company to its directors during the current year 
is in accordance with the provisions of Section 197 
of the Act. The remuneration paid to any director is 
not in excess of the limit laid down under Section 197 
of the Act. The Ministry of Corporate Affairs has not 
prescribed other details under Section 197(16) of the 
Act which are required to be commented upon by us.
For B S R & Co. LLP
Chartered Accountants
Firm‚Äôs Registration No.: 101248W/W-100022
Sreeja Marar
Partner
Place: Mumbai	
 Membership No.: 111410
Date: 02 May 2024	
 ICAI UDIN: 24111410BKGQOA9656
Annual Report 2023-24
190
191
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Standalone
Annexure A to the Independent Auditor‚Äôs Report 
on the Standalone Financial Statements of Ajanta Pharma Limited for the year ended 31 March 2024
(Referred to in paragraph 1 under ‚ÄòReport on Other Legal and Regulatory Requirements‚Äô section of our report of even 
date)
(i)	
(a)	
(A)	 The Company has maintained proper 
records showing full particulars, including 
quantitative details and situation of 
Property, Plant and Equipment.
	
	
(B)	 The Company has maintained proper 
records showing full particulars of 
intangible assets.
	
(b)	
According to the information and explanations 
given to us and on the basis of our examination 
of the records of the Company, the Company 
has a regular programme of physical verification 
of its Property, Plant and Equipment by which 
all property, plant and equipment are verified 
in a phased manner over a period of 3 years. 
In accordance with this programme, certain 
property, plant and equipment were verified 
during the year. In our opinion, this periodicity of 
physical verification is reasonable having regard 
to the size of the Company and the nature of its 
assets. No material discrepancies were noticed 
on such verification.
	
(c)	
According to the information and explanations 
given to us and on the basis of our examination 
of the records of the Company, the title deeds 
of immovable properties (other than immovable 
properties where the Company is the lessee 
and the leases agreements are duly executed in 
favour of the lessee) disclosed in the standalone 
financial statements are held in the name of 
the Company.
	
(d)	
According to the information and explanations 
given to us and on the basis of our examination 
of the records of the Company, the Company has 
not revalued its Property, Plant and Equipment 
(including Right of Use assets) or intangible 
assets or both during the year.
	
(e)	
According to the information and explanations 
given to us and on the basis of our examination 
of the records of the Company, there are no 
proceedings initiated or pending against the 
Company for holding any benami property under 
the Prohibition of Benami Property Transactions 
Act, 1988 and rules made thereunder.
(ii) 	 (a)	
The inventory, except goods-in-transit and 
stocks lying with third parties, has been physically 
verified by the management during the year.For 
stocks lying with third parties at the year-end, 
written confirmations have been obtained 
and for goods-in-transit subsequent evidence 
of receipts has been linked with inventory 
records. In our opinion, the frequency of such 
verification is reasonable and procedures and 
coverage as followed by management were 
appropriate. No discrepancies were noticed on 
verification between the physical stocks and the 
book records that were more than 10% in the 
aggregate of each class of inventory.
	
(b)	
According to the information and explanations 
given to us and on the basis of our examination 
of the records of the Company, the Company 
has been sanctioned working capital limits in 
excess of five crore rupees, in aggregate, from 
banks or financial institutions on the basis of 
security of current assets. In our opinion, the 
quarterly returns or statements filed by the 
Company with such banks or financial institutions 
are in agreement with the books of account of 
the Company.
(iii)	
According to the information and explanations given 
to us and on the basis of our examination of the 
records of the Company, the Company has not made 
any investments, provided guarantee or security or 
granted any loans or advances in the nature of loans, 
secured or unsecured, to companies, firms, limited 
liability partnerships or any other parties during the 
year other than loan to employees. The Company has 
granted employee loans during the year. Accordingly, 
we have reported the provisions of clauses 3(iii)(a) to 
3(iii)(f) of the Order to the extent applicable to the 
Company with respect to employee loans.
	
(a)	
Based on the audit procedures carried on by 
us and as per the information and explanations 
given to us the Company has provided employee 
loans as below:
Particulars
Loans (K in Crore)
Aggregate amount during the year 
Others
 1.22
Balance outstanding as at 
balance sheet date  
Others
 2.19
(b)	
According to the information and explanations 
given to us and based on the audit procedures 
conducted by us, in our opinion the terms and 
conditions of the grant of loans during the year 
are prima facie, not prejudicial to the interest of 
the Company.
(c)	
According to the information and explanations 
given to us and on the basis of our examination 
of the records of the Company, in the case of 
loans given, in our opinion the repayment of 
principal and payment of interest has been 
stipulated and the repayments or receipts have 
been regular. Further, the Company has not 
given any advance in the nature of loan to any 
party during the year.
(d)	
According to the information and explanations 
given to us and on the basis of our examination of 
the records of the Company, there is no overdue 
amount for more than ninety days in respect of 
loans given. Further, the Company has not given 
any advances in the nature of loans to any party 
during the year.
(e)	
According to the information and explanations 
given to us and on the basis of our examination 
of the records of the Company, there is no loan 
or advance in the nature of loan granted falling 
due during the year, which has been renewed 
or extended or fresh loans granted to settle the 
overdues of existing loans given to same parties.
(f)	
According to the information and explanations 
given to us and on the basis of our examination 
of the records of the Company, the Company has 
not granted any loans or advances in the nature 
of loans either repayable on demand or without 
specifying any terms or period of repayment.
(iv)	 According to the information and explanations given 
to us and on the basis of our examination of the 
records of the Company, the Company has not given 
any loans, or provided any guarantee or security as 
specified under Section 185 and 186 of the Companies 
Act, 2013 (‚Äúthe Act‚Äù). In respect of the investments 
made by the Company, in our opinion the provisions 
of Section 186 of the Act have been complied with
(v)	
The Company has not accepted any deposits or 
amounts which are deemed to be deposits from 
the public. Accordingly, clause 3(v) of the Order is 
not applicable.
(vi)	 We have broadly reviewed the books of accounts 
maintained by the Company pursuant to the 
rules prescribed by the Central Government for 
maintenance of cost records under Section 148(1) 
of the Act in respect of its manufactured goods and 
are of the opinion that prima facie, the prescribed 
accounts and records have been made and 
maintained. However, we have not carried out a 
detailed examination of the records with a view to 
determine whether these are accurate or complete.
(vii)	 (a)	
The Company does not have liability in respect of 
Service tax, Duty of excise, Sales tax and Value added 
tax during the year since effective 01 July 2017, these 
statutory dues has been subsumed into GST.
	
	
According to the information and explanations 
given to us and on the basis of our examination 
of the records of the Company, in our opinion 
amounts deducted / accrued in the books of 
account in respect of undisputed statutory 
dues including Goods and Service Tax, Provident 
Fund, Employees State Insurance, Income-Tax, 
Duty of Customs or Cess or other statutory dues 
have been regularly deposited by the Company 
with the appropriate authorities.
	
	
According to the information and explanations 
given to us and on the basis of our examination 
of the records of the Company, no undisputed 
amounts payable in respect of Goods and 
Service Tax, Provident Fund, Employees State 
Insurance, Income-Tax, Duty of Customs or Cess 
or other statutory dues were in arrears as at 31 
March 2024 for a period of more than six months 
from the date they became payable.
	
(b)	
According to the information and explanations given to us and on the basis of our examination of the records 
of the Company, statutory dues relating to Goods and Service Tax, Provident Fund, Employees State Insurance, 
Income-Tax, Duty of Customs or Cess or other statutory dues which have not been deposited on account of 
any dispute are as follows:
H in Crore
Name of the statute
Nature of 
the dues
Amount 
demanded
Amount not 
deposited 
under 
dispute
Amount 
deposited 
under 
dispute
Period to which 
the amount 
relates
Forum where dispute is 
pending
Central Goods & Service Tax 
Act, 2017
GST
0.26
0.25
0.01
FY 2017-18
CESTAT, Hyderabad
Central Goods & Service Tax 
Act, 2017
GST
0.01
0.01
-
FY 2017-18
CESTAT, Palghar
Central Excise Act 1944
Excise 
duty 
0.20
0.20
-
FY 2010-11 to 
FY 2015-16
CESTAT, Bengaluru
Annual Report 2023-24
192
193
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Standalone
H in Crore
Name of the statute
Nature of 
the dues
Amount 
demanded
Amount not 
deposited 
under 
dispute
Amount 
deposited 
under 
dispute
Period to which 
the amount 
relates
Forum where dispute is 
pending
Central Excise Act 1944
Excise 
duty 
0.05
0.05
-
FY 2006-07 to 
FY 2010-11
CESTAT, Mumbai
Central Goods & Service Tax 
Act, 2017
GST
0.06
0.03
0.03
F.Y. 2017-18
CESTAT (Odisha)
Central Goods & Service Tax 
Act, 2017
GST
0.29
0.28
0.01
F.Y. 2017-18
Joint Commissioner 
Appeals (UP)
Central Goods & Service Tax 
Act, 2017
GST
0.07
0.07
-
FY 2017-18
Joint Commissioner 
Appeals (Bihar)
Central Goods & Service Tax 
Act, 2017
GST
0.13
0.13
-
FY 2018-19
Joint Commissioner 
Appeals (Bihar)
Gujarat VAT Act
CST
0.02
0.02
-
FY 2017-18
Assistant Commissioner, 
Ahmedabad
Central Goods & Service Tax 
Act, 2017
GST
0.07
0.07
-
FY 2017-18
Joint Commissioner 
Appeals - (Kerala)
Central Goods & Service Tax 
Act, 2017
GST
0.06
0.06
-
FY 2018-19
Joint Commissioner 
Appeals - Bengaluru
Central Goods & Service Tax 
Act, 2017
GST
2.59
2.59
-
FY 2017-18
Additional 
Commissioner of State 
Tax, Appeal (AP)
(viii)	 According to the information and explanations 
given to us and on the basis of our examination of 
the records of the Company, the Company has not 
surrendered or disclosed any transactions, previously 
unrecorded as income in the books of account, in the 
tax assessments under the Income Tax Act, 1961 as 
income during the year.
(ix)	 (a)	
According to the information and explanations 
given to us and on the basis of our examination 
of the records of the Company, the Company 
has not defaulted in repayment of loans and 
borrowing or in the payment of interest thereon 
to any lender.
	
(b)	
According to the information and explanations 
given to us and on the basis of our examination 
of the records of the Company, the Company 
has not been declared a wilful defaulter by any 
bank or financial institution or government or 
government authority.
	
(c)	
According to the information and explanations 
given to us by the management, the Company 
has not obtained any term loans during the 
year. Accordingly, clause 3(ix)(c) of the Order is 
not applicable.
	
(d)	
According to the information and explanations 
given to us and on an overall examination of the 
balance sheet of the Company, we report that 
no funds raised on short-term basis have been 
used for long-term purposes by the Company.
	
(e)	
According to the information and explanations 
given to us and on an overall examination of 
the standalone financial statements of the 
Company, we report that the Company has 
not taken any funds from any entity or person 
on account of or to meet the obligations of 
its subsidiaries, associates or joint ventures as 
defined under the Act.
	
(f)	
According to the information and explanations 
given to us and procedures performed by us, we 
report that the Company has not raised loans 
during the year on the pledge of securities held 
in its subsidiaries, joint ventures or associate 
companies (as defined under the Act).
(x)	
(a)	
The Company has not raised any moneys by 
way of initial public offer or further public offer 
(including debt instruments). Accordingly, clause 
3(x)(a) of the Order is not applicable.
	
(b)	
According to the information and explanations 
given to us and on the basis of our examination 
of the records of the Company, the Company has 
not made any preferential allotment or private 
placement of shares or fully or partly convertible 
debentures during the year. Accordingly, clause 
3(x)(b) of the Order is not applicable.
(xi)	 (a)	
Based on examination of the books and records 
of the Company and according to the information 
and explanations given to us, considering the 
principles of materiality outlined in Standards 
Annexure A to the Independent Auditor‚Äôs Report
on Auditing, we report that no fraud by the 
Company or on the Company has been noticed 
or reported during the course of the audit.
	
(b)	
According to the information and explanations 
given to us, no report under sub-section (12) 
of Section 143 of the Act has been filed by the 
auditors in Form ADT-4 as prescribed under Rule 
13 of the Companies (Audit and Auditors) Rules, 
2014 with the Central Government.
	
(c)	
We have taken into consideration the whistle 
blower complaints received by the Company 
during the year while determining the nature, 
timing and extent of our audit procedures.
(xii)	 According to the information and explanations 
given to us, the Company is not a Nidhi Company. 
Accordingly, clause 3(xii) of the Order is not applicable.
(xiii)	 In our opinion and according to the information and 
explanations given to us, the transactions with related 
parties are in compliance with Section 177 and 188 
of the Act, where applicable, and the details of the 
related party transactions have been disclosed in the 
standalone financial statements as required by the 
applicable accounting standards.
(xiv)	 (a)	
Based on information and explanations provided 
to us and our audit procedures, in our opinion, 
the Company has an internal audit system 
commensurate with the size and nature of 
its business.
	
(b)	
We have considered the internal audit reports 
of the Company issued till date for the period 
under audit.
(xv)	 In our opinion and according to the information 
and explanations given to us, the Company has 
not entered into any non-cash transactions with its 
directors or persons connected to its directors and 
hence, provisions of Section 192 of the Act are not 
applicable to the Company.
(xvi)	 (a)	
The Company is not required to be registered 
under Section 45-IA of the Reserve Bank of India 
Act, 1934. Accordingly, clause 3(xvi)(a) of the 
Order is not applicable.
	
(b)	
The Company is not required to be registered 
under Section 45-IA of the Reserve Bank of India 
Act, 1934. Accordingly, clause 3(xvi)(b) of the 
Order is not applicable.
	
(c)	
The Company is not a Core Investment Company 
(CIC) as defined in the regulations made by the 
Reserve Bank of India. Accordingly, clause 3(xvi)
(c) of the Order is not applicable.
	
(d)	
The Company is not part of any group (as per 
the provisions of the Core Investment Companies 
(Reserve Bank) Directions, 2016 as amended). 
Accordingly, the requirements of clause 3(xvi)(d) 
are not applicable.
(xvii)	The Company has not incurred cash losses in 
the current and in the immediately preceding 
financial year.
(xviii) There has been no resignation of the statutory 
auditors during the year. Accordingly, clause 3(xviii) 
of the Order is not applicable.
(xix)	 According to the information and explanations given 
to us and on the basis of the financial ratios, ageing 
and expected dates of realisation of financial assets 
and payment of financial liabilities, other information 
accompanying the standalone financial statements, 
our knowledge of the Board of Directors and 
management plans and based on our examination 
of the evidence supporting the assumptions, nothing 
has come to our attention, which causes us to believe 
that any material uncertainty exists as on the date of 
the audit report that the Company is not capable of 
meeting its liabilities existing at the date of balance 
sheet as and when they fall due within a period of one 
year from the balance sheet date. We, however, state 
that this is not an assurance as to the future viability 
of the Company. We further state that our reporting is 
based on the facts up to the date of the audit report 
and we neither give any guarantee nor any assurance 
that all liabilities falling due within a period of one 
year from the balance sheet date, will get discharged 
by the Company as and when they fall due.
(xx)	 In our opinion and according to the information and 
explanations given to us, there is no unspent amount 
under sub-section (5) of Section 135 of the Act 
pursuant to any project. Accordingly, clauses 3(xx)(a) 
and 3(xx)(b) of the Order are not applicable.
For B S R & Co. LLP
Chartered Accountants
Firm‚Äôs Registration No.: 101248W/W-100022
Sreeja Marar
Partner
Place: Mumbai	
 Membership No.: 111410
Date: 02 May 2024	
 ICAI UDIN: 24111410BKGQOA9656
Annual Report 2023-24
194
195
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Standalone
Annexure B to the Independent Auditor‚Äôs Report 
on the standalone financial statements of Ajanta Pharma Limited for the year ended 31 March 2024
Report on the internal financial controls with reference to the aforesaid standalone financial statements under Clause 
(i) of Sub-section 3 of Section 143 of the Act
(Referred to in paragraph 2(A)(g) under ‚ÄòReport on Other Legal and Regulatory Requirements‚Äô section of our report of 
even date)
Opinion
We have audited the internal financial controls with 
reference to financial statements of Ajanta Pharma Limited 
(‚Äúthe Company‚Äù) as of 31 March 2024 in conjunction with 
our audit of the standalone financial statements of the 
Company for the year ended on that date.
In our opinion, the Company has, in all material respects, 
adequate internal financial controls with reference to 
financial statements and such internal financial controls 
were operating effectively as at 31 March 2024, based 
on the internal financial controls with reference to 
financial statements criteria established by the Company 
considering the essential components of internal control 
stated in the Guidance Note on Audit of Internal Financial 
Controls Over Financial Reporting issued by the Institute 
of Chartered Accountants of India (the ‚ÄúGuidance Note‚Äù).
Management‚Äôs 
and 
Board 
of 
Directors‚Äô 
Responsibilities for Internal Financial Controls
The Company‚Äôs Management and the Board of Directors 
are responsible for establishing and maintaining internal 
financial controls based on the internal financial controls 
with reference to financial statements criteria established 
by the Company considering the essential components 
of internal control stated in the Guidance Note. These 
responsibilities include the design, implementation and 
maintenance of adequate internal financial controls that 
were operating effectively for ensuring the orderly and 
efficient conduct of its business, including adherence 
to company‚Äôs policies, the safeguarding of its assets, 
the prevention and detection of frauds and errors, the 
accuracy and completeness of the accounting records, 
and the timely preparation of reliable financial information, 
as required under the Act.
Auditor‚Äôs Responsibility
Our responsibility is to express an opinion on the 
Company‚Äôs internal financial controls with reference to 
financial statements based on our audit. We conducted 
our audit in accordance with the Guidance Note and 
the Standards on Auditing, prescribed under Section 
143(10) of the Act, to the extent applicable to an audit 
of internal financial controls with reference to financial 
statements. Those Standards and the Guidance Note 
require that we comply with ethical requirements and plan 
and perform the audit to obtain reasonable assurance 
about whether adequate internal financial controls with 
reference to financial statements were established and 
maintained and if such controls operated effectively in all 
material respects.
Our audit involves performing procedures to obtain audit 
evidence about the adequacy of the internal financial 
controls with reference to financial statements and their 
operating effectiveness. Our audit of internal financial 
controls with reference to financial statements included 
obtaining an understanding of internal financial controls 
with reference to financial statements, assessing the 
risk that a material weakness exists, and testing and 
evaluating the design and operating effectiveness of 
internal control based on the assessed risk. The procedures 
selected depend on the auditor‚Äôs judgement, including the 
assessment of the risks of material misstatement of the 
standalone financial statements, whether due to fraud 
or error.
We believe that the audit evidence we have obtained is 
sufficient and appropriate to provide a basis for our audit 
opinion on the Company‚Äôs internal financial controls with 
reference to financial statements.
Meaning of Internal Financial Controls with 
Reference to Financial Statements
A company‚Äôs internal financial controls with reference to 
financial statements is a process designed to provide 
reasonable assurance regarding the reliability of financial 
reporting and the preparation of financial statements 
for external purposes in accordance with generally 
accepted accounting principles. A company‚Äôs internal 
financial controls with reference to financial statements 
include those policies and procedures that (1) pertain 
to the maintenance of records that, in reasonable 
detail, accurately and fairly reflect the transactions and 
dispositions of the assets of the company; (2) provide 
reasonable assurance that transactions are recorded as 
necessary to permit preparation of financial statements 
in accordance with generally accepted accounting 
principles, and that receipts and expenditures of the 
company are being made only in accordance with 
authorisations of management and directors of the 
company; and (3) provide reasonable assurance regarding 
prevention or timely detection of unauthorised acquisition, 
use, or disposition of the company‚Äôs assets that could 
have a material effect on the financial statements.
Inherent Limitations of Internal Financial Controls 
with Reference to Financial Statements
Because of the inherent limitations of internal financial 
controls with reference to financial statements, including 
the possibility of collusion or improper management 
override of controls, material misstatements due to error 
or fraud may occur and not be detected. Also, projections 
of any evaluation of the internal financial controls with 
reference to financial statements to future periods are 
subject to the risk that the internal financial controls 
with reference to financial statements may become 
inadequate because of changes in conditions, or that 
the degree of compliance with the policies or procedures 
may deteriorate.
For B S R & Co. LLP
Chartered Accountants
Firm‚Äôs Registration No.: 101248W/W-100022
Sreeja Marar
Partner
Place: Mumbai	
 Membership No.: 111410
Date: 02 May 2024	
 ICAI UDIN: 24111410BKGQOA9656
Annual Report 2023-24
196
197
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Standalone
Standalone Balance Sheet
as at 31 March 2024
H in Crore
Particulars
Note
 As at 
31 March 2024 
 As at 
31 March 2023 
ASSETS
Non-current assets
(a)
Property, plant and equipment 
8
 1,376.86 
 1,399.84 
(b)
Capital work-in-progress 
8
 256.45 
 209.47 
(c)
Right-of-use assets
8
 75.42 
 79.29 
(d)
Other intangible assets (other than self generated)
8
 12.61 
 4.88 
(e)
Financial assets
(i)	
Investments
9
 37.09 
 42.99 
(ii)	
Other non-current financial assets
10
 8.92 
 10.99 
(f)
Non-current tax assets (net)
11
 - 
 0.83 
(g)
Other non-current assets
12
 8.42 
 5.31 
Total non-current assets
 1,775.77 
 1,753.60 
Current assets
(a)
Inventories
13
 677.79 
 683.77 
(b)
Financial assets
(i)	
Investments
14
 330.05 
 510.27 
(ii)	
Trade receivables
15
 1,207.67 
 977.63 
(iii)	 Cash and cash equivalents
16
 61.78 
 268.85 
(iv)	 Bank balances other than cash and cash equivalents
17
 1.28 
 1.07 
(v)	 Loans
18
 15.40 
 17.01 
(vi)	 Other financial assets
19
 19.02 
 2.48 
(c)
Other current assets
20
 119.83 
 82.19 
 2,432.82 
 2,543.27 
Assets classified as held for sale
21
 8.85 
 7.92 
Total current assets
 2,441.67 
 2,551.19 
Total assets
 4,217.44 
 4,304.79 
EQUITY AND LIABILITIES
Equity
(a)
Equity share capital
22
 25.27 
 25.27 
(b)
Other equity
23
 3,388.30 
 3,221.18 
Total equity
 3,413.57 
 3,246.45 
Liabilities
Non-current liabilities
(a)
Financial liabilities
(i) 	 Lease liabilities
24
 22.42 
 24.95 
(ii) 	 Other financial liabilities
25
 1.37 
 1.01 
(b)
Provisions
26
 39.54 
 24.15 
(c)
Deferred tax liabilities (net)
27
 108.50 
 97.72 
(d)
Other non-current liabilities
28
 2.34 
 2.67 
Total non-current liabilities
 174.17 
 150.50 
Current liabilities
(a)
Financial liabilities
(i)	
Lease liabilities
29
 8.10 
 7.95 
(ii)	
Trade payables
30
	
(a)	 total outstanding dues of micro enterprises and small enterprises
 20.64 
 37.94 
	
(b)	 total outstanding dues of creditors other than micro enterprises and  
small enterprises
 363.10 
 315.08 
(iii)	 Other financial liabilities
31
 122.56 
 498.22 
(b)
Other current liabilities
32
 59.73 
 23.15 
(c)
Provisions
33
 17.76 
 14.02 
(d)
Current tax liabilities (net)
34
 37.30 
 11.48 
 629.19 
 907.84 
Liabilities classified as held for sale
35
 0.51 
 - 
Total current liabilities
 629.70 
 907.84 
Total liabilities
 803.87 
 1,058.34 
Total equity and liabilities
 4,217.44 
 4,304.79 
Material accounting policies
1 to 7
The notes referred to above form an integral part of standalone financials statements
 8 to 66 
As per our report of even date attached 
For B S R & Co. LLP
For and on behalf of Board of Directors of 
Chartered Accountants 
Ajanta Pharma Limited
Firm's Registration No.: 101248W/W-100022
CIN - L24230MH1979PLC022059
Sreeja Marar
Yogesh M. Agrawal
Rajesh M. Agrawal
Partner 
Managing Director
Joint Managing Director
Membership No.: 111410
DIN: 00073673
DIN: 00302467
Arvind K. Agrawal
Gaurang C. Shah
Place: Mumbai
Chief Financial Officer
Company Secretary
Date: 02 May 2024
FCS No.: 6696
Standalone Statement of Profit and Loss 
for the year ended 31 March 2024
H in Crore
Particulars
Note
 Year ended 
31 March 2024 
 Year ended 
31 March 2023 
INCOME
	
Revenue from operations
36
 3,971.12 
 3,411.27 
	
Other income
37
 116.48 
 132.75 
Total income
 4,087.60 
 3,544.02 
EXPENSES
	
Cost of materials consumed
38
 939.43 
 878.36 
	
Purchase of stock-in-trade
39
 162.16 
 149.04 
	
Changes in inventories of finished goods/ stock-in-trade/ work-in-progress
40
 (22.17)
 (21.99)
	
Employee benefits expense
41
 834.16 
 720.41 
	
Finance costs
42
 6.80 
 5.23 
	
Depreciation and amortisation expense
43
 132.16 
 126.95 
	
Other expenses
44
 938.11 
 986.17 
Total expenses
 2,990.65 
 2,844.17 
Profit before tax 
 1,096.95 
 699.85 
Tax expense:
65
	
-	
Current tax
	
	
	
For current year
 253.74 
 122.40 
	
	
	
For earlier years
 23.84 
 21.66 
	
-	
Deferred tax (net)
 12.13 
 (2.93)
Total tax expense
 289.71 
 141.13 
Profit for the year
 807.24 
 558.72 
Other comprehensive income/(loss)
Items that will not be reclassified subsequently to profit or loss:
Re-measurement of defined benefit liability/(assets)
 (3.88)
 (3.49)
Income tax relating to items that will not be reclassified to profit or loss
 1.36 
 1.22 
Net other comprehensive income/(loss) that will not be reclassified subsequently to 
profit or loss
 
 (2.52)
 (2.27)
Other comprehensive income/(loss) for the year (net of income tax)
 (2.52)
 (2.27)
Total comprehensive income for the year
 804.72 
 556.45 
Earnings per equity share (Face Value K 2/-)
46
	
Basic (H)
 64.11 
 43.61 
	
Diluted (H)
 64.06 
 43.61 
Material accounting policies
1 to 7
The notes referred to above form an integral part of standalone financials 
statements 
 8 to 66 
As per our report of even date attached 
For B S R & Co. LLP
For and on behalf of Board of Directors of 
Chartered Accountants 
Ajanta Pharma Limited
Firm's Registration No.: 101248W/W-100022
CIN - L24230MH1979PLC022059
Sreeja Marar
Yogesh M. Agrawal
Rajesh M. Agrawal
Partner 
Managing Director
Joint Managing Director
Membership No.: 111410
DIN: 00073673
DIN: 00302467
Arvind K. Agrawal
Gaurang C. Shah
Place: Mumbai
Chief Financial Officer
Company Secretary
Date: 02 May 2024
FCS No.: 6696
Annual Report 2023-24
198
199
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Standalone
Standalone Statement of Changes in Equity 
for the year ended 31 March 2024
A. Equity share capital (Refer note 22)
H in Crore
Particulars
Balance as at 
1 April 2023
Changes in Equity 
Share Capital due 
to prior period 
errors
Restated balance 
at the beginning 
of the current 
reporting period
Changes in equity 
share capital 
during the year 
Balance As at 
31 March 2024
Authorised
 30.00 
 - 
 30.00 
 - 
 30.00 
Issued, Subscribed & Paid up  
(Changes in equity share on account of 
ESOP H 2,000)
 25.27 
 - 
 25.27 
0.00
 25.27 
H in Crore
Particulars
Balance as at 
1 April 2022
Changes in Equity 
Share Capital due 
to prior period 
errors
Restated balance 
at the beginning 
of the current 
reporting period
Changes in equity 
share capital 
during the year
Balance as at 
31 March 2023
Authorised
 30.00 
 - 
 30.00 
 - 
 30.00 
Issued, Subscribed & Paid up
 17.17 
 - 
 17.17 
 8.10 
 25.27 
B. 
Other equity (Refer note 23)
H in Crore
Particulars
Reserves and Surplus
Items of other 
comprehensive 
income
 Total Other 
Equity 
 Capital 
Redemption 
Reserve 
 Securities 
Premium 
 General 
Reserve 
 Employee 
Stock Options 
Outstanding 
Account 
 Retained 
Earnings 
(Re-
measurement 
gains (losses) 
on defined 
benefit plans) 
Balance as at 1 April 2022
 2.62 
 - 
 460.21 
 0.30  2,694.98 
 (6.10)
 3,152.01 
Profit for the year
 - 
 - 
 - 
 - 
 558.72 
 - 
 558.72 
Other comprehensive income (net of 
tax)
 - 
 - 
 - 
 - 
 - 
 (2.27)
 (2.27)
Total comprehensive income
 - 
 - 
 - 
 - 
 558.72 
 (2.27)
 556.45 
Utilised for allotment of Bonus Shares 
(Refer note 22.1)
 (2.62)
 (0.18)
 (5.73)
 - 
 - 
 - 
 (8.53)
Utilised for buy-back of Equity Shares 
(Refer note 22.8)
 - 
 - 
 (315.00)
 - 
 - 
 - 
 (315.00)
Payment of Expenses for buyback of 
shares (Refer note 22.8)
 - 
 - 
 - 
 - 
 (1.44)
 - 
 (1.44)
Transfer to Capital Redemption 
Reserve for buyback of Equity Shares 
(Refer note 22.8)
 0.44 
 - 
 - 
 - 
 - 
 - 
 0.44 
Exercised stock options
 - 
 0.18 
 - 
 (0.18)
 - 
 - 
 - 
Share-based payment expense
 - 
 - 
 - 
 0.22 
 - 
 - 
 0.22 
Deemed Investment in Subsidiary on 
account of ESOP
 - 
 - 
 - 
 - 
 - 
 - 
 - 
ESOP Cancelled/Lapsed during the 
year
 - 
 - 
 - 
 - 
 - 
 - 
 - 
Dividend paid
 - 
 - 
 - 
 - 
 (89.69)
 - 
 (89.69)
Tax on buyback of Equity Shares (Refer 
note 22.8)
 - 
 - 
 - 
 - 
 (73.28)
 - 
 (73.28)
Balance as at 31 March 2023
 0.44 
 - 
 139.48 
 0.34  3,089.29 
 (8.37)
 3,221.18 
Profit for the year
 - 
 - 
 - 
 - 
 807.24 
-
 807.24 
Other comprehensive income (net of 
tax)
 - 
 - 
 - 
 - 
 - 
 (2.52)
 (2.52)
Total comprehensive income
 - 
 - 
 - 
 - 
 807.24 
 (2.52)
 804.72 
Utilised for allotment of Bonus Shares 
(Refer note 22.1)
 - 
 - 
 - 
 - 
 - 
 - 
 - 
Utilised for buy-back of Equity Shares 
(Refer note 22.8)
 - 
 - 
 - 
 - 
 - 
 - 
 - 
Standalone Statement of Changes in Equity 
for the year ended 31 March 2024
H in Crore
Particulars
Reserves and Surplus
Items of other 
comprehensive 
income
 Total Other 
Equity 
 Capital 
Redemption 
Reserve 
 Securities 
Premium 
 General 
Reserve 
 Employee 
Stock Options 
Outstanding 
Account 
 Retained 
Earnings 
(Re-
measurement 
gains (losses) 
on defined 
benefit plans) 
Payment of Expenses for buyback of 
shares (Refer note 22.8)
 - 
 - 
 - 
 - 
 (0.92)
 - 
 (0.92)
Transfer to Capital Redemption 
Reserve for buyback of Equity Shares 
(Refer note 22.8)
 - 
 - 
 - 
 - 
 - 
 - 
 - 
Exercised stock options
 - 
 0.18 
 - 
 (0.18)
 - 
 - 
 - 
Share-based payment expense 
 - 
 - 
 - 
 5.06 
 - 
 - 
 5.06 
Deemed Investment in Subsidiary on 
account of ESOP
 - 
 - 
 - 
 0.62 
 - 
 - 
 0.62 
ESOP Cancelled/Lapsed during the 
year
 - 
 - 
 - 
 (0.19)
 - 
 - 
 (0.19)
Dividend paid
 - 
 - 
 - 
 - 
 (642.17)
 - 
 (642.17)
Tax on buyback of Equity Shares (Refer 
note 22.8)
 - 
 - 
 - 
 - 
 - 
 - 
 - 
Balance as at 31 March 2024
 0.44 
 0.18 
 139.48 
 5.65  3,253.44 
 (10.89)
 3,388.30 
Nature of Reserves
a)	 Capital Redemption Reserve
	
As per Companies Act, 2013, capital redemption reserve is created on redemption of preference shares and when 
company purchases its own shares out of free reserves or securities premium. A sum equal to the nominal value of 
the shares redeemed or purchased is transferred to capital redemption reserve.
b)	
Securities Premium
	
Securities premium account comprises of premium on issue of shares. The reserve is utilised in accordance with 
the specific provision of the Companies Act, 2013.
c)	
General Reserve
	
The General reserve is used from time to time to transfer profits from retained earnings for appropriation purposes.
d)	 Employees Stock Options Outstanding Account
	
The fair value of the equity-settled share-based payment transactions are debited to Statement of Profit and 
Loss and if related to employee of subsidiary then debited to investment in subsidiary account with corresponding 
credit to Employee Stock Options Outstanding Account over the vesting period of the options.
e)	
Retained Earnings
	
Retained Earnings are the profits that the Company has earned till date less any transfer to general reserve, 
dividends or other distributions paid to shareholders.
Material accounting policies	
	
	
	
	
	
	
	
	
	
1 to 7
See accompanying notes forming part of the standalone financial statements	
8 to 66
As per our report of even date attached 
For B S R & Co. LLP
For and on behalf of Board of Directors of 
Chartered Accountants 
Ajanta Pharma Limited
Firm's Registration No.: 101248W/W-100022
CIN - L24230MH1979PLC022059
Sreeja Marar
Yogesh M. Agrawal
Rajesh M. Agrawal
Partner 
Managing Director
Joint Managing Director
Membership No.: 111410
DIN: 00073673
DIN: 00302467
Arvind K. Agrawal
Gaurang C. Shah
Place: Mumbai
Chief Financial Officer
Company Secretary
Date: 02 May 2024
FCS No.: 6696
Annual Report 2023-24
200
201
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Standalone
Standalone Statement of Cash Flow 
for the year ended 31 March 2024
H in Crore
 Particulars 
 Year ended 
31 March 2024 
 Year ended 
31 March 2023 
A. 
CASH FLOW FROM OPERATING ACTIVITIES
Profit before tax 
 1,096.95 
 699.85 
Adjustment for:
Depreciation and amortisation expense
 132.16 
 126.95 
Loss/ (Gain) on sale/ retirement of property, plant and equipment (net)
 (3.49)
 1.52 
Finance cost
 6.80 
 5.23 
Dividend from subsidiaries
 (29.13)
 (35.14)
Loss/(Gain) on fair value of investment
 9.11 
 2.30 
Loss/(Gain) on fair value of derivative
 (22.82)
 18.82 
Income from investments & deposits
 (38.44)
 (25.31)
Deferred Government Grant
 (0.33)
 (0.33)
Equity settled share-based payment
 4.87 
 0.22 
Unrealised foreign exchange Gain
 (9.42)
 (14.08)
Impairment (Gain)/Loss on financial assets
 - 
 (0.84)
Operating cash flow before working capital changes
 1,146.26 
 779.19 
Changes in working capital:
Decrease in other non-current financial assets
 1.33 
 0.85 
Decrease in non-current assets
 - 
 0.20 
Decrease/(Increase) in inventories
 5.98 
 (48.67)
Decrease/(Increase) in current loans
 1.61 
 (10.88)
(Increase)/Decrease in trade receivables
 (221.02)
 81.94 
Decrease in other current financial assets
 6.28 
 15.20 
(Increase)/Decrease in other current assets
 (37.64)
 5.16 
Increase/(Decrease) in non-current other financial liabilities
 0.36 
 (0.09)
Increase in non-current other liabilities
 0.66 
 0.66 
Increase in non-current provisions
 15.39 
 4.83 
Increase in trade payables
 30.86 
 78.46 
(Decrease) in other current financial liabilities
 (0.75)
 (11.89)
Increase/(Decrease) in other current liabilities
 36.58 
 (34.06)
Liabilities classified as held for sale
 0.51 
 - 
Increase in current provisions
 1.22 
 0.95 
Cash generated from operating activities
 987.63 
 861.85 
Net income tax paid
 (252.28)
 (125.56)
Net cash generated from operating activities (a)
 735.35 
 736.29 
B. 
CASH FLOW FROM INVESTING ACTIVITIES
Capital expenditure on property, plant and equipment & intangible assets including 
capital advances
 (152.57)
 (175.66)
Proceeds from sale of property, plant and equipment
 12.18 
 0.57 
Bank balances not considered as cash and cash equivalents
 0.44 
 4.35 
Dividend from subsidiaries
 29.13 
 35.14 
Purchase of current investments
 (2,079.76)
 (1,666.86)
Proceeds from sale of current investments
 2,257.39 
 1,276.15 
Interest income on investments and deposits
 38.21 
 25.00 
Net cash generated/(used) in investing activities (b)
 105.02 
 (501.31)
Standalone Statement of Cash Flow 
for the year ended 31 March 2024
H in Crore
 Particulars 
 Year ended 
31 March 2024 
 Year ended 
31 March 2023 
C. 
CASH FLOW FROM FINANCING ACTIVITIES
Proceeds from Issue of Equity Shares (Current Year H 2,000, 31 March 2023 H 2,000) 
0.00
0.00
Interest paid
 (3.42)
 (1.76)
Payment of lease liability (includes interest of H 3.38 Crore in current year and H 3.47 
Crore in previous year)
 (12.91)
 (12.23)
Payment for buyback of equity shares (Refer note 22.8)
 (315.00)
 - 
Payment for tax on buyback of equity shares (Refer note 22.8)
 (73.28)
 - 
Payment of expenses for buyback of equity shares (Refer note 22.8)
 (0.92)
 (1.44)
Dividend paid
 (642.17)
 (89.69)
Net cash used in financing activities (c)
 (1,047.70)
 (105.12)
Net (Decrease) / Increase in cash and cash equivalents (a+b+c)
 (207.33)
 129.86 
Cash and cash equivalents as at the beginning of the year
 268.85 
 139.83 
Cash and cash equivalents as at the end of the year 
 61.52 
 269.69 
Reconciliation of cash and cash equivalents with the Balance sheet
Cash and cash equivalents as at the end of the year 
 61.52 
 269.69 
Unrealised gain/(loss) on foreign currency cash and cash equivalents
 0.26 
 (0.84)
Cash and cash equivalents restated balance as per balance sheet (Refer Note 16)
 61.78 
 268.85 
Figures in brackets indicates outflow. 
Notes:
1. 	 The above Cash Flow Statement has been prepared under the ‚ÄòIndirect Method‚Äô as set out in the Indian Accounting Standard 7 (Ind AS 7) 
‚ÄúStatement of Cash Flow‚Äú under Section 133 of the Companies Act, 2013.
2. 	 Cash comprises cash on hand, current accounts and deposits with banks. Cash equivalents are short-term balances (with an original 
maturity of three months or less from the date of acquisition).
3. 	 During the year the Company paid H 17.32 Crore (31 March 2023 H 16.37 Crore) towards corporate social responsibility (CSR) expenditure 
included in corporate social responsibility expenditure (Refer note 55).
4. 	 Movement in lease liabilities (Refer note 52).
Material accounting policies	
	
	
	
	
	
	
	
	
	
1 to 7
See accompanying notes forming part of the standalone financial statements	
8 to 66
As per our report of even date attached 
For B S R & Co. LLP
For and on behalf of Board of Directors of 
Chartered Accountants 
Ajanta Pharma Limited
Firm's Registration No: 101248W/W-100022
CIN - L24230MH1979PLC022059
Sreeja Marar
Yogesh M. Agrawal
Rajesh M. Agrawal
Partner 
Managing Director
Joint Managing Director
Membership No. 111410
DIN: 00073673
DIN: 00302467
Arvind K. Agrawal
Gaurang C. Shah
Place: Mumbai
Chief Financial Officer
Company Secretary
Date: 02 May 2024
FCS No. 6696
Notes to the Standalone Financial Statements
for the year ended 31 March 2024
Notes to the Standalone Financial Statements
for the year ended 31 March 2024
1. 
Corporate Information
Ajanta Pharma Limited (‚Äúthe Company‚Äù) is a public 
limited company incorporated and domiciled in India. 
Its shares are listed on Bombay Stock Exchanges and 
National Stock Exchange. The Registered office of 
the Company is located at Ajanta House, Charkop, 
Kandivali (West), Mumbai.
The Company is primarily involved in development, 
manufacturing and marketing of speciality 
pharmaceutical finished dosages.
2 
Basis of Preparation
	
Statement of Compliance:
These standalone financial statements have been 
prepared in accordance with the Indian Accounting 
Standards (‚ÄòInd AS‚Äô) as per the Companies (Indian 
Accounting Standards) Rules, 2015, as amended 
from time to time, notified under Section 133 of 
the Companies Act, 2013 (‚ÄòAct‚Äô) and other relevant 
provisions of the Act. These standalone financial 
statements have been prepared on an accrual 
basis and under the historical cost basis, except 
otherwise stated.
The standalone financial statements for the year 
ended 31 March 2024 have been reviewed by the 
Audit Committee and subsequently approved by the 
Board of Directors at its meeting held on 02 May 2024.
	
Use of Estimates and Judgements:
The preparation of standalone financial statements 
in conformity with Ind AS requires management to 
make judgements , estimates and assumptions that 
affect the application of accounting policies and the 
reported amounts of assets, liabilities, income and 
expenses and the disclosure of contingent liabilities 
on the date of the financial statements. Actual results 
could differ from those estimates. Estimates and under 
lying assumptions are reviewed on an ongoing basis. 
Any revision to accounting estimates is recognised 
prospectively in current and future periods.
	
Judgements:
Information about judgements made in applying 
accounting policies that have the most significant 
effects on the amounts recognised in the financial 
statements is included in the following notes
 
Classification of Lease as per Ind AS 116:
Ind AS 116 Leases requires a lessee to determine the 
lease term as the non-cancellable period of a lease 
adjusted with any option to extend or terminate the 
lease, if the use of such option is reasonably certain. 
The Company makes an assessment on the expected 
lease term on lease by lease basis and thereby 
assesses whether it is reasonably certain that any 
options to extend or terminate the contract will be 
exercised. In evaluating the lease term, the Company 
considers factors such as any significant leasehold 
improvements undertaken over the lease term, 
costs relating to the termination of lease and the 
importance of the underlying lease to the Company‚Äôs 
operations taking into account the location of the 
underlying asset and the availability of the suitable 
alternatives. The lease term in future periods is 
reassessed to ensure that the lease term reflects the 
current economic circumstances. The discount rate 
is generally based on the incremental borrowing rate 
specific to the lease being evaluated or for a portfolio 
of leases with similar characteristics.
	
Estimates:
Information about assumptions and estimation 
uncertainties at the reporting date that have a 
significant risk of resulting in a material adjustment to 
the carrying amounts of assets and liabilities within the 
next financial year is included in the following notes.
	
Recognition of Current and Deferred tax 
assets:
The Company‚Äôs tax charge on ordinary activities is 
the sum of the total current and deferred tax charges. 
The calculation of the Company‚Äôs total tax charge 
necessarily involves a degree of estimation in respect 
of certain items whose tax treatment cannot be finally 
determined until resolution has been reached with the 
relevant tax authority or, as appropriate, through a 
formal legal process. The final resolution of some of 
these items may give rise to material profits/losses 
and/or cash flows.
The complexity of the Company‚Äôs structure makes 
the degree of estimation more challenging. The 
resolution of issues is not always within the control 
of the Company and it is often dependent on the 
efficiency of the legal processes in the relevant taxing 
jurisdictions in which the Company operates. Issues 
can, and often do, take many years to resolve.
Payments in respect of tax liabilities for an accounting 
period result from payments on account and on the 
final resolution of open items. As a result there can 
be substantial differences between the tax charge in 
the Statement of Profit and Loss and tax payments.
The recognition of deferred tax assets is based upon 
whether it is more likely than not that sufficient and 
suitable taxable profits will be available in the future 
against which the reversal of temporary differences 
can be deducted. To determine the future taxable 
profits, reference is made to the latest available 
profit forecasts. Where the temporary differences 
are related to losses, relevant tax law is considered 
to determine the availability of the losses to offset 
against the future taxable profits.
	
Property, Plant and Equipment:
Useful lives of tangible assets are based on the life 
prescribed in Schedule II of the Act. In cases, where 
the useful lives are different from that prescribed in 
Schedule II, they are based on technical advice, taking 
into account the nature of the asset, the estimated 
usage of the asset, the operating conditions of the 
asset, past history of replacement, anticipated 
technological changes, manufacturers‚Äô warranties 
and maintenance support.
	
Intangible Assets:
Intangible assets majorly consist software licences 
which are amortised over licence period which 
equates the economic useful life ranging between 
2-5 years on a straight-line basis over the period of 
its economic useful life.
 
Recognition and Measurement of Defined 
Benefit Obligations:
The obligation arising from the defined benefit plan 
is determined on the basis of actuarial valuation. Key 
actuarial assumptions include discount rate, trends 
in salary escalation and vested future benefits and 
life expectancy. The discount rate is determined with 
reference to market yields at the end of the reporting 
period on the government bonds. The period to 
maturity of the underlying bonds correspond to 
the probable maturity of the post-employment 
benefit obligations.
	
Allowance for Uncollected Accounts 
Receivable and Advances:
Trade receivables do not carry any interest and 
are stated at their normal value as reduced by 
appropriate allowances for estimated irrecoverable 
amounts. Individual trade receivables are written 
off when management seems them not collectible. 
Impairment is made using expected credit loss model.
The impairment provisions for financial assets are 
based on assumption about risk of default and 
expected loss rates. Judgement in making these 
assumption and selecting the inputs to the impairment 
calculation are based on past history, existing market 
condition as well as forward-looking estimates at the 
end of each reporting period.
	
Allowances for inventories:
Management reviews the inventory age listing on 
a periodic basis. The review involves comparison 
of the carrying value of the aged inventory items. 
The purpose is to ascertain whether an allowance 
is required to be made in the standalone financial 
statement for any obsolete and slow-moving items. 
Management is satisfied that adequate allowance 
for obsolete and slow-moving inventories has been 
made in the financial statements.
Management also reviews net realisable value for all 
its inventory and is satisfied that adequate allowance 
has been made in the financial statements.
	
Contingencies:
Management judgement is required for estimating 
the possible outflow of resources, if any, in respect of 
contingencies/claim/litigations against the Company 
as it is not possible to predict the outcome of pending 
matters with accuracy.
	
Impairment Reviews:
An impairment exists when the carrying value of 
an asset or cash generating unit (‚ÄòCGU‚Äô) exceeds 
its recoverable amount. Recoverable amount is 
the higher of its fair value less costs to sell and its 
value in use. The value in use calculation is based 
on a discounted cash flow model. In calculating the 
value in use, certain assumptions are required to be 
made in respect of highly uncertain matters, including 
management‚Äôs expectations of growth in EBITDA, 
long-term growth rates; and the selection of discount 
rates to reflect the risks involved.
	
Provision for Anticipated Sales Return:
In determining the provision for anticipated sales 
returns, estimates for probable saleable and non-
saleable returns of goods from the customers 
are made on scientific basis after factoring in the 
historical data of such returns and its trend.
3. 
Functional and Presentation Currency
The financial statements are presented in Indian 
Rupees (‚ÄòINR‚Äô or ‚ÄòRupees‚Äô or ‚ÄòH‚Äô or ‚ÄòH‚Äô) which is the 
functional currency for the Company.
Annual Report 2023-24
202
203
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Standalone
Notes to the Standalone Financial Statements
for the year ended 31 March 2024
Notes to the Standalone Financial Statements
for the year ended 31 March 2024
4. 
Rounding of Amounts
All amounts disclosed in the financial statements and 
notes have been rounded off to the nearest Crore.
5. 
Current/non-current classification
An entity shall classify an asset as current when-
(a)	
it expects to realise the asset, or intends to sell 
or consume it, in its normal operating cycle;
(b)	
it holds the asset primarily for the purpose 
of trading;
(c)	
it expects to realise the asset within twelve 
months after the reporting period; or
(d)	
the asset is cash or a cash equivalent unless the 
asset is restricted from being exchanged or used 
to settle a liability for at least twelve months 
after the reporting period.
An entity shall classify all other assets as non-current.
An entity shall classify a liability as current when-
(a)	
it expects to settle the liability in its normal 
operating cycle;
(b)	
it holds the liability primarily for the purpose 
of trading;
(c)	
the liability is due to be settled within twelve 
months after the reporting period; or
(d)	
it does not have an unconditional right to 
defer settlement of the liability for at least 
twelve months after the reporting period. 
Terms of a liability that could, at the option of 
the counterparty, result in its settlement by 
the issue of equity instruments do not affect 
its classification.
An entity shall classify all other liabilities as 
non-current.
	
Operating Cycle:
An operating cycle is the time between the acquisition 
of assets for processing and their realisation in cash 
or cash equivalents.
Based on the nature of products/activities of the 
Company and the normal time between acquisition of 
assets and their realisation in cash or cash equivalents, 
the Company has determined its operating cycle as 
twelve months for the purpose of classification of its 
assets and liabilities as current and non-current.
6. 
Material Accounting Policies
6.1 Property, Plant and Equipment
	
Recognition and measurement:
Items of PPE are carried at cost less accumulated 
depreciation and impairment losses, if any. The 
cost of an item of PPE comprises its purchase price, 
including import duties and other non-refundable 
taxes or levies and any directly to the attributable 
cost of bringing the assets to its working condition for 
its intended use and any trade discount and rebates 
are deducted in arriving at purchase price. Cost 
of the assets also includes interest on borrowings 
attributable to acquisition of qualifying fixed assets 
up to the date the asset is ready for its intended use 
incurred up to that date.
Such cost includes the cost of replacing part of the 
plant and equipment and borrowing costs for long-
term construction projects if the recognition criteria are 
met. When significant parts of plant and equipment 
are required to be replaced at intervals, the Company 
depreciates these components separately based 
on their specific useful lives. Likewise, when a major 
inspection is performed, its cost is recognised in the 
carrying amount of the plant and equipment as a 
replacement if the recognition criteria are satisfied. All 
other repair and maintenance costs are recognised in 
the statement of profit or loss as incurred.
Cost of Items of Property, plant and equipment not 
ready for intended use as on the balance sheet date, 
is disclosed as capital work-in-progress. Advances 
given towards acquisition of property, plant and 
equipment outstanding at each balance sheet date 
are disclosed as Capital Advance under Other non-
current assets.
All identifiable revenue expenses including interest 
incurred in respect of various projects/expansion, 
net of income earned during the project development 
stage prior to its intended use, are considered as pre-
operative expenses and disclosed under Capital 
Work in Progress.
Capital expenditure on Property, plant and 
equipment for research and development is 
classified under property, plant and equipment and 
is depreciated on the same basis as other property, 
plant and equipment.
Property, plant and equipment are derecognised 
either on disposal or when the asset retires from 
active use. Losses arising in the case of the retirement 
of property, plant and equipment and gains or 
losses arising from disposal of property, plant and 
equipment are recognised in the statement of profit 
and loss in the year of occurrence.
	
Transition to Ind AS:
The cost of property, plant and equipment as at 1 
April 2016, the Companies date of transition to Ind AS, 
was determined with reference to its carrying value 
recognised as per the previous GAAP (deemed cost), 
as at the date of transition to Ind AS.
	
Subsequent expenditure:
Subsequent expenditure is capitalised only if it is 
probable that the future economic benefits associated 
with the expenditure will flow to the Company and the 
cost of the item can be measured reliably.
	
Depreciation:
Depreciation is the systematic allocation of the 
depreciable amount of PPE over its useful life and is 
provided on a straight-line basis over the useful lives 
as prescribed under Schedule II to the Act or as per 
technical assessment. The residual values, useful lives 
and method of depreciation of PPE is reviewed at 
each financial year end and adjusted prospectively, 
if appropriate.
Depreciation on additions/disposals is provided on 
a pro-rata basis i.e. from/up to the date on which is 
asset is ready to use/disposed off. Freehold land is 
not depreciated.
The estimated useful lives of Tangible assets are 
as follows
PPE
Useful Life
Buildings*
5 Years to 60 Years
Plant and Equipment*
3 Years to 25 Years
Furniture and Fixtures*
10 Years
Vehicles
8 Years to 10 Years
Office Equipments*
3 Years to 5 Years
* For these class of assets, the useful life of assets is different than 
the prescribed life as per Part C of Schedule II of the Companies 
Act, 2013. The different useful life is based on internal technical 
evaluation by the Company and historical usage of assets.
Dies & Punches having useful life of 3 years as per 
technical evaluation and management estimate and 
Solar Plants having useful life of 25 years.
Property, plant and equipment which are added/
disposed off during the year, depreciation is provided 
on pro-rata basis.
Building constructed on leasehold land are 
depreciated based on the useful life specified in 
Schedule II to the Companies Act, 2013, where the 
lease period of the land is beyond the life of the 
building. In other cases, building constructed on 
leasehold land are amortised over the primary lease 
period of the land.
6.2 Intangible Assets
Intangible assets are recognised when it is probable 
that the future economic benefits that are attributable 
to the assets will flow to the Company and the cost of 
the assets can be measured reliably.
Intangible assets are carried at cost less accumulated 
amortisation and impairment losses, if any. Internally 
generated intangibles, excluding development 
costs as defined in Ind AS, are not capitalised and 
the related expenditure is reflected in Statement of 
profit and loss in the period in which the expenditure 
is incurred.
Software is amortised over their estimated useful life 
on straight-line basis from the date they are available 
for intended use or the period of the license as 
applicable, subject to impairment test.
The amortisation period and the amortisation method 
for an intangible assets with a finite useful life are 
reviewed at least at the end of each reporting period. 
Changes in the expected useful life or the expected 
pattern of consumption of future economic benefits 
embodied in the asset are considered to modify the 
amortisation period or method, as appropriate, and 
are treated as changes in accounting estimates.
Gains or losses arising from derecognition of an 
intangible asset are measured as the difference 
between the net disposal proceeds and the 
carrying amount of the asset and are recognised 
in the statement of profit and loss when the assets 
are derecognised.
	
Research and Development:
Revenue expenditure on research is recognised in the 
statement of profit and loss in the period in which it 
is incurred.
Development expenditure incurred on an individual 
project is carried forward when its future recoverability 
can reasonably be regarded as assured. Any 
expenditure carried forward is amortised over the 
period of expected future sales from the related 
project. The carrying value of development costs is 
reviewed for impairment annually when the asset is 
Annual Report 2023-24
204
205
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Standalone
Notes to the Standalone Financial Statements
for the year ended 31 March 2024
Notes to the Standalone Financial Statements
for the year ended 31 March 2024
not yet in use, and otherwise when events or changes 
in circumstances indicate that the carrying value may 
not be recoverable.
6.3 Investment Property
Investment property is property held either to earn 
rental income or for capital appreciation or for both, 
but not for sale in the ordinary course of business, use 
in the production or supply of goods or services or for 
administrative purposes. Upon initial recognition, an 
investment property is measured at cost, including 
related transaction cost. Subsequent to initial 
recognition, investment property is measured at cost 
less accumulated depreciation and accumulated 
impairment losses, if any.
The Company depreciates investment property 
using the following useful lives from the date of 
original purchase.
Investment 
Property
Management estimate 
of useful life
Useful life as per 
Schedule II
Building
21 years
30 and 60 years
Any gain or loss on disposal of an investment property 
is recognised in profit or loss.
The fair values of investment property is disclosed in 
the notes. Fair values are determined on the basis of 
valuation done by registered valuer.
	
Impairment on non-financial assets:
The Company‚Äôs non-financial assets other than 
inventories and deferred tax assets, are reviewed at 
each reporting date to determine whether there is any 
indication of impairment. If any such indication exists, 
then the asset‚Äôs recoverable amount is estimated.
For impairment testing, assets that do not generate 
independent cash inflows (i.e. corporate assets) are 
grouped together into cash-generating units (CGUs). 
Each CGU represents the smallest group of assets that 
generates cash inflows that are largely independent 
of the cash inflows of other assets or CGUs.
The recoverable amount of a CGU is the higher of its 
value in use and its fair value less costs to sell. Value 
in use is based on the estimated future cash flows, 
discounted to their present value using a discount 
rate that reflects current market assessments of the 
time value of money and the risks specific to the CGU.
An impairment loss is recognised if the carrying 
amount of an asset or CGU exceeds its estimated 
recoverable amount. Impairment loss recognised 
in respect of a CGU is allocated first to reduce the 
carrying amounts of the assets of the CGU (or group 
of CGUs) on a pro rata basis.
An impairment loss in respect of assets for which 
impairment loss has been recognised in prior periods, 
the Company reviews at each reporting date whether 
there is any indication that the loss has decreased or 
no longer exists. An impairment loss is reversed if there 
has been a change in the estimates used to determine 
the recoverable amount. Such a reversal is made only 
to the extent that the asset‚Äôs carrying amount does 
not exceed the carrying amount that would have 
been determined, net of depreciation or amortisation, 
if no impairment loss had been recognised.
The following intangible assets are tested for 
impairment each financial year even if there is no 
indication that the asset is impaired:
i)	
An intangible asset that is not yet available for 
use; and
ii)	
An intangible asset that is amortised over a 
period exceeding ten years from the date when 
the asset is available for use.
6.4 Non-current Assets Classified as Held for Sale
Assets are classified as held for sale and stated at the 
lower of carrying amount and fair value less costs to 
sell if the asset is available for immediate sale and its 
sale is highly probable. Such assets or group of assets 
are presented separately in the Balance Sheet as 
‚ÄúAssets Classified as Held for Sale‚Äù. Once classified as 
held for sale, intangible assets, investment property 
and property, plant and equipment are no longer 
amortised or depreciated.
6.5 Financial Instruments
Trade receivables and debt securities issued are 
initially recognised when they originate. All other 
financial assets and financial liabilities are initially 
recognised when the Company becomes a party to 
the contractual provisions of the instrument.
A financial asset (unless it is a trade receivable without 
a significant financing component) or financial liability 
is initially measured at fair value plus or minus, for 
an item not at FVTPL, transaction costs that are 
directly attributable to its acquisition or issue. A trade 
receivable without a significant financing component 
is initially measured at the transaction price.
A financial instrument is any contract that gives rise to 
a financial asset of one entity and a financial liability 
or equity instrument of another entity.
	
Financial Assets:
	
Classification:
The Company classifies financial assets as 
subsequently measured at amortised cost, fair value 
through other comprehensive income or fair value 
through profit or loss, on the basis of its business model 
for managing the financial assets and the contractual 
cash flow characteristics of the financial asset.
	
Initial Recognition and Measurement:
All financial assets excluding trade receivable(not 
measured subsequently at fair value through 
profit or loss) are recognised initially at fair value 
plus transaction costs that are attributable to the 
acquisition of the financial asset.
	
Subsequent Measurement:
For the purpose of subsequent measurement, financial 
assets are classified in two broad categories:
‚Ä¢	 Financial assets at fair value (FVTPL /FVTOCI)
‚Ä¢	 Financial assets at amortised cost
When assets are measured at fair value, gains and 
losses are either recognised in the statement of profit 
and loss (i.e. fair value through profit or loss (FVTPL)), 
or recognised in other comprehensive income (i.e. fair 
value through other comprehensive income (FVOCI)).
	
Financial Assets measured at amortised cost (net of 
write down for impairment, if any):
Financial assets are measured at amortised cost 
when asset is held within a business model, whose 
objective is to hold assets for collecting contractual 
cash flows and contractual terms of the asset give 
rise on specified dates to cash flows that are solely 
payments of principal and interest. Such financial 
assets are subsequently measured at amortised 
cost using the effective interest rate (EIR) method less 
impairment, if any. The losses arising from impairment 
are recognised in the Statement of profit and loss.
	
Financial Assets measured at Fair Value through 
Other Comprehensive Income (‚ÄúFVTOCI‚Äù):
Financial assets under this category are measured 
initially as well as at each reporting date at fair 
value, when asset is held within a business model, 
whose objective is to hold assets for both collecting 
contractual cash flows and selling financial assets. 
Fair value movements are recognised in the other 
comprehensive income.
	
Financial Assets measured at Fair Value through 
Profit or Loss (‚ÄúFVTPL‚Äù):
Financial assets under this category are measured 
initially as well as at each reporting date at fair value 
with all changes recognised in profit or loss.
	
Investment in Subsidiary:
Investment in equity instruments of Subsidiaries 
are measured at cost. In the financial statements, 
investment in subsidiaries is carried at cost. The 
carrying amount is reduced to recognise any 
impairment in the value of investment.
	
Investment in Equity Instruments:
Equity instruments which are held for trading are 
classified as at FVTPL. Fair value changes on the 
instrument, excluding dividends, are recognised in 
profit or loss.
	
Investment in Debt Instruments:
A debt instrument is measured at amortised cost 
or at FVTOCI. Any debt instrument, which does not 
meet the criteria for categorisation as at amortised 
cost or as FVOCI, is classified as at FVTPL. Debt 
instruments included within the FVTPL category are 
measured at fair value with all changes recognised 
in the Statement of profit and loss.
	
Derecognition of Financial Assets:
A financial asset is primarily derecognised when 
the rights to receive cash flows from the asset have 
expired or the Company has transferred its rights to 
receive cash flows from the asset.
	
Impairment of Financial Assets:
In accordance with Ind AS 109, the Company applies 
expected credit loss (ECL) model for measurement and 
recognition of impairment loss on the financial assets 
that are debt instruments and trade receivables.
	
Financial Liabilities:
	
Classification:
The Company classifies all financial liabilities as 
subsequently measured at amortised cost or FVTPL.
	
Initial Recognition and Measurement:
All financial liabilities are recognised initially at fair value 
and, in the case of loans, borrowings and payables, 
net of directly attributable transaction costs.
Annual Report 2023-24
206
207
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Standalone
Notes to the Standalone Financial Statements
for the year ended 31 March 2024
Notes to the Standalone Financial Statements
for the year ended 31 March 2024
Financial liabilities include trade and other payables, 
loans and borrowings including bank overdrafts and 
derivative financial instruments.
	
Subsequent Measurement:
Financial liabilities at fair value through profit or 
loss include financial liabilities held for trading and 
financial liabilities designated upon initial recognition 
as at fair value through profit or loss. Interest-bearing 
loans and borrowings are subsequently measured at 
amortised cost using the Effective Interest Rate (EIR) 
method. Gains and losses are recognised in profit or 
loss when the liabilities are derecognised as well as 
through EIR amortisation process. Amortised cost is 
calculated by taking into account any discount or 
premium on acquisition and fees or costs that are 
an integral part of the EIR. The EIR amortisation is 
included as finance costs in the Statement of Profit 
and Loss.
	
Derecognition of Financial Liabilities:
A financial liability is derecognised when the obligation 
under the liability is discharged or cancelled or 
expires. When an existing financial liability is replaced 
by another from the same lender on substantially 
different terms, or the terms of an existing liability 
are substantially modified, such an exchange or 
modification is treated as the derecognition of the 
original liability and the recognition of a new liability. 
The difference in the respective carrying amounts is 
recognised in the Statement of Profit and Loss.
	
Derivative Financial Instrument:
The Company uses derivative financial instruments, 
such as forward currency contracts to mitigate 
its foreign currency risks. Such derivative financial 
instruments are initially recognised at fair value on 
the date on which a derivative contract is entered 
into and are subsequently re-measured at fair value. 
Derivatives are carried as financial assets when 
the fair value is positive and as financial liabilities 
when the fair value is negative. Any changes therein 
are generally recognised in the statement of profit 
and loss.
6.6 Inventories
Raw materials and packing materials are valued at 
lower of cost (on moving weighted average basis) 
and the net realisable value, cost of which includes 
duties and taxes (net off CENVAT and Goods and 
Service Tax wherever applicable). Cost of imported 
raw materials and packing materials lying in bonded 
warehouse includes the amount of customs duty. 
Finished products including traded goods and 
work-in-progress are valued at lower of cost and net 
realisable value.
The cost of finished goods and work-in-progress have 
been computed to include all cost of purchases, cost 
of conversion, appropriate share of fixed production 
overheads based on normal operating capacity and 
other related cost incurred in bringing the inventories 
to their present location and condition.
Net realisable value is the estimated selling price in 
the ordinary course of business, less the estimated 
costs of completion and selling expenses necessary 
to make the sale.
Slow and non-moving material, products nearing 
expiry, defective inventory are fully provided for and 
valued at net realisable value.
Goods and materials in transit are valued at actual 
cost incurred up to the date of balance sheet. 
Materials and other items held for use in production 
of inventories are not written down, if the finished 
products in which they will be used are expected to 
be sold at or above cost.
Consumables and other materials procured for R&D 
purpose are charged off when acquired.
The comparison of cost and Net realisable value is 
made on an item-by-item basis.
6.7 Cash and Cash Equivalents
Cash and Cash Equivalents comprise of cash on 
hand and cash at bank including fixed deposit/highly 
liquid investments with original maturity period of 
three months or less that are readily convertible to 
known amounts of cash and which are subject to an 
insignificant risk of changes in value.
For the purpose of the statement of cash flows, cash 
and cash equivalents consist of cash and short-term 
deposits, as defined above, as they are considered 
an integral part of the Company‚Äôs cash management.
6.8 Cash Flow Statement
Cash flows are reported using the indirect method, 
whereby net profit before tax is adjusted for the 
effects of transactions of a non-cash nature, any 
deferrals or accruals of past or future operating cash 
receipts or payments and item of income or expenses 
associated with investing or financing cash flows. The 
cash flow from operating, investing and financing 
activities of the Company are segregated.
6.9 Foreign Currency Transactions
Transactions in foreign currencies are translated into 
the Company‚Äôs functional currency at the exchange 
rates at the dates of the transactions.
Monetary assets and liabilities denominated in foreign 
currencies are translated into the functional currency 
at the exchange rate at the reporting date. Non-
monetary assets and liabilities that are measured 
at fair value in a foreign currency are translated 
into the functional currency at the exchange rate 
when the fair value was determined. Non-monetary 
assets and liabilities that are measured based on 
historical cost in a foreign currency are not translated. 
Foreign currency exchange differences are generally 
recognised in the statement of profit and loss.
Exchange differences arising on the settlement of 
monetary items or on translating monetary items 
at rates different from those at which they were 
translated on initial recognition during the period or 
in previous Financial Statements are recognised in 
the Standalone Statement of Profit and Loss in the 
period in which they arise. When a gain or loss on a 
non-monetary item is recognised in Other 
Comprehensive Income, any exchange component of 
that gain or loss is recognised in Other Comprehensive 
Income. Conversely, when a gain or loss on a non-
monetary item is recognised in Standalone Statement 
of Profit and Loss, any exchange component of that 
gain or loss is recognised in Standalone Statement 
of Profit and Loss.
6.10 Revenue Recognition
	
Sale of Goods:
Revenue is measured based on the transaction 
price adjusted for discounts and rebates, which 
is specified in a contract with customer. Revenue 
are net of estimated returns and taxes collected 
from customers.
Revenue from sale of goods is recognised at point 
in time when control is transferred to the customer 
and it is probable that consideration will be collected. 
Control of goods is transferred upon the shipment of 
the goods to the customer or when goods is made 
available to the customer as per terms agreed.
The transaction price is documented on the sales 
invoice and payment is generally due as per agreed 
credit terms with customer.
The consideration can be fixed or variable. Variable 
consideration is only recognised when it is highly 
probable that a significant reversal will not occur.
Sales return is variable consideration that is recognised 
and recorded based on historical experience, market 
conditions and provided for in the year of sale as 
reduction from revenue. The methodology and 
assumptions used to estimate returns are monitored 
and adjusted regularly in line with trade practices, 
historical trends, past experience and projected 
market conditions.
Interest income: Interest income is recognised with 
reference to the Effective Interest Rate method.
Dividend income: Dividend from investment is 
recognised as revenue when right to receive 
is established.
	
Income from Export Benefits and Other Incentives
Export benefits available under prevalent schemes 
are accrued as revenue in the year in which the goods 
are exported and/or services are rendered only when 
their reasonable assurance that the conditions 
attached to them will be complied with, and the 
amounts will be received. Export benefit receivables 
are carried at net realisable value.
6.11 Employee Benefits
All employee benefits payable wholly within twelve 
months of rendering service are classified as short-
term employee benefits. Benefits such as salaries, 
wages, short-term compensated absences, 
performance incentives etc., and the expected cost 
of bonus, ex-gratia are recognised during the period 
in which the employee renders related service.
	
(i)	
Defined benefit plans
The Company provides for gratuity, a defined 
benefit retirement plan (‚Äòthe Gratuity Plan‚Äô) 
covering eligible employees. The Gratuity 
Plan provides a lump-sum payment to vested 
employees at retirement, death, incapacitation 
or termination of employment, of an amount 
based on the respective employee‚Äôs salary and 
the tenure of employment with the Company.
Liabilities with regard to Gratuity Plan are 
determined by actuarial valuation, performed by 
an independent actuary, at each balance sheet 
date using the Projected Unit Credit Method.
The Company fully contributes all ascertained 
liabilities to the Ajanta Pharma Limited Group 
Gratuity Trust (the Trust). Trustees administer 
contributions made to the Trust and contributions 
are invested in a scheme with Life Insurance 
Annual Report 2023-24
208
209
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Standalone
Notes to the Standalone Financial Statements
for the year ended 31 March 2024
Notes to the Standalone Financial Statements
for the year ended 31 March 2024
Corporation of India as permitted by laws 
of India.
The retirement benefit obligations recognised 
in the balance sheet represents the present 
value of the defined benefit obligations 
reduced by the fair value of scheme assets. Any 
asset resulting from this calculation is limited 
to the present value of available refunds and 
reductions in future contributions to the scheme. 
The Company recognises the net obligation of 
a defined benefit plan in its balance sheet as 
an asset or liability. Actuarial gains and losses 
are recognised in full in the other comprehensive 
income for the period in which they occur. The 
effect of any plan amendments are recognised 
in the Statement of Profit and Loss.
	
(ii)	 Defined contribution plans
Contributions to defined contribution plans are 
recognised as expense when employees have 
rendered services entitling them to such benefits.
The Company pays provident fund contributions 
to publicly administered provident funds as per 
local regulations. The Company has no further 
payment obligations once the contributions 
have been paid. The contributions are 
accounted for as defined contribution plans and 
the contributions are recognised as employee 
benefit expense when they are due. Prepaid 
contributions are recognised as an asset to the 
extent that a cash refund or a reduction in the 
future payments is available.
	
(iii)	 Compensated absences
The Company has a policy on compensated 
absences which are both accumulating and 
non-accumulating in nature. The expected 
cost of accumulating compensated absences 
is determined by actuarial valuation performed 
by an independent actuary at each balance 
sheet date using projected unit credit method 
on the additional amount expected to be paid/
availed within twelve months as a result of the 
unused entitlement that has accumulated at the 
balance sheet date.
Compensated absences which are not expected 
to occur within twelve months after the end of 
the period in which the employee renders the 
related services are recognised as a liability 
at the present value of the defined benefit 
obligation at the balance sheet date.
Expense on non-accumulating compensated 
absences is recognised in the period in which 
the absences occur.
	
(iv)	 Share-based compensation
Employees Stock Options Plans (‚ÄúESOPs‚Äù): 
The grant date fair value of options granted 
to employees is recognised as an employee 
expense, over the period that the employees 
become unconditionally entitled to the options. 
The expense is recorded for each separately 
vesting portion of the award as if the award 
was, in substance, multiple awards. The increase 
in equity recognised in connection with share-
based payment transaction is presented as a 
separate component in equity under ‚ÄúEmployee 
Stock Options Outstanding Reserve‚Äù. The amount 
recognised as an expense is adjusted to reflect 
the actual number of stock options that vest. 
The options granted to employees of subsidiary 
is recognised as an equity investment.
The Company recognises compensation 
expense relating to share-based payments in 
net profit using fair-value in accordance with Ind 
AS 102, Share-Based Payment.
6.12 Borrowing Costs
Borrowing costs directly attributable to the 
acquisition, construction or production of an asset 
that necessarily takes a substantial period of time to 
get ready for its intended use or sale are capitalised 
as part of the cost of the asset. All other borrowing 
costs are expensed in the period in which they occur. 
Borrowing costs consist of interest and other costs 
that an entity incurs in connection with the borrowing 
of funds. Borrowing cost also includes exchange 
differences to the extent regarded as an adjustment 
to the borrowing costs.
6.13 Leases
The Company‚Äôs lease asset classes primarily consist of 
leases for land and buildings. The Company assesses 
whether a contract contains a lease, at inception of 
a contract. A contract is, or contains, a lease if the 
contract conveys the right to control the use of an 
identified asset for a period of time in exchange for 
consideration. To assess whether a contract conveys 
the right to control the use of an identified asset, the 
Company assesses whether: (1) the contract involves 
the use of an identified asset (2) the Company has 
substantially all of the economic benefits from use of 
the asset through the period of the lease and (3) the 
Company has the right to direct the use of the asset.
At the date of commencement of the lease, the 
Company recognises a right-of-use asset (‚ÄúROU‚Äù) 
and a corresponding lease liability for all lease 
arrangements in which it is a lessee, except for 
leases with a term of twelve months or less (short-
term leases) and low value leases. For these short-
term and low value leases, the Company recognises 
the lease payments as an operating expense on a 
straight-line basis over the term of the lease.
Certain lease arrangements includes the options to 
extend or terminate the lease before the end of the 
lease term. ROU assets and lease liabilities includes 
these options when it is reasonably certain that they 
will be exercised.
The right-of-use assets are initially recognised at 
cost, which comprises the initial amount of the lease 
liability adjusted for any lease payments made at or 
prior to the commencement date of the lease plus 
any initial direct costs less any lease incentives. They 
are subsequently measured at cost less accumulated 
depreciation and impairment losses.
Right-of-use assets are depreciated from the 
commencement date on a straight-line basis over 
the shorter of the lease term and useful life of the 
underlying asset. Right of use assets are evaluated 
for recoverability whenever events or changes in 
circumstances indicate that their carrying amounts 
may not be recoverable. For the purpose of 
impairment testing, the recoverable amount (i.e. the 
higher of the fair value less cost to sell and the value-
in-use) is determined on an individual asset basis 
unless the asset does not generate cash flows that 
are largely independent of those from other assets. 
In such cases, the recoverable amount is determined 
for the Cash Generating Unit (CGU) to which the 
asset belongs.
The lease liability is initially measured at amortised 
cost at the present value of the future lease 
payments. The lease payments are discounted using 
the generally accepted interest rate. Lease liabilities 
are remeasured with a corresponding adjustment to 
the related right of use asset if the Company changes 
its assessment if whether it will exercise an extension 
or a termination option.
Lease liability and ROU asset have been separately 
presented in the Balance Sheet and lease payments 
have been classified as financing cash flows.
Leases for which the Company is a lessor is classified 
as a finance or operating lease. Whenever the terms 
of the lease transfer substantially all the risks and 
rewards of ownership to the lessee, the contract is 
classified as a finance lease. All other leases are 
classified as operating leases.
In respect of assets given on operating lease, lease 
rentals are accounted in the Statement of Profit 
and Loss, on accrual basis in accordance with the 
respective lease agreements.
6.14 Government Grants
Government grants are initially recognised as deferred 
income at fair value if there is reasonable assurance 
that they will be received and the Company will 
comply with the conditions associated with the grant;
‚Ä¢	 In case of capital grants, they are then recognised 
in Standalone Statement of Profit and Loss as other 
income on a systematic basis over the useful life 
of the asset.
‚Ä¢	 In case of grants that compensate the Company 
for expenses incurred are recognised in Standalone 
Statement of Profit and Loss on a systematic basis 
in the periods in which the expenses are recognised.
6.15 Earnings Per Share
Basic earnings per equity share is computed by 
dividing the net profit attributable to the equity 
holders of the Company by the weighted average 
number of equity shares outstanding during the 
period. Diluted earnings per equity share is computed 
by dividing the net profit attributable to the equity 
holders of the Company by the weighted average 
number of equity shares considered for deriving basic 
earnings per equity share and also the weighted 
average number of equity shares that could have 
been issued upon conversion of all dilutive potential 
equity shares. The dilutive potential equity shares are 
adjusted for the proceeds receivable had the equity 
shares been actually issued at fair value. Dilutive 
potential equity shares are deemed converted as of 
the beginning of the period, unless issued at a later 
date. Dilutive potential equity shares are determined 
independently for each period presented.
6.16 Income Taxes
Income tax expense comprises current and deferred 
income tax.
Current tax is recognised in statement of profit or loss, 
except when they relate to items that are recognised 
in other comprehensive income or directly in equity, 
in which case, the current tax is also recognised in 
other comprehensive income or directly in equity 
Annual Report 2023-24
210
211
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Standalone
Notes to the Standalone Financial Statements
for the year ended 31 March 2024
Notes to the Standalone Financial Statements
for the year ended 31 March 2024
respectively. Current income tax for current and prior 
periods is recognised at the amount expected to be 
paid to or recovered from the tax authorities, using 
the tax rates and tax laws that have been enacted 
by the balance sheet date. Deferred income tax 
assets and liabilities are recognised for all temporary 
differences arising between the tax bases of assets 
and liabilities and their carrying amounts in the 
financial statements.
Deferred tax assets are reviewed at each reporting 
date and are reduced to the extent that it is no longer 
probable that the related tax benefit will be realised.
Deferred income tax assets and liabilities are 
measured using tax rates and tax laws that have 
been enacted or substantively enacted by the 
balance sheet date and are expected to apply to 
taxable income in the years in which those temporary 
differences are expected to be recovered or settled. 
The effect of changes in tax rates on deferred income 
tax assets and liabilities is recognised as income or 
expense in the period that includes the enactment 
or the substantive enactment date. A deferred 
income tax asset is recognised to the extent that it is 
probable that future taxable profit will be available 
against which the deductible temporary differences 
and tax losses can be utilised. The Company offsets 
current tax assets and current tax liabilities, where 
it has a legally enforceable right to set off the 
recognised amounts and where it intends either to 
settle on a net basis, or to realise the asset and settle 
the liability simultaneously.
Management periodically evaluates positions taken 
in the tax returns with respect to situations in which 
applicable tax regulations are subject to interpretation 
and establishes provisions where appropriate.
6.17 Dividends to Shareholders
Annual dividend distribution to the shareholders is 
recognised as a liability in the period in which the 
dividends are approved by the shareholders. Any 
interim dividend paid is recognised on approval by 
Board of Directors. Dividend payable is recognised 
directly in equity.
6.18 Provisions, Contingent Liabilities, Contingent 
Assets and Commitments
	
General:
Provisions (legal and constructive) are recognised 
when the Company has a present obligation (legal 
or constructive) as a result of a past event and it is 
probable that an outflow of resources will be required 
to settle the obligation, in respect of which a reliable 
estimate can be made.
Provisions (excluding retirement benefits and 
compensated absences) are not discounted to its 
present value and are determined based on best 
estimate required to settle the obligation at the 
balance sheet date. These are reviewed at each 
balance sheet date and adjusted to reflect the 
current best estimates.
If there is any expectation that some or all of the 
provision will be reimbursed, the reimbursement is 
recognised as a separate asset but only when the 
reimbursement is virtually certain. The expense relating 
to a provision is presented in the statement of profit 
and loss net of any virtually certain reimbursement.
If the effect of the time value of money is material, 
provisions are discounted using a current pre-tax rate 
that reflects, when appropriate, the risk specific to the 
liability. When discounting is used, the increase in the 
provision due to the passage of time is recognised 
as a finance cost.
Contingent liability is disclosed in the case of:
‚Ä¢	 A present obligation arising from past events, when 
it is not probable that an outflow of resources will 
be required to settle the obligation;
‚Ä¢	 A present obligation arising from past events, when 
no reliable estimates is possible;
‚Ä¢	 A possible obligation arising from past events, 
unless the probability of outflow of resources 
is remote.
Contingent liabilities are not recognised but disclosed 
in the standalone financial statements. Contingent 
assets are neither recognised nor disclosed in the 
financial statements.
Commitments include the amount of purchase order 
(net of advances) issued to parties for completion of 
assets and Non-cancellable operating lease.
Provisions, contingent liabilities, contingent assets 
and commitments are reviewed at each balance 
sheet date.
6.19 Fair Value Measurement
The Company measures financial instruments, such 
as, derivatives at fair value at each balance sheet 
date in accordance with Ind AS 113.
Financials Statements have been prepared on the 
historical cost basis except for the following material 
items in the statement of financial position:
‚Ä¢	 Derivative financial instruments (mainly forward 
currency contracts) are measured at fair value 
received from Bank.
‚Ä¢	 Mutual Funds are measured at fair values as per 
Net Asset Value (NAV).
‚Ä¢	 Employee Stock Option Plan (ESOP) at fair values 
as per Black Scholes option pricing model.
Fair value is the price that would be received 
to sell an asset or settle a liability in an ordinary 
transaction between market participants at the 
measurement date.
The fair value of an asset or a liability is measured 
using the assumptions that market participants 
would use when pricing the asset or liability, assuming 
that market participants act in their economic 
best interest.
A fair value measurement of a non-financial asset 
takes into account a market participant‚Äôs ability to 
generate economic benefits by using the asset in its 
highest and best use or by selling it to another market 
participant that would use the asset in its highest and 
best use.
The Company uses valuation techniques that are 
appropriate in the circumstances and for which 
sufficient data are available to measure fair value, 
maximising the use of relevant observable inputs and 
minimising the use of unobservable inputs.
All assets and liabilities for which fair value is 
measured or disclosed in the financial statements are 
categorised within the fair value hierarchy, described 
as follows, based on the lowest level input that is 
significant to the fair value measurement as a whole:
‚Ä¢	 Level 1 ‚Äî Quoted (unadjusted) market prices in 
active markets for identical assets or liabilities.
‚Ä¢	 Level 2 ‚Äî Valuation techniques for which the 
lowest level input that is significant to the fair value 
measurement is directly or indirectly observable.
‚Ä¢	 Level 3 ‚Äî Valuation techniques for which the 
lowest level input that is significant to the fair value 
measurement is unobservable.
For assets and liabilities that are recognised in the 
financial statements on a recurring basis, the Company 
determines whether transfers have occurred between 
levels in the hierarchy by re-assessing categorisation 
(based on the lowest level input that is significant to 
the fair value measurement as a whole) at the end of 
each reporting period.
For the purpose of fair value disclosures, the Company 
has determined classes of assets and liabilities on 
the basis of the nature, characteristics and risks of 
the asset or liability and the level of the fair value 
hierarchy as explained above.
7. 
Recent Accounting Pronouncements
Ministry of Corporate Affairs (‚ÄúMCA‚Äù) notifies new 
standard or amendments to the existing standards 
under Companies (Indian Accounting Standards) 
Rules as issued from time to time. For the year 
ended 31 March 2024, MCA has not notified any new 
standards or amendments to the existing standards 
applicable to the Company.
Annual Report 2023-24
212
213
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Standalone
Notes to the Standalone Financial Statements
as at 31 March 2024
Notes to the Standalone Financial Statements
as at 31 March 2024
8.  Property, Plant and Equipment, Capital Work-In -Progress, investment Properties and other 
Intangible Assets (other than self generated)	
8.1 Current Year 
H in Crore
Particulars 
Gross Block (Cost or Deemed cost) 
Accumulated Depreciation/Amortisation 
Net Block 
As at 
1 April 
2023 
 Additions 
 Disposals 
 As at 
31 March 
2024 
 As at 
1 April 
2023 
 For the 
year 
Disposals 
 As at 
31 March 
2024 
 As at 
31 March 
2024 
(A) Property, plant and 
equipment 
Freehold land** 
 155.55 
 - 
 8.85 
 146.70 
 - 
 - 
 - 
 - 
 146.70 
Buildings 
 597.57 
 11.79 
 - 
 609.36 
 149.74 
 15.89 
 - 
 165.63 
 443.73 
Plant and equipments 
 1,027.03 
 69.66 
 2.84 
 1,093.85 
 388.80 
 70.49 
 2.38 
 456.91 
 636.94 
Laboratory equipments 
 196.17 
 10.49 
 0.03 
 206.63 
 92.90 
 18.21 
 0.01 
 111.10 
 95.53 
Furniture and fixtures 
 90.17 
 1.89 
 0.01 
 92.05 
 54.17 
 5.69 
 0.01 
 59.85 
 32.20 
Vehicles 
 3.37 
 0.04 
 - 
 3.41 
 2.29 
 0.22 
 - 
 2.51 
 0.90 
Office equipments 
 25.67 
 2.07 
 0.21 
 27.53 
 18.56 
 2.31 
 0.20 
 20.67 
 6.86 
Computers 
 34.18 
 7.96 
 0.57 
 41.57 
 23.41 
 4.69 
 0.53 
 27.57 
 14.00 
Total 
 2,129.71 
 103.90 
 12.51 
 2,221.10 
 729.87 
 117.50 
 3.13 
 844.24 
 1,376.86 
(B) Other Intangible assets 
Computer Software 
 26.00 
 11.61 
 - 
 37.61 
 21.12 
 3.88 
 - 
 25.00 
 12.61 
Total 
 26.00 
 11.61 
 - 
 37.61 
 21.12 
 3.88 
 - 
 25.00 
 12.61 
Total (A)+(B) 
 2,155.71 
 * 115.51 
 12.51 
 2,258.71 
 750.99 
 121.38 
 3.13 
 869.24 
 1,389.47 
(C) Investment Properties 
 - 
 - 
 - 
 - 
 - 
 - 
 - 
 - 
 - 
(D) Capital work-in-progress# 
 209.47 
 169.63 
 122.65 
 256.45 
 - 
 - 
 - 
 - 
 256.45 
Total (A)+(B)+(C)+(D)
 1,645.92 
* Addition includes H 4.83 Crore used for Research and Development.
** Freehold land H 8.85 Crore classified as assets held for sale (refer note 21).
#Capital work-in-progress ageing
H in Crore
Particulars
Amount in Capital Work-In-Progress for a period of
Total 
Less than 
1 year 
1-2 years 
2-3 years 
More than 
3 years 
Projects in progress (*) 
 121.75 
 36.65 
 38.86 
 59.19 
 256.45 
* Project execution plans are assessed on an annual basis and all the projects are executed as per rolling annual plan.
CWIP includes cost incurred on corporate house under construction and is schedule to meet the annual rolling plan 
though there is delay as compared to the original plan due to delays in Government approval, pandemic and various 
other pediments outside of management control at various stages. There are no identified overruns from budgeted cost.
8.2 Previous Year
H in Crore
Particulars 
Gross Block (Cost or Deemed Cost) 
Accumulated Depreciation/Amortisation 
Net Block 
As at 
1 April 
2022 
 Additions 
 Disposals 
 As at 
31 March 
2023
 As at 
1 April 
2022 
 For the 
year 
Disposals 
 As at 
31 March 
2023 
 As at 
31 March 
2023 
(A) Property, plant and 
equipment 
Freehold land 
 155.55 
 - 
 - 
 155.55 
 - 
 - 
 - 
 - 
 155.55 
Buildings 
 579.33 
 18.87 
 0.63 
 597.57 
 133.85 
 16.01 
 0.12 
 149.74 
 447.83 
Plant and equipments 
 979.45 
 52.14 
 4.56 
 1,027.03 
 323.26 
 68.96 
 3.42 
 388.80 
 638.23 
Laboratory equipments 
 178.08 
 18.70 
 0.61 
 196.17 
 76.65 
 16.64 
 0.39 
 92.90 
 103.27 
H in Crore
Particulars 
Gross Block (Cost or Deemed Cost) 
Accumulated Depreciation/Amortisation 
Net Block 
As at 
1 April 
2022 
 Additions 
 Disposals 
 As at 
31 March 
2023
 As at 
1 April 
2022 
 For the 
year 
Disposals 
 As at 
31 March 
2023 
 As at 
31 March 
2023 
Furniture and fixtures 
 83.88 
 6.40 
 0.11 
 90.17 
 48.72 
 5.49 
 0.04 
 54.17 
 36.00 
Vehicles 
 3.37 
 - 
 - 
 3.37 
 2.05 
 0.24 
 - 
 2.29 
 1.08 
Office equipments 
 23.59 
 2.31 
 0.23 
 25.67 
 16.58 
 2.20 
 0.22 
 18.56 
 7.11 
Computers 
 28.17 
 6.94 
 0.93 
 34.18 
 20.09 
 4.17 
 0.85 
 23.41 
 10.77 
Total 
 2,031.42 
 105.36 
 7.07 
 2,129.71 
 621.20 
 113.71 
 5.04 
 729.87 
 1,399.84 
(B) Other Intangible assets 
Computer Software 
 23.89 
 2.11 
 - 
 26.00 
 18.07 
 3.05 
 - 
 21.12 
 4.88 
Total 
 23.89 
 2.11 
 - 
 26.00 
 18.07 
 3.05 
 - 
 21.12 
 4.88 
Total (A)+(B) 
 2,055.31 
 * 107.47 
 7.07 
 2,155.71 
 639.27 
 116.76 
 5.04 
 750.99 
 1,404.72 
(C) Investment Properties** 
 10.93 
 - 
 10.93 
 - 
 2.52 
 0.49 
 3.01 
 - 
 - 
(D) Capital work-in-progress# 
 152.86 
 164.08 
 107.47 
 209.47 
 - 
 - 
 - 
 - 
 209.47 
Total (A)+(B)+(C)+(D)
 1,614.19 
* Addition includes H 18.20 Crore used for Research and Development.
** Investment property classified as held for sale (refer note 21)
#Capital work-in-progress ageing
H in Crore
Particulars
Amount in Capital Work-In-Progress for a period of
Total 
Less than 1 year 
1-2 years 
2-3 years 
More than 
3 years 
 Projects in progress (*) 
 97.81 
 51.86 
 29.37 
 30.43 
 209.47 
* Project execution plans are assessed on an annual basis and all the projects are executed as per rolling annual plan. 
Right-Of-Use Assets
8.3 Current Year
 Particulars 
Gross Block (Cost or Deemed Cost) 
Accumulated Depreciation/Amortisation 
Net Block 
 As at 
1 April 
2023 
 Additions 
 Disposals 
 As at 
31 March 
2024 
As at 
1 April 
2023 
 For the 
year  Disposals 
 As at 
31 March 
2024 
 As at 
31 March 
2024 
Right-of-use assets 
Leasehold properties 
 27.98 
 7.15 
 1.10 
 34.03 
 8.46 
 9.83 
 0.86 
 17.43 
 16.60 
Leasehold land 
 62.59 
 - 
 - 
 62.59 
 2.82 
 0.95 
 - 
 3.77 
 58.82 
Total 
 90.57 
 7.15 
 1.10 
 96.62 
 11.28 
 10.78 
 0.86 
 21.20 
 75.42 
8.4 Previous Year
 Particulars 
Gross Block (Cost or Deemed Cost) 
Accumulated Depreciation/Amortisation 
Net Block 
 As at 
1 April 
2022 
 Additions 
 Disposals 
 As at 
31 March 
2023 
As at 
1 April 
2022 
 For the 
year  Disposals 
 As at 
31 March 
2023 
 As at 
31 March 
2023
 Right-of-use assets 
 Leasehold properties 
 34.35 
 21.17 
 27.54 
 27.98 
 27.19 
 8.75 
 27.48 
 8.46 
 19.52 
 Leasehold land 
 62.59 
 - 
 - 
 62.59 
 1.87 
 0.95 
 - 
 2.82 
 59.77 
 Total 
 96.94 
 21.17 
 27.54 
 90.57 
 29.06 
 9.70 
 27.48 
 11.28 
 79.29 
Annual Report 2023-24
214
215
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Standalone
Notes to the Standalone Financial Statements
as at 31 March 2024
Notes to the Standalone Financial Statements
as at 31 March 2024
9. 
Investments (Non-current) 
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Unquoted (At cost) 
In Subsidiary Companies 
Ajanta Pharma (Mauritius) Ltd. 
6,13,791 (31 March 2023 6,13,791) Ordinary Shares of Mauritian Rupees 100 each fully paid up 
 9.44 
 9.44 
Ajanta Pharma USA Inc 
10,000 (31 March 2023 10,000) Common Stock of USD 100 each fully paid up (includes H 1.62 
Crore in current year, H 1.00 Crore in previous year related to ESOP granted to employee of 
subsidiary) 
 7.69 
 7.07 
Ajanta Pharma Philippines Inc. 
20,00,000 (31 March 2023 20,00,000) Ordinary Shares of Philippines Peso 100 each fully paid up 
 1.38 
 1.38 
Ajanta Pharma Nigeria Limited 
6,00,00,000 (31 March 2023 6,00,00,000) Ordinary Shares of Nigerian Naira 1 each fully paid up 
 1.37 
 1.37 
Less: Impairment in the value of investments (refer note 63) 
 (1.37)
 (1.37)
In Joint Venture 
Turkmenderman Ajanta Pharma Ltd.
2,00,000 (31 March 2023 2,00,000) Shares of USD 10 each fully paid-up 
 - 
 - 
Less: Impairment in the value of investments* 
 - 
 - 
In Others at fair value 
OPGS Power Gujarat Private Limited 
1,95,000 (31 March 2023 1,95,000) Shares of H 0.19 each 
0.00
0.00
(Current Year H 37,050, Previous Year H 37,050) 
In Membership Share in LLP (at Fair Value through Profit or Loss)
ABCD Technologies LLP (Percentage share 4.03%)
 18.58 
 25.10 
 37.09 
 42.99 
Aggregate value of unquoted investments 
 45.41 
 51.31 
Aggregate value of unquoted investments (net of impairment) 
 37.09 
 42.99 
Aggregate market value of quoted investments 
 - 
 - 
Aggregate amount of impairment in value of non-current investment 
 8.32 
 8.32 
* The Company has made full provision for investment in aggregate value of unquoted investments in Turkmenderman Ajanta Pharma Limited 
in year 2014-15 and the carrying value of investment is considered as Nil. 
10. Other Non-Current Financial Assets
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Unsecured, considered good unless otherwise stated
Security Deposits 
 4.55 
 6.14 
Financial asset at amortised cost 
 4.16 
 3.90 
In deposit accounts with banks with maturity of more than 12 months from the balance sheet 
date 
-	
Under lien 
 0.19 
 0.84 
Interest accrued on fixed deposits with Banks 
 0.02 
 0.11 
 8.92 
 10.99 
11. Non-Current Tax Assets (Net)
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Income tax paid (net of provision H 122.40 Crore 31 March 2023) 
 - 
 0.83 
 - 
 0.83 
12. Other Non-Current Assets
(Unsecured, considered good unless otherwise stated)
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Capital advances 
 7.88 
 4.77 
VAT receivable 
 0.02 
 0.02 
Octroi refund receivable 
 0.52 
 0.52 
 8.42 
 5.31 
13. Inventories
(At lower of cost and net realisable value)
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Raw materials 
 233.25 
 264.40 
Packing materials 
 54.71 
 51.71 
Work-in-progress 
 54.35 
 52.46 
Finished goods (including in transit H 120.57 Crore, 31 March 2023 H 90.06 Crore)
 291.31 
 278.59 
Stock-in-trade (including in transit H 5.02 Crore, 31 March 2023 H 3.49 Crore)
 44.17 
 36.61 
 677.79 
 683.77 
During the year, the Company recorded inventory write downs of H 4.95 Crore (31 March 2023 H 4.42 Crore). These adjustments were included 
in cost of material consumed and changes in inventories.
14. Current Investments
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Measured at Fair Value through Profit or Loss 
Quoted 
Investments in Market Linked Non-Convertible Debentures 
 37.12 
 161.56 
Investment in Mutual Funds 
 10.24 
 178.32 
Measured at Amortised Cost 
Quoted 
Investments in Non-Convertible Debentures 
 251.79 
 46.18 
Unquoted 
Investment in Commercial Papers 
 30.90 
 124.21 
 330.05 
 510.27 
Aggregate book value of quoted investments 
 299.15 
 386.06 
Aggregate market value of quoted investments 
 299.15 
 386.06 
Aggregate book value of unquoted investments (net of impairment) 
 30.90 
 124.21 
Aggregate amount of impairment in value of investments 
 - 
 - 
Annual Report 2023-24
216
217
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Standalone
Notes to the Standalone Financial Statements
as at 31 March 2024
Notes to the Standalone Financial Statements
as at 31 March 2024
15. Trade Receivables
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Unsecured, considered good unless otherwise stated 
Trade receivables considered good
 1,207.67 
 977.63 
Trade receivables which have significant increase in credit risk
 2.70 
 2.82 
Trade receivables credit impaired
 6.13 
 8.22 
 1,216.50 
 988.67 
Less: Loss allowance 
 (8.83)
 (11.04)
Total Trade receivables 
 1,207.67 
 977.63 
Break-up of security details
(i)	 Trade receivables considered good- Secured
 - 
 - 
(ii)	 Trade receivables considered good- Unsecured
 1,207.67 
 977.63 
(iii)	 Trade receivables which have significant increase in credit risk
 2.70 
 2.82 
(iv)	 Trade receivables - credit impaired
 6.13 
 8.22 
Total
 1,216.50 
 988.67 
Less: Loss allowance 
 (8.83)
 (11.04)
Total Trade receivables
 1,207.67 
 977.63 
Of the above, trade receivables from related parties are as below:
Trade Receivable due from related parties
 787.91 
 634.66 
Less: Loss allowance 
 (1.07)
 (0.52)
Net Trade receivables
 786.84 
 634.14 
For details of trade receivable owing from related parties, refer note 54.
Ageing Schedule for Trade Receivables as at 31 March 2024
 H in Crore 
Particulars
 Not Due 
 Outstanding for following period from due date of payment 
 Total 
 Less than 
6 months 
 6 months 
-1 year 
 1 -2 year 
 2-3 years  More than 
3 years 
(i)	 Undisputed Trade receivables ‚Äì 
considered good
 815.71 
 378.68 
 12.70 
 0.58 
 - 
 - 
 1,207.67 
(ii)	 Undisputed Trade Receivables ‚Äì 
which have significant increase in 
credit risk
 - 
 - 
 - 
 - 
 - 
 - 
 - 
(iii)	 Undisputed Trade Receivables ‚Äì 
credit impaired
 - 
 1.71 
 1.13 
 0.10 
 2.28 
 0.91 
 6.13 
(iv)	 Disputed Trade Receivables ‚Äì 
considered good
 - 
 - 
 - 
 - 
 - 
 - 
 - 
(v)	 Disputed Trade Receivables ‚Äì which 
have significant increase in credit risk
 - 
 - 
 - 
 - 
 2.70 
 - 
 2.70 
(vi)	 Disputed Trade Receivables ‚Äì credit 
impaired
 - 
 - 
 - 
 - 
 - 
 - 
 - 
Total
 815.71 
 380.39 
 13.83 
 0.68 
 4.98 
 0.91 
 1,216.50 
Less - Loss Allowance
 (8.83)
Total Trade Receivables
 1,207.67 
Ageing Schedule for Trade Receivables as at 31 March 2023
 H in Crore 
Particulars
 Not Due 
 Outstanding for following period from due date of payment 
 Total 
 Less than 
6 months 
 6 months - 
1 year 
 1 -2 year 
 2-3 years 
 More than 
3 years 
(i)	 Undisputed Trade receivables ‚Äì 
considered good
 779.65 
 194.09 
 1.49 
 2.40 
 - 
 - 
 977.63 
(ii)	 Undisputed Trade Receivables ‚Äì 
which have significant increase in 
credit risk
 - 
 - 
 - 
 - 
 - 
 - 
 - 
(iii)	 Undisputed Trade Receivables ‚Äì 
credit impaired
-
 0.80 
 0.59 
 6.50 
 0.06 
 0.27 
 8.22 
(iv)	 Disputed Trade Receivables ‚Äì 
considered good
 - 
 - 
 - 
 - 
 - 
 - 
 - 
(v)	 Disputed Trade Receivables ‚Äì which 
have significant increase in credit risk
 - 
 - 
 - 
 - 
 - 
 2.82 
 2.82 
(vi)	 Disputed Trade Receivables ‚Äì credit 
impaired
 - 
 - 
 - 
 - 
 - 
 - 
 - 
Total
 779.65 
 194.89 
 2.08 
 8.90 
 0.06 
 3.09 
 988.67 
Less - Loss Allowance
 (11.04)
Total Trade Receivables
 977.63 
There are no unbilled receivables, hence the same is not disclosed in the ageing schedule.
There are no other trade receivables which have significant increase in credit risk, refer note 49 B for information about 
credit risk and market risk of trade receivables.
The loss allowance on trade receivable has been computed on the basis of Ind AS 109, Financial Instruments which 
require such allowance to be made even for trade receivable considered good on the basis that credit risk exists even 
though it may be very low. The Company exposure to credit and currency risk and loss allowance related to trade 
receivable are disclosed in note 49 B.
16. Cash and Cash Equivalents
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Cash and cash equivalents (as per Ind AS 7 - "Statement of cash flows") 
Bank Balances 
-	
In Current Accounts 
 22.85 
 37.19 
-	
In EEFC Accounts 
 38.93 
 185.16 
In Deposit Accounts (with original maturity of 3 months or less)* 
-	
Under Lien 
 - 
 46.50 
 61.78 
 268.85 
Balance of H Nil (Previous year H 46.50 Crore) includes deposits account is subject to restrictions on account of share brought back 
17. Bank Balances Other than Cash and Cash Equivalents
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Earmarked balances with banks 
-	
Unpaid dividend
 0.72 
 0.82 
-	
Unpaid Sale Proceeds of Fractional Shares (31 March 2024 H 24,226 {including deposit of  
H 8,935} and 31 March 2023 H 25,289 {including deposit of H 9,998})
0.00
0.00
In deposit accounts (with original maturity of more than 3 months but less than 12 months)
-	
Under Lien 
 0.56 
 0.25 
 1.28 
 1.07 
Annual Report 2023-24
218
219
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Standalone
Notes to the Standalone Financial Statements
as at 31 March 2024
Notes to the Standalone Financial Statements
as at 31 March 2024
18. Loans
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Advance to employees 
 13.21 
 14.93 
Loans to employees 
 2.19 
 2.08 
 15.40 
 17.01 
 H in Crore 
Particulars
 As at 
31 March 2024 
 As at 
31 March 2023 
Loans to employees
Secured, considered good 
 - 
 - 
Unsecured, considered good 
 2.19 
 2.08 
Significant increase in Credit Risk 
 - 
 - 
Credit impaired 
 - 
 - 
19. Other Current Financial Assets
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Interest receivable 
 6.54 
 2.48 
Forward exchange contracts used for hedging 
 12.48 
 - 
 19.02 
 2.48 
20. Other Current Assets
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Advances other than capital advances 
Advance to vendors 
- 	 Considered Good 
 34.42 
 20.99 
Prepaid expenses 
 16.50 
 12.91 
Other advances recoverable 
 5.79 
 4.85 
Balance with Statutory/Govt. Authorities 
- 	 GST receivable 
 54.29 
 40.26 
- 	 Customs duty receivable 
 0.01 
 0.01 
Export benefits receivable 
 8.82 
 3.17 
 119.83 
 82.19 
21. Assets Classified as Held for Sale
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Assets held for sale (Refer note 64) 
 8.85 
 7.92 
 8.85 
 7.92 
22. Equity Share Capital
Particulars
As at 31 March 2024
As at 31 March 2023
 Number of 
Shares 
D in Crore
 Number of 
Shares 
D in Crore
Authorised
Equity shares of H 2 each
 15,00,00,000 
 30.00 
 15,00,00,000 
 30.00 
Issued, subscribed and paid up:
Issued, subscribed and fully paid up Equity Shares  
of H 2 each
 12,59,15,655 
 25.18 
 12,59,14,655 
 25.18 
Add: Shares Forfeited
 7,66,500 
 0.09 
 7,66,500 
 0.09 
Total 
 12,66,82,155 
 25.27 
 12,66,81,155 
 25.27 
22.1 Movement in Equity Share Capital
Particulars
As at 31 March 2024
As at 31 March 2023
 Number of 
Shares 
D in Crore
 Number of 
Shares 
D in Crore
Equity shares outstanding at the beginning of the year
 12,59,14,655 
 25.18 
 8,54,15,770 
 17.08 
Add: Equity shares allotted during the year against option's 
exercised under employee stock option plan
 1,000 
0.00#
 1,000 
 0.00* 
Less: Equity Shares extinguished on buyback of shares 
(Refer note 22.8)
 - 
 - 
 (22,10,500)
 (0.44)
Add: Equity shares allotted during the year as Bonus@
 - 
 - 
 4,27,07,885 
 8.54 
Add: Equity shares allotted during the year as Bonus 
on ESOP option's exercised (Current Year Nil, Previous 
Year 500) 
 - 
 - 
 500 
 0.00** 
Equity Shares outstanding at the end of the year
 12,59,15,655 
 25.18 
 12,59,14,655 
 25.18 
# H 2,000 * H 2,000 ** H 1,000
@ In the previous year, the Company has allotted the bonus shares at a ratio of 1:2 in it‚Äôs Board Meeting held on 24 June 2022. Accordingly, 
the number of shares increased from 8,54,16,770 to 12,81,25,155. The paid-up capital on account of Bonus issue of H 2.62 Crore has been 
appropriated from Capital Redemption Reserve, H 0.18 Crore has been appropriated from Securities Premium and H 5.73 Crore has been 
appropriated from General Reserve.
22.2 Rights Attached to Equity Shares
The Company has only one class of equity shares with voting rights having a par value of H 2 per share. The Company 
declares and pays dividends in Indian Rupees. Any interim dividend paid is recognised on the approval by Board 
of Directors.
The following dividends were declared and paid by the Company during the year ended: 
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Interim and final equity dividend were declared and paid for financial year 2022-23 at H 7.00 
per equity share 
 - 
 89.69 
Interim and final equity dividend were declared and paid for financial year 2023-24 at H 51.00 
per equity share 
 642.17 
 - 
Total 
 642.17 
 89.69 
In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets 
of the Company, after distribution of all preferential amounts. The distribution will be in proportion to the numbers of 
equity shares held by shareholders.
Dividends and tax thereon have not been recognised as liabilities in the year to which they pertain to and is recorded 
in the year in which they have been approved in the Annual General Meeting. 
Annual Report 2023-24
220
221
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Standalone
Notes to the Standalone Financial Statements
as at 31 March 2024
Notes to the Standalone Financial Statements
as at 31 March 2024
22.3 Details of Shareholders Holding more than 5% Equity Shares
Name of Shareholders
As at 31 March 2024
As at 31 March 2023
 Number of 
Shares 
 % of total 
shares 
 Number of 
Shares 
 % of total 
shares 
Yogesh M. Agrawal, trustee Yogesh Agrawal Trust
 1,82,33,038 
 14.48 
 1,82,33,038 
 14.48 
Rajesh M. Agrawal, trustee Rajesh Agrawal Trust
 1,82,33,039 
 14.48 
 1,82,33,039 
 14.48 
Ravi P. Agrawal, trustee Ravi Agrawal Trust
 1,63,86,623 
 13.01 
 1,63,86,623 
 13.01 
Aayush M. Agrawal, trustee Aayush Agrawal Trust
 1,42,37,664 
 11.31 
 1,42,37,664 
 11.31 
Gabs Investments Private Limited
 1,25,88,393 
 10.00 
 1,25,88,393 
 10.00 
22.4 Equity shares reserved for issuance under Employee Stock Options Scheme 2011 of the Company
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
 Number of 
Shares 
 Number of 
Shares 
Equity shares*
 - 
 10,95,250 
* During the year, the Company made the decision to withdraw the Employee Stock Options Scheme 2011 in the Nomination & Remuneration 
Committee meeting held on 31 January 2024, with immediate effect.
22.5 Equity shares reserved for issuance under Share-based Incentive Plan 2019 of the Company
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
 Number of 
Shares 
 Number of 
Shares 
Equity shares 
 4,94,500 
 4,95,500 
22.6 Aggregate number of equity shares issued during last five years pursuant to Employee Stock 
Options Scheme 2011 & Share-based Incentive Plan 2019
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
 Number of 
Shares 
 Number of 
Shares 
Equity shares 
 2,28,250 
 2,27,250 
22.7 Equity shares allotted as fully paid up bonus Shares during the period of five years immediately 
preceding the balance sheet date
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
 Number of 
Shares 
 Number of 
Shares 
Bonus Shares on allotment of ESOP in FY 2022-23
 500 
 500 
Bonus Shares issued in FY 2022-23
 4,27,07,885 
 4,27,07,885 
22.8 Equity shares extinguished on buy-back
For the year ended on 31 March 2024
Board of Directors have approved buy back of its 10,28,881 equity shares, being 0.82% of the total paid up equity 
share capital (prior buyback) at H 2,770 per equity share for an aggregate amount of H 285.00 Crore on 02 May 2024.
For the year ended on 31 March 2023
The Board of Directors of the Company, at its meeting held on 10 March 2023 had approved the proposal of Buy-back 
of 22,10,500 fully paid-up equity shares of the Company of face value of H 2 each at a price of H 1,425/- per equity 
share, on a proportionate basis, for an aggregate amount not exceeding H 315.00 Crore through the tender offer 
process (‚ÄúBuyback‚Äù), in accordance with the provisions of the Companies Act, 2013, and rules made thereunder, and 
the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018 (the ‚ÄúSEBI Buyback Regulations‚Äù). 
The buyback issue opened on 31 March 2023 and closed on 10 April 2023. The Company has taken the impact of 
buyback in previous financial year and paid in current financial year, for this Company has utilised its General Reserve 
(H 315.00 Crore) for the buyback of its equity shares. Total transaction cost of H 2.36 Crore (current year H 0.92 Crore 
and previous year H 1.44 Crore) incurred towards buyback and tax of H 73.28 Crore was offset from retained earnings. 
In accordance with Section 69 of the Companies Act 2013, the Company has created Capital Redemption Reserve 
of H 0.44 Crore equal to the nominal value of the shares bought back as an appropriation from the General Reserve.
For the year ended on 31 March 2022
The Company bought back 11,20,000 equity shares for an aggregate amount not exceeding of H 285.60 Crore being 
1.29% of the total paid up equity share capital (prior buyback) at H 2,550 per equity share. The equity shares bought 
back were extinguished on 28 February 2022.
For the year ended on 31 March 2021
The Company bought back 7,35,000 equity shares for an aggregate amount not exceeding of H 136 Crore being 0.84% 
of the total paid up equity share capital (prior buyback) at H 1,850 per equity share. The equity shares bought back 
were extinguished on 30 December 2020.
For the year ended on 31 March 2019
The Company bought back 7,69,230 equity shares for an aggregate amount not exceeding of H 100 Crore being 0.87% 
of the total paid up equity share capital (prior buyback) at H 1,300 per equity share. The equity shares bought back 
were extinguished on 26 March 2019.
22.9 Details of Equity Shares held by Promoters at the End of the Year
Name of Promoter
As at 31 March 2024
As at 31 March 2023
 Number of 
Shares 
 % of total 
shares 
 % Change 
during the 
year 
 Number of 
Shares 
 % of total 
shares 
 % Change 
during the 
year 
Yogesh M. Agrawal, trustee Yogesh Agrawal Trust
 1,82,33,038 
 14.48 
 -  1,82,33,038 
 14.48 
 47.28 
Rajesh M. Agrawal, trustee Rajesh Agrawal Trust
 1,82,33,039 
 14.48 
 -  1,82,33,039 
 14.48 
 47.28 
Ravi P. Agrawal, trustee Ravi Agrawal Trust
 1,63,86,623 
 13.01 
 -  1,63,86,623 
 13.01 
 33.48 
Aayush M. Agrawal, trustee Aayush Agrawal Trust
 1,42,37,664 
 11.31 
 -  1,42,37,664 
 11.31 
 16.11 
Gabs Investments Private Limited
 1,25,88,393 
 10.00 
 -  1,25,88,393 
 10.00 
 50.00 
Ganga Exports being represented by Mr. Yogesh M. 
Agrawal, Mr. Rajesh M. Agrawal & Mr. Ravi P. Agrawal
 33,79,297 
 2.68 
 - 
 33,79,297 
 2.68 
 46.94 
Ravi P. Agrawal
 2,85,000 
 0.23 
 - 
 2,85,000 
 0.23 
 50.00 
Aayush M. Agrawal
 30,000 
 0.02 
 - 
 30,000 
 0.02 
 50.00 
23. Other Equity
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Capital redemption reserve 
	
Balance at the beginning of the year 
 0.44 
 2.62 
	
Add: Amount transferred upon buyback of shares 
 - 
 0.44 
	
Less: Utilised for allotment of bonus shares 
 - 
 (2.62)
Balance as at the year end 
 0.44 
 0.44 
Securities premium 
	
Balance at the beginning of the year 
 - 
 - 
	
Add: Addition during the year 
 0.18 
 0.18 
	
Less: Utilisation for buyback of shares 
 - 
 - 
	
Less: Utilised for allotment of bonus shares 	
 - 
 (0.18)
Balance as at the year end 
 0.18 
 - 
Annual Report 2023-24
222
223
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Standalone
Notes to the Standalone Financial Statements
as at 31 March 2024
Notes to the Standalone Financial Statements
as at 31 March 2024
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
General reserve 
	
Balance at the beginning of the year 
 139.48 
 460.21 
	
Less: Utilised for buyback of shares
 - 
 (315.00)
	
Less: Utilised for allotment of bonus shares 
 - 
 (5.73)
Balance as at the year end 
 139.48 
 139.48 
Employee stock options outstanding account 
	
Balance at the beginning of the year 
 0.34 
 0.30 
	
Add: Share-based payment expense 
 5.06 
 0.22 
	
Add: Deemed Investment in Subsidiary (refer note 9) 
 0.62 
 - 
	
Less: Exercised during the year 
 (0.18)
 (0.18)
	
Less: Cancelled/Lapsed during the year 
 (0.19)
 - 
Balance as at the year end 
 5.65 
 0.34 
Other items of other comprehensive income (Re-measurement gains (losses) on defined  
benefit plans) 
	
Balance at the beginning of the year 
 (8.37)
 (6.10)
	
Add: Amount transferred 
 (2.52)
 (2.27)
Balance as at the year end 
 (10.89)
 (8.37)
Retained earnings 
	
Balance at the beginning of the year 
 3,089.29 
 2,694.98 
	
Profit for the year 
 807.24 
 558.72 
Less: Appropriations 
	
-	
Interim dividend on equity shares
 (642.17)
 (89.69)
	
-	
Expense relating to buyback of shares
 (0.92)
 (1.44)
	
-	
Tax on buyback of shares 
 - 
 (73.28)
Balance at the year end 
 3,253.44 
 3,089.29 
Total 
 3,388.30 
 3,221.18 
24. Lease Liabilities
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Lease liabilities 
 22.42 
 24.95 
 22.42 
 24.95 
25. Other Non-Current Financial Liabilities
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Security deposits payable
 1.37 
 1.01 
 1.37 
 1.01 
26. Provisions (Non-Current)
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Provision for employee benefits (net) 
	
Gratuity (Refer note 47.2) 
 13.50 
 2.32 
	
Compensated absences (Refer note 47.3) 
 26.04 
 21.83 
 39.54 
 24.15 
27. Deferred Tax Liabilities (Net)
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Tax effect of items constituting - Deferred tax liabilities 
Difference in tax base of property, plant and equipment 
 (A) 
 143.50 
 132.02 
Unrealised gain/loss on securities carried at FVOCI/FVTPL 
 (B) 
 (0.91)
 (0.80)
Tax effect of items constituting - Deferred tax assets 
MAT credit entitlement 
 (C) 
 - 
 2.98 
Disallowance under income tax 
 (D) 
 34.09 
 30.52 
Deferred tax liabilities (net) 
 (A+B-C-D) 
 108.50 
 97.72 
28. Other Non-Current Liabilities
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Deferred government grant 
 2.34 
 2.67 
 2.34 
 2.67 
29. Lease Liabilities
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Lease liabilities 
 8.10 
 7.95 
 8.10 
 7.95 
30. Trade Payables
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Total outstanding dues of micro enterprises and small enterprises 
 20.64 
 37.94 
Total outstanding dues of creditors other than micro enterprises and small enterprises 
 363.10 
 315.08 
 383.74 
 353.02 
The following is ageing schedule for Trade payables as at 31 March 2024:
 H in Crore 
Particulars
Unbilled
Not due
Less than 
1 year
1-2 years
2-3 years
More than 
3 years
Total
(i)	 MSME 
 - 
 20.64 
 - 
 - 
 - 
 - 
 20.64 
(ii)	 Others
 1.19 
 331.58 
 30.17 
 0.16 
 - 
 - 
 363.10 
(iii)	 Disputed dues ‚Äì MSME 
 - 
 - 
 - 
 - 
 - 
 - 
 - 
(iv)	 Disputed dues ‚Äì Others
 - 
 - 
 - 
 - 
 - 
 - 
 - 
Total
 1.19 
 352.22 
 30.17 
 0.16 
 - 
 - 
 383.74 
The following is ageing schedule for Trade payables as at 31 March 2023:
 H in Crore 
Particulars
Unbilled
Not due
Less than 
1 year
1-2 years
2-3 years
More than 
3 years
Total
(i)	 MSME 
 - 
 37.94 
 - 
 - 
 - 
 - 
 37.94 
(ii)	 Others
 11.93 
 267.22 
 35.86 
 0.07 
 - 
 - 
 315.08 
(iii)	 Disputed dues ‚Äì MSME 
 - 
 - 
 - 
 - 
 - 
 - 
 - 
(iv)	 Disputed dues ‚Äì Others
 - 
 - 
 - 
 - 
 - 
 - 
 - 
Total
 11.93 
 305.16 
 35.86 
 0.07 
 - 
 - 
 353.02 
(Refer note 58 for disclosures relating to Micro and Small Enterprises) 
Annual Report 2023-24
224
225
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Standalone
Notes to the Standalone Financial Statements
for the year ended 31 March 2024
Notes to the Standalone Financial Statements
as at 31 March 2024
31. Other Current Financial Liabilities
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Unpaid dividend* 
 0.72 
 0.82 
Unpaid sale proceeds of fractional shares* (31 March 2024 H 15,291 and 31 March 2023 H 
15,291) 
0.00
0.00
Capital creditors 
 43.18 
 29.82 
Book overdraft 
 1.56 
 3.84 
Employee benefits payable 
 29.29 
 8.85 
Provision for anticipated sales return (Refer note 51.2) 
 47.80 
 47.80 
Forward exchange contracts used for hedging 
 - 
 18.82 
Other payables 
 0.01 
 - 
Liability on account of share buy back 
 - 
 388.27 
 122.56 
 498.22 
* There are no amounts due and outstanding to be credited to Investor Education & Protection Fund as at 31 March 2024. 
32. Other Current Liabilities
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Advances from customers 
 39.32 
 10.01 
Deferred government grant 
 0.33 
 0.33 
Statutory dues payable 
 20.08 
 12.81 
 59.73 
 23.15 
33. Provisions (Current)
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Provision for employee benefits (net) 
Gratuity (Refer note 47.2) 
 10.73 
 8.71 
Compensated absences (Refer note 47.3) 
 7.03 
 5.31 
 17.76 
 14.02 
34. Current Tax Liabilities (Net)
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Provision for tax (net of income tax assets)
 37.30 
 11.48 
 37.30 
 11.48 
35. Liabilities Classified as Held for Sale
 H in Crore 
Particulars 
 As at 
31 March 2024 
 As at 
31 March 2023 
Liability against Assets held for sale (Refer note 64)
 0.51 
 - 
 0.51 
 - 
36. Revenue from Operations
 H in Crore 
Particulars 
 Year ended 
31 March 2024 
 Year ended 
31 March 2023 
Sale of products (Refer note 51) 
Finished goods 
 3,448.28 
 2,993.23 
Stock-in-trade 
 475.72 
 382.92 
Other operating revenues 
Export incentives 
 27.16 
 14.85 
Others 
 19.96 
 20.27 
 3,971.12 
 3,411.27 
37. Other Income
 H in Crore 
Particulars 
 Year ended 
31 March 2024 
 Year ended 
31 March 2023 
Dividend from subsidiary companies 
 29.13 
 35.14 
Income from financial assets carried at FVTPL 
	
Gain on sale/redemption of Current Investments 
 11.12 
 17.12 
	
Gain on financial instrument at FVTPL 
 22.82 
 - 
Income on financial assets carried at amortised cost 
	
Interest on deposits with banks 
 0.15 
 0.52 
	
Interest from others 
 27.55 
 7.92 
Net gain on disposal of Property, Plant and Equipment 
 3.49 
 - 
Bad debts written back, allowance for doubtful trade receivables (net) 
 - 
 0.84 
Exchange difference (Net) 
 20.34 
 68.48 
Miscellaneous income 
 1.88 
 2.73 
 116.48 
 132.75 
38. Cost of Materials Consumed
 H in Crore 
Particulars 
 Year ended 
31 March 2024 
 Year ended 
31 March 2023 
Raw material consumed 
 752.99 
 697.27 
Packing material consumed 
 186.44 
 181.09 
 939.43 
 878.36 
39. Purchases of Stock-In-Trade 
 H in Crore 
Particulars 
 Year ended 
31 March 2024 
 Year ended 
31 March 2023 
Purchases of stock-in-trade
 162.16 
 149.04 
 162.16 
 149.04 
227
Corporate Overview
Statutory Reports
Financial Statements
Notice
Solid Foundation. Crafting the Future.
Standalone
Annual Report 2023-24
226
Ajanta Pharma Limited
Notes to the Standalone Financial Statements
for the year ended 31 March 2024
Notes to the Standalone Financial Statements
for the year ended 31 March 2024
40. Changes in inventories of Finished Goods, Work-In-Progress and Stock-In-Trade
 H in Crore 
Particulars 
 Year ended 
31 March 2024 
 Year ended 
31 March 2023 
Inventories at the beginning of the year: 
Finished goods 
 278.59 
 260.65 
Work-in-progress 
 52.46 
 46.50 
Stock-in-trade 
 36.61 
 38.52 
 (A) 
 367.66 
 345.67 
Inventories at the end of the year: 
Finished goods 
 291.31 
 278.59 
Work-in-progress 
 54.35 
 52.46 
Stock-in-trade 
 44.17 
 36.61 
 (B) 
 389.83 
 367.66 
Changes in inventories: 
Finished goods 
 (12.72)
 (17.94)
Work-in-progress 
 (1.89)
 (5.96)
Stock-in-trade 
 (7.56)
 1.91 
 (A) - (B) 
 (22.17)
 (21.99)
41. Employee Benefits Expense
 H in Crore 
Particulars 
 Year ended 
31 March 2024 
 Year ended 
31 March 2023 
Salaries, wages and bonus 
 766.55 
 672.76 
Contribution to provident and other funds 
 33.45 
 30.52 
Gratuity expenses (Refer note 47) 
 20.35 
 7.76 
Share-based payment expenses (Refer note 48) 
 4.87 
 0.22 
Staff welfare expenses 
 8.94 
 9.15 
 834.16 
 720.41 
42. Finance Cost
 H in Crore 
Particulars 
 Year ended 
31 March 2024 
 Year ended 
31 March 2023 
Interest expenses 
 6.80 
 5.23 
 6.80 
 5.23 
43. Depreciation and Amortisation Expense (Refer note 8)
 H in Crore 
Particulars 
 Year ended 
31 March 2024 
 Year ended 
31 March 2023 
Depreciation on property, plant and equipment 
 117.50 
 113.71 
Amortisation on intangible assets 
 3.88 
 3.05 
Depreciation on right-of-use assets 
 10.78 
 9.70 
Depreciation on investment property 
 - 
 0.49 
 132.16 
 126.95 
44. Other Expenses
 H in Crore 
Particulars 
 Year ended 
31 March 2024 
 Year ended 
31 March 2023 
Selling expenses 
 212.35 
 185.20 
Clearing and forwarding 
 96.22 
 164.65 
Medical literature expenses 
 11.79 
 15.58 
Field Travelling Expenses 
 42.96 
 38.92 
Consultancy charges 
 58.77 
 44.90 
Travelling expenses 
 94.48 
 72.52 
Processing charges 
 13.63 
 13.59 
Power and fuel 
 66.44 
 65.53 
Advertisement and publicity 
 4.49 
 5.02 
Consumption of stores and spare parts 
 48.75 
 66.33 
Rent (Refer note 52) 
 4.45 
 6.04 
Rates and taxes 
 1.43 
 1.62 
Legal and professional fees 
 38.58 
 39.19 
Postage, telephone and stationery expenses 
 8.01 
 8.21 
Repairs and maintenance 
-	
Buildings 
 4.07 
 5.30 
-	
Plant and machinery 
 38.42 
 41.85 
-	
Computers and others 
 11.94 
 12.53 
Insurance 
 13.00 
 13.31 
Donation (Refer note 62) 
 5.57 
 4.79 
Directors sitting fees 
 0.37 
 0.32 
Clinical and analytical charges 
 37.59 
 55.55 
Loss on sale/discard of property, plant and equipment (net) 
 - 
 1.52 
Product registration expenses 
 51.30 
 45.90 
Corporate social responsibility expenses (Refer note 55) 
 17.32 
 16.37 
Commission to directors 
 0.12 
 6.72 
Loss on Investment at FVTPL 
 9.11 
 2.30 
Loss on financial instrument at FVTPL 
 - 
 18.82 
Miscellaneous expenses 
 46.95 
 33.59 
 938.11 
 986.17 
45. Capital Management:
Company‚Äôs policy is to maintain a strong capital base so as to maintain investor, creditor and market confidence and 
to sustain future development of the business. Management monitors the return (EBIT) on capital, as well as the level 
of dividends to equity shareholders. The Company‚Äôs objective for capital management is to maximise shareholder 
value, safeguard business continuity and support the growth of the Company. The Company determines the capital 
requirement based on annual operating plans and long-term and other strategic investment plans. 
Annual Report 2023-24
228
229
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Standalone
Notes to the Standalone Financial Statements
for the year ended 31 March 2024
Notes to the Standalone Financial Statements
for the year ended 31 March 2024
46. Basic and Diluted Earnings per Share is Calculated as under:
The numerator and denominator used to calculate basic and diluted earnings per share:
Particulars 
 Year ended 
31 March 2024 
 Year ended 
31 March 2023 
Profit attributable to equity shareholders for Basic EPS (H in Crore) 
(A)
807.24
558.72
Add: Dilutive effect on profit (H in Crore)
(B)
-
-
Numerator for calculating dilutive earnings per share (H in Crore) 
(C=A+B)
807.24
558.72
Weighted average number of equity shares outstanding for Basic EPS 
(D)
12,59,15,562
12,81,18,877
Add: Dilutive effect of ESOP outstanding number of equity shares*
(E)
90,479
3,994
Weighted average number of equity shares for Diluted EPS 
(F=D+E)
12,60,06,041
12,81,22,871
Face value per equity share (H)
2
2
Basic earnings per share (H) 
(A/D)
64.11
43.61
Diluted earnings per share (H) 
(C/F)
64.06
43.61
* On account of Share based Incentive Plan 2019 -(Refer note 48). 
47. Employee Benefits
As required by Ind AS 19 ‚ÄòEmployee Benefits‚Äô the disclosures are as under:
47.1 Defined Contribution Plans
The Company offers its employee‚Äôs defined contribution plans in the form of provident fund (PF) and Employees‚Äô pension 
scheme (EPS) with the government, and certain state plans such as Employees‚Äô State Insurance (ESI). PF and EPS cover 
substantially all regular employees and the ESI covers certain employees. Contributions are made to the Government‚Äôs 
administered funds. While both the employees and the Company pay predetermined contributions into the Provident 
Fund and the ESI Scheme, contributions into the Pension fund is made only by the Company. The contributions are 
normally based on a certain proportion of the employee‚Äôs salary. The Company does not have any liability beyond 
depositing these amounts in to the government administered fund. During the year, the Company has made the 
following contributions:
 H in Crore 
Particulars 
 Year ended 
31 March 2024 
 Year ended 
31 March 2023 
Provident fund and employee‚Äôs pension scheme
32.93
29.75
Employees state insurance and others
0.52
0.77
Total
33.45
30.52
47.2 Defined benefit plans
Gratuity:
The Company makes annual contributions to Employees‚Äô Group Gratuity-cum Life Assurance (Cash Accumulation) 
Scheme of LIC, a funded defined benefit plan for qualifying employees. The Companies scheme provides for payment 
to vested employees as under:
On normal retirement/ early retirement/ withdrawal/ resignation:
As per the provisions of Payments of Gratuity Act, 1972 with vesting period of 5 years of service. A benefit ceiling of 
H 0.20 Crore is applied only for Directors.
On the Death in Service:
As per the provisions of Payment of Gratuity Act, 1972 without any vesting period.
The most recent actuarial valuation of plan assets and the present value of the defined benefit obligation for gratuity 
were carried out as at 31 March 2024. The present value of the defined benefit obligations and the related current 
service cost and past service cost, were measured using the Projected Unit Credit Method.
Based on the actuarial valuation obtained in this respect, the following table sets out the status of the gratuity plan 
and the amounts recognised in the Company‚Äôs financial statements as at the Balance Sheet date:
 H in Crore 
Particulars 
As at 
31 March 2024
As at 
31 March 2023
i)
Changes in Defined Benefit Obligation
Opening defined benefit obligation
58.78
48.19
Current service cost
9.59
7.59
Interest cost
3.93
2.99
Actuarial loss/(gain)
-	
changes in financial assumptions
0.67
(1.53)
-	
changes in demographic assumptions
-
-
-	
experience adjustments
2.68
5.21
Past service cost
10.27
-
Benefit (paid)
(4.59)
(3.67)
Closing defined benefit obligation
81.33 	
58.78
ii)
Changes in Value of Plan Assets
Opening value of plan assets
47.75
41.92
Interest Income
3.43
2.82
Return on plan assets excluding amounts included in Interest Income
(0.53)
0.18
Contributions by employer
11.04
6.49
Benefits (paid)
(4.59)
(3.66)
Closing value of plan assets
57.10
47.75
iii)
Amount recognised in the Balance Sheet
Present value of funded obligations as at year end
81.33
58.78
Fair value of the plan assets as at year end
(57.10)
(47.75)
Net liability recognised as at the year end 
24.23
11.03
iv)
Expenses recognised in the Statement of Profit and Loss
Current service cost
9.59
7.59
Past service cost
10.27
-
Net Interest cost
0.49
0.17
Net expenses recognised in the Statement of Profit and Loss
20.35
7.76
v)
Expenses recognised in the Statement of Other Comprehensive Income
Net actuarial loss/(gain) recognised in the current year
-	
changes in financial assumptions
0.67
(1.53)
-	
change in demographic assumption
-
-
-	
experience adjustments
2.68
5.20
Return on plan assets excluding amounts included in Interest Income
0.53
(0.18)
Net Expenses/(Income) recognised in the Statement of Other Comprehensive Income
3.88
3.49
vi)
Asset information
Insurer Managed Funds (100%)
(Fund is Managed by LIC as per IRDA guidelines, category-wise composition of the plan 
assets is not available)
100%
100%
Annual Report 2023-24
230
231
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Standalone
Notes to the Standalone Financial Statements
for the year ended 31 March 2024
Notes to the Standalone Financial Statements
for the year ended 31 March 2024
 H in Crore 
Particulars 
As at 
31 March 2024
As at 
31 March 2023
vii)
Principal actuarial assumptions used 
Discount rate (p.a.)
7.20%
7.35%
Mortality Rate
Indian Assured 
Lives Mortality 
(2012-14)
Indian Assured 
Lives Mortality 
(2012-14)
Salary growth rate (p.a.)
9.00% for next 
1 year and 7.00% 
thereafter 
9.00% for next 
1 year and 7.00% 
thereafter 
Weighted average duration of defined benefit obligation (Years)
5.83
6.33
Withdrawal Rate (%)
Age Band
25 and below
40%
40%
26 to 35
24%
24%
36 to 45
12%
12%
46 to 55
8%
8%
56 and above
8%
8%
viii)
Estimate of amount of contribution in immediate next year
10.73
8.72
Sensitivity Analysis
Reasonably possible changes at the reporting date to one of the relevant actuarial assumptions, holding other 
assumptions constant, would have affected the defined benefit obligation as shown below:
H in Crore
Particulars
As at 31 March 2024
As at 31 March 2023
Increase
Decrease
Increase
Decrease
Discount rate (0.5% movement)
79.15
83.64
57.13
60.54
Salary growth rate (0.5% movement)
83.70
79.06
60.28
57.32
Withdrawal rate (W.R.) Sensitivity (10% movement)
81.09
81.55
58.74
58.80
Although the analysis does not take into account full distribution of cash flows expected under the plan, it does provide 
an approximation of sensitivity of assumptions. The estimate of future increase in compensation levels, considered in 
the actuarial valuation, have been taken on account of inflation, seniority, promotion and other relevant factors such 
as supply and demand in the employment market.
47.3 Leave Encashment
The Company‚Äôs employees are entitled for compensated absences which are allowed to be accumulated and encashed 
as per the Company‚Äôs policies. The liability of compensated absences, which is non-funded, has been provided based 
on report of independent actuary using ‚ÄúProjected Unit Credit Method‚Äù.
Accordingly, H 33.07 Crore (Previous Year H 27.14 Crore) being liability as at the year-end for compensated absences as 
per actuarial valuation has been provided in the accounts.
48. Share-Based Payments
Company has established ‚ÄúEmployee Stock Options Scheme 2011‚Äù (‚ÄòESOP-2011‚Äô) and ‚ÄúShare-based Incentive Plan 2019‚Äù 
as approved in earlier year by the shareholders of the Company and Compensation committee of Board of Directors 
for key Employees of the Group. The options issued under the above scheme vest in a phased manner.
During the year, the Company made the decision to withdraw the Employee Stock Options Scheme 2011 in the 
Nomination & Remuneration Committee meeting held on 31 January 2024, with immediate effect.
During the year 91,350 option have been granted and 3,750 option cancelled by the Company under the Share-based 
Incentive Plan 2019 to the employees (including KMP‚Äôs) of the Group.
Grant Date
No. of Option Granted
No. of Option Cancelled
Exercise price
Vesting Period
10 May 2022
-
2,000
-
-
05 May 2023
11,600
1,750
H 2/-
05 May 2024 to 05 May 2026
27 July 2023
79,750
-
H 2/-
27 July 2024 to 01 January 2027
Details of options granted during the year to Key Managerial Personnel are as below:
Name of the Employee
Designation
Number of options
Grant/exercise price
Mr. Arvind K. Agrawal
Chief Financial Officer
3,000
H 2/-
Mr. Gaurang C. Shah
Company Secretary
1,500
H 2/-
The options are granted at an exercise price which is in accordance with the relevant SEBI guidelines in force, at the 
time of such grants. Each option entitles the holder to exercise the right to apply for and seek allotment of one equity 
share of H 2/- each. 
The particulars of the options under Share-based Incentive Plan 2019 are as below:
Particulars 
As at 
31 March 2024
 Nos.
As at 
31 March 2023
 Nos.
Option outstanding as at the beginning of the year
4,000
3,000
Add: Option granted during the year 
91,350
2,000
Less: Option exercised during the year
1,000
1,000
Less: Option lapsed/cancelled during the year
3,750
-
Option outstanding as at the year end 
90,600
4,000
Particulars
As at 
31 March 2024 
Nos.
Range of 
Exercise Prices 
(D)
Weighted 
Average 
Exercise Prices 
(D)
Weighted 
Average 
share price 
at the date of 
exercise (D)
Weighted 
Average 
Contractual 
life (Years)
Options outstanding as at the beginning of the 
year
4,000
2.00
2.00
-
1.60
Add: Options granted during the year 
91,350
2.00
2.00
-
1.36
Less: Options exercised during the year 
1,000
2.00
2.00
1,312.60
-
Less: Options lapsed/cancelled during the year
3,750
-
-
-
-
Options outstanding as at the year End 
90,600
2.00
2.00
-
1.37
Particulars
As at 
31 March 2023 
Nos.
Range of 
Exercise Prices 
(D)
Weighted 
Average 
Exercise Prices 
(D)
Weighted 
Average share 
price at the 
date of exercise 
(D)
Weighted 
Average 
Contractual life 
(Years)
Options outstanding as at the beginning of the 
year
3,000
2.00
2.00
-
1.08
Add: Options granted during the year 
2,000
2.00
2.00
-
1.31
Less: Options exercised during the year 
1,000
2.00
2.00
1,147.41
-
Less: Options lapsed/cancelled during the year
-
-
-
-
-
Options outstanding as at the year End 
4,000
2.00
2.00
-
1.60
Annual Report 2023-24
232
233
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Standalone
Notes to the Standalone Financial Statements
for the year ended 31 March 2024
Notes to the Standalone Financial Statements
for the year ended 31 March 2024
Effect of Share-Based Plan in Profit & Loss and Balance Sheet 
For details of the related employee benefits expense and investment in subsidiary, refer note 41 and 9 respectively.
Description of the method and significant assumptions used during the year to estimate the fair values of the options, 
including the following weighted average information: 
Variables 
Weighted Average Information
Plan 
Share-Based Incentive Plan 2019
Particulars 
500 
option
3,000 
option
3,000 
option
2,000 
option
11,600 
option
79,750 
option
Grant date 
27 September 2019 20 May 2020
30 April 2021
10 May 2022
05 May 2023
27 July 2023
Last date for acceptance 
27 October 2019 19 June 2020
30 May 2021
09 June 2022
03 June 2023
25 August 2023
Risk free rate (%) 
5.20
5.20
4.53
7.06
7.05
7.14
Expected Life (years) 
2
1
1 to 3
3 to 4
1 to 3
1 to 4
Volatility (%) 
13.74
14.67
14.57
13.12
13.12
13.12
Dividend yield (%) 
0.55
0.71
0.76
0.68
0.86
0.86
Price of the underlying share in the 
market at the time of option grant 
H 1,055
H 1,439
H 1,842
H 1,105
H 1,298
H 1,553
Fair value of options
H 1,041
H 1,425
H 1,792
H 1,078
H 1,273
H 1,522
Exercise price
H 2
H 2
H 2
H 2
H 2
H 2
The particulars of the options Share-based Incentive Plan 2019 granted to Employees of Subsidiary are as below:
Variables 
Weighted Average Information
Plan 
Share Based Incentive Plan 2019
Particulars 
500 
option
3,000 
option
13,000 
option
Grant date 
27 September 2019
20 May 2020
27 July 2023
Last date for acceptance 
27 October 2019
19 June 2020
25 August 2023
Risk free rate (%) 
5.20
5.20
7.14
Expected Life (years) 
2
1
1 to 4
Volatility (%) 
13.74
14.67
13.12
Dividend yield (%) 
0.55
0.71
0.86
Price of the underlying share in the market at the time of option grant 
H 1,055
H 1,439
H 1,553
Fair value of options
H 1,041
H 1,425
H 1,522
Exercise price
H 2
H 2
H 2
Valuation of Stock Options
The fair value of stock options granted during the period has been measured using the Black‚ÄìScholes option pricing 
model at the date of the grant. The Black-Scholes option pricing model includes assumptions regarding dividend yields, 
expected volatility, expected terms and risk free interest rates. They key inputs and assumptions used are as follows:
Share price: The closing price on NSE as on the date of grant has been considered for valuing the options granted.
Exercise Price: Exercise Price is the market price or face value or such other price as determined by the Remuneration 
and Compensation Committee.
Expected Volatility: The historical volatility of the stock till the date of grant has been considered to calculate the fair 
value of the options.
Expected Option Life: Expected Life of option is the period for which the Company expects the options to be live. The 
minimum life of a stock option is the minimum period before which the options cannot be exercised and the maximum 
life is the period after which the options cannot be exercised.
Expected dividends: Expected dividend yield has been calculated as an average of dividend yields for four years 
preceding the date of the grant.
Risk free interest rate: The risk-free interest rate on the date of grant considered for the calculation is the interest 
rate applicable for a maturity equal to the expected life of the options based on the zero-coupon yield curve for 
Government Securities.
These assumptions reflect management‚Äôs best estimates, but these assumptions involve inherent market uncertainties 
based on market conditions generally outside of the Company‚Äôs control. As a result, if other assumptions had been 
used in the current period, stock-based compensation expense could have been materially impacted. Further, if 
management uses different assumptions in future periods, stock-based compensation expense could be materially 
impacted in future years. The Company has granted stock options to employees of a subsidiary, the estimated fair 
value of stock options issued are included in the carrying value of the investment in the said subsidiary on a straight-
line basis over the requisite service period of each separately vesting portion of the award.
49. Financial Instrument- Fair Values and Risk Management
A.  Fair Value Measurements
H in Crore
Financial instruments by category
As at 31 March 2024
As at 31 March 2023
FVTPL
Amortised cost
FVTPL
Amortised cost
Financial assets
Forward exchange contracts used for hedging 
12.48
-
-
-
Investment in subsidiaries 
-
18.51
-
17.89
Investment in Limited liability partnership 
18.58
-
25.10
-
Investments in Mutual funds/Bonds/NCDs
47.36
282.69
339.88
170.39
Investment in unquoted equity shares (current year  
H 37,050, previous year H 37,050)
-
0.00
-
0.00
Trade receivables
-
1207.67
-
977.63
Other non-current financial assets
-
8.92
-
10.99
Cash and cash equivalents
-
61.78
-
268.85
Bank balances other than cash and cash equivalents
-
1.28
-
1.07
Current loans
-
15.40
-
17.01
Interest receivable
-
6.54
-
2.48
Total financial assets
78.42
 1602.79
364.98
 1466.31
Financial liabilities
Book overdrafts
-
1.56
 -
3.84
Other non-current financial liabilities
-
1.37
-
1.01
Non-current lease liabilities
-
22.42
-
24.95
Capital creditors
-
43.18
-
29.82
Unpaid dividend
-
0.72
-
0.82
Employee benefits payable
-
29.29
-
8.85
Unpaid sale proceeds of fractional shares (current year  
H 15,291 and previous year H 15,291)
-
0.00
-
0.00
Current lease liabilities
-
8.10
-
7.95
Provision for anticipated sales return
-
47.80
-
47.80
Forward exchange contracts used for hedging
-
-
18.82
-
Other payables
-
0.01
-
-
Liability on account of share buy back
-
-
-
388.27
Trade payables
-
383.74
-
353.02
Total financial liabilities
-
538.19
18.82
866.33
Fair value measurement of lease liabilities is not required.
Annual Report 2023-24
234
235
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Standalone
Notes to the Standalone Financial Statements
for the year ended 31 March 2024
Notes to the Standalone Financial Statements
for the year ended 31 March 2024
Fair Value Hierarchy
This section explains the judgements and estimates made in determining the fair values of the financial instruments 
that are (a) recognised and measured at fair value and (b) measured at amortised cost and for which fair values are 
disclosed in the financial statements. To provide an indication about the reliability of the inputs used in determining 
fair value, the Company has classified its financial instruments into the three levels prescribed under the accounting 
standard. An explanation of each level follows underneath the table.
H in Crore
Financial assets and liabilities measured at fair value
As at 31 March 2024
As at 31 March 2023
Level
Level
I
II
III
I
II
III
Financial assets
Recurring fair value measurements
Forward exchange contracts used for hedging
-
12.48
-
-
-
-
Investment in Mutual Funds
10.24
-
-
178.32
-
-
Investment in NC MLDs
-
37.12
-
-
161.56
-
Investment in Limited liability partnership
-
-
18.58
-
-
25.10
Total Financial Assets
10.24
49.60
18.58
178.32
161.56
25.10
Financial Liabilities 
Forward exchange contracts used for hedging
-
-
-
-
18.82
-
Total Financial liabilities
-
-
-
-
18.82
-
Level 1: Level 1 hierarchy includes financial instruments measured using quoted prices. This includes mutual funds that 
have declared buyback NAV. The mutual funds are valued using the closing NAV.
Level 2: The fair value of financial instruments that are not traded in an active market (like Mark to market derivatives and 
Non-convertible market link debenture) is determined using valuation techniques which maximise the use of observable 
market data and rely as little as possible on entity-specific estimates. If all significant inputs required to fair value as 
instrument are observable, the instrument is included in level 2.
Level 3: If one or more of the significant inputs is not based on observable market data, the instrument is included in 
level 3. 
Measurement of Fair Values:
Valuation techniques and significant unobservable inputs:
The following tables show the valuation techniques used in measuring Level 2 & Level 3 fair values, for financial instruments 
measured at fair value in the statement of financial position, as well as the significant unobservable inputs used:
Type
Valuation Technique
Significant unobservable  
Inputs
Inter-relationship between significant 
unobservable inputs and fair value 
measurement
Derivative instruments
Forward pricing: The fair value is determined 
using quoted forward exchange rates at 
the reporting date.
Not applicable
Not applicable
Non-Current Financial 
assets (Investment)
Discounted Cash flow: The valuation 
model considers the present value of 
expected receipts/payment discounted 
using appropriate discounting rates.
Not applicable
Not applicable
B.	
Financial Risk Management 
Company has exposure to following risks arising from financial instruments:
i.	
credit risk
ii.	
liquidity risk
iii.	
market risk
iv.	
currency risk
Risk Management Framework
Company‚Äôs board of directors has overall responsibility for the establishment and oversight of the Company‚Äôs risk 
management framework. Management is responsible for developing and monitoring the Company‚Äôs risk management 
policies, under the guidance of Audit Committee.
Company‚Äôs risk management policies are established to identify and analyse the risks faced by it, to set appropriate 
risk limits and controls and to monitor risks and adherence to limits. Risk management policies and systems are reviewed 
regularly to reflect changes in market conditions and the Company‚Äôs activities. Company, through its training and 
procedures aims to maintain a disciplined and constructive control environment in which all employees understand 
their roles and obligations.
Company‚Äôs Audit committee oversees how management monitors compliance with the Company‚Äôs risk management 
policies and procedures, and reviews the adequacy of the risk management framework in relation to the risks faced 
by the Company. The Audit committee is assisted in its oversight role by internal audit. Internal audit undertakes both 
regular and ad hoc reviews of risk management controls and procedures, the results of which are reported to the 
Audit committee. 
i.	
Credit Risk 
	
Credit risk is the risk that a counter party will not meet its obligations under a financial instrument or customer 
contract, leading to a financial loss. The Company is exposed to credit risk from its operating activities (primarily 
trade receivables) and from its financing activities, including deposits with banks and mutual funds, foreign 
exchange transactions and other financial instruments.
	
Impairment: 
	
The following table provides information about the exposure to credit risk and expected credit loss for 
trade receivables:
H in Crore
Particulars
As at 31 March 2024
Carrying amount
Weighted 
average loss rate
Loss allowance
Group Debtors 
787.92
0.14%
1.07
Past due up to 180 days
408.18
0.15%
0.62
Past due 181 - 365 days 
13.83
8.24%
1.14
Past dues 366 - 730 days
0.68
16.18%
0.11
Past dues 731 - 1096 days
4.98
100.00%
4.98
More than 1096 days
0.91
100.00%
0.91
Total
1,216.50
 
8.83
Annual Report 2023-24
236
237
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Standalone
Notes to the Standalone Financial Statements
for the year ended 31 March 2024
Notes to the Standalone Financial Statements
for the year ended 31 March 2024
H in Crore
Particulars
As at 31 March 2023
Carrying amount
Weighted average 
loss rate
Loss allowance
Group Debtors 
634.66
0.08%
0.52
Past due up to 180 days
339.88
0.08%
0.28
Past due 181 - 365 days
2.08
28.50%
0.59
Past dues 366 - 730 days
8.90
73.00%
6.50
Past dues 731 - 1096 days
0.06
100.00%
0.06
More than 1096 days
3.09
100.00%
3.09
 Total
988.67
 
11.04
a)	
Trade Receivables 
Customer credit risk is managed by each business unit subject to the Company‚Äôs established policy, procedures 
and control relating to customer credit risk management. Trade receivables, which are non-interest bearing, are 
mainly from stockists, distributors and customers and are generally on 14 days to 270 days credit term excluding 
wholly-owned subsidiaries. Outstanding customer receivables are regularly monitored. The Company has no 
concentration of credit risk as the customer base is widely distributed both economically and geographically.
As at 31 March 2024, Company had 32 customers, excluding wholly-owned subsidiaries (31 March 2023: 37 
customers) that owed the Company more than H 0.50 Crore each and accounted for approximately 27% and 26% 
respectively of the total outstanding as at 31 March 2024 and 31 March 2023.
	
Expected Credit Loss Assessment
As per simplified approach, the Company makes provision of expected credit losses on trade receivable using a 
provision matrix to mitigate the risk of default payment and make appropriate provision at each reporting date 
wherever required. The trend of the bad debts is negligible.
 H in Crore 
Particulars 
As at 
31 March 2024
As at 
31 March 2023
Gross Carrying amount
1216.50
988.67
Average Expected loss rate
0.73%
1.12%
Carrying amount of trade receivables (net of impairment)
1207.67
977.63
The movement in the allowance for impairment in respect of trade receivables during the year was as follows:
 H in Crore 
Particulars 
As at 
31 March 2024
As at 
31 March 2023
Balance as at the beginning of the year
11.04
14.74
Impairment loss/(gain) recognised (net)
-
(0.84)
Amounts written off
(2.21)
(2.86)
Balance as at the year end
8.83
11.04
During the previous year impairment gain has been recognised due to writeback of allowance of trade receivable.
b)	
Financial Instruments
Company limits its exposure to credit risk by investing in liquid securities issued by mutual funds having a credit 
ranking of at least 3 and above from CRISIL or equivalent rating agency. Company monitors changes in credit risk 
by tracking published external credit ranking. Based on its on-going assessment of counterparty risk, the Company 
adjusts its exposure to various counterparties.
ii.	
Liquidity Risk
Liquidity risk is the risk that the Company may not be able to meet its present and future cash and collateral 
obligations without incurring unacceptable losses. The Company‚Äôs objective is to, at all times maintain optimum 
levels of liquidity to meet its cash and collateral requirements. The Company closely monitors its liquidity position 
and deploys a robust cash management system. It maintains adequate sources of financing including bilateral 
loans, debt, and overdraft from banks at an optimised cost. Working capital requirements are adequately 
addressed by internally generated funds. Trade receivables are kept within manageable levels.
Company aims to maintain the level of its cash and cash equivalents and other highly marketable debt investments 
at an amount in excess of expected cash outflows on financial liabilities over the next six months. The ratio of cash 
and cash equivalents and other highly marketable debt investments to outflows is 0.62 at 31 March 2024 (0.86 at 
31 March 2023).
	
Exposure to liquidity Risk
The following are the remaining contractual maturities of financial liabilities at the reporting date. The amounts are 
gross and undiscounted, and include estimated interest payments and exclude the impact of netting agreements.
	
As at 31 March 2024
H in Crore
Particulars
Carrying 
Amount
Contractual Cash Flows
Total
0-12 months
1-2 years
2-5 years
More than 
5 years
Trade Payables 
383.74
383.74
383.58
0.16
-
-
Other Financial 
Liabilities
123.93
123.93
122.56
1.37
-
-
Lease Liabilities
30.52
30.52
8.10
4.99
3.29
14.14
Total
538.19
538.19
514.24
6.52
3.29
14.14
	
As at 31 March 2023
H in Crore
Particulars 
Carrying 
Amount
Contractual Cash Flows
Total
0-12 months
1-2 years
2-5 years
More than 
5 years
Trade Payables 
353.02
353.02
352.95
0.07
-
-
Other Financial 
Liabilities
499.23
499.23
498.22
1.01
-
-
Lease Liabilities
32.90
32.90
7.95
7.95
4.58
12.42
Total
885.15
885.15
859.12
9.03
4.58
12.42
iii.	
Market risk
Market risk is the risk that changes in market prices ‚Äì such as foreign exchange rates, interest rates and equity prices 
‚Äì will affect the Company‚Äôs income or the value of its holdings of financial instruments. The objective of market 
risk management is to manage and control market risk exposures within acceptable parameters, while optimising 
the return. Financial instruments affected by market risk include loans and borrowings, deposits, investments, and 
derivative financial instruments.
The Company‚Äôs activities expose it to a variety of financial risks, including the effects of changes in foreign currency 
exchange rates and interest rates. The Company uses derivative financial instruments such as foreign exchange 
contracts to manage its exposures to foreign exchange fluctuations. All such transactions are carried out within 
the guidelines set by the risk management committee.
	
Sensitivity Analysis on Interest rate
The Company‚Äôs fixed rate bank deposits and securities are carried at amortised cost. They are therefore not 
subject to interest rate risk as defined in Ind AS 107, since neither the carrying amount nor the future cash flow will 
fluctuate because of a change in market interest rates.
Annual Report 2023-24
238
239
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Standalone
Notes to the Standalone Financial Statements
for the year ended 31 March 2024
Notes to the Standalone Financial Statements
for the year ended 31 March 2024
	
Sensitivity Analysis on Equity prices
The Company has invested its surplus funds primarily in debt based mutual funds. The value of investment in these 
mutual fund schemes is reflected though Net Asset Value (NAV) declared by the Asset Management Company 
on daily basis. The Company has not performed a sensitivity analysis on these mutual funds based on estimated 
fluctuations in their NAV as in management‚Äôs opinion, such analysis would not display a correct picture.
iv.	 Currency Risk
Company is exposed to currency risk to the extent that there is a mismatch between the currencies in which sales, 
purchases and borrowings are denominated and the functional currency of Company. The currencies in which 
these transactions are primarily denominated are US dollars, Australian dollars, Great Britain Pound and Euro.
At any point in time, Company covers foreign currency risk by taking appropriate percentage of its foreign currency 
exposure, as approved by risk management committee in line with the laid down policy approved by the Board. 
Company uses forward exchange contracts to mitigate its currency risk, most with a maturity of less than one 
year from the reporting date. In respect of other monetary assets and liabilities denominated in foreign currencies, 
the Company‚Äôs policy is to ensure that its net exposure is kept to an acceptable level by buying or selling foreign 
currencies at spot rates when necessary to address short-term imbalances.
	
The following table analyses foreign currency risk as at 31 March 2024:
H in Crore
Particulars
USD
EUR
AUD
GBP
Total
Bank balances
34.61
4.32
-
-
38.93
Trade and other receivables
1,099.61
4.74
-
-
1,104.35
Trade and other payables
21.64
1.81
-
-
23.45
Net assets/(liabilities)
1,112.58
7.25
-
-
1,119.83
The following table analyses foreign currency risk as at 31 March 2023:
H in Crore
Particulars
USD
EUR
AUD
GBP
Total
Bank balances
181.56
3.60
-
-
185.16
Trade and other receivables
873.73
5.98
-
-
879.71
Trade and other payables
23.23
3.26
0.01
0.01
26.51
Net assets/(liabilities)
1,032.06
6.32
(0.01)
(0.01)
1,038.36
For the year ended 31 March 2024 every percentage point depreciation/appreciation in the exchange rate for the 
closing balances between the Indian Rupee and respective currencies would affect the Company‚Äôs incremental 
profit before tax as per below:
H in Crore
Particulars
Change in currency 
exchange rate
Effect on profit 
before tax
USD
+1%/(-1%)
11.13/(11.13)
EUR
+1%/(-1%)
0.07/(0.07)
AUD
+1%/(-1%)
-/(-)
GBP
+1%/(-1%)
-/(-)
For the year ended 31 March 2023 every percentage point depreciation/appreciation in the exchange rate 
between the Indian Rupee and respective currencies has affected the Company‚Äôs incremental profit before tax 
as per below:
H in Crore
Particulars
Change in currency 
exchange rate
Effect on profit 
before tax
USD
+1%/(-1%)
10.32/(10.32)
EUR
+1%/(-1%)
0.06/(0.06)
AUD
+1%/(-1%)
0.00/(0.00)
GBP
+1%/(-1%)
0.00/(0.00)
50. Note on Foreign Currency Exposures on Assets and Liabilities
A.	 Disclosure on Foreign Currency Exposure on Forward Contracts
During the year, the Company has entered into forward exchange contract, being derivative instruments to mitigate 
foreign currency risk, to establish the amount of currency in Indian Rupees required or available at the settlement 
date of certain payables and receivables. 
The following are the outstanding foreign currency forward contracts entered into by the Company:
Particulars
As at 
31 March 2024
As at 
31 March 2023
Buy or Sell
Cross Currency
Foreign Currency 
Amount in Crore
Foreign Currency 
Amount in Crore
EUR
5.00
5.80
SELL
INR
USD
13.20
8.05
SELL
INR
B.	
Disclosure on Foreign Currency Exposure on Assets and Liabilities 
The year-end foreign currency exposures that have not been mitigated by a derivative instrument or otherwise 
are as below:
Particulars
D in Crore 
D in Crore 
Foreign Currency 
Amount in Crore
Foreign Currency 
Amount in Crore
Foreign Currency
As at 
31 March 2024
As at 
31 March 2023
As at 
31 March 2024
As at 
31 March 2023
Amount Receivable
35.28
396.99
0.42
4.83
USD
0.04
-
#0.00
-
GBP
Amount Payable
57.35
32.21
0.69
0.39
USD
4.08
3.27
0.05
0.04
EUR
-
0.01
-
*0.00
AUD
-
0.01
-
**0.00
GBP
(# GBP 4,084 * GBP 639 ** AUD 1,800)
51. Disaggregation of Revenue 
The operations of the Company are limited to only one segment viz. pharmaceuticals and related products. Revenue 
from contract with customers is from sale of manufactured goods. Sale of goods are made at a point in time and revenue 
is recognised upon satisfaction of the performance obligations which is typically upon dispatch/delivery. The Company 
has a credit evaluation policy based on which the credit limits for the trade receivables are established. There is no 
significant financing component as the credit period provided by the Company is not significant.
Annual Report 2023-24
240
241
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Standalone
Notes to the Standalone Financial Statements
for the year ended 31 March 2024
Notes to the Standalone Financial Statements
for the year ended 31 March 2024
51.1 Revenue
Primary Geographical Markets
 H in Crore 
Particulars 
Year ended 
31 March 2024
Year ended 
31 March 2023
India
1,307.76
1,174.00
Emerging Market
1,509.30
1,356.92
Africa Institution
248.60
190.23
USA
858.34
655.00
Total revenue from contract with customers
3,924.00
3,376.15
Timing of revenue recognition
Goods transferred at a point in time
3,924.00
3,376.15
Variable components such as discounts and rebates continue to be recognised as deduction from revenue in compliance 
with Ind AS 115.
 H in Crore 
Revenue Break-up
Year ended 
31 March 2024
Year ended 
31 March 2023
Revenue as per contracted price
3,894.00
3,454.42
Adjusted for:
Sales Return
38.18
33.58
Trade Discounts
85.40
57.39
Others (Price Adjustment, anticipated sales return) 
(153.58)
(12.70)
(30.00)
78.27
Net Revenue
3,924.00
3,376.15
The Company normally sells goods on credit which varies from 14 to 21 days for domestic sales and 30 to 270 days in 
case of export sales. This does not involve any significant financing element.
Revenue from two customers exceed 10% of Company‚Äôs Total Revenue amounting to H 1,326.19 Crore.
51.2 Provision for Anticipated Sales Return:
Provision has been made towards probable return of goods from customers, as per Indian Accounting Standard 
(Ind AS 115) estimated by management based on past trends.
 H in Crore 
Particulars 
As at 
31 March 2024
As at 
31 March 2023
Balance at the beginning of the year
47.80
40.60
Add: Provisions made during the year
-
7.20
Less: Amount written back/utilised during the year
-
-
Balance at the end of the year
47.80
47.80
51.3 Contract Liability (Advances from Customers):
 H in Crore 
Particulars 
As at 
31 March 2024
As at 
31 March 2023
Contract Liabilities
39.32
10.01
The Contract liability outstanding at the beginning of the year has been recognised as revenue during the year ended 
31 March 2024.
52. Disclosure for Leases under Ind AS 116 ‚Äì ‚ÄúLease‚Äù: 
Company has taken various premises under operating lease. These are generally cancellable and ranges from 11 
months to 5 years and are renewable by mutual consent on mutually agreeable terms. Some of these lease agreements 
have price escalation clauses. There are no restrictions imposed by these lease arrangements and there are no sub 
leases. There are no contingent rents. A single discount rate has been applied to a portfolio of leases with reasonably 
similar characteristics.
Right-Of-Use Assets
 H in Crore
Particulars
Leasehold 
properties
Leasehold land
Total
Cost
As at 1 April 2023
27.98
62.59
90.57
Additions to ROU assets
7.15
-
7.15
De-recognition of ROU assets
(1.10)
-
(1.10)
Balance as at 31 March 2024
34.03
62.59
96.62
Accumulated depreciation and impairment
As at 1 April 2023
8.46
2.82
11.28
Depreciation
9.83
0.95
10.78
Eliminated on disposals of assets
(0.86)
-
(0.86)
Balance as at 31 March 2024
17.43
3.77
21.20
 H in Crore
Particulars
Leasehold 
properties
Leasehold land
Total
Cost
As at 1 April 2022
34.35
62.59
96.94
Additions to ROU assets
21.17
-
21.17
De-recognition of ROU assets
(27.54)
-
(27.54)
Balance as at 31 March 2023
27.98
62.59
90.57
Accumulated depreciation and impairment
As at 1 April 2022
27.19
1.87
29.06
Depreciation
8.75
0.95
9.70
Eliminated on disposals of assets
(27.48)
-
(27.48)
Balance as at 31 March 2023
8.46
2.82
11.28
 H in Crore
Carrying amounts
As at 1 April 2023
79.29 
Balance as at 31 March 2024
75.42 
 H in Crore
Carrying amounts
As at 1 April 2022
67.88 
Balance as at 31 March 2023
79.29 
Annual Report 2023-24
242
243
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Standalone
Notes to the Standalone Financial Statements
for the year ended 31 March 2024
Notes to the Standalone Financial Statements
for the year ended 31 March 2024
Lease Expenses Recognised in Statement of Profit and Loss not Included in the Measurement of Lease 
Liabilities:
 H in Crore 
Particulars
Year ended 
31 March 2024
Year ended 
31 March 2023
Short-term and low value lease expense
4.45
6.04
Total lease expense
4.45
6.04
Cash Outflow on Leases 
 H in Crore 
Particulars
Year ended 
31 March 2024
Year ended 
31 March 2023
Repayment of lease liabilities (includes interest of H 3.38 Crore in current year and H 3.47 Crore in 
previous year)
(12.91)
(12.23)
Total cash outflow on leases
(12.91)
(12.23)
Movement in Lease Liabilities
 H in Crore 
Particulars
Year ended 
31 March 2024
Year ended 
31 March 2023
Opening Lease liabilities
32.90
20.49
Addition during the year
7.15
21.17
Interest accrued during the year
3.38
3.47
Payment of Lease liabilities (including interest)
(12.91)
(12.23)
Closing Lease liabilities
30.52
32.90
Non-Current 
22.42
24.95
Current
8.10
7.95
Maturity Analysis of Lease Liabilities ‚Äì Contractual Undiscounted Cash Flows:
 H in Crore 
Particulars
Year ended 
31 March 2024
Year ended 
31 March 2023
Less than one year
11.68
10.66
One to five years
17.97
15.92
More than five years
93.69
94.10
53. Contingent Liabilities and commitments:
Contingent Liabilities
 H in Crore 
Particulars 
As at 
31 March 2024
As at 
31 March 2023
Claims against the Company not acknowledged as debt
i.
Customs Duty on import under Advance License Scheme, pending fulfilment of Ex-ports 
obligation. 
5.10
2.32
ii.
Disputed Octroi. 
Amount paid under protest and included under ‚ÄúOther Current Assets‚Äù H 0.52 Crore (Previous 
Year H 0.52 Crore)
0.52
0.52
iii.
Excise duty, Service Tax, VAT and GST disputed by the Company 
3.81
1.10
iv.
Other matter 
0.61
0.61
The Company has two ongoing patent litigations as on 31 March 2024. No liability is expected to arise from 
these litigations.
The Company does not expect the outcome of the matters stated above to have a material adverse impact on the 
Company‚Äôs financial condition, results of operations or cash flows.
Future cash outflows in respect of liability under clause (i) is dependent on terms agreed upon with the parties, in respect 
of clauses (ii) to (iv) is dependent on decisions by relevant authorities of respective disputes.
Code on Social Security, 2020
The new Code on Social Security, 2020 (Code) has been enacted, which could impact the contributions by the Company 
towards Provident Fund and Gratuity. The effective date from which the changes are applicable is yet to be notified 
and the rules are yet to be framed. The Company will complete its evaluation and will give appropriate impact in its 
financial statements in the period in which the Code becomes effective and the related rules are published.
Commitments
Estimated amounts of contracts remaining to be executed on capital account and not provided for, net of advances 
H 151.35 Crore (Previous Year H 86.97 Crore).
54. Related party disclosure as required by Ind AS 24 are given below: - 
A)	 Relationships where Control Exist:
Category I - Subsidiaries:
Ajanta Pharma (Mauritius) Ltd.
(APML)
Ajanta Pharma Mauritius International Ltd.
(APMIL) ‚Äì (Wound up dated 27 September 2022)
Ajanta Pharma Nigeria Limited
(APNL)
Ajanta Pharma USA Inc
(APUI)
Ajanta Pharma Philippines Inc.
(APPI) 
Category II - Directors and Key Management Personnel:
Mr. Mannalal B. Agrawal
Chairman
Mr. Madhusudan B. Agrawal
Executive Vice-Chairman
Mr. Yogesh M. Agrawal
Managing Director
Mr. Rajesh M. Agrawal
Joint Managing Director
Mr. Chandrakant M. Khetan
Independent Director
Mr. K. H. Viswanathan
Independent Director
Mr. Prabhakar Dalal
Independent Director
Dr. Anjana Grewal
Independent Director
Mr. Arvind K. Agrawal
Chief Financial Officer
Mr. Gaurang C. Shah
Company Secretary
Category III - Enterprise over which persons covered under Category II above are able to exercise significant control:
Gabs Investments Private Limited
Seth Bhagwandas Agrawal Charitable Trust
Ganga Exports being represented by Mr. Yogesh M. Agrawal, Mr. Rajesh M. Agrawal and Mr. Ravi P. Agrawal
Mannalal Agrawal Trust, Trustee ‚Äì Mr. Mannalal B. Agrawal
Yogesh Agrawal Trust, Trustee ‚Äì Mr. Yogesh M. Agrawal
Rajesh Agrawal Trust, Trustee ‚Äì Mr. Rajesh M. Agrawal
Ravi Agrawal Trust, Trustee ‚Äì Mr. Ravi P. Agrawal
Aayush Agrawal Trust, Trustee ‚Äì Mr. Aayush M. Agrawal
Ajanta Pharma Limited Group Gratuity Trust
Samta Purushottam Agrawal Memorial Foundation
Mamta and Madhusudan Agrawal Memorial Foundation
Annual Report 2023-24
244
245
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Standalone
Notes to the Standalone Financial Statements
for the year ended 31 March 2024
Notes to the Standalone Financial Statements
for the year ended 31 March 2024
Manisha Yogesh Agrawal Foundation
Smriti Rajesh Agrawal Foundation
Ajanta Foundation
A.I. Printers
Category IV - Others (Close Member of Key Management Personnel):
Ms. Tanya Agrawal
Mr. Aayush M. Agrawal 
Mr. Ravi P. Agrawal 
Mr. Yash Agrawal
B) 
The Following Transactions were Carried out with Related Parties:
 H in Crore 
Sr.  
No. 
Particulars
Category
Year ended 
31 March 2024
Year ended 
31 March 2023
1.
Sale of Goods
APML
I
10.96
50.90
APPI
I
181.55
156.24
APUI
I
839.07
655.00
2.
Purchase of Packing Material
A.I. Printers
III
0.05
-
3.
Investment 
APUI
I
0.62
-
4.
Dividend from Subsidiary Companies
APPI
I
29.13
35.14
5.
Expenses Reimbursement to 
APNL
I
0.21
0.33
6.
Compensation to Key Management and Others
6.1
Short-Term Employee Benefits
Remuneration
Mr. Madhusudan B. Agrawal
II
4.21
3.62
Mr. Yogesh M. Agrawal
II
13.60
12.33
Mr. Rajesh M. Agrawal
II
13.60
12.33
Mr. Arvind K. Agrawal
II
1.84
1.57
Mr. Gaurang C. Shah
II
0.97
0.88
Ms. Tanya Agrawal
IV
0.11
0.10
Mr. Yash Agrawal
IV
0.04
-
Commission to Executive Director
Mr. Yogesh M. Agrawal
II
8.00
3.30
Mr. Rajesh M. Agrawal
II
8.00
3.30
Commission and Sitting Fees to Non-Executive Director
Mr. Mannalal B. Agrawal
II
0.08
0.07
Mr. Chandrakant M. Khetan
II
0.14
0.12
Mr. K. H. Viswanathan
II
0.11
0.09
Mr. Prabhakar Dalal
II
0.10
0.08
Dr. Anjana Grewal
II
0.09
0.07
6.2
Post-employment benefits
II & IV
2.38
0.44
6.3
Shared Based Payment
Mr. Arvind K. Agrawal
II
0.11
-
Mr. Gaurang C. Shah
II
0.05
-
 H in Crore 
Sr.  
No. 
Particulars
Category
Year ended 
31 March 2024
Year ended 
31 March 2023
7.
Dividend Paid
Key Management Personnel
II
0.20
0.03
Others
III & IV
425.20
63.21
8.
Corporate Social Responsibility Expense
Seth Bhagwandas Agrawal Charitable Trust
III
-
0.90
Samta Puroshattam Agrawal Memorial Foundation
III
5.35
5.86
Ajanta Foundation
III
0.31
0.20
Mamta and Madhusudan Agrawal Memorial Foundation
III
3.75
4.45
Manisha Yogesh Agrawal Foundation
III
0.73
0.25
9.
Contribution made to group gratuity trust paid to LIC
Ajanta Pharma Limited Group Gratuity Trust
III
11.04
6.85
10.
Other Income from subsidiary
APUI
I
1.43
1.19
11.
Buyback of Equity Share
Yogesh M. Agrawal, Trustee Yogesh Agrawal Trust
III
-
48.07
Rajesh M. Agrawal, Trustee Rajesh Agrawal Trust
III
-
48.07
Ravi P. Agrawal, Trustee Ravi Agrawal Trust
III
-
43.28
Aayush M. Agrawal, Trustee Aayush Agrawal Trust
III
-
39.34
Ganga Exports being represented by Yogesh M. Agrawal, Rajesh M. 
Agrawal and Ravi P. Agrawal
III
-
10.04
Mr. Arvind K. Agrawal
II
-
0.11
Mr. Gaurang C. Shah
II
-
0.00*
Mr. Chandrakant M. Khetan
II
-
0.00#
* H45,600 # H 21,375
C) Amount Outstanding as at end of the Year
 H in Crore 
Sr. 
No
Particulars
Category
As at 
31 March 2024
As at 
31 March 2023
1.
Trade receivables
APPI
I
61.71
43.30
APUI
I
726.20
568.80
APML
I
-
22.56
2.
Investments in
APML
I
9.44
9.44
APPI
I
1.38
1.38
APUI
I
7.69
7.07
APNL
I
1.37
1.37
Less: Impairment of Investment in Subsidiary
I
(1.37)
 (1.37)
3.
Trade payables 
A.I. Printers
III
0.05
-
4.
Advance to Vendor
APNL
I
0.14
0.04
5.
Other receivables
APUI
I
1.09
0.62
6.
Advance Received
APML 
I
18.12
-
7.
Other Advances
Ajanta Foundation
III
0.01
-
Manisha Yogesh Agrawal Foundation
III
0.02
-
Annual Report 2023-24
246
247
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Standalone
Notes to the Standalone Financial Statements
for the year ended 31 March 2024
Notes to the Standalone Financial Statements
for the year ended 31 March 2024
 H in Crore 
Sr. 
No
Particulars
Category
As at 
31 March 2024
As at 
31 March 2023
8.
Commission payable to Executive Director
Mr. Yogesh M. Agrawal
II
8.00
3.30
Mr. Rajesh M. Agrawal
II
8.00
3.30
9.
Commission payable to Non-Executive Director
Mr. Chandrakant M. Khetan
II
0.05
0.04
Mr. K. H. Viswanathan
II
0.03
0.03
Mr. Prabhakar Dalal
II
0.03
0.03
Dr. Anjana Grewal
II
0.03
0.03
10.
Buyback amount payable 
Yogesh M. Agrawal, Trustee Yogesh Agrawal Trust
III
-
48.07
Rajesh M. Agrawal, Trustee Rajesh Agrawal Trust
III
-
48.07
Ravi P. Agrawal, Trustee Ravi Agrawal Trust
III
-
43.28
Aayush M. Agrawal, Trustee Aayush Agrawal Trust
III
-
39.34
Ganga Exports being represented by Yogesh M. Agrawal, Rajesh M. 
Agrawal and Ravi P. Agrawal
III
-
10.04
Mr. Arvind K. Agrawal
II
-
0.11
Mr. Gaurang C. Shah
II
-
0.00*
Mr. Chandrakant M. Khetan
II
-
0.00#
* H45,600 # H 21,375
Based on the internal and external transfer pricing review and validation, the Company believes that all transactions 
with associated enterprises are undertaken on the basis of arm‚Äôs length principle. Outstanding balances at the 
year-end are unsecured and interest free and settlement occurs in cash. Details related to ESOP given to Employees 
of Subsidiary provided in note 48.
In the previous year, Ajanta Pharma (Mauritius) International Limited, a wholly-owned subsidiary of Ajanta Pharma 
(Mauritius) Limited, was wound up and removed from register of companies u/s 308 of the Companies Act 2001 
(Mauritius) by Business registration department dated 27 September 2022
55. Contribution Towards Corporate Social Responsibility (‚ÄúCSR‚Äù):
As per Section 135 of the Act, a CSR committee has been formed by the Company. The funds are utilised during the 
year on the activities which are specified in schedule VII of the Act. The utilisation is done by way of direct and indirect 
contribution towards various activities. 
The particulars of CSR expenditure are as follows:
 H in Crore 
Sr. 
No
Particulars
Year ended 
31 March 2024
Year ended 
31 March 2023
(a)
Amount required to be spent by the Company during the year
16.43
15.54
(b)
Amount approved by the Board to be spent during the year
16.43
15.54
(c)
Amount spend during the year:
(i) 	 Construction/acquisition of asset
-
-
(ii) 	 On purposes other than (i) above
17.32
16.37
(iii) 	Shortfall at the end of the year
-
-
(iv) 	Total of previous year shortfall 
-
-
(v) 	 Nature of CSR activities
Promoting education, Medical 
assistance, Community development 
& promoting of sports
(d)
Details of related party transactions (refer note 54)
10.14
11.66
56.	 The Company has presented data relating to its segments based on its consolidated financial statements, 
which are presented in the same Annual Report. Accordingly, in terms of paragraph 4 of the Indian Accounting 
Standard (Ind AS 108) ‚ÄúOperating Segments‚Äù, no disclosures related to segments are presented in this standalone 
financial statement.
57. Remuneration to Auditors (Excluding GST):
 H in Crore 
Particulars
Year ended 
31 March 2024
Year ended 
31 March 2023
-	
Audit Fees
0.29
0.25
-	
Limited review
0.32
0.28
-	
For Certification and other matters (including OPE) 
0.25
0.22
58. Details of dues to Micro and Small Enterprises as defined under the Micro, Small and Medium 
enterprises development act, 2006
This information has been determined to the extent such parties have been identified on the basis of information 
available with the Company.
 H in Crore 
Particulars
Year ended 
31 March 2024
Year ended 
31 March 2023
a)
The principal amount and the interest due thereon remaining unpaid to any supplier as at 
the end of each accounting year
Principal amount due to micro and small enterprises
20.64
37.94
Interest due on above
-
-
b)
The amount of interest paid by the buyer as per Section 16 of the Micro, Small and Medium 
Enterprises Development Act, 2006, along with the amounts of the payment made to the 
supplier beyond the appointed day during each accounting year.
-
-
c)
The amount of interest due and payable for the period of delay in making payment (which 
have been paid but beyond the appointed day during the year) but without adding the 
interest specified under Micro, Small and Medium Enterprises Development Act, 2006.
-
-
d)
The amount of interest accrued and remaining unpaid at the end of each accounting year.
-
-
e)
The amount of further interest remaining due and payable even in the succeeding years, 
until such date when the interest dues as above are actually paid to the small enterprise for 
the purpose of disallowance as a deductible expenditure under Section 23 of Micro, Small 
and Medium Enterprises Development Act, 2006.
-
-
59. Ratios ‚Äì Additional Regulatory Information
Ratio
Numerator
Denominator
As at 
31 March 2024
As at 
31 March 2023
Variance (%)
Current Ratio (in times)*
Total current assets
Total current liabilities
3.88
2.81
37.98
Debt - Equity Ratio (in times)
Total Debt (Lease 
liability)
Total equity
0.01
0.01
-
Debt Service Coverage Ratio 
(in times)
Earnings available for 
debt service
Debt Service
-
-
-
Return on Equity (%)**
Profit for the year less 
preference dividend 
(if any)
Average total equity
24.24%
17.42%
39.18
Inventory Turnover Ratio (in 
times)
Sale of products
Average Inventory
5.76
5.12
12.58
Trade receivables turnover 
ratio (in times)
Revenue from 
Operations
Average Trade 
Receivable
3.63
3.38
7.67
Trade payables turnover ratio 
(in times)
Net Credit Purchases 
(Raw material, packing 
material and purchase 
of traded goods)
Average Trade 
Payables
2.91
3.36
(13.28)
Net capital turnover ratio (in 
times)
Revenue from 
operations
Working Capital (Total 
current assets less 
Total current liabilities)
2.19
2.08
5.58
Annual Report 2023-24
248
249
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Standalone
Notes to the Standalone Financial Statements
for the year ended 31 March 2024
Notes to the Standalone Financial Statements
for the year ended 31 March 2024
Ratio
Numerator
Denominator
As at 
31 March 2024
As at 
31 March 2023
Variance (%)
Net profit ratio (%)**
Profit for the year
Revenue from 
operations
20.33%
16.38%
24.11
Return on capital employed 
(ROCE) (%)**
Profit before tax and 
finance costs
Capital Employed (Net 
worth + Lease liability 
+ Deferred tax liability)
31.07%
20.93%
48.46
Return on investment (%)***
Income generated from 
invested funds
Average invested 
funds
8.87%
6.13%
44.70
* The liability provided for share buy-back was paid in the current year, hence current ratio improved.
** This improvement in profitability can be attributed to the combined benefits of reduction in API prices, reduced logistics costs and stabilisation 
in US price erosion.
*** During the year investment made for longer period with higher interest rate.
60. Research and Development Expenditure
A unit of the Company has been recognised by Department of Scientific and Industrial Research (DSIR) as in-house 
research and development unit. The amount of capital and revenue expenditure are as below.
 H in Crore 
Particulars
Year ended 
31 March 2024
Year ended 
31 March 2023
Amount in respect to 
Capital Expenditure
4.83
18.20
Revenue Expenditure
207.73
237.01
Total
212.56
255.21
61. Utilisation of Borrowed Funds and Share Premium
A.	
The Company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign 
entities (Intermediaries) with the understanding that the Intermediary shall:
	
(a)	
directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on 
behalf of the Company (Ultimate Beneficiaries) or
	
(b)	
provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.
B.	
The Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) 
with the understanding (whether recorded in writing or otherwise) that the Company shall:
	
(a)	
directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on 
behalf of the Funding Party (Ultimate Beneficiaries) or
	
(b)	
provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
62. Donation
Donation includes political contribution to Bharatiya Janata Party of H 5.00 Crore in the current year and H 4.00 Crore 
in the previous year (through electoral bond).
63. Impairment of Investment in Subsidiary
The Company in prior years has made full provision for investment in aggregate value of unquoted investment in Ajanta 
Pharma Nigeria Limited and the carrying value of investment is considered as Nil.
64. Assets Classified as Held for Sale
During the year the Company has entered into agreement for sale of its one of the freehold land assets, for which 
H 0.51 Crore advance has been received and recognised as Liability against Assets held for sale, subject to fulfilment of 
certain condition. Transaction is expected to be completed in the next year. The said freehold land assets aggregating 
to H 8.85 Crore has been reclassified from Property, plant and equipment to assets held for sale.
In the previous year the Company has entered into agreement for sale of its investment properties, and the said 
properties aggregating to H 7.92 Crore has been reclassified from investment properties to assets held for sale.
Rental income recognised in profit or loss for investment properties aggregates to H 0.01 Crore (previous year H 0.35 
Crore). Maintenance and other expenses aggregating to H 0.01 Crore (previous year H 0.04 Crore).
65. Income Tax
a) Current Income Tax
 H in Crore 
Particulars
Year ended 
31 March 2024
Year ended 
31 March 2023
Amount recognised in statement of profit and loss
Current tax on profit for the year
253.74
122.40
Adjustment for current tax of prior periods*
23.84
21.66
Total Current tax expenses
277.58
144.06
Deferred tax expense/(benefit)
Origination and reversal of timing difference
9.15
0.05
MAT Credit Entitlement
2.98
(2.98)
Total Deferred Tax expenses
12.13
(2.93)
Total Income tax expense recognised in the income statement 
289.71
141.13
* Tax expenses for prior periods amounting to H 23.84 Crore (Previous year tax credit H 21.66 Crore) comprises short tax provision for 
FY 2022-23 and reversal of certain deductions which were non-deductible based on subsequent judicial rulings.
b) 
Reconciliation of Effective Tax Rate
The following is a reconciliation of the Company‚Äôs effective tax rate
 H in Crore 
Particulars
Year ended 
31 March 2024
Year ended 
31 March 2023
Accounting profit before income taxes
1,096.95
699.85
Enacted tax rate in India (%)
34.94
34.94
Computed expected tax expenses
383.32
244.53
Effect of non-deductible expenses
42.18
15.21
Temporary difference which is reversed during the Tax Holiday period
(0.49)
(1.76)
Tax effect which is chargeable at different rate
-
(9.62)
Others deductible expenses
(13.00)
(18.04)
Adjustment for current tax of prior periods
23.84
21.66
Mat Credit Entitlement
2.98
(2.98)
Deduction for Tax Holiday Unit
(149.12)
(107.87)
Income tax expenses
289.71
141.13
Effective tax rate
26.41%
20.17%
Annual Report 2023-24
250
251
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Standalone
Notes to the Standalone Financial Statements
for the year ended 31 March 2024
Notes to the Standalone Financial Statements
for the year ended 31 March 2024
c)	
Recognised Deferred Asset and Liability
H in Crore
Particulars
Deferred tax asset 
Deferred tax liabilities
Net deferred tax asset/
(liabilities)
As at 
31 March 
2024
As at 
31 March 
 2023
As at 
31 March 
2024
As at 
31 March 
 2023
As at 
31 March 
2024
As at 
31 March 
 2023
Property, Plant and equipment
-
-
143.50
132.02
(143.50)
(132.02)
Gain on Investment at FVTPL
0.91
0.80
-
-
0.91
0.80
Leave Encashment
11.55
9.48
-
-
11.55
9.48
Provision for return of Expired 
Goods
16.70
16.70
-
-
16.70
16.70
Diminution in value of Investment
2.76
0.48
-
-
2.76
0.48
MAT Credit Entitlement
-
2.98
-
-
-
2.98
Provision for Loss Allowance
3.08
3.86
-
-
3.08
3.86
Net deferred tax asset/(liabilities)
35.00
34.30
143.50
132.02
(108.50)
(97.72)
d) Movement in Deferred Tax Balances 31 March 2024
H in Crore
Particulars
Net balance 
as at 
31 March 
2023
Recognised 
in Profit and 
loss
Net balance 
as at
31 March 
2024
Deferred tax 
asset
Deferred tax 
liabilities
Property, plant and equipment
(132.02)
(11.48)
(143.50)
-
143.50
Gain on Investment at FVTPL
0.80
0.11
0.91
0.91
-
Leave Encashment
9.48
2.07
11.55
11.55
-
Provision for return of Expired Goods
16.70
-
16.70
16.70
-
Diminution in value of Investment
0.48
2.28
2.76
2.76
-
MAT Credit Entitlement
2.98
(2.98)
-
-
-
Provision for Loss Allowance
3.86
(0.78)
3.08
3.08
-
Net deferred tax asset/(liabilities)
(97.72)
(10.78)
(108.50)
35.00
143.50
e)  Movement in Deferred Tax Balances 31 March 2023
H in Crore
Particulars
Net balance 
as at 
31 March 
2022
Recognised in 
Profit and loss
Net balance 
as at
31 March 
2023
Deferred tax 
asset
Deferred tax 
liabilities
Property, plant and equipment
(126.89)
(5.13)
(132.02)
-
132.02
Gain on Investment at FVTPL
(3.13)
3.93
0.80
0.80
-
Leave Encashment
8.33
1.15
9.48
9.48
-
Provision for return of Expired Goods
14.19
2.51
16.70
16.70
-
Diminution in value of Investment
0.48
-
0.48
0.48
-
MAT Credit Entitlement
-
2.98
2.98
2.98
-
Provision for Loss Allowance
5.15
(1.29)
3.86
3.86
-
Net deferred tax asset/(liabilities)
(101.87)
4.15
(97.72)
34.30
132.02
The charge relating to temporary differences during the year ended 31 March 2024 are primarily on account of 
property plant and equipment and gain on investment at FVTPL partially offset by provision for return of expired 
goods, provision for loss allowance, compensated absences. The credit to temporary differences during the year 
ended 31 March 2023 are primarily on account of property plant and equipment and gain on investment at FVTPL 
partially offset by provision for return of expired goods, provision for loss allowance, compensated absences. 
Current tax assets and current tax liabilities and the deferred tax assets and deferred tax liabilities relate to income 
taxes levied by the same authority.
66. Additional disclosures required by Schedule III (amendments dated 24 March 2021) to the Companies 
Act, 2013
 
A. Relationship with Struck off Company
	
	
There is no such transaction with the companies struck off under Companies Act, 2013 or Companies Act, 1956.
	
B.	
Undisclosed Income
	
	
There is no income surrendered or disclosed as income during the current or previous year in the tax assessments 
under the Income Tax Act, 1961, that has not been recorded in the books of account.
	
C.	 Utilisation of Borrowings Availed from Banks
	
	
The borrowings obtained by the Company from banks have been applied for the purposes for which such 
loans were taken.
 
D. Details of Benami Property Held
	
	
No proceedings have been initiated on or are pending against the Company for holding benami property 
under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and Rules made thereunder.
 
E. 
Wilful Defaulter
	
	
The Company has not been declared wilful defaulter by any bank or financial institution or government or any 
government authority.
	
F.	
Compliance with Number of Layers of Companies
	
	
The Company has complied with the number of layers prescribed under the Companies Act, 2013.
	
G.	 Compliance with Approved Scheme(s) of Arrangements
	
	
The Company has not entered into any scheme of arrangement which has an accounting impact on current 
or previous financial year.
 
H. Details of Crypto Currency or Virtual Currency
	
	
The Company has not traded or invested in crypto currency or virtual currency during the current or 
previous year.
As per our report of even date attached 
For B S R & Co. LLP
For and on behalf of Board of Directors of 
Chartered Accountants 
Ajanta Pharma Limited
Firm's Registration No.: 101248W/W-100022
CIN - L24230MH1979PLC022059
Sreeja Marar
Yogesh M. Agrawal
Rajesh M. Agrawal
Partner 
Managing Director
Joint Managing Director
Membership No.: 111410
DIN: 00073673
DIN: 00302467
Arvind K. Agrawal
Gaurang C. Shah
Place: Mumbai
Chief Financial Officer
Company Secretary
Date: 02 May 2024
FCS No.: 6696
Annual Report 2023-24
252
253
Corporate Overview
Statutory Reports
Financial Statements
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Standalone
NOTICE is hereby given that Forty-fifth Annual General 
Meeting of the Members of Ajanta Pharma Limited will be 
held on Thursday, 18 July 2024 at 11:00 a.m. IST through 
Video Conferencing (‚ÄúVC‚Äù)/or Other Audio-Visual Means 
(‚ÄúOAVM‚Äù), to transact the following business:
ORDINARY BUSINESS:
1.	
To receive, consider and adopt:
	
a)	
the Audited Standalone Financial Statements 
of the Company for the Financial Year ended 
31 March 2024 together with the Reports of the 
Board of Directors and the Auditors thereon; and
	
b)	
the Audited Consolidated Financial Statements 
of the Company for the Financial year ended 
31 March 2024 together with the Report of the 
Auditors thereon.
2.	
To confirm the interim dividend(s) for the financial year 
ended 31 March 2024, and, in this regard, pass the 
following resolution as an Ordinary Resolution.
	
‚ÄúRESOLVED THAT the first interim dividend of H¬†25 per 
equity share and second interim dividend of H¬†26 per 
equity share; aggregating to a sum of H¬†51 per equity 
share on face value of H¬†2/- each fully paid up for the 
FY 2024, as approved by the Board of Directors of 
the Company and already paid, be and are hereby 
confirmed/ratified.‚Äù
3.	
To appoint a Director in place of Mr. Mannalal B. 
Agrawal (DIN: 00073828), who retires by rotation and 
being eligible, offers himself for re-appointment.
SPECIAL BUSINESS:
4.	
To consider appointment of Mr. David Rasquinha 
(DIN: 01172654) as an Independent Director of the 
Company and, if thought fit, to pass the following 
resolution as a Special Resolution:
	
‚ÄúRESOLVED THAT pursuant to the provisions of Section 
149, 152 read with Schedule IV of the Companies 
Act 2013 (the Act), Regulation 17 (1C) of SEBI 
(Listing Obligations and Disclosure Requirements) 
Regulations, 2015 and other applicable provisions 
(including any statutory modification or re-enactment 
thereof for the time being in force), in accordance 
with the provisions of Articles of Association of the 
Company and based on the recommendation of the 
Nomination and Remuneration Committee, Mr. David 
Rasquinha (DIN: 01172654) who was appointed as an 
Additional Non-Executive Independent Director of the 
Company by the Board of Directors with effect from 
02 May 2024 and in respect of whom, the Company 
has received a notice in writing from a Member under 
Section 160(1) of the Act proposing his candidature 
for the office of Director, be and is hereby appointed 
as an Independent Director of the Company for a 
term of 5 (five) years from 02 May 2024, not liable to 
retire by rotation;
	
RESOLVED FURTHER THAT any Director or the Key 
Managerial Personnel of the Company be and are 
hereby severally authorised to do all such acts, deeds, 
matters and things and take all such steps as may 
be necessary, proper or expedient for appointment 
of Mr. David Rasquinha (DIN: 01172654), as an 
Independent Director of the Company.‚Äô‚Äô
5.	
To consider appointment of Ms. Medha Joshi 
(DIN: 00328174) as an Independent Director of the 
Company and, if thought fit, to pass the following 
resolution as a Special Resolution:
	
‚ÄúRESOLVED THAT pursuant to the provisions of Section 
149, 152 read with Schedule IV of the Companies 
Act 2013 (the Act), Regulation 17 (1C) of SEBI 
(Listing Obligations and Disclosure Requirements) 
Regulations, 2015 and other applicable provisions 
(including any statutory modification or re-enactment 
thereof for the time being in force), in accordance 
with the provisions of Articles of Association of the 
Company and based on the recommendation of 
the Nomination and Remuneration Committee, 
Ms. Medha Joshi (DIN: 00328174) who was appointed 
as an Additional Non-Executive Independent Director 
of the Company by the Board of Directors with 
effect from 02 May 2024 and in respect of whom, 
the Company has received a notice in writing from 
a Member under Section 160(1) of the Act proposing 
her candidature for the office of Director, be and is 
hereby appointed as an Independent Director of the 
(CIN No. L24230MH1979PLC022059)
Regd. Office: ‚ÄúAjanta House‚Äù, Charkop, Kandivali (West), Mumbai ‚Äì 400 067
Tel No.: +91 022 6606 1000
Website: www.ajantapharma.com; e-mail: investorgrievance@ajantapharma.com
NOTICE
Company for a term of 5 (five) years from 02 May 2024, 
not liable to retire by rotation;
	
RESOLVED FURTHER THAT any Director or the Key 
Managerial Personnel of the Company be and are 
hereby severally authorised to do all such acts, deeds, 
matters and things and take all such steps as may be 
necessary, proper or expedient for appointment of 
Ms. Medha Joshi (DIN: 00328174), as an Independent 
Director of the Company.‚Äô‚Äô
6.	
To consider appointment of Mr. Rajesh Dalal 
(DIN: 03504969) as an Independent Director of 
the Company and, if thought fit, to pass with or 
without modification(s) the following resolution as a 
Special Resolution:
	
‚ÄúRESOLVED THAT pursuant to the provisions of Section 
149, 152 read with Schedule IV of the Companies 
Act 2013 (the Act), Regulation 17 (1C) of SEBI 
(Listing Obligations and Disclosure Requirements) 
Regulations, 2015 and other applicable provisions 
(including any statutory modification or re-enactment 
thereof for the time being in force), in accordance 
with the provisions of Articles of Association of the 
Company and based on the recommendation of the 
Nomination and Remuneration Committee, Mr. Rajesh 
Dalal (DIN: 03504969) who was appointed as an 
Additional Non-Executive Independent Director of the 
Company by the Board of Directors with effect from 
02 May 2024 and in respect of whom, the Company 
has received a notice in writing from a Member under 
Section 160(1) of the Act proposing his candidature 
for the office of Director, be and is hereby appointed 
as an Independent Director of the Company for a 
term of 5 (five) years from 02 May 2024, not liable to 
retire by rotation;
	
RESOLVED FURTHER THAT any Director or the Key 
Managerial Personnel of the Company be and are 
hereby severally authorised to do all such acts, deeds, 
matters and things and take all such steps as may be 
necessary, proper or expedient for appointment of 
Mr. Rajesh Dalal (DIN: 03504969), as an Independent 
Director of the Company.‚Äô‚Äô
7.	
To consider appointment of Ms. Simi Thapar (DIN: 
10470498) as an Independent Director of the 
Company and, if thought fit, to pass the following 
resolution as a Special Resolution:
	
‚ÄúRESOLVED THAT pursuant to the provisions of Section 
149, 152 read with Schedule IV of the Companies 
Act 2013 (the Act), Regulation 17 (1C) of SEBI 
(Listing Obligations and Disclosure Requirements) 
Regulations, 2015 and other applicable provisions 
(including any statutory modification or re-enactment 
thereof for the time being in force), in accordance 
with the provisions of Articles of Association of the 
Company and based on the recommendation of the 
Nomination and Remuneration Committee, Ms. Simi 
Thapar (DIN: 10470498) who was appointed as an 
Additional Non-Executive Independent Director of the 
Company by the Board of Directors with effect from 
02 May 2024 and in respect of whom, the Company 
has received a notice in writing from a Member under 
Section 160(1) of the Act proposing her candidature 
for the office of Director, be and is hereby appointed 
as an Independent Director of the Company for a 
term of 5 (five) years from 02 May 2024, not liable to 
retire by rotation;
	
RESOLVED FURTHER THAT any Director or the Key 
Managerial Personnel of the Company be and are 
hereby severally authorised to do all such acts, deeds, 
matters and things and take all such steps as may be 
necessary, proper or expedient for appointment of 
Ms. Simi Thapar (DIN: 10470498), as an Independent 
Director of the Company.‚Äô‚Äô
8.	
To consider ratification of remuneration of Cost 
Auditors for the financial year 2024-2025 and if 
thought fit, to pass with or without modification(s), 
the following resolution as an Ordinary Resolution:
	
"RESOLVED THAT pursuant to the provisions of 
Section 148 and other applicable provisions, if any, 
of the Companies Act, 2013, the Companies (Audit 
and Auditors) Rules, 2014 and the Companies 
(Cost Records and Audit) Rules, 2014 (including any 
statutory modification(s) or re-enactment thereof, for 
the time being in force)-, remuneration of H¬†6.50 lakh 
plus GST and reimbursement of actual travel and out 
of pocket expenses, fixed by the Board for M/s. RA & 
Co., Cost Accountants, (Firm Registration No. 000242), 
Cost Auditors of the Company to conduct the audit 
of the cost records maintained by the Company for 
the financial year ending 31 March 2025, be and is 
hereby ratified;
Annual Report 2023-24
254
255
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
	
RESOLVED FURTHER THAT any Director or the Key 
Managerial Personnel of the Company be and are 
hereby authorised to do all acts and take all such 
steps as may be necessary, proper or expedient to 
give effect to this Resolution.‚Äù
By order of the Board of Directors
Gaurang C. Shah
VP ‚Äì Legal & Company Secretary
02 May 2024
Membership No. F6696
Registered office:
"Ajanta House‚Äù, Charkop,
Kandivali (West),
Mumbai ‚Äì 400 067
NOTES:
1.	
An Explanatory Statement pursuant to Section 102 
of the Companies Act, 2013 ("the Act‚Äù), which sets 
out details relating to Item No. 4 to 8 of the Notice is 
annexed hereto.
2.	
Pursuant to Regulation 36 of the SEBI (Listing 
Obligations 
and 
Disclosure 
Requirements) 
Regulations, 2015 (‚ÄúListing Regulations‚Äù) and 
Secretarial Standard on General Meetings issued by 
the Institute of Company Secretaries of India, details 
of Director seeking reappointment forms part of this 
notice and is appended to the notice.
3.	
The Ministry of Corporate Affairs (‚ÄúMCA‚Äù) and 
Securities and Exchange Board of India (‚ÄúSEBI‚Äù), have 
vide various circulars allowed companies to send the 
annual reports to shareholders only on e-mail and 
to hold Annual General Meeting (‚ÄúAGM‚Äù) through VC 
or OAVM without the physical presence of members 
at a common venue. Hence, in accordance with 
these Circulars, the 45th AGM of the Members of the 
Company is being held through VC/ OAVM. The venue 
of the Meeting shall be deemed to be the registered 
office of the Company.
4.	
To support the green initiative and as per relaxation 
given by the Government, only electronic copy of 
the Annual report for the year ended 31 March 2024 
and Notice of the 45th AGM are being sent to the 
Members whose mail IDs are available with your 
Company/ DP(s). Annual Report and the notice of the 
45th Annual General Meeting are also posted on the 
website www.ajantapharma.com for download. The 
AGM Notice can also be accessed from the websites 
i.e. BSE Limited (www.bseindia.com), National Stock 
Exchange of India Limited (www.nseindia.com) and 
National Securities Depository Limited (www.evoting.
nsdl.com).
5.	
Since this AGM is being held through VC / OAVM, 
physical attendance of Members has been dispensed 
with. Accordingly, the facility for appointment of 
proxies by the Members will not be available for the 
AGM and hence the Proxy Form, Attendance Slip and 
Route Map are not annexed to this Notice. However, 
in pursuance of Section 112 and 113 of the Act, 
representatives of the members such as the President 
of India or the Governor of a State or body corporate 
can attend the AGM through VC / OAVM and cast 
their votes through e-Voting.
6.	
In case of joint holders attending the Meeting, the 
member whose name appears as the first holder in 
the order of names as per Register of Members will be 
entitled to vote.
7.	
Institutional/Corporate Shareholders (i.e. other than 
individuals/ HUF/ NRI, etc.) are required to send 
a scanned copy (PDF / JPG format) of its Board 
or governing body resolution/authorisation etc., 
authorising its representative to attend the AGM 
through VC / OAVM on its behalf and to vote through 
remote e-Voting. The said resolution/ authorisation 
shall be sent to the Scrutiniser by e-mail through its 
registered e-mail address to alwyn.co@gmail.com 
with a copy marked to evoting@nsdl.co.in, at least 
48 hours before the commencement of AGM.
8.	
Following documents will be available for inspection 
electronically to the members during the AGM:
	
i.	
Register of Directors and Key Managerial Personnel;
	
ii.	
Register of securities held by Directors and Key 
Managerial Personnel;
	
iii.	
Register of Contracts or Arrangements in which 
the directors are interested;
	
iv.	
Certificate from the Secretarial Auditors of 
the Company certifying that the Company‚Äôs 
Share Based Incentive Plan ‚Äì 2019 is being 
implemented in accordance with SEBI (Share 
Based Employee Benefits and Sweat Equity) 
Regulations, 2021.
NOTICE
9.	
All other documents referred to in the Notice will also 
be available for electronic inspection without any 
fee by the members from the date of circulation of 
this Notice up to the date of AGM, i.e. ¬≠18 July 2024. 
Members seeking to inspect such documents can send 
an e-mail to investorgrievance@ajantapharma.com
10.	 Pursuant to the provisions of Section 108 of the 
Companies Act, 2013 read with Rule 20 of the 
Companies (Management and Administration) Rules, 
2014 and Regulation 44 of SEBI Listing Regulation 
and MCA Circulars, the Company is providing facility 
of remote e-Voting to its Members in respect of 
the business to be transacted at the AGM. For this 
purpose, the Company has engaged NSDL as the 
authorised e-Voting agency. Accordingly, the facility 
of casting votes by a member using remote e-Voting 
as well as the e-Voting system on the date of the AGM 
will be provided by NSDL.
11.	 Members can join the AGM in the VC / OAVM 
mode 15 minutes before and after the scheduled 
time of the commencement of the Meeting by 
following the procedure mentioned in the Notice. 
The facility of participation at the AGM through VC 
/ OAVM will be made available to at least 1000 
members on first come first served basis. This will not 
include large Shareholders (Shareholders holding 
2% or more shareholding), Promoters, Directors, 
Institutional Investors, Key Managerial Personnel, the 
Chairpersons of the Audit Committee, Nomination 
and Remuneration Committee and Stakeholders' 
Relationship Committee Auditors etc. are allowed to 
attend the AGM without restriction on account of first 
come first served basis.
12.	 The attendance of the Members attending the AGM 
through VC / OAVM will be counted for the purpose of 
ascertaining the quorum under Section 103 of the Act.
13.	 Instructions for Shareholders for remote e-Voting 
and joining the AGM are as under:
	
The remote e-Voting period begins on Monday 
15¬†July 2024 at 9:00 a.m. and ends on Wednesday 
17¬†July 2024 at 5:00 p.m. The remote e-Voting module 
shall be disabled by NSDL for voting thereafter. The 
Members, whose names appear in the Register of 
Members/ Beneficial Owners as on the cut-off date 
i.e. Wednesday, 10 July 2024 may cast their vote 
electronically. The voting right of shareholders shall 
be in proportion to their share in the paid-up equity 
share capital of the Company as on the cut-off date, 
being Wednesday, 10 July 2024. The way to vote 
electronically on NSDL e-Voting system consists of 
‚ÄúTwo Steps‚Äù which are mentioned below:
Step 1: Access to NSDL e-Voting system
A)	
Login method for e-Voting and joining virtual 
meeting 
for 
Individual 
shareholders 
holding 
securities in demat mode.
	
In terms of SEBI circular dated 09 December 2020 
on e-Voting facility provided by Listed Companies 
Individual shareholders holding securities in demat 
mode are allowed to vote through their demat 
account maintained with Depositories and Depository 
Participants. Shareholders are advised to update 
their mobile number and e-mail Id in their demat 
accounts in order to access e-Voting facility.
Annual Report 2023-24
256
257
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Login method for Individual shareholders holding securities in demat mode is given below:
Type of shareholders
Login Method
Individual Shareholders 
holding securities in 
demat mode with NSDL
1. Existing IDeAS user can visit the e-Services website of NSDL viz. https://eservices.nsdl.com either on 
a Personal Computer or on a mobile. On the e-Services home page click on the ‚ÄúBeneficial Owner‚Äù 
icon under ‚ÄúLogin‚Äù which is available under ‚ÄòIDeAS‚Äô section , this will prompt you to enter your existing 
User ID and Password. After successful authentication, you will be able to see e-Voting services under 
Value added services. Click on ‚ÄúAccess to e-Voting‚Äù under e-Voting services and you will be able to see 
e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be re-directed 
to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual 
meeting & voting during the meeting.
2. If you are not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. 
Select ‚ÄúRegister Online for IDeAS Portal‚Äù or click at https://eservices.nsdl.com/SecureWeb/ IdeasDirectReg.jsp
3. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www. evoting.
nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is 
launched, click on the icon ‚ÄúLogin‚Äù which is available under ‚ÄòShareholder/Member‚Äô section. A new screen 
will open. You will have to enter your User ID (i.e. your sixteen digit demat account number held with NSDL), 
Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will 
be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or 
e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your 
vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.
4. Shareholders/Members can also download NSDL Mobile App ‚ÄúNSDL Speede‚Äù facility by scanning the QR 
code mentioned below for seamless voting experience.
Individual Shareholders 
holding securities in 
demat mode with CDSL
1. Users who have opted for CDSL Easi/Easiest facility, can login through their existing user id and password. 
Option will be made available to reach e-Voting page without any further authentication. The users to 
login Easi /Easiest are requested to visit CDSL website www.cdslindia.com and click on login icon & New 
System Myeasi Tab and then use your existing Myeasi username & password.
2. After successful login the Easi/Easiest user will be able to see the e-Voting option for eligible companies 
where the e-Voting is in progress as per the information provided by company. On clicking the e-Voting 
option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote 
during the remote e-Voting period or joining virtual meeting & voting during the meeting. Additionally, 
there are also links provided to access the system of all e-Voting Service Providers, so that the user can 
visit the e-Voting Service Providers website directly.
3. If the user is not registered for Easi/Easiest, option to register is available at CDSL website 
www.cdslindia.com and click on login & New System Myeasi Tab and then click on registration option. 
4. Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN 
No. from e-Voting link available on www.cdslindia.com home page. The system will authenticate the 
user by sending OTP on registered Mobile & E-mail as recorded in the Demat Account. After successful 
authentication, user will be able to see the e-Voting option where the e-Voting is in progress and also 
able to directly access the system of all e-Voting Service Providers.
Individual Shareholders 
(holding securities in 
demat mode) login 
through their depository 
participants
You can also login using the login credentials of your demat account through your Depository Participant 
registered with NSDL / CDSL for e-Voting facility. Upon logging in, you will be able to see e-Voting option. Click 
on e-Voting option, you will be redirected to NSDL / CDSL Depository site after successful authentication, 
wherein you can see e-Voting feature. Click on company name or e-Voting service provider i.e. NSDL and 
you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or 
joining virtual meeting & voting during the meeting.
NOTICE
Important note: Members who are unable to retrieve User ID/Password are advised to use Forgot User ID and Forgot 
Password option available at above mentioned website:
Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related 
to login through Depository i.e. NSDL and CDSL.
Login type
Helpdesk details
Individual Shareholders holding 
securities in demat mode with NSDL
Members facing any technical issue in login can contact NSDL helpdesk by sending a request at 
evoting@nsdl.co. in or call at 022 - 4886 7000 and 022 - 2499 7000.
Individual Shareholders holding 
securities in demat mode with CDSL
Members facing any technical issue in login can contact CDSL helpdesk by sending a request at 
helpdesk.evoting@cdslindia.com or contact at toll free no. 1800 22 55 33.
B)	
Login Method for e-Voting and joining virtual meeting for shareholders other than Individual shareholders 
holding securities in demat mode and for shareholders holding securities in physical mode.
	
1.	
Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl. com/ 
either on a Personal Computer or on a mobile.
	
2.	
Once the home page of e-Voting system is launched, click on the icon ‚ÄúLogin‚Äù which is available under 
‚ÄòShareholder/Member‚Äô section.
	
3.	
A new screen will open. You will have to enter your User ID, your Password/OTP and a Verification Code as 
shown on the screen. 
	
	
Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at https://eservices.nsdl.com/ 
with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on 
e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.
	
4.	
Your User ID details are given below:
Manner of holding shares i.e. Demat 
(NSDL or CDSL) or Physical
Your User ID is
a) For Members who hold shares in 
demat account with NSDL
8 Character DP ID followed by 8 Digit Client ID
For example if your DP ID is IN300*** and Client ID is 12****** then your user ID is 
IN300***12******.
b) For Members who hold shares in 
demat account with CDSL.
16 Digit Beneficiary ID
For example if your Beneficiary ID is 12************** then your user ID is 12**************
c) For Members holding shares in 
Physical Form.
EVEN Number followed by Folio Number registered with the Company
For example if folio number is 001*** and EVEN is 101456 then user ID is 101456001***
	
5.	
Password details for shareholders other than 
Individual shareholders are given below:
	
	
a)	
If you are already registered for e-Voting, 
then you can use your existing password to 
login and cast your vote.
	
	
b)	
If you are using NSDL e-Voting system for the 
first time, you will need to retrieve the ‚Äòinitial 
password‚Äô which was communicated to you. 
Once you retrieve your ‚Äòinitial password‚Äô, 
you need to enter the ‚Äòinitial password‚Äô 
and the system will force you to change 
your password.
	
	
c)	
How to retrieve your ‚Äòinitial password‚Äô?
	
	
	
(i)	
If your e-mail ID is registered in your 
demat account or with the Company, 
your ‚Äòinitial password‚Äô is communicated 
to you on your e-mail ID. Trace the 
e-mail sent to you from NSDL from your 
mailbox. Open the e-mail and open the 
attachment i.e. a .pdf file. Open the .pdf 
file. The password to open the .pdf file is 
your 8 digit client ID for NSDL account, 
last 8 digits of client ID for CDSL 
account or folio number for shares held 
in physical form. The .pdf file contains 
your ‚ÄòUser ID‚Äô and your ‚Äòinitial password‚Äô.
Annual Report 2023-24
258
259
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
	
	
(ii)	
If your e-mail ID is not registered, please 
follow steps mentioned below in process 
for those shareholders whose e-mail ids are 
not registered.
	
6.	
If you are unable to retrieve or have not 
received the ‚ÄúInitial password‚Äù or have forgotten 
your password:
	
	
a)	
Click on ‚ÄúForgot User Details/Password?‚Äù(If 
you are holding shares in your demat 
account with NSDL or CDSL) option 
available on www.evoting.nsdl.com.
	
	
b)	
"Physical User Reset Password?‚Äù (If you are 
holding shares in physical mode) option 
available on www.evoting.nsdl.com.
	
	
c)	
If you are still unable to get the password 
by aforesaid two options, you can send a 
request at evoting@nsdl.co.in mentioning 
your demat account number/folio number, 
your PAN, your name and your registered 
address etc.
	
	
d)	
Members can also use the OTP (One Time 
Password) based login for casting the votes 
on the e-Voting system of NSDL.
	
7.	
After entering your password, tick on Agree 
to ‚ÄúTerms and Conditions‚Äù by selecting on the 
check box.
	
8.	
Now, you will have to click on ‚ÄúLogin‚Äù button.
	
9.	
After you click on the ‚ÄúLogin‚Äù button, Home page 
of e-Voting will open.
Step 2: Cast your vote electronically and join 
General Meeting on NSDL e-Voting system.
a)	
After successful login at Step 1, you will be able to 
see all the companies ‚ÄúEVEN‚Äù in which you are holding 
shares and whose voting cycle and General Meeting 
is in active status.
b)	
Select ‚ÄúEVEN‚Äù of company for which you wish to 
cast your vote during the remote e-Voting period 
and casting your vote during the General Meeting. 
For joining virtual meeting, you need to click on 
‚ÄúVC / OAVM‚Äù link placed under ‚ÄúJoin Meeting‚Äù.
c)	
Now you are ready for e-Voting as the Voting 
page opens.
d)	
Cast your vote by selecting appropriate options i.e. 
assent or dissent, verify/modify the number of shares 
for which you wish to cast your vote and click on 
‚ÄúSubmit‚Äù and also ‚ÄúConfirm‚Äù when prompted.
NOTICE
e)	
Upon confirmation, the message ‚ÄúVote cast 
successfully‚Äù will be displayed. f. You can also take 
the printout of the votes cast by you by clicking on 
the print option on the confirmation page.
g)	
Once you confirm your vote on the resolution, you will 
not be allowed to modify your vote.
General Guidelines for shareholders
a)	
Institutional shareholders (i.e. other than individuals, 
HUF, NRI etc.) are required to send scanned copy 
(PDF / JPG Format) of the relevant Board Resolution/
Authority letter etc. with attested specimen signature 
of the duly authorised signatory(ies) who are 
authorised to vote, to the Scrutiniser by e-mail to 
alwyn.co@gmail.com with a copy marked to evoting@
nsdl.co.in. Institutional shareholders (i.e. other than 
individuals, HUF, NRI etc.) can also upload their Board 
Resolution/ Power of Attorney/ Authority Letter etc. 
by clicking on ‚ÄúUpload Board Resolution/Authority 
Letter‚Äù displayed under ‚Äúe-Voting‚Äù tab in their login.
b)	
It is strongly recommended not to share your 
password with any other person and take utmost 
care to keep your password confidential. Login 
to the e-Voting website will be disabled upon five 
unsuccessful attempts to key in the correct password. 
In such an event, you will need to go through the 
‚ÄúForgot User Details/Password?‚Äù or ‚ÄúPhysical User 
Reset Password?‚Äù option available on https://www.
evoting.nsdl.com/ to reset the password.
c)	
Any person holding shares in physical form and non-
individual shareholders, who acquires shares of the 
Company and becomes member of the Company 
after the notice is sent through e-mail and holding 
shares as of the cut-off date i.e. Wednesday, 10 July 
2024 may obtain the login ID and password by 
sending a request at evoting@nsdl.co.in or Issuer/RTA. 
However, if you are already registered with NSDL for 
remote e-Voting, then you can use your existing user 
ID and password for casting your vote. If you forgot 
your password, you can reset your password by using 
‚ÄúForgot User Details/Password‚Äù or ‚ÄúPhysical User 
Reset Password‚Äù option available on https://www.
evoting.nsdl.com/ or call on 022 - 4886 7000 and 
022 - 2499 7000. In case of Individual Shareholders 
holding securities in demat mode who acquires 
shares of the Company and becomes a Member of 
the Company after sending of the Notice and holding 
shares as of the cut-off date i.e. Wednesday, 10 July 
2024, may follow steps mentioned in the Notice of the 
AGM under ‚ÄúAccess to NSDL e-Voting system‚Äù.
d)	
In case of any queries, you may refer the Frequently 
Asked Questions (FAQs) for Shareholders and 
e-Voting user manual for Shareholders available at 
the download section of www.evoting.nsdl.com or call 
on.: 22 - 4886 7000 and 022 - 2499 7000 or send a 
request to Ms. Pallavi Mhatre at evoting@nsdl.co.in
Process for those shareholders whose e-mail 
ids are not registered with the depositories for 
procuring user id and password and registration of 
e mail ids for e-Voting for the resolutions set out in 
this notice:
a)	
In case shares are held in physical mode, please 
provide Folio No., Name of shareholder, scanned 
copy of the share certificate (front and back), PAN 
(self-attested scanned copy of PAN card), AADHAR 
(self-attested scanned copy of Aadhar Card) to 
Company‚Äôs Registrar & Share Transfer Agent ("RTA"), 
Link Intime India Private Limited, 101, 247 Park, L. B. S. 
Marg, Vikhroli West, Mumbai - 400 083.
b)	
In case shares are held in demat mode, please 
contact your Depository Participant and get your 
mail ID registered with them. If you are an Individual 
shareholder holding securities in demat mode, you 
are requested to refer to the login method explained 
at step 1 (A) i.e. Login method for e-Voting and joining 
virtual meeting for Individual shareholders holding 
securities in demat mode.
c)	
Alternatively shareholder/members may send a 
request to evoting@nsdl.co.in for procuring user 
id and password for e-Voting by providing above 
mentioned documents.
d)	
In terms of SEBI circular dated 09 December 2020 
on e-Voting facility provided by Listed Companies, 
Individual shareholders holding securities in demat 
mode are allowed to vote through their demat 
account maintained with Depositories and Depository 
Participants. Shareholders are required to update 
their mobile number and e-mail ID correctly in their 
demat account in order to access e-Voting facility.
Instructions for Members for e-Voting on the day 
of the AGM are as under:
a)	
The procedure for e-Voting on the day of the AGM is 
same as the instructions mentioned above for remote 
e-Voting.
b)	
Only those Members/shareholders, who will be 
present in the AGM through VC / OAVM facility and 
have not casted their vote on the Resolutions through 
remote e-Voting and are otherwise not barred from 
doing so, shall be eligible to vote through e-Voting 
system in the AGM.
c)	
Members who have voted through remote e-Voting 
will be eligible to attend the AGM. However, they will 
not be eligible to vote at the AGM.
d)	
The details of the person who may be contacted 
for any grievances connected with the facility for 
e-Voting on the day of the AGM shall be the same 
person mentioned for remote e-Voting.
Instructions for Members for attending the AGM 
are as under:
a)	
Member will be provided with a facility to attend the 
AGM through VC / OAVM through the NSDL e-Voting 
system. Members may access by following the steps 
mentioned above for Access to NSDL e-Voting system. 
After successful login, you can see link of ‚ÄúVC / OAVM‚Äù 
placed under ‚ÄúJoin meeting‚Äù menu against company 
name. You are requested to click on VC / OAVM 
link placed under Join Meeting menu. The link for 
VC / OAVM will be available in Shareholder/Member 
login where the EVEN of Company will be displayed. 
Please note that the members who do not have the 
User ID and Password for e-Voting or have forgotten 
the User ID and Password may retrieve the same by 
following the remote e-Voting instructions mentioned 
in the notice to avoid last minute rush.
b)	
Members are encouraged to join the Meeting through 
Laptops for better experience.
c)	
Further Members will be required to allow Camera 
and use Internet with a good speed to avoid any 
disturbance during the meeting.
d)	
Please note that Participants connecting from Mobile 
Devices or Tablets or through Laptop connecting via 
Mobile Hotspot may experience Audio/Video loss due 
to fluctuation in their respective network. It is therefore 
recommended to use Stable Wi-Fi or LAN Connection 
to mitigate any kind of aforesaid glitches.
e)	
Shareholders who would like to express their views 
/ask questions during the meeting may register 
themselves as a speaker by sending their request 
in advance from Thursday, 11 July 2024 (9:00 a.m. 
IST) to Tuesday 16 July 2024 (5:00 p.m. IST) prior to 
meeting mentioning their name, demat account 
number/folio number, e-mail id, mobile number, 
PAN at investorgrievance@ajantapharma.com. The 
shareholders who do not wish to speak during the 
AGM but have queries may send their queries in 
advance 5 days prior to meeting mentioning their 
name, demat account number/folio number, e-mail 
id, mobile number, PAN at investorgrievance@
ajantapharma.com. These queries will be replied to 
by your Company suitably by e-mail.
Annual Report 2023-24
260
261
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
14.	 Mr. Alwyn D‚ÄôSouza, a Practicing Company Secretary, 
Mumbai (Membership No. FCS 5559 & Certificate of 
Practice No. 5137) and failing him, Mr. Jay D‚ÄôSouza, 
(Membership No. FCS 3058 & Certificate of Practice 
No. 6915) has been appointed as the Scrutiniser 
to scrutinise the voting and ensuring that remote 
e-Voting process is conducted in a fair and transparent 
manner. The Scrutiniser will submit his report to the 
Chairman of the Company or to any other person 
authorised by the Chairman after the completion 
of the scrutiny of the e-Voting (votes casted during 
the AGM and votes casted through remote e-Voting), 
within 2 working days of the conclusion of the AGM. 
The result declared along with the Scrutiniser‚Äôs report 
shall be communicated to the Stock Exchanges, NSDL 
& RTA and will also be displayed on your Company‚Äôs 
website, www.ajantapharma.com.
15.	 Members are requested to address all correspondence 
in connection with shares held by them, to the 
Company‚Äôs RTA viz., Link Intime India Private Limited, 
101, 247 Park, L. B. S. Marg, Vikhroli West, Mumbai - 
400 083 by quoting their Folio number or their DPID 
and Client ID number, as the case may be.
16.	 Members are requested to do following, if not 
done yet:
	
i)	
Provide/update details of their bank accounts 
indicating the name of the bank, branch, 
account number and the nine-digit MICR code 
and IFSC code (as appearing on the cheque) 
along with photocopy of the cheque/cancelled 
cheque, self- attested identity proof and 
address proof, for remittance of dividend through 
ECS / NEFT and prevent fraudulent encashment 
of dividend warrants.
	
(ii)	
Dematerialise the shares held in physical form.
	
(iii)	
Update Permanent Account Number (PAN) 
against folio/demat account as also for deletion 
of name of deceased holder, transmission/
transposition of shares.
	
(iv)	 Members holding shares in dematerialised form 
are requested to intimate/update all particulars 
of bank mandates, PAN, nominations, power of 
attorney, change of address, e-mail address, 
contact numbers etc. to their Depository 
Participants (DPs). Members holding shares in 
physical form are requested to intimate such 
details to the RTA and file nomination form SH-13.
17.	 NRI Members are requested to inform the 
RTA immediately:
	
(i)	
Particulars of their bank account maintained 
in India with complete name, branch, account 
type, account number and address of the bank 
with pin code number, if not furnished earlier; and
	
(ii)	
Change in their residential status and 
address in India on their return to India for 
permanent settlement.
By order of the Board of Directors
Gaurang C. Shah
VP ‚Äì Legal & Company Secretary
02 May 2024
Membership No. F6696
Registered office:
‚ÄúAjanta House‚Äù, Charkop,
Kandivali (West),
Mumbai ‚Äì 400 067
NOTICE
Item No. 4, 5, 6 and 7
Pursuant to Section 161(1) of the Companies Act, 2013 
(‚Äúthe Act‚Äù) and the Articles of Association of the Company, 
the Board at its meeting held on 02 May 2024, based on 
recommendations of the Nomination and Remuneration 
Committee, appointed Mr. David Rasquinha (DIN: 
01172654), Ms. Medha Joshi (DIN: 00328174), Mr. Rajesh 
Dalal (DIN: 03504969) and Ms. Simi Thapar (DIN: 10470498), 
as Additional Non-Executive Independent Directors of 
the Company.
In terms of the provisions of Section 161(1) of the Act, 
Mr. David Rasquinha, Ms. Medha Joshi, Mr. Rajesh Dalal 
and Ms. Simi Thapar hold office as Additional Director(s) 
till the date of the ensuing 45th Annual General Meeting 
(AGM) scheduled on 18 July 2024.
The Company has received the following from them:
(i)	
Consent in writing to act as Director in Form DIR-2 
pursuant to Rule 8 of the Companies (Appointment 
& Qualification of Directors) Rules, 2014 (‚Äúthe 
Appointment Rules‚Äù);
(ii)	
Intimation in Form DIR-8 in terms of the Appointment 
Rules to the effect that they are not disqualified under 
sub-section (2) of Section 164 of the Act;
(iii)	
A declaration to the effect that they meet the criteria 
of independence as provided in sub-section (6) 
of Section 149 of the Act and under the 
LODR Regulations;
(iv)	 Confirmation that they are not aware of any 
circumstance or situation which exists or may 
be reasonably anticipated that could impair or 
impact their ability to discharge their duties as an 
Independent Director of the Company;
(v)	
A declaration that they are in compliance with Rules 
6(1) and 6(2) of the Appointment Rules with respect 
to their registration to the Data Bank of Independent 
Directors maintained by the Indian Institute of 
Corporate Affairs(‚ÄúIICA‚Äù).
The Company has received a notice in writing from a 
member proposing their candidature under Section 160 
of the Act.
Brief Profiles of these Directors are as follows:
Mr. David Rasquinha:
Mr. David is an international finance veteran with over 
40 years‚Äô experience in export credits and cross-border 
financial transactions. He superannuated from India 
Exim Bank as the Managing Director and Chief Executive 
Officer after serving it for nearly four decades. During his 
tenure with India EXIM bank, he served as a member on 
several Working Groups set up by the Reserve Bank of 
India as well as the Government of India for facilitation 
measures for exporters, working capital finance etc. He 
is an expert analyst and speaker on the Indian economy 
and other key issues. His insights on export credit and the 
Indian economy are often sought in panel discussions 
and seminars, by overseas equity and fixed-income 
investors in Japan, Singapore, Hong Kong, London, USA. 
Mr. David holds a first-class graduate degree in Economics 
from Bombay University and a post graduate degree in 
Business Management from the XLRI, Jamshedpur where 
he was awarded the Gold Medal in Economics. He is 
also an Independent Director on the Boards of Afcons 
Infrastructure Ltd., Ion Exchange Ltd. and Unity Small 
Finance Bank.
Ms. Medha Joshi:
Ms. Medha Joshi is a banking industry stalwart with expertise 
in an array of subjects including risk management and 
forensic audit. She retired from IDBI Bank as Chief General 
Manager after 35-years of service. During her association 
with IDBI Bank she managed Corporate Banking, 
Investments, Human Resources, Risk Management, Retail 
banking, Rehabilitation Finance, Corporate Finance 
and Merchant Banking. Post retirement, she has been 
associated with HDFC Ergo as advisor and with National 
Stock exchange (NSE) / Bombay Stock Exchange (BSE) as 
Arbitrator. She is a Certified Associate of Indian Institute of 
Bankers (CAIIB) and a degree holder in MBA.
Mr. Rajesh Dalal:
Mr. Dalal is a healthcare industry veteran with over four-
decades experience in the field of business management 
and strategic advisory. In 1980, he joined Johnson & 
Johnson India as a product manager and rose through 
the ranks to become the managing director at J&J 
Medical India, the medical device business. He was also 
EXPLANATORY STATEMENT PURSUANT TO SECTION 102(1) OF THE COMPANIES ACT, 2013
Annual Report 2023-24
262
263
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Pursuant to Regulation 36(3) of the Listing Regulations and 
Para 1.2.5 of Secretarial Standard ‚Äì 2 on General Meetings 
issued by the Institute of Company Secretaries of India (‚ÄúICSI‚Äù), 
requisite particulars of Mr. David Rasquinha, Ms. Medha 
Joshi, Ms. Simi Thapar and Mr. Rajesh Dalal including their 
brief profile and specific areas of expertise are given in this 
Addendum to the AGM Notice as ‚ÄúAnnexure 1‚Äù.
Draft letters of appointment of Mr. David Rasquinha, 
Ms. Medha Joshi, Ms. Simi Thapar and Mr. Rajesh Dalal 
setting out the terms and conditions of their appointment 
is available electronically for inspection by the Members. 
The same are also available for inspection at the registered 
office of the Company during office hours on all working 
days from the date of dispatch of the Notice till the date 
of AGM.
Pursuant to the provisions of Regulation 17(1C) of the Listing 
Regulations, the Company is required to obtain approval 
of shareholders for the appointment of Independent 
Directors at the next general meeting or within a time 
period of 3 (three) months from the date of appointment, 
whichever is earlier.
The Board recommends the resolution as set out at Item 
No. 4, 5, 6 and 7 in the 45th AGM Notice for approval of the 
Members of the Company as a Special Resolution.
Except Mr. David Rasquinha, Ms. Medha Joshi, Ms. Simi 
Thapar and Mr. Rajesh Dalal and their relatives, no other 
Director(s) and Key Managerial Personnel(s) or their 
relatives, are in any way, concerned or interested, 
financially or otherwise, in this resolution.
Item No. 8
In accordance with the provisions of Section 148 of the 
Act, the Companies (Audit and Auditors) Rules, 2014 and 
the Companies (Cost Records and Audit) Rules, 2014 
(including any statutory modification(s) or re-enactment 
thereof, for the time being in force), the Board of Directors 
of the Company on the recommendation of the Audit 
Committee, approved the appointment of M/s. RA & Co., 
Cost Accountants, as the Cost Auditors of the Company 
for the financial year 2024-25, for conducting the audit 
of the cost records of the Company at a remuneration of 
H¬†6.50 lacs plus GST and reimbursement of actual travel 
and out of pocket expenses.
Vice President (Asia) M&A at J&J Medical Asia and was 
simultaneously an Executive Director at J&J Medical China 
till 2010. Post retirement from J&J, he became a venture 
partner with OrbiMed Asia Fund where he was associated 
for the next 4 years. He has been advisor to several private 
equity firms like Tata Healthcare Fund, Advent, Baring 
Asia/ PWC, Gaja Capital, Khazana and multinational 
corporations like Philips Netherlands, Intuitive Surgical USA, 
Alltech USA/ China, etc. He is also independent director 
on the Boards of Entero Healthcare Solutions Ltd. and 
Ascent Meditech Ltd. He holds an MBA from Jamnalal Bajaj 
Institute of Management Studies and B. Tech from Indian 
Institute of Technology, Madras.
Ms. Simi Thapar:
Ms. Thapar is an expert in asset financing and leasing 
solutions that help corporates forward their ESG goals. She 
is currently working as Chief Country Officer & Director with 
CSI Renting India Pvt. Ltd., a multinational organisation with 
presence in 50 countries, offering equipment leasing and 
lifecycle solutions to the enterprise segment. It is subsidiary 
of Tokyo Century Corporation, Japan. Prior to this, she was 
with Tata Capital for 8 years as a business head. She has 
been a speaker and panellist at various industry forums 
in India, USA, Hongkong, Singapore, Dubai and London 
for talks on asset financing, leasing solutions, women 
leadership and women in BFSI. She is a member of Diversity 
& Inclusion, and CSR committees of the American Chamber 
of Commerce in India. She has been instrumental in setting 
up NGO for economic empowerment of disadvantaged 
women. She is also member of NGOs for initiatives in the 
field of spiritual well-being, education, and healthcare for 
the disadvantaged community. She has a post graduate 
degree in commerce from Mumbai University along with 
Diploma in Business Finance & Business Management. 
She has also secured ‚ÄòMasters in Change‚Äô degree from 
INSEAD, Singapore.
Mr. David Rasquinha, Ms. Medha Joshi, Ms. Simi Thapar 
and Mr. Rajesh Dalal possesses the repertoire of skills, 
attributes, and competencies identified by the Board 
as also as per the ‚ÄúPolicy for determining qualification of 
Directors‚Äù and the ‚ÄúPolicy on Board diversity‚Äù.
In the opinion of the Board, these Directors fulfils the 
conditions for their appointment as Independent Directors, 
as specified in the Act and the Listing Regulations and 
are independent of the management. Their induction on 
Ajanta‚Äôs Board will immensely benefit the Company.
NOTICE
The remuneration payable to the Cost Auditors is required 
to be ratified by the Members of the Company.
Based on the certification received from the Cost Auditors, 
it may be noted that:
(i)	
They are in full time practice as Cost Accountants 
within the meaning of The Cost & Works Accountants 
Act, 1959 (23 of 1959) and hold valid Certificates 
of Practice;
(ii)	
They are not disqualified under any of the provisions 
specified under Sections 141(3) and 148(5) the 
Companies Act, 2013;
(iii)	
They are independent Cost Accountants and maintain 
an arm‚Äôs length relationship with the Company.
Accordingly, the consent of the Members is sought for 
passing an Ordinary Resolution as set out in Item No. 8 of 
this Notice for ratification of remuneration payable to the 
Cost Auditors for the financial year 2024-25.
None of the Directors and/or, Key Managerial Personnel 
and their relatives are concerned with or interested, 
financially or otherwise, in the said Resolution.
By order of the Board of Directors
Gaurang C. Shah
VP ‚Äì Legal & Company Secretary
02 May 2024
Membership No. F6696
Registered office:
‚ÄúAjanta House‚Äù, Charkop,
Kandivali (West),
Mumbai ‚Äì 400 067
Annual Report 2023-24
264
265
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
Details of the Director seeking appointment/re-appointment at Forty-Fifth Annual General Meeting (pursuant to 
Regulation 36 of the Listing Regulations and Clause 1.2.5 of Secretarial Standard on General Meetings).
Name of Director
Mr. Mannalal B. Agrawal
Mr. David Rasquinha
Ms. Medha Joshi
Date of Birth
26 March 1947
01 June 1961
24 June 1956
DIN No.
00073828
01172654
00328174
Nationality
Indian
Indian
Indian
Date of Appointment
31 December 1979
02 May 2024
02 May 2024
Expertise in Specific  
Functional Area
‚Ä¢ 
Industry knowledge
‚Ä¢ 
Business acumen
‚Ä¢ 
Management & admin
‚Ä¢	
Corporate Governance
‚Ä¢ 
Taxation
‚Ä¢ 
Finance
‚Ä¢ 
Accounting
‚Ä¢ 
Business management
‚Ä¢ 
Financial management
‚Ä¢ 
Forex management
‚Ä¢	
Global business
‚Ä¢	
Corporate governance
‚Ä¢	
Economics
‚Ä¢ 
Communication skills
‚Ä¢ 
Stakeholder relationship
‚Ä¢	
Sustainability
‚Ä¢ 
HR
‚Ä¢ 
Finance & Accounts
‚Ä¢ 
Corporate Banking
‚Ä¢ 
HR & employee 
engagement
‚Ä¢ 
Forex & Risk management
‚Ä¢ 
Policy making
‚Ä¢ 
Fund raising & Investment
‚Ä¢ 
Strategic thinking 
‚Ä¢ 
Sales & Marketing
Qualifications:
(i) Educational
B.Com
B.Com, Business Management 
from the XLRI, Jamshedpur with 
gold medal in economics. 
M.Com, executive MBA, CAIIB.
(ii) Experience in years
40+
39+
35+
No. of shares held in  
the Company
Nil
Nil
Nil
Relationship with other Directors 
and Key Managerial Personnel
Father of Mr. Yogesh  
M. Agrawal & Mr. Rajesh  
M. Agrawal and brother of  
Mr. Madhusudan B. Agrawal
None
None
No. of Board meetings attended 
during FY 2024
Four
N.A
N.A
Other Directorships in Companies None 
1. Afcons Infrastructure Ltd. 
2. Aquanomics Systems Ltd.
3. Ion Exchange Ltd.
4. HSBC Trustees (India)  
(P) Ltd.
5. Unity Small Finance Bank 
Ltd.
None
Membership of committees 
(M- Member; C- Chairman)
Ajanta Pharma Limited ‚Äì Audit 
Committee (M); Corporate 
Social Responsibility 
Committee (C)
1. Afcons Infrastructure Ltd. - 
Audit (M) & NRC (M)
2. Aquanomics Systems Ltd. - 
Audit (M) & NRC (M)
3. HSBC Trustees (India) (P) Ltd. 
- Audit (M) & RMC (M)
4. Unity Small Finance Bank 
Ltd. - Audit (M) & RMC (M)
5. Ajanta Pharma Limited - 
Audit (C); NRC (M)
Ajanta Pharma Limited - CSR 
& Sustainability Committee (M); 
Nomination & Remuneration 
Committee (M)
Terms and conditions of 
appointment
Liable to be retire by rotation
As per the details provided 
under the Resolution and 
Explanatory Statement
As per the details provided 
under the Resolution and 
Explanatory Statement
Details of remuneration sought 
to be paid
N.A.
Sitting Fees & Commission
Sitting Fees & Commission
Name of Director
Mr. Rajesh Dalal
Ms. Simi Thapar
Date of Birth
12 September 1953
20 August 1969
DIN No.
03504969
10470498
Nationality
Indian
Indian
Date of Appointment
02 May 2024
02 May 2024
Expertise in Specific  
Functional Area
‚Ä¢ 
Business management & 
transformation
‚Ä¢ 
M & A
‚Ä¢	
Healthcare industry 
‚Ä¢	
Corporate Governance
‚Ä¢ 
Sales & marketing
‚Ä¢ 
Investment banking
‚Ä¢ 
Finance & Accounting
‚Ä¢ 
Sales & Marketing
‚Ä¢ 
Chief Country Officer & 
Director with CSI Renting 
India Pvt. Ltd.
‚Ä¢ 
Member of American 
Chamber of Commerce 
D&I
Qualifications:
(i) Educational
MBA in Marketing, B. Tech. in 
Mechanical Engineering from 
IIT Madras. 
Post graduate degree from 
Mumbai University. Diploma 
in Business Finance & 
Business Management
(ii) Experience in years
40+
40+
No. of shares held in  
the Company
Nil
Nil
Relationship with other Directors 
and Key Managerial Personnel
None
None
No. of Board meetings attended 
during FY 2024
N.A
N.A
Other Directorships in Companies 1. Entero Healthcare 
Solutions Limited
2. Ascent Meditech Limited
3. Biogenomics Limited
1. CSI Renting India  
Private Limited
Membership of committees (M- 
Member; C- Chairman)
Ajanta Pharma Limited 
- Audit Committee (M); 
Nomination & Remuneration 
Committee (C); Risk 
Management Committee (M) 
Ajanta Pharma Limited 
- Audit Committee (M); 
Stakeholders Relationship 
Committee (M) 
Terms and conditions of 
appointment
As per the details provided 
under the Resolution and 
Explanatory Statement
As per the details provided 
under the Resolution and 
Explanatory Statement
Details of remuneration sought 
to be paid
Sitting Fees & Commission
Sitting Fees Commission
Annual Report 2023-24
266
267
Notice
Ajanta Pharma Limited
Solid Foundation. Crafting the Future.
(CIN No. L24230MH1979PLC022059)
Redg. Office: Ajanta House, Charkop,
Kandivali (West), Mumbai ‚Äì 400 067
Tel No.: 022 6606 1000
Website: www.ajantapharma.com
E-mail: investorgrievance@ajantapharma.com
Concept, content and design at                         |  whatsup@stirrup.works
